<?xml version="1.0" encoding="UTF-8"?>
<aggregateKnowledgeResponse xmlns="http://www.w3.org/2005/Atom">
	<feed>
		<title>Initial treatment of depression in adults</title>
		<category term="C0031809" scheme="gov.nih.nlm.semanticType.hlca" label="physical examination"/>
		<category term="C0150618" scheme="gov.nih.nlm.semanticType.hlca" label="history, physical"/>
		<category term="C3263684" scheme="gov.nih.nlm.semanticType.topp" label="screened"/>
		<category term="C0619701" scheme="gov.nih.nlm.semanticType.horm" label="II"/>
		<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalization"/>
		<category term="C0013808" scheme="gov.nih.nlm.semanticType.topp" label="Electroconvulsive therapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0035029" scheme="gov.nih.nlm.semanticType.topp" label="Relaxation techniques"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C1259875" scheme="gov.nih.nlm.semanticType.phsu" label="STAR"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="Psychotherapy"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0004933" scheme="gov.nih.nlm.semanticType.topp" label="behavioral therapy"/>
		<category term="C0009244" scheme="gov.nih.nlm.semanticType.topp" label="cognitive therapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0309872" scheme="gov.nih.nlm.semanticType.phsu" label="prevent"/>
		<category term="C0871787" scheme="gov.nih.nlm.semanticType.topp" label="Interpersonal psychotherapy"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="Pharmacotherapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C2003848" scheme="gov.nih.nlm.semanticType.topp" label="drug therapy"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0556895" scheme="gov.nih.nlm.semanticType.topp" label="combination therapy"/>
		<category term="C0556895" scheme="gov.nih.nlm.semanticType.topp" label="combination therapy"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0003290" scheme="gov.nih.nlm.semanticType.phsu" label="tricyclic antidepressants"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0360105" scheme="gov.nih.nlm.semanticType.phsu" label="selective serotonin reuptake inhibitors"/>
		<category term="C0629984" scheme="gov.nih.nlm.semanticType.strd" label="TCAs"/>
		<category term="C0758711" scheme="gov.nih.nlm.semanticType.orch" label="serotonin"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin reuptake inhibitors"/>
		<category term="C3653413" scheme="gov.nih.nlm.semanticType.phsu" label="monoamine oxidase inhibitors"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="Antidepressants"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0016365" scheme="gov.nih.nlm.semanticType.phsu" label="fluoxetine"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0008845" scheme="gov.nih.nlm.semanticType.phsu" label="citalopram"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="Antidepressants"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="Drugs"/>
		<category term="C0391422" scheme="gov.nih.nlm.semanticType.orch" label="impact"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressive"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0074393" scheme="gov.nih.nlm.semanticType.phsu" label="sertraline"/>
		<category term="C1099456" scheme="gov.nih.nlm.semanticType.phsu" label="escitalopram"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0074393" scheme="gov.nih.nlm.semanticType.phsu" label="sertraline"/>
		<category term="C1099456" scheme="gov.nih.nlm.semanticType.phsu" label="escitalopram"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0017313" scheme="gov.nih.nlm.semanticType.hlca" label="care patients"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0162758" scheme="gov.nih.nlm.semanticType.phsu" label="reuptake inhibitors, serotonin"/>
		<category term="C0360105" scheme="gov.nih.nlm.semanticType.phsu" label="selective serotonin reuptake inhibitors"/>
		<category term="C0758711" scheme="gov.nih.nlm.semanticType.orch" label="serotonin"/>
		<category term="C1319313" scheme="gov.nih.nlm.semanticType.phsu" label="norepinephrine reuptake inhibitors"/>
		<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin reuptake inhibitors"/>
		<category term="C3252015" scheme="gov.nih.nlm.semanticType.phsu" label="RR"/>
		<category term="C3537213" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin/norepinephrine reuptake inhibitors"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0003290" scheme="gov.nih.nlm.semanticType.phsu" label="tricyclic antidepressants"/>
		<category term="C3540022" scheme="gov.nih.nlm.semanticType.phsu" label="MAO inhibitors"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0049506" scheme="gov.nih.nlm.semanticType.phsu" label="mirtazapine"/>
		<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
		<category term="C0085208" scheme="gov.nih.nlm.semanticType.phsu" label="bupropion"/>
		<category term="C0245561" scheme="gov.nih.nlm.semanticType.phsu" label="duloxetine"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0049506" scheme="gov.nih.nlm.semanticType.phsu" label="mirtazapine"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRI"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0003290" scheme="gov.nih.nlm.semanticType.phsu" label="tricyclic antidepressants"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0016365" scheme="gov.nih.nlm.semanticType.phsu" label="fluoxetine"/>
		<category term="C0040805" scheme="gov.nih.nlm.semanticType.phsu" label="trazodone"/>
		<category term="C0049506" scheme="gov.nih.nlm.semanticType.phsu" label="mirtazapine"/>
		<category term="C0070122" scheme="gov.nih.nlm.semanticType.phsu" label="paroxetine"/>
		<category term="C0074393" scheme="gov.nih.nlm.semanticType.phsu" label="sertraline"/>
		<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
		<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
		<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
		<category term="C0245561" scheme="gov.nih.nlm.semanticType.phsu" label="duloxetine"/>
		<category term="C1880288" scheme="gov.nih.nlm.semanticType.phsu" label="desvenlafaxine"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
		<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="Venlafaxine"/>
		<category term="C0245561" scheme="gov.nih.nlm.semanticType.phsu" label="Duloxetine"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0039052" scheme="gov.nih.nlm.semanticType.phsu" label="sympathomimetic drug"/>
		<category term="C1875809" scheme="gov.nih.nlm.semanticType.phsu" label="sympathomimetic"/>
		<category term="C0085208" scheme="gov.nih.nlm.semanticType.phsu" label="Bupropion"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
		<category term="C0049506" scheme="gov.nih.nlm.semanticType.phsu" label="Mirtazapine"/>
		<category term="C0758711" scheme="gov.nih.nlm.semanticType.orch" label="serotonin"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
		<category term="C0049506" scheme="gov.nih.nlm.semanticType.phsu" label="Mirtazapine"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
		<category term="C0008845" scheme="gov.nih.nlm.semanticType.phsu" label="citalopram"/>
		<category term="C1259875" scheme="gov.nih.nlm.semanticType.phsu" label="STAR"/>
		<category term="C0008845" scheme="gov.nih.nlm.semanticType.phsu" label="citalopram"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="Drug"/>
		<category term="C3469597" scheme="gov.nih.nlm.semanticType.hlca" label="Drug Administration"/>
		<category term="C3540798" scheme="gov.nih.nlm.semanticType.imft" label="Food"/>
		<category term="C0008845" scheme="gov.nih.nlm.semanticType.phsu" label="citalopram"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
		<category term="C0016365" scheme="gov.nih.nlm.semanticType.phsu" label="fluoxetine"/>
		<category term="C0008845" scheme="gov.nih.nlm.semanticType.phsu" label="citalopram"/>
		<category term="C1259875" scheme="gov.nih.nlm.semanticType.phsu" label="STAR"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
		<category term="C0085208" scheme="gov.nih.nlm.semanticType.phsu" label="bupropion"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="Antidepressant"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C0457454" scheme="gov.nih.nlm.semanticType.hlca" label="discontinuation"/>
		<category term="C0008845" scheme="gov.nih.nlm.semanticType.phsu" label="citalopram"/>
		<category term="C1259875" scheme="gov.nih.nlm.semanticType.phsu" label="STAR"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C2003848" scheme="gov.nih.nlm.semanticType.topp" label="drug therapy"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0332293" scheme="gov.nih.nlm.semanticType.topp" label="treated by"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C1096649" scheme="gov.nih.nlm.semanticType.topp" label="antidepressant therapy"/>
		<category term="C0677908" scheme="gov.nih.nlm.semanticType.topp" label="Maintenance therapy"/>
		<category term="C0677908" scheme="gov.nih.nlm.semanticType.topp" label="maintenance therapy"/>
		<category term="C0332293" scheme="gov.nih.nlm.semanticType.topp" label="treated by"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C0040615" scheme="gov.nih.nlm.semanticType.phsu" label="antipsychotics"/>
		<category term="C0073393" scheme="gov.nih.nlm.semanticType.phsu" label="risperidone"/>
		<category term="C0123091" scheme="gov.nih.nlm.semanticType.phsu" label="quetiapine"/>
		<category term="C0171023" scheme="gov.nih.nlm.semanticType.phsu" label="olanzapine"/>
		<category term="C0299792" scheme="gov.nih.nlm.semanticType.phsu" label="aripiprazole"/>
		<category term="C0006949" scheme="gov.nih.nlm.semanticType.phsu" label="carbamazepine"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0064636" scheme="gov.nih.nlm.semanticType.phsu" label="lamotrigine"/>
		<category term="C0080356" scheme="gov.nih.nlm.semanticType.phsu" label="valproate"/>
		<category term="C0619701" scheme="gov.nih.nlm.semanticType.horm" label="II"/>
		<category term="C0628655" scheme="gov.nih.nlm.semanticType.phsu" label="meet"/>
		<category term="C1276998" scheme="gov.nih.nlm.semanticType.phsu" label="mood stabilizing drug"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C0040616" scheme="gov.nih.nlm.semanticType.phsu" label="Anxiolytics"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0003290" scheme="gov.nih.nlm.semanticType.phsu" label="tricyclic antidepressants"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
		<category term="C0360105" scheme="gov.nih.nlm.semanticType.phsu" label="selective serotonin reuptake inhibitors"/>
		<category term="C0758711" scheme="gov.nih.nlm.semanticType.orch" label="serotonin"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin reuptake inhibitors"/>
		<category term="C0011812" scheme="gov.nih.nlm.semanticType.phsu" label="dextroamphetamine"/>
		<category term="C0025810" scheme="gov.nih.nlm.semanticType.phsu" label="methylphenidate"/>
		<category term="C0030800" scheme="gov.nih.nlm.semanticType.phsu" label="pemoline"/>
		<category term="C0066677" scheme="gov.nih.nlm.semanticType.phsu" label="modafinil"/>
		<category term="C0304403" scheme="gov.nih.nlm.semanticType.phsu" label="Psychostimulants"/>
		<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0066677" scheme="gov.nih.nlm.semanticType.phsu" label="modafinil"/>
		<category term="C0002844" scheme="gov.nih.nlm.semanticType.horm" label="androgen"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0025876" scheme="gov.nih.nlm.semanticType.horm" label="metyrapone"/>
		<category term="C0026088" scheme="gov.nih.nlm.semanticType.phsu" label="mifepristone"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
		<category term="C3252015" scheme="gov.nih.nlm.semanticType.phsu" label="RR"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C0041014" scheme="gov.nih.nlm.semanticType.horm" label="Triiodothyronine"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C1099456" scheme="gov.nih.nlm.semanticType.phsu" label="escitalopram"/>
		<category term="C1572759" scheme="gov.nih.nlm.semanticType.orch" label="monohydrate"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0010132" scheme="gov.nih.nlm.semanticType.horm" label="corticotropin releasing factors"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0050605" scheme="gov.nih.nlm.semanticType.aapp" label="corticotropin"/>
		<category term="C1261322" scheme="gov.nih.nlm.semanticType.hlca" label="investigation"/>
		<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoid"/>
		<category term="C1259875" scheme="gov.nih.nlm.semanticType.phsu" label="STAR"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="Antidepressants"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C2930737" scheme="gov.nih.nlm.semanticType.phsu" label="energy"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="Antidepressants"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C1096649" scheme="gov.nih.nlm.semanticType.topp" label="antidepressant therapy"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
		<category term="C3540763" scheme="gov.nih.nlm.semanticType.phsu" label="various"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0397581" scheme="gov.nih.nlm.semanticType.topp" label="artery"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="Venlafaxine"/>
		<category term="C0085208" scheme="gov.nih.nlm.semanticType.phsu" label="bupropion"/>
		<category term="C0245561" scheme="gov.nih.nlm.semanticType.phsu" label="duloxetine"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0628655" scheme="gov.nih.nlm.semanticType.phsu" label="meet"/>
		<category term="C0001701" scheme="gov.nih.nlm.semanticType.topp" label="aerobic exercise"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C1096649" scheme="gov.nih.nlm.semanticType.topp" label="antidepressant therapy"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0031765" scheme="gov.nih.nlm.semanticType.topp" label="light therapy"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0003290" scheme="gov.nih.nlm.semanticType.phsu" label="tricyclic antidepressants"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0360105" scheme="gov.nih.nlm.semanticType.phsu" label="selective serotonin reuptake inhibitors"/>
		<category term="C0629984" scheme="gov.nih.nlm.semanticType.strd" label="TCAs"/>
		<category term="C0758711" scheme="gov.nih.nlm.semanticType.orch" label="serotonin"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin reuptake inhibitors"/>
		<category term="C3653413" scheme="gov.nih.nlm.semanticType.phsu" label="monoamine oxidase inhibitors"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C0006462" scheme="gov.nih.nlm.semanticType.phsu" label="buspirone"/>
		<category term="C0085208" scheme="gov.nih.nlm.semanticType.phsu" label="bupropion"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C0677908" scheme="gov.nih.nlm.semanticType.topp" label="maintenance therapy"/>
		<category term="C0677908" scheme="gov.nih.nlm.semanticType.topp" label="maintenance therapy"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0963297" scheme="gov.nih.nlm.semanticType.orch" label="benzodiazepine"/>
		<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
		<category term="C2003848" scheme="gov.nih.nlm.semanticType.topp" label="drug therapy"/>
		<category term="C1171947" scheme="gov.nih.nlm.semanticType.phsu" label="commit"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0871787" scheme="gov.nih.nlm.semanticType.topp" label="interpersonal psychotherapy"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C3542961" scheme="gov.nih.nlm.semanticType.phsu" label="nervous system"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0004933" scheme="gov.nih.nlm.semanticType.topp" label="behavioral therapy"/>
		<category term="C0009244" scheme="gov.nih.nlm.semanticType.topp" label="cognitive-behavioral therapy"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0871787" scheme="gov.nih.nlm.semanticType.topp" label="interpersonal psychotherapy"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0556895" scheme="gov.nih.nlm.semanticType.topp" label="combination therapy"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0556895" scheme="gov.nih.nlm.semanticType.topp" label="combination therapy"/>
		<category term="C0556895" scheme="gov.nih.nlm.semanticType.topp" label="combination therapy"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0004933" scheme="gov.nih.nlm.semanticType.topp" label="behavioral therapy"/>
		<category term="C0009244" scheme="gov.nih.nlm.semanticType.topp" label="cognitive-behavioral therapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0033972" scheme="gov.nih.nlm.semanticType.topp" label="combined therapy"/>
		<category term="C0419168" scheme="gov.nih.nlm.semanticType.topp" label="other psychotherapies"/>
		<category term="C0871787" scheme="gov.nih.nlm.semanticType.topp" label="interpersonal psychotherapy"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0242905" scheme="gov.nih.nlm.semanticType.phsu" label="atypical antidepressants"/>
		<category term="C0758711" scheme="gov.nih.nlm.semanticType.orch" label="serotonin"/>
		<category term="C1319313" scheme="gov.nih.nlm.semanticType.phsu" label="norepinephrine reuptake inhibitors"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
		<category term="C3537213" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin-norepinephrine reuptake inhibitors"/>
		<category term="C0074393" scheme="gov.nih.nlm.semanticType.phsu" label="sertraline"/>
		<category term="C1099456" scheme="gov.nih.nlm.semanticType.phsu" label="escitalopram"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0308902" scheme="gov.nih.nlm.semanticType.phsu" label="duration"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
		<category term="C0016365" scheme="gov.nih.nlm.semanticType.phsu" label="fluoxetine"/>
		<category term="C0049506" scheme="gov.nih.nlm.semanticType.phsu" label="mirtazapine"/>
		<category term="C0070122" scheme="gov.nih.nlm.semanticType.phsu" label="paroxetine"/>
		<category term="C0074393" scheme="gov.nih.nlm.semanticType.phsu" label="sertraline"/>
		<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
		<category term="C0085228" scheme="gov.nih.nlm.semanticType.phsu" label="fluvoxamine"/>
		<category term="C0168388" scheme="gov.nih.nlm.semanticType.phsu" label="reboxetine"/>
		<category term="C0245561" scheme="gov.nih.nlm.semanticType.phsu" label="duloxetine"/>
		<category term="C1099456" scheme="gov.nih.nlm.semanticType.phsu" label="escitalopram"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0008845" scheme="gov.nih.nlm.semanticType.phsu" label="citalopram"/>
		<category term="C0074393" scheme="gov.nih.nlm.semanticType.phsu" label="sertraline"/>
		<category term="C0457454" scheme="gov.nih.nlm.semanticType.hlca" label="Discontinuation"/>
		<category term="C1099456" scheme="gov.nih.nlm.semanticType.phsu" label="escitalopram"/>
		<category term="C3653915" scheme="gov.nih.nlm.semanticType.phsu" label="other antidepressants"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0457454" scheme="gov.nih.nlm.semanticType.hlca" label="discontinuation"/>
		<category term="C0008845" scheme="gov.nih.nlm.semanticType.phsu" label="citalopram"/>
		<category term="C1099456" scheme="gov.nih.nlm.semanticType.phsu" label="escitalopram"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0049506" scheme="gov.nih.nlm.semanticType.phsu" label="mirtazapine"/>
		<category term="C3653915" scheme="gov.nih.nlm.semanticType.phsu" label="other antidepressants"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0008845" scheme="gov.nih.nlm.semanticType.phsu" label="citalopram"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0040805" scheme="gov.nih.nlm.semanticType.phsu" label="trazodone"/>
		<category term="C0085208" scheme="gov.nih.nlm.semanticType.phsu" label="bupropion"/>
		<category term="C1099456" scheme="gov.nih.nlm.semanticType.phsu" label="escitalopram"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0008845" scheme="gov.nih.nlm.semanticType.phsu" label="citalopram"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0016365" scheme="gov.nih.nlm.semanticType.phsu" label="fluoxetine"/>
		<category term="C0049506" scheme="gov.nih.nlm.semanticType.phsu" label="mirtazapine"/>
		<category term="C0068485" scheme="gov.nih.nlm.semanticType.phsu" label="nefazodone"/>
		<category term="C0070122" scheme="gov.nih.nlm.semanticType.phsu" label="paroxetine"/>
		<category term="C0074393" scheme="gov.nih.nlm.semanticType.phsu" label="sertraline"/>
		<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
		<category term="C0085208" scheme="gov.nih.nlm.semanticType.phsu" label="bupropion"/>
		<category term="C0085228" scheme="gov.nih.nlm.semanticType.phsu" label="fluvoxamine"/>
		<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
		<category term="C0016365" scheme="gov.nih.nlm.semanticType.phsu" label="fluoxetine"/>
		<category term="C0040805" scheme="gov.nih.nlm.semanticType.phsu" label="trazodone"/>
		<category term="C0049506" scheme="gov.nih.nlm.semanticType.phsu" label="mirtazapine"/>
		<category term="C0070122" scheme="gov.nih.nlm.semanticType.phsu" label="paroxetine"/>
		<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
		<category term="C0085208" scheme="gov.nih.nlm.semanticType.phsu" label="bupropion"/>
		<category term="C0016365" scheme="gov.nih.nlm.semanticType.phsu" label="fluoxetine"/>
		<category term="C0040805" scheme="gov.nih.nlm.semanticType.phsu" label="trazodone"/>
		<category term="C0049506" scheme="gov.nih.nlm.semanticType.phsu" label="mirtazapine"/>
		<category term="C0070122" scheme="gov.nih.nlm.semanticType.phsu" label="paroxetine"/>
		<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
		<category term="C0124598" scheme="gov.nih.nlm.semanticType.phsu" label="kg"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
		<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0758711" scheme="gov.nih.nlm.semanticType.orch" label="serotonin"/>
		<category term="C1319313" scheme="gov.nih.nlm.semanticType.phsu" label="norepinephrine reuptake inhibitors"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
		<category term="C3537213" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin-norepinephrine reuptake inhibitors"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0068485" scheme="gov.nih.nlm.semanticType.phsu" label="nefazodone"/>
		<category term="C0971637" scheme="gov.nih.nlm.semanticType.phsu" label="agomelatine"/>
		<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRI"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0008845" scheme="gov.nih.nlm.semanticType.phsu" label="citalopram"/>
		<category term="C1259875" scheme="gov.nih.nlm.semanticType.phsu" label="STAR"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
		<category term="C1099456" scheme="gov.nih.nlm.semanticType.phsu" label="escitalopram"/>
		<category term="C1099456" scheme="gov.nih.nlm.semanticType.phsu" label="escitalopram"/>
		<category term="C0016365" scheme="gov.nih.nlm.semanticType.phsu" label="fluoxetine"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="Antidepressants"/>
		<category term="C0016365" scheme="gov.nih.nlm.semanticType.phsu" label="fluoxetine"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0002600" scheme="gov.nih.nlm.semanticType.phsu" label="amitriptyline"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="Meta"/>
		<category term="C0070122" scheme="gov.nih.nlm.semanticType.phsu" label="paroxetine"/>
		<category term="C0245561" scheme="gov.nih.nlm.semanticType.phsu" label="duloxetine"/>
		<category term="C0971637" scheme="gov.nih.nlm.semanticType.phsu" label="agomelatine"/>
		<category term="C3653413" scheme="gov.nih.nlm.semanticType.phsu" label="monoamine oxidase inhibitors"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebos"/>
		<category term="C0628655" scheme="gov.nih.nlm.semanticType.phsu" label="meeting"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="Antidepressants"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0004933" scheme="gov.nih.nlm.semanticType.topp" label="behavioral therapy"/>
		<category term="C0009244" scheme="gov.nih.nlm.semanticType.topp" label="Cognitive-behavioral therapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="Psychotherapies"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0871787" scheme="gov.nih.nlm.semanticType.topp" label="interpersonal psychotherapy"/>
		<category term="C0004933" scheme="gov.nih.nlm.semanticType.topp" label="behavioral therapy"/>
		<category term="C0009244" scheme="gov.nih.nlm.semanticType.topp" label="cognitive-behavioral therapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapies"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0344211" scheme="gov.nih.nlm.semanticType.topp" label="supportive therapy"/>
		<category term="C0474215" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapies (behavioral"/>
		<category term="C0599237" scheme="gov.nih.nlm.semanticType.topp" label="psychodynamic therapy"/>
		<category term="C0871787" scheme="gov.nih.nlm.semanticType.topp" label="interpersonal psychotherapy"/>
		<category term="C1303140" scheme="gov.nih.nlm.semanticType.topp" label="problem solving therapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapies"/>
		<category term="C0557035" scheme="gov.nih.nlm.semanticType.hlca" label="help therapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="Psychotherapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0221295" scheme="gov.nih.nlm.semanticType.topp" label="supportive psychotherapy"/>
		<category term="C0419168" scheme="gov.nih.nlm.semanticType.topp" label="other psychotherapies"/>
		<category term="C1261382" scheme="gov.nih.nlm.semanticType.topp" label="psychodynamic psychotherapy"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0871787" scheme="gov.nih.nlm.semanticType.topp" label="interpersonal psychotherapy"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0001758" scheme="gov.nih.nlm.semanticType.hlca" label="after treatment"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="adding"/>
		<category term="C0004361" scheme="gov.nih.nlm.semanticType.topp" label="autogenic training"/>
		<category term="C0035029" scheme="gov.nih.nlm.semanticType.topp" label="relaxation techniques"/>
		<category term="C0150316" scheme="gov.nih.nlm.semanticType.topp" label="progressive muscle relaxation"/>
		<category term="C0150627" scheme="gov.nih.nlm.semanticType.topp" label="imagery"/>
		<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
		<category term="C0004933" scheme="gov.nih.nlm.semanticType.topp" label="behavioral therapy"/>
		<category term="C0009244" scheme="gov.nih.nlm.semanticType.topp" label="cognitive-behavioral therapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="add"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0001701" scheme="gov.nih.nlm.semanticType.topp" label="Aerobic exercise"/>
		<category term="C0624791" scheme="gov.nih.nlm.semanticType.imft" label="running"/>
		<category term="C0872279" scheme="gov.nih.nlm.semanticType.topp" label="resistance training"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C0017313" scheme="gov.nih.nlm.semanticType.hlca" label="care patients"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="Meta"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="Psychotherapy"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0017313" scheme="gov.nih.nlm.semanticType.hlca" label="care patients"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C0040616" scheme="gov.nih.nlm.semanticType.phsu" label="Anxiolytics"/>
		<category term="C1569452" scheme="gov.nih.nlm.semanticType.phsu" label="refusal"/>
		<category term="C3540798" scheme="gov.nih.nlm.semanticType.imft" label="food"/>
		<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalization"/>
		<category term="C0002600" scheme="gov.nih.nlm.semanticType.phsu" label="amitriptyline"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0871787" scheme="gov.nih.nlm.semanticType.topp" label="interpersonal psychotherapy"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0556895" scheme="gov.nih.nlm.semanticType.topp" label="combination therapy"/>
		<category term="C0013806" scheme="gov.nih.nlm.semanticType.topp" label="ECT"/>
		<category term="C0013808" scheme="gov.nih.nlm.semanticType.topp" label="electroconvulsive therapy"/>
		<category term="C0556895" scheme="gov.nih.nlm.semanticType.topp" label="combination therapy"/>
		<category term="C0013806" scheme="gov.nih.nlm.semanticType.topp" label="ECT"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="Meta"/>
		<category term="C0013806" scheme="gov.nih.nlm.semanticType.topp" label="ECT"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0013806" scheme="gov.nih.nlm.semanticType.topp" label="ECT"/>
		<category term="C0556895" scheme="gov.nih.nlm.semanticType.topp" label="combination therapy"/>
		<category term="C0040615" scheme="gov.nih.nlm.semanticType.phsu" label="antipsychotics"/>
		<category term="C0758711" scheme="gov.nih.nlm.semanticType.orch" label="serotonin"/>
		<category term="C1319313" scheme="gov.nih.nlm.semanticType.phsu" label="norepinephrine reuptake inhibitors"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
		<category term="C3537213" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin-norepinephrine reuptake inhibitors"/>
		<category term="C0008845" scheme="gov.nih.nlm.semanticType.phsu" label="citalopram"/>
		<category term="C0016365" scheme="gov.nih.nlm.semanticType.phsu" label="fluoxetine"/>
		<category term="C0070122" scheme="gov.nih.nlm.semanticType.phsu" label="paroxetine"/>
		<category term="C0074393" scheme="gov.nih.nlm.semanticType.phsu" label="sertraline"/>
		<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
		<category term="C0245561" scheme="gov.nih.nlm.semanticType.phsu" label="duloxetine"/>
		<category term="C0758711" scheme="gov.nih.nlm.semanticType.orch" label="serotonin"/>
		<category term="C1099456" scheme="gov.nih.nlm.semanticType.phsu" label="escitalopram"/>
		<category term="C1319313" scheme="gov.nih.nlm.semanticType.phsu" label="norepinephrine reuptake inhibitors"/>
		<category term="C1533126" scheme="gov.nih.nlm.semanticType.phsu" label="milnacipran"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
		<category term="C3537213" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin-norepinephrine reuptake inhibitors"/>
		<category term="C0758711" scheme="gov.nih.nlm.semanticType.orch" label="serotonin"/>
		<category term="C1319313" scheme="gov.nih.nlm.semanticType.phsu" label="norepinephrine reuptake inhibitors"/>
		<category term="C3537213" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin-norepinephrine reuptake inhibitors"/>
		<category term="C0040805" scheme="gov.nih.nlm.semanticType.phsu" label="trazodone"/>
		<category term="C0049506" scheme="gov.nih.nlm.semanticType.phsu" label="mirtazapine"/>
		<category term="C0758711" scheme="gov.nih.nlm.semanticType.orch" label="serotonin"/>
		<category term="C1319313" scheme="gov.nih.nlm.semanticType.phsu" label="norepinephrine reuptake inhibitors"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
		<category term="C3537213" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin-norepinephrine reuptake inhibitors"/>
		<category term="C0040805" scheme="gov.nih.nlm.semanticType.phsu" label="trazodone"/>
		<category term="C0049506" scheme="gov.nih.nlm.semanticType.phsu" label="mirtazapine"/>
		<category term="C0049506" scheme="gov.nih.nlm.semanticType.phsu" label="mirtazapine"/>
		<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
		<category term="C0049506" scheme="gov.nih.nlm.semanticType.phsu" label="mirtazapine"/>
		<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
		<category term="C0457454" scheme="gov.nih.nlm.semanticType.hlca" label="discontinuation"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0003290" scheme="gov.nih.nlm.semanticType.phsu" label="Tricyclic antidepressants"/>
		<category term="C3653915" scheme="gov.nih.nlm.semanticType.phsu" label="other antidepressants"/>
		<category term="C0002600" scheme="gov.nih.nlm.semanticType.phsu" label="amitriptyline"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0009010" scheme="gov.nih.nlm.semanticType.phsu" label="clomipramine"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C3653915" scheme="gov.nih.nlm.semanticType.phsu" label="other antidepressants"/>
		<category term="C0002600" scheme="gov.nih.nlm.semanticType.phsu" label="amitriptyline"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
		<category term="C3653915" scheme="gov.nih.nlm.semanticType.phsu" label="other antidepressants"/>
		<category term="C0002600" scheme="gov.nih.nlm.semanticType.phsu" label="amitriptyline"/>
		<category term="C0008845" scheme="gov.nih.nlm.semanticType.phsu" label="citalopram"/>
		<category term="C0009010" scheme="gov.nih.nlm.semanticType.phsu" label="clomipramine"/>
		<category term="C0011685" scheme="gov.nih.nlm.semanticType.phsu" label="desipramine"/>
		<category term="C0016365" scheme="gov.nih.nlm.semanticType.phsu" label="fluoxetine"/>
		<category term="C0024778" scheme="gov.nih.nlm.semanticType.phsu" label="maprotiline"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0070122" scheme="gov.nih.nlm.semanticType.phsu" label="paroxetine"/>
		<category term="C0085228" scheme="gov.nih.nlm.semanticType.phsu" label="fluvoxamine"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
		<category term="C0457454" scheme="gov.nih.nlm.semanticType.hlca" label="discontinuation"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0457454" scheme="gov.nih.nlm.semanticType.hlca" label="Discontinuation"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0556895" scheme="gov.nih.nlm.semanticType.topp" label="combination therapy"/>
		<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
		<category term="C0457454" scheme="gov.nih.nlm.semanticType.hlca" label="discontinuation"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0029151" scheme="gov.nih.nlm.semanticType.topp" label="pill"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0871787" scheme="gov.nih.nlm.semanticType.topp" label="interpersonal psychotherapy"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0360105" scheme="gov.nih.nlm.semanticType.phsu" label="selective serotonin reuptake inhibitors"/>
		<category term="C0758711" scheme="gov.nih.nlm.semanticType.orch" label="serotonin"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin reuptake inhibitors"/>
		<category term="C3653915" scheme="gov.nih.nlm.semanticType.phsu" label="other antidepressants"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapies"/>
		<category term="C0004933" scheme="gov.nih.nlm.semanticType.topp" label="behavioral therapy"/>
		<category term="C0009244" scheme="gov.nih.nlm.semanticType.topp" label="cognitive-behavioral therapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0419168" scheme="gov.nih.nlm.semanticType.topp" label="other psychotherapies"/>
		<category term="C0871787" scheme="gov.nih.nlm.semanticType.topp" label="interpersonal psychotherapy"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="Antidepressants"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimens"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0758711" scheme="gov.nih.nlm.semanticType.orch" label="serotonin"/>
		<category term="C1319313" scheme="gov.nih.nlm.semanticType.phsu" label="norepinephrine reuptake inhibitors"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
		<category term="C3537213" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin-norepinephrine reuptake inhibitors"/>
		<category term="C3653915" scheme="gov.nih.nlm.semanticType.phsu" label="other antidepressants"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<id>1725</id>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H2"/>
			<id>169590</id>
			<summary>
				<section label="INITIAL EVALUATION" id="2">
					<fragment>Patients who have symptoms of depression should be evaluated with a history, physical examination, and limited laboratory testing (if indicated) to rule out secondary medical causes.</fragment>
				</section>
			</summary>
			<category term="C0031809" scheme="gov.nih.nlm.semanticType.hlca" label="physical examination"/>
			<category term="C0150618" scheme="gov.nih.nlm.semanticType.hlca" label="history, physical"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H3"/>
			<id>169591</id>
			<summary>
				<section label="Distinguishing unipolar and bipolar depression" id="3">
					<fragment>Patients with depressive symptoms should be screened for bipolar disorder.</fragment>
				</section>
			</summary>
			<category term="C3263684" scheme="gov.nih.nlm.semanticType.topp" label="screened"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H3"/>
			<id>169595</id>
			<summary>
				<section label="Distinguishing unipolar and bipolar depression" id="3">
					<fragment>Patients with bipolar disorder are frequently misdiagnosed as having unipolar depression, particularly patients with bipolar II disorder or bipolar disorder NOS who do not exhibit overt symptoms of mania.</fragment>
				</section>
			</summary>
			<category term="C0619701" scheme="gov.nih.nlm.semanticType.horm" label="II"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H4"/>
			<id>169599</id>
			<summary>
				<section label="Suicidal ideation" id="4">
					<fragment>Assessment for the presence of suicidal ideation is of paramount importance in all depressed patients.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H4"/>
			<id>169600</id>
			<summary>
				<section label="Suicidal ideation" id="4">
					<fragment>However, the ability of clinicians to predict suicide attempts and completed suicide is poor.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H4"/>
			<id>169607</id>
			<summary>
				<section label="Suicidal ideation" id="4">
					<fragment>Evaluation in an emergency department and/or hospitalization should be considered for patients at significant risk of suicide.</fragment>
				</section>
			</summary>
			<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalization"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H5"/>
			<id>169608</id>
			<summary>
				<section label="Severe depression" id="5">
					<fragment>Patients who are felt to have severe depression (eg, significant distress or decrease in function), whether or not they are suicidal, should be referred to a psychiatrist for management.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H5"/>
			<id>169613</id>
			<summary>
				<section label="Severe depression" id="5">
					<fragment>Depression, who need treatment for substance abuse.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H5"/>
			<id>169616</id>
			<summary>
				<section label="Severe depression" id="5">
					<fragment>Electroconvulsive therapy should be considered as an initial treatment for life-threatening depression.</fragment>
				</section>
			</summary>
			<category term="C0013808" scheme="gov.nih.nlm.semanticType.topp" label="Electroconvulsive therapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H6"/>
			<id>169617</id>
			<summary>
				<section label="Assessment tool" id="6">
					<fragment>The nine-item Patient Health Questionnaire (PHQ-9) is a self-report, standardized, depression rating scale that can be used to diagnose major depression and measure its severity.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H8"/>
			<id>169623</id>
			<summary>
				<section label="Discussing diagnosis" id="8">
					<fragment>Depression is associated with both emotional symptoms (mood changes) and physical symptoms (ie, fatigue, headache, abdominal pain, muscle tension).</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H8"/>
			<id>169625</id>
			<summary>
				<section label="Discussing diagnosis" id="8">
					<fragment>Depression is a physical illness, associated with biologic changes in neurochemistry in the brain.</fragment>
				</section>
			</summary>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H8"/>
			<id>169626</id>
			<summary>
				<section label="Discussing diagnosis" id="8">
					<fragment>Treatment with medication and/or psychotherapy generally shortens the course of depression and diminishes symptoms.</fragment>
				</section>
			</summary>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H9"/>
			<id>169628</id>
			<summary>
				<section label="Reluctant patients" id="9">
					<fragment>A patient diary that records sleep, mood, appetite, and concentration difficulties during this period may be useful in encouraging patients to accept treatment.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H10"/>
			<id>169630</id>
			<summary>
				<section label="Adherence to medications" id="10">
					<fragment>Patients who will be treated with medication should be told the following, at the initiation of treatment: Do not stop medications without talking with the prescribing clinician.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H11"/>
			<id>169640</id>
			<summary>
				<section label="Lifestyle advice" id="11">
					<fragment>However, exercise alone is not an effective treatment strategy for most patients with major depression.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H11"/>
			<id>169641</id>
			<summary>
				<section label="Lifestyle advice" id="11">
					<fragment>Relaxation techniques may be tried for patients with minimal symptoms.</fragment>
				</section>
			</summary>
			<category term="C0035029" scheme="gov.nih.nlm.semanticType.topp" label="Relaxation techniques"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H11"/>
			<id>169642</id>
			<summary>
				<section label="Lifestyle advice" id="11">
					<fragment>A meta-analysis of 11 trials found that relaxation reduced self-reported symptoms compared to no treatment, but was not as effective as psychological treatment.</fragment>
				</section>
			</summary>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H12"/>
			<id>169644</id>
			<summary>
				<section label="TREATMENT GOALS" id="12">
					<fragment>In the prospective Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study, 3671 outpatients with unipolar major depression who improved following treatment with pharmacotherapy and/or psychotherapy were subsequently followed for up to 12 months.</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="C1259875" scheme="gov.nih.nlm.semanticType.phsu" label="STAR"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H12"/>
			<id>169645</id>
			<summary>
				<section label="TREATMENT GOALS" id="12">
					<fragment>Relapse appeared to occur less frequently in patients who remitted, compared with patients who responded (reduction of baseline symptoms &gt;=50 percent) but did not remit.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H13"/>
			<id>169647</id>
			<summary>
				<section label="PSYCHOTHERAPY" id="13">
					<fragment>Psychotherapy, alone or in combination with antidepressant medication, is an option for patients with mild to moderate major depression.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="Psychotherapy"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H13"/>
			<id>169651</id>
			<summary>
				<section label="PSYCHOTHERAPY" id="13">
					<fragment>Starting antidepressants earlier than twelve weeks may be considered as well, because many patients do not optimally benefit from psychotherapy without a concurrent antidepressant.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H13"/>
			<id>169653</id>
			<summary>
				<section label="PSYCHOTHERAPY" id="13">
					<fragment>A broad range of psychological interventions appear to be effective for the treatment of depression.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H13"/>
			<id>169654</id>
			<summary>
				<section label="PSYCHOTHERAPY" id="13">
					<fragment>The Depression Guideline Panel of the Agency for Health Care Policy and Research (AHCPR) concluded that for patients with major depression, the efficacy of cognitive therapy, behavioral therapy, and interpersonal therapy was 46, 55, and 52 percent, respectively.</fragment>
				</section>
			</summary>
			<category term="C0004933" scheme="gov.nih.nlm.semanticType.topp" label="behavioral therapy"/>
			<category term="C0009244" scheme="gov.nih.nlm.semanticType.topp" label="cognitive therapy"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H13"/>
			<id>169657</id>
			<summary>
				<section label="PSYCHOTHERAPY" id="13">
					<fragment>Interpersonal psychotherapy also appears to prevent recurrence of major depression, but not as effectively as medication.</fragment>
				</section>
			</summary>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="C0309872" scheme="gov.nih.nlm.semanticType.phsu" label="prevent"/>
			<category term="C0871787" scheme="gov.nih.nlm.semanticType.topp" label="Interpersonal psychotherapy"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H13"/>
			<id>169658</id>
			<summary>
				<section label="PSYCHOTHERAPY" id="13">
					<fragment>A 2007 representative survey of the United States general population found that among outpatients treated for unipolar depressive disorders, the proportion using psychotherapy alone was 6 percent, and the proportion using psychotherapy plus pharmacotherapy was 43 percent.</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H13"/>
			<id>169659</id>
			<summary>
				<section label="PSYCHOTHERAPY" id="13">
					<fragment>These percentages are conservative estimates, because they do not include patients treated for an adjustment disorder, many if not most of whom were probably suffering from a depressive syndrome.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H14"/>
			<id>169660</id>
			<summary>
				<section label="PHARMACOTHERAPY VERSUS PSYCHOTHERAPY" id="14">
					<fragment>Pharmacotherapy and manual-based psychotherapy are each efficacious for treating depression.</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="Pharmacotherapy"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H14"/>
			<id>169661</id>
			<summary>
				<section label="PHARMACOTHERAPY VERSUS PSYCHOTHERAPY" id="14">
					<fragment>Multiple randomized trials of patients in the primary care setting have found similar efficacy for each treatment, with no clear predictors of which treatment is best for individual patients.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H14"/>
			<id>169662</id>
			<summary>
				<section label="PHARMACOTHERAPY VERSUS PSYCHOTHERAPY" id="14">
					<fragment>Guidelines from the National Institute for Clinical Excellence (NICE) in the United Kingdom recommend psychotherapy as initial treatment for patients with mild depression, citing that the risk benefit ratio does not warrant pharmacotherapy for mild symptoms.</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H14"/>
			<id>169663</id>
			<summary>
				<section label="PHARMACOTHERAPY VERSUS PSYCHOTHERAPY" id="14">
					<fragment>The AHCPR Guideline Panel recommends drug therapy alone as the initial treatment for severely depressed patients, and either medication or psychotherapy for mild or moderate depression.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="C2003848" scheme="gov.nih.nlm.semanticType.topp" label="drug therapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H14"/>
			<id>169664</id>
			<summary>
				<section label="PHARMACOTHERAPY VERSUS PSYCHOTHERAPY" id="14">
					<fragment>The panel notes the importance of regular follow-up for patients treated with medication to assure compliance, assess response, and develop a supportive relationship with their clinician.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H15"/>
			<id>169665</id>
			<summary>
				<section label="Combined therapy" id="15">
					<fragment>A systematic review of 12 randomized trials comparing antidepressant treatment alone with antidepressant treatment combined with psychotherapy found a higher response rate for patients in the combination group (OR 1.86, 95% CI 1.38-2.52);</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H15"/>
			<id>169668</id>
			<summary>
				<section label="Combined therapy" id="15">
					<fragment>An earlier meta-analysis comparing psychotherapy alone with antidepressant plus psychotherapy found no significant difference in response rates for mild depression, but significantly increased response to combination therapy for more severe and recurrent depression.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C0556895" scheme="gov.nih.nlm.semanticType.topp" label="combination therapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H15"/>
			<id>169669</id>
			<summary>
				<section label="Combined therapy" id="15">
					<fragment>Most data favor combination therapy for patients with severe, chronic (more than two years) or recurrent symptoms.</fragment>
				</section>
			</summary>
			<category term="C0556895" scheme="gov.nih.nlm.semanticType.topp" label="combination therapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H16"/>
			<id>169670</id>
			<summary>
				<section label="ANTIDEPRESSANTS" id="16">
					<fragment>The major classes of drugs used to treat depression are considered "first generation" (monoamine oxidase inhibitors [MAOIs], and tricyclic antidepressants [TCAs]) and "second generation" (selective serotonin reuptake inhibitors [SSRIs], inhibitors of the reuptake of both serotonin and norepinephrine [SNRIs], and a few drugs with unique modes of action).</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0003290" scheme="gov.nih.nlm.semanticType.phsu" label="tricyclic antidepressants"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0360105" scheme="gov.nih.nlm.semanticType.phsu" label="selective serotonin reuptake inhibitors"/>
			<category term="C0629984" scheme="gov.nih.nlm.semanticType.strd" label="TCAs"/>
			<category term="C0758711" scheme="gov.nih.nlm.semanticType.orch" label="serotonin"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin reuptake inhibitors"/>
			<category term="C3653413" scheme="gov.nih.nlm.semanticType.phsu" label="monoamine oxidase inhibitors"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H17"/>
			<id>169671</id>
			<summary>
				<section label="Efficacy" id="17">
					<fragment>Antidepressants are beneficial for patients with unipolar major depression.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="Antidepressants"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H17"/>
			<id>169672</id>
			<summary>
				<section label="Efficacy" id="17">
					<fragment>In a meta-analysis of patient level data from 37 randomized trials (8477 patients with major depression) that compared either fluoxetine (modal dose 20 mg per day) or venlafaxine (modal dose range 75 to 150 mg per day) with placebo for six weeks, the primary findings included the following: Remission occurred in more patients who received active drug than placebo (43 versus 29 percent).</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0016365" scheme="gov.nih.nlm.semanticType.phsu" label="fluoxetine"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H17"/>
			<id>169674</id>
			<summary>
				<section label="Efficacy" id="17">
					<fragment>For patients with acute major depression in the primary care setting, antidepressants are associated with a 50 to 60 percent response rate.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H17"/>
			<id>169675</id>
			<summary>
				<section label="Efficacy" id="17">
					<fragment>In one multicenter "real-world" study (N = 2876 outpatients treated with citalopram), remission occurred in 28 percent, with a mean time to remission of seven weeks.</fragment>
				</section>
			</summary>
			<category term="C0008845" scheme="gov.nih.nlm.semanticType.phsu" label="citalopram"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H13163623"/>
			<id>169680</id>
			<summary>
				<section label="Mild major depression" id="13163623">
					<fragment>Antidepressants appear to be efficacious for unipolar major depression regardless of baseline severity, including patients with mild major depression.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="Antidepressants"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H13163623"/>
			<id>169681</id>
			<summary>
				<section label="Mild major depression" id="13163623">
					<fragment>The belief that pharmacotherapy benefits only severely ill patients stems in part from a meta-analysis of six randomized trials (718 patients, nearly all with major depression) that compared antidepressants with placebo;</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H13163623"/>
			<id>169682</id>
			<summary>
				<section label="Mild major depression" id="13163623">
					<fragment>results suggested a substantial benefit in very severe depression and little or no benefit in mild to moderate depression.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H13163623"/>
			<id>169683</id>
			<summary>
				<section label="Mild major depression" id="13163623">
					<fragment>However, a subsequent, larger meta-analysis of 37 randomized trials (8477 patients with major depression) that compared antidepressants with placebo found that remission at six weeks occurred in more: Mildly ill patients who received active drug than placebo (50 versus 37 percent).</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H13163623"/>
			<id>169684</id>
			<summary>
				<section label="Mild major depression" id="13163623">
					<fragment>Severely ill patients who received active drug than placebo (38 versus 25 percent).</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H13163623"/>
			<id>169686</id>
			<summary>
				<section label="Mild major depression" id="13163623">
					<fragment>Although the larger meta-analysis is more believable than the earlier one and we are confident that antidepressants are efficacious for unipolar major depression of mild severity, nevertheless, there are hundreds of other randomized trials that were not included in the two meta-analyses.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H13163623"/>
			<id>169687</id>
			<summary>
				<section label="Mild major depression" id="13163623">
					<fragment>An analysis that included these other trials would provide a better basis for evaluating the efficacy of pharmacotherapy in mild major depression.</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H18"/>
			<id>169689</id>
			<summary>
				<section label="Choice of antidepressant" id="18">
					<fragment>As an example, a meta-analysis of 93 randomized trials (&gt;20,000 patients with unipolar major depression) found treatment effects among second-generation antidepressants were comparable.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H18"/>
			<id>169695</id>
			<summary>
				<section label="Choice of antidepressant" id="18">
					<fragment>Multiple meta-analyses have evaluated comparisons of antidepressant medications.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H18"/>
			<id>169698</id>
			<summary>
				<section label="Choice of antidepressant" id="18">
					<fragment>Drugs were similar in regard to acute and maintenance phase response rates, impact on quality of life indices, and treatment response for associated symptoms (anxiety, insomnia, pain).</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="Drugs"/>
			<category term="C0391422" scheme="gov.nih.nlm.semanticType.orch" label="impact"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H18"/>
			<id>169705</id>
			<summary>
				<section label="Choice of antidepressant" id="18">
					<fragment>Two meta-analyses evaluated randomized trials of sertraline escitalopram versus other antidepressive agents.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressive"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C0074393" scheme="gov.nih.nlm.semanticType.phsu" label="sertraline"/>
			<category term="C1099456" scheme="gov.nih.nlm.semanticType.phsu" label="escitalopram"/>
			<category term="5" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H18"/>
			<id>169706</id>
			<summary>
				<section label="Choice of antidepressant" id="18">
					<fragment>The studies found both sertraline and escitalopram more effective than the comparator drugs, although it is uncertain if differences were clinically significant.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0074393" scheme="gov.nih.nlm.semanticType.phsu" label="sertraline"/>
			<category term="C1099456" scheme="gov.nih.nlm.semanticType.phsu" label="escitalopram"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H18"/>
			<id>169707</id>
			<summary>
				<section label="Choice of antidepressant" id="18">
					<fragment>In a meta-analysis of 28 randomized, controlled trials involving 5940 primary care patients with major depression, dysthymia, or mixed anxiety depression, newer antidepressants (including selective serotonin reuptake inhibitors, serotonin/norepinephrine reuptake inhibitors, reversible inhibitors of monoamine oxidase, and dopamine antagonists) resulted in higher rates of response than placebo (RR 1.6, 95% CI 1.2-2.1), but rates were similar to those for tricyclic agents.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0017313" scheme="gov.nih.nlm.semanticType.hlca" label="care patients"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C0162758" scheme="gov.nih.nlm.semanticType.phsu" label="reuptake inhibitors, serotonin"/>
			<category term="C0360105" scheme="gov.nih.nlm.semanticType.phsu" label="selective serotonin reuptake inhibitors"/>
			<category term="C0758711" scheme="gov.nih.nlm.semanticType.orch" label="serotonin"/>
			<category term="C1319313" scheme="gov.nih.nlm.semanticType.phsu" label="norepinephrine reuptake inhibitors"/>
			<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin reuptake inhibitors"/>
			<category term="C3252015" scheme="gov.nih.nlm.semanticType.phsu" label="RR"/>
			<category term="C3537213" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin/norepinephrine reuptake inhibitors"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H18"/>
			<id>169708</id>
			<summary>
				<section label="Choice of antidepressant" id="18">
					<fragment>A systematic review of 55 randomized, controlled trials of MAO inhibitors versus tricyclic antidepressants found that MAO inhibitors were less effective for severe depressive disorders but possibly more effective in atypical depressive disorders.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0003290" scheme="gov.nih.nlm.semanticType.phsu" label="tricyclic antidepressants"/>
			<category term="C3540022" scheme="gov.nih.nlm.semanticType.phsu" label="MAO inhibitors"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H18"/>
			<id>169709</id>
			<summary>
				<section label="Choice of antidepressant" id="18">
					<fragment>A systematic review of 46 randomized controlled trials and 24 observational studies of head-to-head comparisons between second-generation antidepressants (SSRIs, bupropion, duloxetine, mirtazapine, and venlafaxine) concluded that there were no significant differences in efficacy or tolerability among these drugs.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0049506" scheme="gov.nih.nlm.semanticType.phsu" label="mirtazapine"/>
			<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
			<category term="C0085208" scheme="gov.nih.nlm.semanticType.phsu" label="bupropion"/>
			<category term="C0245561" scheme="gov.nih.nlm.semanticType.phsu" label="duloxetine"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H18"/>
			<id>169710</id>
			<summary>
				<section label="Choice of antidepressant" id="18">
					<fragment>By contrast, a meta-analysis of 12 randomized trials (2626 patients with major depression) found that response occurred in significantly more patients who received mirtazapine than an SSRI (OR 1.2).</fragment>
				</section>
			</summary>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C0049506" scheme="gov.nih.nlm.semanticType.phsu" label="mirtazapine"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRI"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H18"/>
			<id>169711</id>
			<summary>
				<section label="Choice of antidepressant" id="18">
					<fragment>There is limited evidence that tricyclics may be preferred for more severely depressed patients.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H18"/>
			<id>169712</id>
			<summary>
				<section label="Choice of antidepressant" id="18">
					<fragment>A meta-analysis of 25 randomized controlled trials for treatment of hospitalized, depressed patients found tricyclics were significantly more efficacious compared to SSRIs, but the clinical difference was small.</fragment>
				</section>
			</summary>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H18"/>
			<id>169713</id>
			<summary>
				<section label="Choice of antidepressant" id="18">
					<fragment>The role of tricyclic antidepressants in treating major depression is discussed separately.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0003290" scheme="gov.nih.nlm.semanticType.phsu" label="tricyclic antidepressants"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H18"/>
			<id>169714</id>
			<summary>
				<section label="Choice of antidepressant" id="18">
					<fragment>Patients who have been successfully treated with a well-tolerated drug in the past should resume that agent if depression recurs.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H19"/>
			<id>169719</id>
			<summary>
				<section label="Side effects" id="19">
					<fragment>Prior to prescribing an antidepressant, potential interactions with a patient's preexisting medication regimen should be checked using the drug interaction database available through UpToDate or in other programs.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H19"/>
			<id>169720</id>
			<summary>
				<section label="Side effects" id="19">
					<fragment>Specific antidepressants may cause more weight gain than others.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H19"/>
			<id>169721</id>
			<summary>
				<section label="Side effects" id="19">
					<fragment>A systematic review of second-generation antidepressants evaluated 203 studies and found that mirtazapine and paroxetine were associated more weight gain than other drugs such as fluoxetine, sertraline, trazodone, and venlafaxine.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0016365" scheme="gov.nih.nlm.semanticType.phsu" label="fluoxetine"/>
			<category term="C0040805" scheme="gov.nih.nlm.semanticType.phsu" label="trazodone"/>
			<category term="C0049506" scheme="gov.nih.nlm.semanticType.phsu" label="mirtazapine"/>
			<category term="C0070122" scheme="gov.nih.nlm.semanticType.phsu" label="paroxetine"/>
			<category term="C0074393" scheme="gov.nih.nlm.semanticType.phsu" label="sertraline"/>
			<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H19"/>
			<id>169722</id>
			<summary>
				<section label="Side effects" id="19">
					<fragment>A related issue is the risk of diabetes.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H19"/>
			<id>169724</id>
			<summary>
				<section label="Side effects" id="19">
					<fragment>A cohort study of 1000 people 65 years and older, followed prospectively for up to ten years, found that depressed individuals were more than twice as likely to develop diabetes compared to those without depression, regardless of antidepressant treatment (hazard ratio 2.3, 95% CI 1.3-4.1).</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H19"/>
			<id>169725</id>
			<summary>
				<section label="Side effects" id="19">
					<fragment>In addition, specific antidepressants or antidepressants as a class of medications may possibly be associated with an increased risk of diabetes.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H19"/>
			<id>169726</id>
			<summary>
				<section label="Side effects" id="19">
					<fragment>A nested case-control study found that among approximately 166,000 patients with depression and no sign of diabetes, long-term use (&gt;24 months) of an antidepressant in moderate to high doses was associated with a significantly increased risk of diabetes (incidence rate ratio 1.8, 95% CI 1.4-2.5).</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
			<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H21"/>
			<id>169734</id>
			<summary>
				<section label="SNRIs" id="21">
					<fragment>SNRIs (venlafaxine, duloxetine, and desvenlafaxine) have many similar side effects to SSRIs because of the serotonergic effect of these medications.</fragment>
				</section>
			</summary>
			<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
			<category term="C0245561" scheme="gov.nih.nlm.semanticType.phsu" label="duloxetine"/>
			<category term="C1880288" scheme="gov.nih.nlm.semanticType.phsu" label="desvenlafaxine"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H21"/>
			<id>169737</id>
			<summary>
				<section label="SNRIs" id="21">
					<fragment>Venlafaxine may cause hypertension at dosages of 300 mg or greater.</fragment>
				</section>
			</summary>
			<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="Venlafaxine"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H21"/>
			<id>169739</id>
			<summary>
				<section label="SNRIs" id="21">
					<fragment>Duloxetine may slightly impair glycemic control in patients with diabetes, and has been associated with fatal liver failure in patients with preexisting liver disease and is contraindicated in this subgroup of patients.</fragment>
				</section>
			</summary>
			<category term="C0245561" scheme="gov.nih.nlm.semanticType.phsu" label="Duloxetine"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H23"/>
			<id>169745</id>
			<summary>
				<section label="MAO inhibitors" id="23">
					<fragment>The hypertensive reaction is dose-dependent and can be exacerbated if the patient is also taking a sympathomimetic drug.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0039052" scheme="gov.nih.nlm.semanticType.phsu" label="sympathomimetic drug"/>
			<category term="C1875809" scheme="gov.nih.nlm.semanticType.phsu" label="sympathomimetic"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H24"/>
			<id>169747</id>
			<summary>
				<section label="Other antidepressants" id="24">
					<fragment>Bupropion has significantly fewer adverse effects related to sexual dysfunction than SSRIs, and may be particularly effective for patients who are lethargic.</fragment>
				</section>
			</summary>
			<category term="C0085208" scheme="gov.nih.nlm.semanticType.phsu" label="Bupropion"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H24"/>
			<id>169749</id>
			<summary>
				<section label="Other antidepressants" id="24">
					<fragment>Mirtazapine, a mixed serotonin-norepinephrine antagonist, is sedating.</fragment>
				</section>
			</summary>
			<category term="C0049506" scheme="gov.nih.nlm.semanticType.phsu" label="Mirtazapine"/>
			<category term="C0758711" scheme="gov.nih.nlm.semanticType.orch" label="serotonin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H24"/>
			<id>169750</id>
			<summary>
				<section label="Other antidepressants" id="24">
					<fragment>It has efficacy equivalent to SSRIs and may have a role in the treatment of patients with insomnia and depression.</fragment>
				</section>
			</summary>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
			<category term="5" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H24"/>
			<id>169751</id>
			<summary>
				<section label="Other antidepressants" id="24">
					<fragment>Mirtazapine causes more weight gain than SSRIs.</fragment>
				</section>
			</summary>
			<category term="C0049506" scheme="gov.nih.nlm.semanticType.phsu" label="Mirtazapine"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H25"/>
			<id>169761</id>
			<summary>
				<section label="Dosage" id="25">
					<fragment>In the Sequential Treatment Alternatives to Relieve Depression trial (STAR*D) involving outpatient treatment for 2876 patients with major depression, 80 percent of whom had chronic depression with recurrent episodes, the average dose of citalopram needed to achieve remission was 42 mg daily.</fragment>
				</section>
			</summary>
			<category term="C0008845" scheme="gov.nih.nlm.semanticType.phsu" label="citalopram"/>
			<category term="C1259875" scheme="gov.nih.nlm.semanticType.phsu" label="STAR"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H25"/>
			<id>169762</id>
			<summary>
				<section label="Dosage" id="25">
					<fragment>However, the United States Food and Drug Administration issued warnings that citalopram causes dose-dependent QT interval prolongation that can lead to arrhythmias, and thus recommends that the maximum dose should not exceed 40 mg per day.</fragment>
				</section>
			</summary>
			<category term="C0008845" scheme="gov.nih.nlm.semanticType.phsu" label="citalopram"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="Drug"/>
			<category term="C3469597" scheme="gov.nih.nlm.semanticType.hlca" label="Drug Administration"/>
			<category term="C3540798" scheme="gov.nih.nlm.semanticType.imft" label="Food"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H25"/>
			<id>169763</id>
			<summary>
				<section label="Dosage" id="25">
					<fragment>Additional information about the citalopram warnings and cardiac effects of SSRIs is discussed separately.</fragment>
				</section>
			</summary>
			<category term="C0008845" scheme="gov.nih.nlm.semanticType.phsu" label="citalopram"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H26"/>
			<id>169772</id>
			<summary>
				<section label="up" id="26">
					<fragment>Treatment time to maximal response may be six weeks or longer: In a study of 182 outpatients with major depression who had a sustained acute response to fluoxetine therapy, the probability of response was 56 percent at two weeks, 81 percent at four weeks, and 90 percent at six weeks.</fragment>
				</section>
			</summary>
			<category term="C0016365" scheme="gov.nih.nlm.semanticType.phsu" label="fluoxetine"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H26"/>
			<id>169774</id>
			<summary>
				<section label="up" id="26">
					<fragment>In the multicenter STAR*D trial, 56 percent of those who responded (more than 50 percent improvement) did so at or after eight weeks of treatment with citalopram.</fragment>
				</section>
			</summary>
			<category term="C0008845" scheme="gov.nih.nlm.semanticType.phsu" label="citalopram"/>
			<category term="C1259875" scheme="gov.nih.nlm.semanticType.phsu" label="STAR"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H26"/>
			<id>169782</id>
			<summary>
				<section label="up" id="26">
					<fragment>After two SSRIs have been ineffective, antidepressants from a different class (such as bupropion or venlafaxine) should be chosen.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
			<category term="C0085208" scheme="gov.nih.nlm.semanticType.phsu" label="bupropion"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H26"/>
			<id>169783</id>
			<summary>
				<section label="up" id="26">
					<fragment>Adherence may be further enhanced by facilitating telephone access to the clinician for patient questions about side effects.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H26"/>
			<id>169784</id>
			<summary>
				<section label="up" id="26">
					<fragment>Outcomes and adherence can also be improved with the use of allied health professionals to proactively check on therapeutic response, side effects, and adherence, and to schedule return visits for patients with persistent symptoms.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H27"/>
			<id>169785</id>
			<summary>
				<section label="Duration of treatment" id="27">
					<fragment>Antidepressant medication generally should be taken for a minimum of six to nine months after a first episode of depression.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="Antidepressant"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H27"/>
			<id>169789</id>
			<summary>
				<section label="Duration of treatment" id="27">
					<fragment>Premature discontinuation of antidepressant medication occurs commonly.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="C0457454" scheme="gov.nih.nlm.semanticType.hlca" label="discontinuation"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H27"/>
			<id>169791</id>
			<summary>
				<section label="Duration of treatment" id="27">
					<fragment>In the STAR*D trial, slightly over one quarter of patients treated with citalopram as initial therapy for nonpsychotic major depression discontinued their medication for non-medical reasons within 14 weeks of initiation.</fragment>
				</section>
			</summary>
			<category term="C0008845" scheme="gov.nih.nlm.semanticType.phsu" label="citalopram"/>
			<category term="C1259875" scheme="gov.nih.nlm.semanticType.phsu" label="STAR"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H27"/>
			<id>169795</id>
			<summary>
				<section label="Duration of treatment" id="27">
					<fragment>Patients who have depression in the setting of known precipitants such as psychosocial stresses, bereavement, or loss should continue drug therapy until a significant change in adaptation to those factors has been accomplished, and for a minimum of six months.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C2003848" scheme="gov.nih.nlm.semanticType.topp" label="drug therapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H27"/>
			<id>169799</id>
			<summary>
				<section label="Duration of treatment" id="27">
					<fragment>One study of 251 patients who were being treated by primary care physicians found that 37 percent reported a relapse within 12 months of stopping drug treatment.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0332293" scheme="gov.nih.nlm.semanticType.topp" label="treated by"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H27"/>
			<id>169802</id>
			<summary>
				<section label="Duration of treatment" id="27">
					<fragment>A second prospective study followed 366 patients with depression (median follow-up 10 years) and found that 64 percent who initially recovered from major depression had a recurrence.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H27"/>
			<id>169804</id>
			<summary>
				<section label="Duration of treatment" id="27">
					<fragment>Maintenance antidepressant therapy can decrease the rate of relapse.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="C1096649" scheme="gov.nih.nlm.semanticType.topp" label="antidepressant therapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H27"/>
			<id>169807</id>
			<summary>
				<section label="Duration of treatment" id="27">
					<fragment>Maintenance therapy also appears to be effective in elderly patients.</fragment>
				</section>
			</summary>
			<category term="C0677908" scheme="gov.nih.nlm.semanticType.topp" label="Maintenance therapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H27"/>
			<id>169808</id>
			<summary>
				<section label="Duration of treatment" id="27">
					<fragment>Based upon similar studies, the AHCPR Guideline Panel recommended maintenance therapy for patients with a history of three or more depressive episodes and for those with two previous episodes plus risk factors that would increase the risk of recurrence.</fragment>
				</section>
			</summary>
			<category term="C0677908" scheme="gov.nih.nlm.semanticType.topp" label="maintenance therapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H27"/>
			<id>169809</id>
			<summary>
				<section label="Duration of treatment" id="27">
					<fragment>Patients with double depression (dysthymia and major depression) should also be considered for maintenance treatment.</fragment>
				</section>
			</summary>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H28"/>
			<id>169810</id>
			<summary>
				<section label="OTHER DRUGS" id="28">
					<fragment>Some of the medications used in augmentation therapy for resistant depression may also be appropriate for consideration earlier in therapy in specific patients.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H28"/>
			<id>169811</id>
			<summary>
				<section label="OTHER DRUGS" id="28">
					<fragment>These patients are most appropriately treated by a psychiatrist who can collaborate with the primary care provider.</fragment>
				</section>
			</summary>
			<category term="C0332293" scheme="gov.nih.nlm.semanticType.topp" label="treated by"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H29"/>
			<id>169812</id>
			<summary>
				<section label="Antipsychotics" id="29">
					<fragment>Adjunctive treatment with the second-generation antipsychotics aripiprazole, olanzapine, quetiapine, or risperidone is efficacious for unipolar, nonpsychotic major depression that has not responded to antidepressant monotherapy.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="C0040615" scheme="gov.nih.nlm.semanticType.phsu" label="antipsychotics"/>
			<category term="C0073393" scheme="gov.nih.nlm.semanticType.phsu" label="risperidone"/>
			<category term="C0123091" scheme="gov.nih.nlm.semanticType.phsu" label="quetiapine"/>
			<category term="C0171023" scheme="gov.nih.nlm.semanticType.phsu" label="olanzapine"/>
			<category term="C0299792" scheme="gov.nih.nlm.semanticType.phsu" label="aripiprazole"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H30"/>
			<id>169814</id>
			<summary>
				<section label="Mood stabilizers" id="30">
					<fragment>Patients with mood swings and a strong family history of bipolar disorder may meet criteria for bipolar II disorder, and should be treated with a mood stabilizing drug such as lithium, carbamazepine, valproate, or lamotrigine.</fragment>
				</section>
			</summary>
			<category term="C0006949" scheme="gov.nih.nlm.semanticType.phsu" label="carbamazepine"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0064636" scheme="gov.nih.nlm.semanticType.phsu" label="lamotrigine"/>
			<category term="C0080356" scheme="gov.nih.nlm.semanticType.phsu" label="valproate"/>
			<category term="C0619701" scheme="gov.nih.nlm.semanticType.horm" label="II"/>
			<category term="C0628655" scheme="gov.nih.nlm.semanticType.phsu" label="meet"/>
			<category term="C1276998" scheme="gov.nih.nlm.semanticType.phsu" label="mood stabilizing drug"/>
			<category term="7" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H30"/>
			<id>169817</id>
			<summary>
				<section label="Mood stabilizers" id="30">
					<fragment>Use of lithium to treat unipolar depression is discussed elsewhere.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H31"/>
			<id>169818</id>
			<summary>
				<section label="Anxiolytics" id="31">
					<fragment>Anxiolytics can be used as adjunctive treatment with an antidepressant, particularly for major depression that includes symptoms of anxiety (eg, ruminative thoughts, worrying, and panic attacks), insomnia, or psychomotor agitation.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="C0040616" scheme="gov.nih.nlm.semanticType.phsu" label="Anxiolytics"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H31"/>
			<id>169820</id>
			<summary>
				<section label="Anxiolytics" id="31">
					<fragment>Treatment for anxiety disorders are discussed separately.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H32"/>
			<id>169824</id>
			<summary>
				<section label="St. John&apos;s wort" id="32">
					<fragment>John's wort suggest that it is more effective than placebo and equivalent to tricyclic antidepressants and SSRIs in the short-term treatment of depression.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0003290" scheme="gov.nih.nlm.semanticType.phsu" label="tricyclic antidepressants"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H32"/>
			<id>169825</id>
			<summary>
				<section label="St. John&apos;s wort" id="32">
					<fragment>However, studies in the US do not support its efficacy in the treatment of severe depression, and further research in mild depression is ongoing.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H32"/>
			<id>169827</id>
			<summary>
				<section label="St. John&apos;s wort" id="32">
					<fragment>Patients with mild acute depression can be offered St.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H32"/>
			<id>169830</id>
			<summary>
				<section label="St. John&apos;s wort" id="32">
					<fragment>John's wort not be used in patients with significant major depression.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H32"/>
			<id>169833</id>
			<summary>
				<section label="St. John&apos;s wort" id="32">
					<fragment>Concomitant use with the selective serotonin reuptake inhibitors (SSRIs) may lead to the "serotonin syndrome," characterized by agitation, hyperthermia, diaphoresis, tachycardia, and neuromuscular disturbances including rigidity.</fragment>
				</section>
			</summary>
			<category term="C0360105" scheme="gov.nih.nlm.semanticType.phsu" label="selective serotonin reuptake inhibitors"/>
			<category term="C0758711" scheme="gov.nih.nlm.semanticType.orch" label="serotonin"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin reuptake inhibitors"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H33"/>
			<id>169836</id>
			<summary>
				<section label="Psychostimulants" id="33">
					<fragment>Psychostimulants (dextroamphetamine, methylphenidate, methylamphetamine, and pemoline) and a novel acting agent, modafinil, have been evaluated for both the initial treatment of depression as well as for use as adjunctive therapy in the treatment of resistant depression.</fragment>
				</section>
			</summary>
			<category term="C0011812" scheme="gov.nih.nlm.semanticType.phsu" label="dextroamphetamine"/>
			<category term="C0025810" scheme="gov.nih.nlm.semanticType.phsu" label="methylphenidate"/>
			<category term="C0030800" scheme="gov.nih.nlm.semanticType.phsu" label="pemoline"/>
			<category term="C0066677" scheme="gov.nih.nlm.semanticType.phsu" label="modafinil"/>
			<category term="C0304403" scheme="gov.nih.nlm.semanticType.phsu" label="Psychostimulants"/>
			<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
			<category term="7" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H33"/>
			<id>169838</id>
			<summary>
				<section label="Psychostimulants" id="33">
					<fragment>One study found no difference in symptoms, comparing with treatment with modafinil or placebo.</fragment>
				</section>
			</summary>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0066677" scheme="gov.nih.nlm.semanticType.phsu" label="modafinil"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H35"/>
			<id>169841</id>
			<summary>
				<section label="DHEA" id="35">
					<fragment>Oral supplementation with the adrenal androgen dehydroepiandrosterone (DHEA) may be of some benefit in patients with depression.</fragment>
				</section>
			</summary>
			<category term="C0002844" scheme="gov.nih.nlm.semanticType.horm" label="androgen"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H35"/>
			<id>169842</id>
			<summary>
				<section label="DHEA" id="35">
					<fragment>In a six week crossover trial in 46 patients with major or minor depression who were not treated with an antidepressant medication, patients had significantly lower depression scores while receiving DHEA (30 mg three times daily for three weeks followed by 150 mg three times daily for three weeks) than at baseline or while receiving placebo.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H35"/>
			<id>169844</id>
			<summary>
				<section label="DHEA" id="35">
					<fragment>There is limited evidence on the safety or long-term effectiveness of DHEA and we do not currently recommend it for the treatment of depression.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H35"/>
			<id>169845</id>
			<summary>
				<section label="DHEA" id="35">
					<fragment>Acne and hirsutism have both been described in women participating in longer-term trials of DHEA.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H36"/>
			<id>169846</id>
			<summary>
				<section label="Other" id="36">
					<fragment>Other antiglucocorticoid treatments have also been evaluated for depression.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H36"/>
			<id>169847</id>
			<summary>
				<section label="Other" id="36">
					<fragment>A meta-analysis of five trials in patients with non-psychotic depression found that treatment with one of several antiglucocorticoids (mifepristone, ketoconazole, metyrapone, or DHEA), was associated with a significantly greater response compared to placebo (RR 0.72, 95% CI 0.56-0.91).</fragment>
				</section>
			</summary>
			<category term="C0025876" scheme="gov.nih.nlm.semanticType.horm" label="metyrapone"/>
			<category term="C0026088" scheme="gov.nih.nlm.semanticType.phsu" label="mifepristone"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
			<category term="C3252015" scheme="gov.nih.nlm.semanticType.phsu" label="RR"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H37"/>
			<id>169849</id>
			<summary>
				<section label="Triiodothyronine" id="37">
					<fragment>Triiodothyronine (T3) has been used as augmentation therapy in patients with major depression who have not responded to initial treatment with antidepressant monotherapy, and has been combined with antidepressants at the onset of treatment to accelerate or enhance response.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="C0041014" scheme="gov.nih.nlm.semanticType.horm" label="Triiodothyronine"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H21630324"/>
			<id>169850</id>
			<summary>
				<section label="Creatine" id="21630324">
					<fragment>Creatine may possibly be useful as short term, adjunctive treatment with antidepressants to treat unipolar major depression.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H21630324"/>
			<id>169851</id>
			<summary>
				<section label="Creatine" id="21630324">
					<fragment>An eight-week randomized trial compared creatine monohydrate (5 g per day) plus escitalopram (10 to 20 mg per day) with placebo plus escitalopram in 52 women with unipolar major depression (mostly first episode).</fragment>
				</section>
			</summary>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C1099456" scheme="gov.nih.nlm.semanticType.phsu" label="escitalopram"/>
			<category term="C1572759" scheme="gov.nih.nlm.semanticType.orch" label="monohydrate"/>
			<category term="6" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H21630324"/>
			<id>169853</id>
			<summary>
				<section label="Creatine" id="21630324">
					<fragment>Remission occurred in more patients who received adjunctive creatine than placebo (52 versus 26 percent).</fragment>
				</section>
			</summary>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H38"/>
			<id>169856</id>
			<summary>
				<section label="Investigational drugs" id="38">
					<fragment>Potential drug interventions for depression under investigation include substance P and antagonists of corticotropin releasing factors and glucocorticoid receptors.</fragment>
				</section>
			</summary>
			<category term="C0010132" scheme="gov.nih.nlm.semanticType.horm" label="corticotropin releasing factors"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0050605" scheme="gov.nih.nlm.semanticType.aapp" label="corticotropin"/>
			<category term="C1261322" scheme="gov.nih.nlm.semanticType.hlca" label="investigation"/>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoid"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H39"/>
			<id>169858</id>
			<summary>
				<section label="PSYCHIATRIC CONSULTATION" id="39">
					<fragment>Data from the STAR*D trial indicate that outcomes for initial therapy of depression are the same when identical care is provided either in primary care or psychiatric specialty settings.</fragment>
				</section>
			</summary>
			<category term="C1259875" scheme="gov.nih.nlm.semanticType.phsu" label="STAR"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H40"/>
			<id>169865</id>
			<summary>
				<section label="Collaborative care" id="40">
					<fragment>Collaborative care programs that involve enhanced patient education, integration of psychiatric visits into primary care treatment, and use of non-physician mental health professionals or depression care managers can significantly enhance depression outcomes compared with usual care.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H524936"/>
			<id>169890</id>
			<summary>
				<section label="DYSTHYMIC DISORDER" id="524936">
					<fragment>however, symptoms are not as numerous as in major depression.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H524936"/>
			<id>169892</id>
			<summary>
				<section label="DYSTHYMIC DISORDER" id="524936">
					<fragment>Antidepressants are effective for dysthymic disorder.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="Antidepressants"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H524936"/>
			<id>169893</id>
			<summary>
				<section label="DYSTHYMIC DISORDER" id="524936">
					<fragment>A meta-analysis of 9 randomized trials (1454 patients with dysthymic disorder) found that response (reduction of baseline depression rating scale score &gt;=50 percent) occurred in significantly more patients who received an antidepressant than placebo (52 versus 30 percent).</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H524936"/>
			<id>169896</id>
			<summary>
				<section label="DYSTHYMIC DISORDER" id="524936">
					<fragment>The trials that have examined the use of interpersonal therapy in dysthymic disorder are discussed separately.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H44"/>
			<id>169897</id>
			<summary>
				<section label="Elderly" id="44">
					<fragment>Treatment of depression in older adults is discussed separately.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H45"/>
			<id>169898</id>
			<summary>
				<section label="Pregnancy" id="45">
					<fragment>Treatment of depression in pregnant women is discussed separately.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H46"/>
			<id>169904</id>
			<summary>
				<section label="Depression in medical illness" id="46">
					<fragment>Depression in patients with other medical illnesses is common and an important cause of morbidity.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H46"/>
			<id>169905</id>
			<summary>
				<section label="Depression in medical illness" id="46">
					<fragment>Depression in patients with chronic medical illness is associated with increased physical symptoms;</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H46"/>
			<id>169912</id>
			<summary>
				<section label="Depression in medical illness" id="46">
					<fragment>symptoms such as a low mood and lack of energy may be due to the physical illness and/or to depression.</fragment>
				</section>
			</summary>
			<category term="C2930737" scheme="gov.nih.nlm.semanticType.phsu" label="energy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H351404"/>
			<id>169914</id>
			<summary>
				<section label="Interventions" id="351404">
					<fragment>Antidepressants appear to be effective and safe in patients with medical illness.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="Antidepressants"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H351404"/>
			<id>169915</id>
			<summary>
				<section label="Interventions" id="351404">
					<fragment>In a meta-analysis of 18 efficacy studies including 838 patients with a variety of physical diseases, antidepressant therapy resulted in greater improvement in depressive symptoms than either placebo or no therapy.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C1096649" scheme="gov.nih.nlm.semanticType.topp" label="antidepressant therapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H351404"/>
			<id>169916</id>
			<summary>
				<section label="Interventions" id="351404">
					<fragment>A subsequent meta-analysis of 25 randomized trials, which included 2338 patients with unipolar major depression and various comorbid general medical illnesses, found that response (50 percent or more reduction in baseline depression symptoms) occurred in more patients who received an antidepressant compared with placebo (risk ratio 1.4, 95% CI 1.3-1.6).</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
			<category term="C3540763" scheme="gov.nih.nlm.semanticType.phsu" label="various"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H351404"/>
			<id>169917</id>
			<summary>
				<section label="Interventions" id="351404">
					<fragment>Large trials have found that antidepressants were effective in patients with diabetes and with coronary artery disease.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0397581" scheme="gov.nih.nlm.semanticType.topp" label="artery"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H351404"/>
			<id>169918</id>
			<summary>
				<section label="Interventions" id="351404">
					<fragment>Venlafaxine, bupropion, and duloxetine have been shown to reduce neuropathic pain in patients without depression, and would be preferred drug choices in depressed patients with chronic pain to both alleviate pain symptoms and treat the underlying depression.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="Venlafaxine"/>
			<category term="C0085208" scheme="gov.nih.nlm.semanticType.phsu" label="bupropion"/>
			<category term="C0245561" scheme="gov.nih.nlm.semanticType.phsu" label="duloxetine"/>
			<category term="6" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H351404"/>
			<id>169919</id>
			<summary>
				<section label="Interventions" id="351404">
					<fragment>In a randomized trial of 250 patients with concurrent depression and musculoskeletal pain, a stepped care approach of initial optimization of antidepressant treatment followed by a supervised pain self-management program over 12 weeks significantly improved severity scores for both depression and pain at 6 and 12 month follow-up, compared to usual care.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H351404"/>
			<id>169921</id>
			<summary>
				<section label="Interventions" id="351404">
					<fragment>While treatment of depression in patients with medical illness is effective in improving depression, it is unclear whether such treatment improves medical outcomes.</fragment>
				</section>
			</summary>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H351404"/>
			<id>169922</id>
			<summary>
				<section label="Interventions" id="351404">
					<fragment>There have been conflicting results from clinical trials of treating depression in diabetes and after stroke, and treating depression after acute coronary syndromes has not been shown to improve mortality.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H351404"/>
			<id>169923</id>
			<summary>
				<section label="Interventions" id="351404">
					<fragment>Improvement in medical outcomes may depend upon the specific intervention that is used.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H351404"/>
			<id>169924</id>
			<summary>
				<section label="Interventions" id="351404">
					<fragment>A single-blind, randomized trial, involving 214 patients with depression and poorly controlled diabetes, coronary heart disease, or both, compared treatment as usual with collaborative care, in which a medically supervised nurse provided guideline-based care for managing depression and the medical illness.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H351404"/>
			<id>169926</id>
			<summary>
				<section label="Interventions" id="351404">
					<fragment>For patients with chronic medical illnesses, exercise can reduce depressive symptoms.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H351404"/>
			<id>169927</id>
			<summary>
				<section label="Interventions" id="351404">
					<fragment>A meta-analysis of 90 randomized trials examined the effects of exercise training on depressive symptoms (which did not meet criteria for a depressive disorder) in 10,534 patients with chronic medical illnesses such as cardiovascular disease, chronic pain and fibromyalgia, cancer, spinal cord injury, multiple sclerosis, and chronic obstructive pulmonary disease.</fragment>
				</section>
			</summary>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C0628655" scheme="gov.nih.nlm.semanticType.phsu" label="meet"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H48"/>
			<id>169930</id>
			<summary>
				<section label="Exercise" id="48">
					<fragment>A number of observational studies with methodologic flaws suggest that aerobic exercise is superior to no treatment for patients with major depression.</fragment>
				</section>
			</summary>
			<category term="C0001701" scheme="gov.nih.nlm.semanticType.topp" label="aerobic exercise"/>
			<category term="7" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H48"/>
			<id>169931</id>
			<summary>
				<section label="Exercise" id="48">
					<fragment>A meta-analysis of 25 randomized trials evaluating exercise, compared to standard treatment or no treatment, in patients with depression found that most trials did not analyze by intention to treat, and used inadequate randomization techniques.</fragment>
				</section>
			</summary>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="5" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H48"/>
			<id>169934</id>
			<summary>
				<section label="Exercise" id="48">
					<fragment>Patients who received antidepressant therapy alone had the fastest initial response, but there was no difference between groups at 16 weeks or 10 months.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="C1096649" scheme="gov.nih.nlm.semanticType.topp" label="antidepressant therapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H49"/>
			<id>169937</id>
			<summary>
				<section label="Light therapy" id="49">
					<fragment>A meta-analysis of randomized trials found that bright light therapy in nonseasonal depression was associated with a significant reduction in depression symptom severity with effect sizes similar to those in pharmacotherapy trials.</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0031765" scheme="gov.nih.nlm.semanticType.topp" label="light therapy"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H51"/>
			<id>169951</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="51">
					<fragment>The goal of treatment for depression should be remission of symptoms;</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H51"/>
			<id>169953</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="51">
					<fragment>There are no clear predictors whether psychotherapy or pharmacotherapy is best for individual patients with mild to moderate major depression.</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H51"/>
			<id>169954</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="51">
					<fragment>We recommend that patients with mild to moderate major depression begin either psychotherapy or pharmacotherapy as initial therapy.</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H51"/>
			<id>169955</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="51">
					<fragment>We recommend pharmacotherapy as initial therapy for patients with more severe depression.</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H51"/>
			<id>169956</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="51">
					<fragment>We recommend a combination of pharmacotherapy and psychotherapy for patients with severe chronic (more than two years) or frequently recurrent depression.</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H51"/>
			<id>169957</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="51">
					<fragment>The major classes of drugs used to treat depression are the selective serotonin reuptake inhibitors (SSRIs), inhibitors of the reuptake of both serotonin and norepinephrine (SNRIs), monoamine oxidase inhibitors (MAOIs), and tricyclic antidepressants (TCAs).</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0003290" scheme="gov.nih.nlm.semanticType.phsu" label="tricyclic antidepressants"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0360105" scheme="gov.nih.nlm.semanticType.phsu" label="selective serotonin reuptake inhibitors"/>
			<category term="C0629984" scheme="gov.nih.nlm.semanticType.strd" label="TCAs"/>
			<category term="C0758711" scheme="gov.nih.nlm.semanticType.orch" label="serotonin"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin reuptake inhibitors"/>
			<category term="C3653413" scheme="gov.nih.nlm.semanticType.phsu" label="monoamine oxidase inhibitors"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H51"/>
			<id>169959</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="51">
					<fragment>Patients who have been successfully treated with a well-tolerated drug in the past should resume that agent if depression recurs.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H51"/>
			<id>169969</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="51">
					<fragment>We suggest that patients who have a partial response to an antidepressant at eight weeks be given options of either augmentation (with bupropion or buspirone) or change to another antidepressant.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="C0006462" scheme="gov.nih.nlm.semanticType.phsu" label="buspirone"/>
			<category term="C0085208" scheme="gov.nih.nlm.semanticType.phsu" label="bupropion"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H51"/>
			<id>169972</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="51">
					<fragment>We recommend that antidepressant medication be taken for at least six to nine months after a first episode of depression.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H51"/>
			<id>169974</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="51">
					<fragment>We suggest that maintenance therapy (more than two years of treatment) be given to patients with a history of three or more depressive episodes, for those with dysthymia and major depression, and for those with two previous episodes plus risk factors that would increase the risk of recurrence.</fragment>
				</section>
			</summary>
			<category term="C0677908" scheme="gov.nih.nlm.semanticType.topp" label="maintenance therapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H51"/>
			<id>169975</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="51">
					<fragment>It may be reasonable to consider maintenance therapy for adults who have even one major recurrence.</fragment>
				</section>
			</summary>
			<category term="C0677908" scheme="gov.nih.nlm.semanticType.topp" label="maintenance therapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H51"/>
			<id>169976</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="51">
					<fragment>Anxious patients and those with difficulty sleeping can be offered a short acting benzodiazepine for no more than two weeks along with psychotherapy and/or antidepressant drug therapy.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="C0963297" scheme="gov.nih.nlm.semanticType.orch" label="benzodiazepine"/>
			<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
			<category term="C2003848" scheme="gov.nih.nlm.semanticType.topp" label="drug therapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H51"/>
			<id>169978</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="51">
					<fragment>John's wort . Patients with mild acute depression who nonetheless choose St.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H433147300"/>
			<id>209389</id>
			<summary>
				<section label="DEFINITION OF UNIPOLAR MAJOR DEPRESSION" id="433147300">
					<fragment>Unipolar major depression (major depressive disorder) is diagnosed in patients who have suffered at least one major depressive episode and have no history of mania or hypomania.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H88258302"/>
			<id>209391</id>
			<summary>
				<section label="MILD TO MODERATE MAJOR DEPRESSION" id="88258302">
					<fragment>Patients with mild to moderate major depression manifest: Either no suicidal or homicidal ideation or behavior, or suicidal or homicidal ideation that does not pose an imminent risk (eg, thoughts that family members would be better off if the patient was dead; or fleeting thoughts of killing oneself, with nonexistent or vague plans to commit suicide and no intent).</fragment>
				</section>
			</summary>
			<category term="C1171947" scheme="gov.nih.nlm.semanticType.phsu" label="commit"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H4906985"/>
			<id>209399</id>
			<summary>
				<section label="Choosing treatment" id="4906985">
					<fragment>In addition, randomized trials that compared pharmacotherapy alone with psychotherapy alone in depressed outpatients found that the benefits of each modality were comparable.</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H4906985"/>
			<id>209402</id>
			<summary>
				<section label="Choosing treatment" id="4906985">
					<fragment>However, one advantage provided by psychotherapy (particularly CBT or interpersonal psychotherapy) is that following an acute course of treatment, the benefits often persist and patients remain well.</fragment>
				</section>
			</summary>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="C0871787" scheme="gov.nih.nlm.semanticType.topp" label="interpersonal psychotherapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H4906985"/>
			<id>209406</id>
			<summary>
				<section label="Choosing treatment" id="4906985">
					<fragment>Although preliminary studies suggest that differences in central nervous system functioning (eg, brain glucose metabolism and biochemical changes) may distinguish depressed patients who respond preferentially to pharmacotherapy or psychotherapy, the use of biomarkers to select initial treatment for depression is not standard practice.</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="C3542961" scheme="gov.nih.nlm.semanticType.phsu" label="nervous system"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H4906985"/>
			<id>209407</id>
			<summary>
				<section label="Choosing treatment" id="4906985">
					<fragment>The use of pharmacotherapy plus psychotherapy, pharmacotherapy alone, or psychotherapy alone for mild to moderate depression is consistent with practice guidelines from the American Psychiatric Association and the United Kingdom National Institute for Clinical Excellence (NICE).</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H4906985"/>
			<id>209408</id>
			<summary>
				<section label="Choosing treatment" id="4906985">
					<fragment>However, the NICE guidelines recommend psychotherapy for the initial treatment of patients with mild depression, based upon their judgement that the risk benefit ratio for pharmacotherapy does not justify its use for mild symptoms.</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H4906985"/>
			<id>209409</id>
			<summary>
				<section label="Choosing treatment" id="4906985">
					<fragment>The efficacy of antidepressants alone for mild depression.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H175262611"/>
			<id>209410</id>
			<summary>
				<section label="Antidepressants plus psychotherapy" id="175262611">
					<fragment>For the initial treatment of mild to moderate unipolar major depression, randomized trials indicate that the combination of pharmacotherapy and psychotherapy (eg, cognitive-behavioral therapy or interpersonal psychotherapy) is more efficacious than either pharmacotherapy alone or psychotherapy alone.</fragment>
				</section>
			</summary>
			<category term="C0004933" scheme="gov.nih.nlm.semanticType.topp" label="behavioral therapy"/>
			<category term="C0009244" scheme="gov.nih.nlm.semanticType.topp" label="cognitive-behavioral therapy"/>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="C0871787" scheme="gov.nih.nlm.semanticType.topp" label="interpersonal psychotherapy"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H175262611"/>
			<id>209414</id>
			<summary>
				<section label="Antidepressants plus psychotherapy" id="175262611">
					<fragment>Evidence supporting the superiority of combination therapy over pharmacotherapy alone for the initial treatment of mild to moderate major depression includes many randomized trials.</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0556895" scheme="gov.nih.nlm.semanticType.topp" label="combination therapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H175262611"/>
			<id>209415</id>
			<summary>
				<section label="Antidepressants plus psychotherapy" id="175262611">
					<fragment>As an example, a meta-analysis of 25 randomized trials compared antidepressants alone with combination therapy in 2036 patients with depressive disorders.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C0556895" scheme="gov.nih.nlm.semanticType.topp" label="combination therapy"/>
			<category term="6" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H175262611"/>
			<id>209416</id>
			<summary>
				<section label="Antidepressants plus psychotherapy" id="175262611">
					<fragment>The analysis found a significant, clinically small to moderate effect favoring combination therapy.</fragment>
				</section>
			</summary>
			<category term="C0556895" scheme="gov.nih.nlm.semanticType.topp" label="combination therapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H175262611"/>
			<id>209418</id>
			<summary>
				<section label="Antidepressants plus psychotherapy" id="175262611">
					<fragment>Separate analyses of the three subgroups that received cognitive-behavioral therapy (7 trials), interpersonal psychotherapy (8 trials), or other psychotherapies (10 trials) found that in each case, combined therapy was superior to antidepressants alone.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0004933" scheme="gov.nih.nlm.semanticType.topp" label="behavioral therapy"/>
			<category term="C0009244" scheme="gov.nih.nlm.semanticType.topp" label="cognitive-behavioral therapy"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="C0033972" scheme="gov.nih.nlm.semanticType.topp" label="combined therapy"/>
			<category term="C0419168" scheme="gov.nih.nlm.semanticType.topp" label="other psychotherapies"/>
			<category term="C0871787" scheme="gov.nih.nlm.semanticType.topp" label="interpersonal psychotherapy"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H175262611"/>
			<id>209419</id>
			<summary>
				<section label="Antidepressants plus psychotherapy" id="175262611">
					<fragment>Evidence supporting the superiority of antidepressants plus psychotherapy over psychotherapy alone for the initial treatment of mild to moderate major depression includes many randomized trials.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H175262611"/>
			<id>209420</id>
			<summary>
				<section label="Antidepressants plus psychotherapy" id="175262611">
					<fragment>As an example, a meta-analysis of 16 randomized trials compared psychotherapy alone with combination treatment in 1727 patients with depressive disorders.</fragment>
				</section>
			</summary>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H13396976"/>
			<id>209429</id>
			<summary>
				<section label="Selecting an antidepressant" id="13396976">
					<fragment>For patients with mild to moderate unipolar major depression whose initial treatment includes antidepressants, we suggest SSRIs based upon their efficacy and tolerability in randomized trials.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H13396976"/>
			<id>209430</id>
			<summary>
				<section label="Selecting an antidepressant" id="13396976">
					<fragment>SSRIs are the most widely prescribed class of antidepressants.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H13396976"/>
			<id>209431</id>
			<summary>
				<section label="Selecting an antidepressant" id="13396976">
					<fragment>Reasonable alternatives to SSRIs for the initial treatment of major depression include other second-generation antidepressants such as serotonin-norepinephrine reuptake inhibitors, atypical antidepressants, and serotonin modulators.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0242905" scheme="gov.nih.nlm.semanticType.phsu" label="atypical antidepressants"/>
			<category term="C0758711" scheme="gov.nih.nlm.semanticType.orch" label="serotonin"/>
			<category term="C1319313" scheme="gov.nih.nlm.semanticType.phsu" label="norepinephrine reuptake inhibitors"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
			<category term="C3537213" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin-norepinephrine reuptake inhibitors"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H13396976"/>
			<id>209434</id>
			<summary>
				<section label="Selecting an antidepressant" id="13396976">
					<fragment>Although sertraline is one of the most widely prescribed SSRIs, and there is evidence that suggests escitalopram and sertraline provide the best combination of efficacy and acceptability, each SSRI is suitable for the initial treatment of depression.</fragment>
				</section>
			</summary>
			<category term="C0074393" scheme="gov.nih.nlm.semanticType.phsu" label="sertraline"/>
			<category term="C1099456" scheme="gov.nih.nlm.semanticType.phsu" label="escitalopram"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H13396976"/>
			<id>209435</id>
			<summary>
				<section label="Selecting an antidepressant" id="13396976">
					<fragment>Studies that suggest antidepressants (including SSRIs) differ in their efficacy include a network meta-analysis of 117 randomized trials (mean duration 8 weeks), which compared 12 second-generation antidepressants in nearly 26,000 patients with unipolar major depression.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C0308902" scheme="gov.nih.nlm.semanticType.phsu" label="duration"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H13396976"/>
			<id>209436</id>
			<summary>
				<section label="Selecting an antidepressant" id="13396976">
					<fragment>The investigators concluded that escitalopram and sertraline showed the best combined profile of efficacy and acceptability, based upon the findings that: Response (reduction of baseline symptoms &gt;=50 percent) was more probable with escitalopram, mirtazapine, sertraline, and venlafaxine, compared with duloxetine, fluoxetine, fluvoxamine, paroxetine, and reboxetine.</fragment>
				</section>
			</summary>
			<category term="C0016365" scheme="gov.nih.nlm.semanticType.phsu" label="fluoxetine"/>
			<category term="C0049506" scheme="gov.nih.nlm.semanticType.phsu" label="mirtazapine"/>
			<category term="C0070122" scheme="gov.nih.nlm.semanticType.phsu" label="paroxetine"/>
			<category term="C0074393" scheme="gov.nih.nlm.semanticType.phsu" label="sertraline"/>
			<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
			<category term="C0085228" scheme="gov.nih.nlm.semanticType.phsu" label="fluvoxamine"/>
			<category term="C0168388" scheme="gov.nih.nlm.semanticType.phsu" label="reboxetine"/>
			<category term="C0245561" scheme="gov.nih.nlm.semanticType.phsu" label="duloxetine"/>
			<category term="C1099456" scheme="gov.nih.nlm.semanticType.phsu" label="escitalopram"/>
			<category term="5" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H13396976"/>
			<id>209437</id>
			<summary>
				<section label="Selecting an antidepressant" id="13396976">
					<fragment>Discontinuation of treatment for any reason was less probable with citalopram, escitalopram, and sertraline, compared with other antidepressants.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0008845" scheme="gov.nih.nlm.semanticType.phsu" label="citalopram"/>
			<category term="C0074393" scheme="gov.nih.nlm.semanticType.phsu" label="sertraline"/>
			<category term="C0457454" scheme="gov.nih.nlm.semanticType.hlca" label="Discontinuation"/>
			<category term="C1099456" scheme="gov.nih.nlm.semanticType.phsu" label="escitalopram"/>
			<category term="C3653915" scheme="gov.nih.nlm.semanticType.phsu" label="other antidepressants"/>
			<category term="8" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H13396976"/>
			<id>209438</id>
			<summary>
				<section label="Selecting an antidepressant" id="13396976">
					<fragment>However, a second network meta-analysis (93 randomized trials, &gt;20,000 patients with unipolar major depression) evaluated 13 second-generation antidepressants and concluded that there were no substantial differences in efficacy and discontinuation rates.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C0457454" scheme="gov.nih.nlm.semanticType.hlca" label="discontinuation"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H13396976"/>
			<id>209442</id>
			<summary>
				<section label="Selecting an antidepressant" id="13396976">
					<fragment>As an example, improvement was greater with escitalopram than citalopram, but the average difference on the Montgomery-Asberg Depression Rating Scale, which ranges in score from 0 to 60 points, was 1.5 points.</fragment>
				</section>
			</summary>
			<category term="C0008845" scheme="gov.nih.nlm.semanticType.phsu" label="citalopram"/>
			<category term="C1099456" scheme="gov.nih.nlm.semanticType.phsu" label="escitalopram"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H13396976"/>
			<id>209444</id>
			<summary>
				<section label="Selecting an antidepressant" id="13396976">
					<fragment>Onset of action may be faster with mirtazapine than other antidepressants.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0049506" scheme="gov.nih.nlm.semanticType.phsu" label="mirtazapine"/>
			<category term="C3653915" scheme="gov.nih.nlm.semanticType.phsu" label="other antidepressants"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H13396976"/>
			<id>209447</id>
			<summary>
				<section label="Selecting an antidepressant" id="13396976">
					<fragment>Most depressed patients who are treated with antidepressants require continuation treatment, and beyond that, maintenance treatment may be indicated as well.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H13396976"/>
			<id>209459</id>
			<summary>
				<section label="Selecting an antidepressant" id="13396976">
					<fragment>As an example, trazodone can be beneficial for patients with insomnia, bupropion for patients who prefer to avoid sexual dysfunction or want treatment for comorbid tobacco dependence, and citalopram and escitalopram do not appear to cause drug-drug interactions.</fragment>
				</section>
			</summary>
			<category term="C0008845" scheme="gov.nih.nlm.semanticType.phsu" label="citalopram"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0040805" scheme="gov.nih.nlm.semanticType.phsu" label="trazodone"/>
			<category term="C0085208" scheme="gov.nih.nlm.semanticType.phsu" label="bupropion"/>
			<category term="C1099456" scheme="gov.nih.nlm.semanticType.phsu" label="escitalopram"/>
			<category term="8" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H658861"/>
			<id>209465</id>
			<summary>
				<section label="Side effects" id="658861">
					<fragment>Although some adverse effects (eg, gastrointestinal toxicity) are common across second-generation antidepressants, the incidence of specific side effects during short-term treatment (eg, 6 to 12 weeks) differs among drugs: Diarrhea occurs more often with sertraline than bupropion, citalopram, fluoxetine, fluvoxamine, mirtazapine, nefazodone, paroxetine, and venlafaxine (16 versus 8 percent of patients).</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0008845" scheme="gov.nih.nlm.semanticType.phsu" label="citalopram"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0016365" scheme="gov.nih.nlm.semanticType.phsu" label="fluoxetine"/>
			<category term="C0049506" scheme="gov.nih.nlm.semanticType.phsu" label="mirtazapine"/>
			<category term="C0068485" scheme="gov.nih.nlm.semanticType.phsu" label="nefazodone"/>
			<category term="C0070122" scheme="gov.nih.nlm.semanticType.phsu" label="paroxetine"/>
			<category term="C0074393" scheme="gov.nih.nlm.semanticType.phsu" label="sertraline"/>
			<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
			<category term="C0085208" scheme="gov.nih.nlm.semanticType.phsu" label="bupropion"/>
			<category term="C0085228" scheme="gov.nih.nlm.semanticType.phsu" label="fluvoxamine"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H658861"/>
			<id>209466</id>
			<summary>
				<section label="Side effects" id="658861">
					<fragment>Nausea and vomiting occurs more often with venlafaxine than SSRIs as a class (33 versus 22 percent).</fragment>
				</section>
			</summary>
			<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H658861"/>
			<id>209468</id>
			<summary>
				<section label="Side effects" id="658861">
					<fragment>Somnolence occurs more often with trazodone than bupropion, fluoxetine, mirtazapine, paroxetine, and venlafaxine (42 versus 25 percent).</fragment>
				</section>
			</summary>
			<category term="C0016365" scheme="gov.nih.nlm.semanticType.phsu" label="fluoxetine"/>
			<category term="C0040805" scheme="gov.nih.nlm.semanticType.phsu" label="trazodone"/>
			<category term="C0049506" scheme="gov.nih.nlm.semanticType.phsu" label="mirtazapine"/>
			<category term="C0070122" scheme="gov.nih.nlm.semanticType.phsu" label="paroxetine"/>
			<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
			<category term="C0085208" scheme="gov.nih.nlm.semanticType.phsu" label="bupropion"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H658861"/>
			<id>209469</id>
			<summary>
				<section label="Side effects" id="658861">
					<fragment>Weight gain is greater with mirtazapine than fluoxetine, paroxetine, trazodone, and venlafaxine (0.8 to 3.0 kg after six to eight weeks of treatment).</fragment>
				</section>
			</summary>
			<category term="C0016365" scheme="gov.nih.nlm.semanticType.phsu" label="fluoxetine"/>
			<category term="C0040805" scheme="gov.nih.nlm.semanticType.phsu" label="trazodone"/>
			<category term="C0049506" scheme="gov.nih.nlm.semanticType.phsu" label="mirtazapine"/>
			<category term="C0070122" scheme="gov.nih.nlm.semanticType.phsu" label="paroxetine"/>
			<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
			<category term="C0124598" scheme="gov.nih.nlm.semanticType.phsu" label="kg"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H658861"/>
			<id>209470</id>
			<summary>
				<section label="Side effects" id="658861">
					<fragment>Although antidepressants may be associated with an increased risk of diabetes, the evidence is not compelling and the possible association should not deter clinicians from using antidepressants when indicated.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H658861"/>
			<id>209471</id>
			<summary>
				<section label="Side effects" id="658861">
					<fragment>A nested case-control study found that in approximately 166,000 patients with depression and no sign of diabetes, long-term (&gt;24 months) use of an antidepressant in moderate to high doses was associated with an increased risk of diabetes (incidence rate ratio 1.8, 95% CI 1.4-2.5).</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
			<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H658861"/>
			<id>209473</id>
			<summary>
				<section label="Side effects" id="658861">
					<fragment>A prospective observational study of 1000 people 65 years and older, followed for up to ten years, found that depressed individuals were more than twice as likely to develop diabetes compared to those without depression, regardless of antidepressant treatment (hazard ratio 2.3, 95% CI 1.3-4.1).</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H658861"/>
			<id>209478</id>
			<summary>
				<section label="Side effects" id="658861">
					<fragment>A review of 158 studies estimated that among patients taking antidepressants, asymptomatic mild elevation of serum aminotransferases occurs in 0.5 to 1 percent of patients taking SSRIs or serotonin-norepinephrine reuptake inhibitors, and up to 3 percent of patients taking MAOIs or tricyclics.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0758711" scheme="gov.nih.nlm.semanticType.orch" label="serotonin"/>
			<category term="C1319313" scheme="gov.nih.nlm.semanticType.phsu" label="norepinephrine reuptake inhibitors"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
			<category term="C3537213" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin-norepinephrine reuptake inhibitors"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H658861"/>
			<id>209481</id>
			<summary>
				<section label="Side effects" id="658861">
					<fragment>Although antidepressant induced liver injury is generally idiosyncratic, unpredictable, and not related to dose, patients who are elderly or taking multiple medications may be at higher risk;</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H658861"/>
			<id>209482</id>
			<summary>
				<section label="Side effects" id="658861">
					<fragment>we thus suggest measuring hepatic enzymes in these patients as well as patients with known underlying liver disease, prior to starting antidepressants.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H658861"/>
			<id>209484</id>
			<summary>
				<section label="Side effects" id="658861">
					<fragment>Additional information about drug induced liver injury, including hepatotoxicity due to agomelatine and nefazodone, are discussed separately.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0068485" scheme="gov.nih.nlm.semanticType.phsu" label="nefazodone"/>
			<category term="C0971637" scheme="gov.nih.nlm.semanticType.phsu" label="agomelatine"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H658867"/>
			<id>209488</id>
			<summary>
				<section label="Dose" id="658867">
					<fragment>However, doses lower than the typical starting doses may further reduce adverse effects, particularly in older patients and those sensitive to side effects.</fragment>
				</section>
			</summary>
			<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H658867"/>
			<id>209489</id>
			<summary>
				<section label="Dose" id="658867">
					<fragment>As an example, depressed patients with comorbid anxiety disorders who are started on SSRIs may better tolerate half of the usual starting dose.</fragment>
				</section>
			</summary>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H658867"/>
			<id>209493</id>
			<summary>
				<section label="Dose" id="658867">
					<fragment>As an example, four randomized trials enrolled patients (total N = 609) with unipolar major depression who were unresponsive to three weeks of treatment with an SSRI, and compared increasing the dose with continuing the initial dose.</fragment>
				</section>
			</summary>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRI"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H658867"/>
			<id>209495</id>
			<summary>
				<section label="Dose" id="658867">
					<fragment>However, three weeks is generally regarded as too short an interval for determining whether an antidepressant regimen is beneficial.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H658867"/>
			<id>209498</id>
			<summary>
				<section label="Dose" id="658867">
					<fragment>One review noted that the prevalence of increased metabolism by duplicated genes of CYP2D6 in black Ethiopians was 29 percent, and among whites varied from 1 to 2 percent in Sweden to 7 to 10 percent in Spain.</fragment>
				</section>
			</summary>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H86799927"/>
			<id>209502</id>
			<summary>
				<section label="Early improvement and response" id="86799927">
					<fragment>Among patients with mild to moderate unipolar major depression who start antidepressants, improvement is often apparent within one to two weeks: A meta-analysis of 28 randomized trials (5872 patients with unipolar major depression) that compared SSRIs with placebo found that superior clinical improvement with SSRIs occurred within one week.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H86799927"/>
			<id>209503</id>
			<summary>
				<section label="Early improvement and response" id="86799927">
					<fragment>A pooled analysis of four randomized trials found that the mean time to improvement (reduction of baseline symptoms &gt;=20 percent) in 2532 patients treated with antidepressants was approximately 13 days.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H86799927"/>
			<id>209505</id>
			<summary>
				<section label="Early improvement and response" id="86799927">
					<fragment>A pooled analysis of 41 randomized trials (6562 patients with unipolar major depression who were generally treated for six weeks) found that early improvement (reduction of baseline symptoms within the first two weeks of treatment &gt;=20 percent) was a sensitive predictor of eventual remission (range 87 to 100 percent, depending upon the specific treatment).</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H86799927"/>
			<id>209508</id>
			<summary>
				<section label="Early improvement and response" id="86799927">
					<fragment>A meta-analysis of 41 randomized trials compared antidepressants with placebo in 7121 patients with unipolar major depression.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H658879"/>
			<id>209513</id>
			<summary>
				<section label="Duration of an adequate trial" id="658879">
					<fragment>In addition, the prospective Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study, which treated a sample that was more generalizable than is typically enrolled in randomized trials, found that among 943 patients who were treated with open label citalopram, nearly 25 percent required 10 or 12 weeks of treatment to achieve remission.</fragment>
				</section>
			</summary>
			<category term="C0008845" scheme="gov.nih.nlm.semanticType.phsu" label="citalopram"/>
			<category term="C1259875" scheme="gov.nih.nlm.semanticType.phsu" label="STAR"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H658879"/>
			<id>209515</id>
			<summary>
				<section label="Duration of an adequate trial" id="658879">
					<fragment>A meta-analysis of 28 randomized trials (5872 patients with unipolar major depression) that compared SSRIs with placebo found that the advantage of SSRIs over placebo continued to increase for at least six weeks of treatment, but at a progressively smaller rate.</fragment>
				</section>
			</summary>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H658879"/>
			<id>209516</id>
			<summary>
				<section label="Duration of an adequate trial" id="658879">
					<fragment>A 16 week study enrolled 566 patients with unipolar major depression who were initially treated with open label escitalopram (10 mg per day) for 4 weeks and showed minimal improvement (&lt;30 percent reduction of baseline symptoms).</fragment>
				</section>
			</summary>
			<category term="C1099456" scheme="gov.nih.nlm.semanticType.phsu" label="escitalopram"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H658879"/>
			<id>209518</id>
			<summary>
				<section label="Duration of an adequate trial" id="658879">
					<fragment>Patients who received escitalopram for 8 weeks were then evaluated for response (reduction of baseline symptoms &gt;=50 percent);</fragment>
				</section>
			</summary>
			<category term="C1099456" scheme="gov.nih.nlm.semanticType.phsu" label="escitalopram"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H658879"/>
			<id>209521</id>
			<summary>
				<section label="Duration of an adequate trial" id="658879">
					<fragment>An eight week, prospective, observational study examined response (reduction of baseline symptoms &gt;=50 percent) to fluoxetine 20 mg per day in 143 patients with unipolar major depression.</fragment>
				</section>
			</summary>
			<category term="C0016365" scheme="gov.nih.nlm.semanticType.phsu" label="fluoxetine"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H658879"/>
			<id>209524</id>
			<summary>
				<section label="Duration of an adequate trial" id="658879">
					<fragment>Next step treatments for patients unresponsive to initial treatment of depression are discussed separately.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H9989182"/>
			<id>209525</id>
			<summary>
				<section label="Efficacy of antidepressants" id="9989182">
					<fragment>Antidepressants are beneficial for patients with unipolar major depression.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="Antidepressants"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H9989182"/>
			<id>209526</id>
			<summary>
				<section label="Efficacy of antidepressants" id="9989182">
					<fragment>A meta-analysis of patient level data from 37 randomized trials (N &gt;8400 patients with major depression) compared either fluoxetine (modal dose 20 mg per day) or venlafaxine (modal dose range 75 to 150 mg per day) with placebo for six weeks;</fragment>
				</section>
			</summary>
			<category term="C0016365" scheme="gov.nih.nlm.semanticType.phsu" label="fluoxetine"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H9989182"/>
			<id>209527</id>
			<summary>
				<section label="Efficacy of antidepressants" id="9989182">
					<fragment>remission occurred in more patients who received active drug than placebo (43 versus 29 percent).</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H9989182"/>
			<id>209528</id>
			<summary>
				<section label="Efficacy of antidepressants" id="9989182">
					<fragment>Meta-analyses of randomized, placebo controlled trials have found that many antidepressant classes and other specific antidepressants are efficacious in unipolar major depression, including agomelatine (not available in the United States), duloxetine, paroxetine, tricyclics (including amitriptyline imipramine, and monoamine oxidase inhibitors. However, meta-analyses based upon published randomized trials may overestimate the effect of antidepressants because of selective publication of trials (publication bias).</fragment>
				</section>
			</summary>
			<category term="C0002600" scheme="gov.nih.nlm.semanticType.phsu" label="amitriptyline"/>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="Meta"/>
			<category term="C0070122" scheme="gov.nih.nlm.semanticType.phsu" label="paroxetine"/>
			<category term="C0245561" scheme="gov.nih.nlm.semanticType.phsu" label="duloxetine"/>
			<category term="C0971637" scheme="gov.nih.nlm.semanticType.phsu" label="agomelatine"/>
			<category term="C3653413" scheme="gov.nih.nlm.semanticType.phsu" label="monoamine oxidase inhibitors"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H9989182"/>
			<id>209532</id>
			<summary>
				<section label="Efficacy of antidepressants" id="9989182">
					<fragment>Among the 51 published trials, the results were presented as positive (ie, improvement was greater with the drug than placebo) in 94 percent (48 trials);</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H9989182"/>
			<id>209537</id>
			<summary>
				<section label="Efficacy of antidepressants" id="9989182">
					<fragment>As an example, a meta-analysis of patient level data (37 randomized trials, 8477 patients with unipolar major depression who were assessed with the Hamilton scale) found that improvement with antidepressants and placebo differed by 3 points.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H9989182"/>
			<id>209539</id>
			<summary>
				<section label="Efficacy of antidepressants" id="9989182">
					<fragment>As an example, a meta-analysis of individual patient data from 37 randomized trials found that among 3391 patients with mild to moderate major depression who were treated with placebo, remission occurred in 29 percent.</fragment>
				</section>
			</summary>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H9989182"/>
			<id>209541</id>
			<summary>
				<section label="Efficacy of antidepressants" id="9989182">
					<fragment>Depressed study patients who are treated with placebos receive nonspecific support by meeting regularly with clinicians and research assistants to discuss symptoms and functioning.</fragment>
				</section>
			</summary>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebos"/>
			<category term="C0628655" scheme="gov.nih.nlm.semanticType.phsu" label="meeting"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H9989319"/>
			<id>209544</id>
			<summary>
				<section label="Mildly ill patients" id="9989319">
					<fragment>Antidepressants appear to be efficacious for unipolar major depression regardless of baseline severity, including mild episodes.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="Antidepressants"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H9989319"/>
			<id>209545</id>
			<summary>
				<section label="Mildly ill patients" id="9989319">
					<fragment>A meta-analysis of 37 randomized trials (8477 patients with major depression) that compared antidepressants with placebo found that the rate of remission in mild episodes (scores on the Hamilton rating Scale for Depression &lt;=19; ) at six weeks was greater with active drug than placebo (50 versus 37 percent of patients).</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H9989319"/>
			<id>209548</id>
			<summary>
				<section label="Mildly ill patients" id="9989319">
					<fragment>results suggested a substantial benefit in severe depression and little or no benefit in mild to moderate depression.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H9989319"/>
			<id>209550</id>
			<summary>
				<section label="Mildly ill patients" id="9989319">
					<fragment>In addition, the earlier study included patients with minor depression (N = 77);</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H9989319"/>
			<id>209551</id>
			<summary>
				<section label="Mildly ill patients" id="9989319">
					<fragment>antidepressants are typically not beneficial for minor depression.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H261064214"/>
			<id>209554</id>
			<summary>
				<section label="Psychotherapy" id="261064214">
					<fragment>Psychotherapies that are available to treat unipolar major depression include: Cognitive-behavioral therapy (CBT).</fragment>
				</section>
			</summary>
			<category term="C0004933" scheme="gov.nih.nlm.semanticType.topp" label="behavioral therapy"/>
			<category term="C0009244" scheme="gov.nih.nlm.semanticType.topp" label="Cognitive-behavioral therapy"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="Psychotherapies"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H249197578"/>
			<id>209562</id>
			<summary>
				<section label="Selecting a psychotherapy" id="249197578">
					<fragment>CBT and interpersonal psychotherapy are frequently selected for the initial treatment of mild to moderate unipolar major depression because they have been more widely studied than other types of psychotherapies.</fragment>
				</section>
			</summary>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="C0871787" scheme="gov.nih.nlm.semanticType.topp" label="interpersonal psychotherapy"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H249197578"/>
			<id>209564</id>
			<summary>
				<section label="Selecting a psychotherapy" id="249197578">
					<fragment>As an example, a network meta-analysis of 198 randomized trials (n &gt;15,000 depressed patients) compared the efficacy of seven psychotherapies (behavioral activation, cognitive-behavioral therapy, interpersonal psychotherapy, problem solving therapy, psychodynamic therapy, social skills training, and supportive therapy).</fragment>
				</section>
			</summary>
			<category term="C0004933" scheme="gov.nih.nlm.semanticType.topp" label="behavioral therapy"/>
			<category term="C0009244" scheme="gov.nih.nlm.semanticType.topp" label="cognitive-behavioral therapy"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapies"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C0344211" scheme="gov.nih.nlm.semanticType.topp" label="supportive therapy"/>
			<category term="C0474215" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapies (behavioral"/>
			<category term="C0599237" scheme="gov.nih.nlm.semanticType.topp" label="psychodynamic therapy"/>
			<category term="C0871787" scheme="gov.nih.nlm.semanticType.topp" label="interpersonal psychotherapy"/>
			<category term="C1303140" scheme="gov.nih.nlm.semanticType.topp" label="problem solving therapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H1604650"/>
			<id>209571</id>
			<summary>
				<section label="Clinician guided self help" id="1604650">
					<fragment>Evidence supporting the use of clinician guided self help includes randomized trials.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H1604650"/>
			<id>209573</id>
			<summary>
				<section label="Clinician guided self help" id="1604650">
					<fragment>In addition, patients with moderate depression at baseline appeared to benefit at least as much as mildly ill patients.</fragment>
				</section>
			</summary>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H336164296"/>
			<id>209575</id>
			<summary>
				<section label="Mildly ill patients" id="336164296">
					<fragment>For patients with mild episodes of unipolar major depression who do not require monitoring (eg, patients with no suicidal ideation or behavior), self-guided self help therapy is a reasonable alternative to conventional psychotherapies as well as clinician guided self help therapy.</fragment>
				</section>
			</summary>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapies"/>
			<category term="C0557035" scheme="gov.nih.nlm.semanticType.hlca" label="help therapy"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H336164296"/>
			<id>209576</id>
			<summary>
				<section label="Mildly ill patients" id="336164296">
					<fragment>Self guided interventions utilize similar materials (eg, structured workbook) that are used in clinician guided self help, but self guided self help is conducted independently and involves no contact with a clinician.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H22836773"/>
			<id>209581</id>
			<summary>
				<section label="Efficacy of psychotherapy" id="22836773">
					<fragment>Psychotherapy is efficacious for the initial treatment of mild to moderate unipolar major depression, based upon randomized trials.</fragment>
				</section>
			</summary>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="Psychotherapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H22836773"/>
			<id>209586</id>
			<summary>
				<section label="Efficacy of psychotherapy" id="22836773">
					<fragment>However, meta-analyses appear to overestimate the clinical effect for nearly all types of psychotherapy in treating depression.</fragment>
				</section>
			</summary>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H22836773"/>
			<id>209587</id>
			<summary>
				<section label="Efficacy of psychotherapy" id="22836773">
					<fragment>These inflated effects seem to be the result of low quality studies as well as publication bias.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H22836773"/>
			<id>209589</id>
			<summary>
				<section label="Efficacy of psychotherapy" id="22836773">
					<fragment>Some psychotherapy trials are rigorous and specify a priori hypotheses and analytic tests, develop manuals for the psychotherapies and measure adherence on the part of therapists, use active psychotherapy comparators that control for the nonspecific aspects of psychotherapy, use standardized diagnostic criteria and outcome measures, stratify patients on predetermined risk variables, and blind outcome ratings.</fragment>
				</section>
			</summary>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H22836773"/>
			<id>209593</id>
			<summary>
				<section label="Efficacy of psychotherapy" id="22836773">
					<fragment>As an example, techniques from supportive psychotherapy have been adopted by other psychotherapies, such as psychodynamic psychotherapy.</fragment>
				</section>
			</summary>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="C0221295" scheme="gov.nih.nlm.semanticType.topp" label="supportive psychotherapy"/>
			<category term="C0419168" scheme="gov.nih.nlm.semanticType.topp" label="other psychotherapies"/>
			<category term="C1261382" scheme="gov.nih.nlm.semanticType.topp" label="psychodynamic psychotherapy"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H22836865"/>
			<id>209595</id>
			<summary>
				<section label="Compared with antidepressants" id="22836865">
					<fragment>For patients with mild to moderate unipolar major depression, the evidence indicates that the efficacy of psychotherapy compared with antidepressants at the end of treatment is generally comparable.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H22836865"/>
			<id>209596</id>
			<summary>
				<section label="Compared with antidepressants" id="22836865">
					<fragment>A meta-analysis of 30 randomized trials compared psychotherapy (primarily CBT or interpersonal psychotherapy) with antidepressants in 3178 patients with depressive disorders and found that improvement was comparable for both groups.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C0871787" scheme="gov.nih.nlm.semanticType.topp" label="interpersonal psychotherapy"/>
			<category term="10" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H22836865"/>
			<id>209598</id>
			<summary>
				<section label="Compared with antidepressants" id="22836865">
					<fragment>As an example, a meta-analysis of 28 randomized trials compared psychotherapy with pharmacotherapy for the acute treatment of 3381 patients with unipolar depressive disorders, and found that improvement was comparable;</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="6" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H22836865"/>
			<id>209600</id>
			<summary>
				<section label="Compared with antidepressants" id="22836865">
					<fragment>In the 11 studies (602 patients) that followed patients after treatment ended and assessed their depressive symptoms (mean length of follow-up 15 months), there was a significant, clinically small to moderate effect favoring psychotherapy over antidepressants.</fragment>
				</section>
			</summary>
			<category term="C0001758" scheme="gov.nih.nlm.semanticType.hlca" label="after treatment"/>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H175267570"/>
			<id>209602</id>
			<summary>
				<section label="Relaxation and positive activities" id="175267570">
					<fragment>For patients with mild to moderate unipolar major depression, we suggest adding relaxation techniques (eg, progressive muscle relaxation, relaxation imagery, and autogenic training) to the primary treatment regimen.</fragment>
				</section>
			</summary>
			<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="adding"/>
			<category term="C0004361" scheme="gov.nih.nlm.semanticType.topp" label="autogenic training"/>
			<category term="C0035029" scheme="gov.nih.nlm.semanticType.topp" label="relaxation techniques"/>
			<category term="C0150316" scheme="gov.nih.nlm.semanticType.topp" label="progressive muscle relaxation"/>
			<category term="C0150627" scheme="gov.nih.nlm.semanticType.topp" label="imagery"/>
			<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H175267570"/>
			<id>209604</id>
			<summary>
				<section label="Relaxation and positive activities" id="175267570">
					<fragment>However, a second analysis of nine trials (286 patients) found that relaxation was less effective than psychotherapy (primarily cognitive-behavioral therapy).</fragment>
				</section>
			</summary>
			<category term="C0004933" scheme="gov.nih.nlm.semanticType.topp" label="behavioral therapy"/>
			<category term="C0009244" scheme="gov.nih.nlm.semanticType.topp" label="cognitive-behavioral therapy"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H261064201"/>
			<id>209608</id>
			<summary>
				<section label="Exercise" id="261064201">
					<fragment>We suggest exercise as adjunctive treatment for patients with mild to moderate major depression, based upon evidence from low quality randomized trials.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H261064201"/>
			<id>209610</id>
			<summary>
				<section label="Exercise" id="261064201">
					<fragment>For patients with mild depression, exercise alone rather than as add-on treatment is a reasonable alternative provided patients are sufficiently monitored (eg, every two to four weeks) for worsening symptoms.</fragment>
				</section>
			</summary>
			<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="add"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H261064201"/>
			<id>209614</id>
			<summary>
				<section label="Exercise" id="261064201">
					<fragment>In a separate meta-analysis of four randomized trials that compared exercise with no treatment or placebo in 271 depressed patients who were recruited from clinical settings, there was no advantage for exercise.</fragment>
				</section>
			</summary>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H261064201"/>
			<id>209618</id>
			<summary>
				<section label="Exercise" id="261064201">
					<fragment>Based upon a review of randomized trials, we suggest that clinicians prescribe exercise for depressed patients in the following manner: Modality - Aerobic exercise (eg, walking, running, or cycling) or resistance training (upper and lower body weight lifting).</fragment>
				</section>
			</summary>
			<category term="C0001701" scheme="gov.nih.nlm.semanticType.topp" label="Aerobic exercise"/>
			<category term="C0624791" scheme="gov.nih.nlm.semanticType.imft" label="running"/>
			<category term="C0872279" scheme="gov.nih.nlm.semanticType.topp" label="resistance training"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H167261023"/>
			<id>209629</id>
			<summary>
				<section label="Primary care patients" id="167261023">
					<fragment>Primary care patients with mild to moderate unipolar major depression can benefit when antidepressant treatment occurs within the context of collaborative care.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="C0017313" scheme="gov.nih.nlm.semanticType.hlca" label="care patients"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H167261023"/>
			<id>209631</id>
			<summary>
				<section label="Primary care patients" id="167261023">
					<fragment>Meta-analyses of randomized trials have shown that depression outcomes are superior with collaborative care, compared with usual care (antidepressants alone).</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="Meta"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H167261023"/>
			<id>209633</id>
			<summary>
				<section label="Primary care patients" id="167261023">
					<fragment>Psychotherapy is also a reasonable alternative to collaborative care for depressed patients who are treated in primary care settings.</fragment>
				</section>
			</summary>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="Psychotherapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H167261023"/>
			<id>209634</id>
			<summary>
				<section label="Primary care patients" id="167261023">
					<fragment>The evidence for the efficacy of collaborative care is discussed separately, as is the efficacy of antidepressants alone and psychotherapy alone for primary care patients.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0017313" scheme="gov.nih.nlm.semanticType.hlca" label="care patients"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H1883132"/>
			<id>209635</id>
			<summary>
				<section label="Anxiety and insomnia" id="1883132">
					<fragment>Anxiolytics can be used to augment an antidepressant for initially treating major depressive episodes that include symptoms of anxiety (eg, ruminative thoughts, worrying, and panic attacks), insomnia, or psychomotor agitation.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="C0040616" scheme="gov.nih.nlm.semanticType.phsu" label="Anxiolytics"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H88258338"/>
			<id>209643</id>
			<summary>
				<section label="SEVERE MAJOR DEPRESSION" id="88258338">
					<fragment>Grossly impaired functioning (eg, food and fluid refusal leading to malnutrition and dehydration).</fragment>
				</section>
			</summary>
			<category term="C1569452" scheme="gov.nih.nlm.semanticType.phsu" label="refusal"/>
			<category term="C3540798" scheme="gov.nih.nlm.semanticType.imft" label="food"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H88258338"/>
			<id>209644</id>
			<summary>
				<section label="SEVERE MAJOR DEPRESSION" id="88258338">
					<fragment>Severely ill patients should be referred to a psychiatrist for management and generally require hospitalization.</fragment>
				</section>
			</summary>
			<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalization"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H4906992"/>
			<id>209645</id>
			<summary>
				<section label="Choosing treatment" id="4906992">
					<fragment>For patients with severe unipolar major depression, we suggest initial treatment with the combination of pharmacotherapy and psychotherapy, based upon randomized trials in patients with mild to moderate depressionsertraline or amitriptyline) with clinical management (psychoeducation and support) plus an antidepressant in 124 patients with major depression who were hospitalized for five weeks.</fragment>
				</section>
			</summary>
			<category term="C0002600" scheme="gov.nih.nlm.semanticType.phsu" label="amitriptyline"/>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H4906992"/>
			<id>209646</id>
			<summary>
				<section label="Choosing treatment" id="4906992">
					<fragment>Response (reduction of baseline symptoms &gt;=50 percent) occurred in more patients treated with adjunctive interpersonal psychotherapy than clinical management (70 versus 51 percent), and improvement of functioning was also superior with interpersonal psychotherapy.</fragment>
				</section>
			</summary>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="C0871787" scheme="gov.nih.nlm.semanticType.topp" label="interpersonal psychotherapy"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H4906992"/>
			<id>209648</id>
			<summary>
				<section label="Choosing treatment" id="4906992">
					<fragment>However, a reasonable alternative to combination therapy for severe major depression is pharmacotherapy alone, based upon randomized trials in patients with severe depression.</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0556895" scheme="gov.nih.nlm.semanticType.topp" label="combination therapy"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H4906992"/>
			<id>209649</id>
			<summary>
				<section label="Choosing treatment" id="4906992">
					<fragment>Another reasonable alternative to combination therapy for the initial treatment of severe major depression is electroconvulsive therapy (ECT), especially for patients who require a fast response (eg, patients with suicidal ideation or behavior that is life-threatening).</fragment>
				</section>
			</summary>
			<category term="C0013806" scheme="gov.nih.nlm.semanticType.topp" label="ECT"/>
			<category term="C0013808" scheme="gov.nih.nlm.semanticType.topp" label="electroconvulsive therapy"/>
			<category term="C0556895" scheme="gov.nih.nlm.semanticType.topp" label="combination therapy"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H4906992"/>
			<id>209650</id>
			<summary>
				<section label="Choosing treatment" id="4906992">
					<fragment>Meta-analyses of randomized trials indicate that ECT is more efficacious than any other treatment for severe major depression.</fragment>
				</section>
			</summary>
			<category term="C0013806" scheme="gov.nih.nlm.semanticType.topp" label="ECT"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="Meta"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H4906992"/>
			<id>209653</id>
			<summary>
				<section label="Choosing treatment" id="4906992">
					<fragment>An overview of ECT is discussed separately, as are indications for and efficacy of ECT in unipolar major depression, medical consultation for ECT, and the technique for performing ECT.</fragment>
				</section>
			</summary>
			<category term="C0013806" scheme="gov.nih.nlm.semanticType.topp" label="ECT"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H4906992"/>
			<id>209654</id>
			<summary>
				<section label="Choosing treatment" id="4906992">
					<fragment>The use of combination therapy, pharmacotherapy alone, or ECT for severe unipolar major depression is consistent with practice guidelines from the American Psychiatric Association and the United Kingdom National Institute for Clinical Excellence (NICE).</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0013806" scheme="gov.nih.nlm.semanticType.topp" label="ECT"/>
			<category term="C0556895" scheme="gov.nih.nlm.semanticType.topp" label="combination therapy"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H88260056"/>
			<id>209657</id>
			<summary>
				<section label="Choosing an antidepressant" id="88260056">
					<fragment>Randomized trials have demonstrated that antipsychotics combined with either serotonin-norepinephrine reuptake inhibitors or SSRIs are efficacious for unipolar major depression with psychotic features.</fragment>
				</section>
			</summary>
			<category term="C0040615" scheme="gov.nih.nlm.semanticType.phsu" label="antipsychotics"/>
			<category term="C0758711" scheme="gov.nih.nlm.semanticType.orch" label="serotonin"/>
			<category term="C1319313" scheme="gov.nih.nlm.semanticType.phsu" label="norepinephrine reuptake inhibitors"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
			<category term="C3537213" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin-norepinephrine reuptake inhibitors"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H88260056"/>
			<id>209659</id>
			<summary>
				<section label="Choosing an antidepressant" id="88260056">
					<fragment>A pooled analysis of 15 randomized trials (1752 patient with unipolar major depression) compared serotonin-norepinephrine reuptake inhibitors (duloxetine, milnacipran, and venlafaxine) with SSRIs (citalopram, escitalopram, fluoxetine, paroxetine, and sertraline. In the subgroup of hospitalized patients (n = 436), remission occurred in more patients who received serotonin-norepinephrine reuptake inhibitors than SSRIs (52 versus 29 percent).</fragment>
				</section>
			</summary>
			<category term="C0008845" scheme="gov.nih.nlm.semanticType.phsu" label="citalopram"/>
			<category term="C0016365" scheme="gov.nih.nlm.semanticType.phsu" label="fluoxetine"/>
			<category term="C0070122" scheme="gov.nih.nlm.semanticType.phsu" label="paroxetine"/>
			<category term="C0074393" scheme="gov.nih.nlm.semanticType.phsu" label="sertraline"/>
			<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
			<category term="C0245561" scheme="gov.nih.nlm.semanticType.phsu" label="duloxetine"/>
			<category term="C0758711" scheme="gov.nih.nlm.semanticType.orch" label="serotonin"/>
			<category term="C1099456" scheme="gov.nih.nlm.semanticType.phsu" label="escitalopram"/>
			<category term="C1319313" scheme="gov.nih.nlm.semanticType.phsu" label="norepinephrine reuptake inhibitors"/>
			<category term="C1533126" scheme="gov.nih.nlm.semanticType.phsu" label="milnacipran"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
			<category term="C3537213" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin-norepinephrine reuptake inhibitors"/>
			<category term="15" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H88260056"/>
			<id>209660</id>
			<summary>
				<section label="Choosing an antidepressant" id="88260056">
					<fragment>This was consistent with the finding that remission was greater in outpatients who received serotonin-norepinephrine reuptake inhibitors.</fragment>
				</section>
			</summary>
			<category term="C0758711" scheme="gov.nih.nlm.semanticType.orch" label="serotonin"/>
			<category term="C1319313" scheme="gov.nih.nlm.semanticType.phsu" label="norepinephrine reuptake inhibitors"/>
			<category term="C3537213" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin-norepinephrine reuptake inhibitors"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H88260056"/>
			<id>209661</id>
			<summary>
				<section label="Choosing an antidepressant" id="88260056">
					<fragment>A reasonable alternative to serotonin-norepinephrine reuptake inhibitors or SSRIs is mirtazapine: A six-week randomized trial compared mirtazapine (24 to 72 mg per day) with trazodone (150 to 450 mg per day) in 200 patients hospitalized for major depression.</fragment>
				</section>
			</summary>
			<category term="C0040805" scheme="gov.nih.nlm.semanticType.phsu" label="trazodone"/>
			<category term="C0049506" scheme="gov.nih.nlm.semanticType.phsu" label="mirtazapine"/>
			<category term="C0758711" scheme="gov.nih.nlm.semanticType.orch" label="serotonin"/>
			<category term="C1319313" scheme="gov.nih.nlm.semanticType.phsu" label="norepinephrine reuptake inhibitors"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
			<category term="C3537213" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin-norepinephrine reuptake inhibitors"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H88260056"/>
			<id>209662</id>
			<summary>
				<section label="Choosing an antidepressant" id="88260056">
					<fragment>Response (reduction of baseline symptoms &gt;=50 percent) occurred in more patients treated with mirtazapine than trazodone (78 versus 61 percent).</fragment>
				</section>
			</summary>
			<category term="C0040805" scheme="gov.nih.nlm.semanticType.phsu" label="trazodone"/>
			<category term="C0049506" scheme="gov.nih.nlm.semanticType.phsu" label="mirtazapine"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H88260056"/>
			<id>209664</id>
			<summary>
				<section label="Choosing an antidepressant" id="88260056">
					<fragment>An eight-week randomized trial compared mirtazapine (mean dose 50 mg per day) with venlafaxine (mean dose 255 mg per day) in 157 inpatients and found that response was comparable (62 and 52 percent).</fragment>
				</section>
			</summary>
			<category term="C0049506" scheme="gov.nih.nlm.semanticType.phsu" label="mirtazapine"/>
			<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H88260056"/>
			<id>209665</id>
			<summary>
				<section label="Choosing an antidepressant" id="88260056">
					<fragment>In addition, discontinuation of treatment due to adverse effects occurred in fewer patients who received mirtazapine than venlafaxine (15 versus 5 percent).</fragment>
				</section>
			</summary>
			<category term="C0049506" scheme="gov.nih.nlm.semanticType.phsu" label="mirtazapine"/>
			<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
			<category term="C0457454" scheme="gov.nih.nlm.semanticType.hlca" label="discontinuation"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H88260056"/>
			<id>209666</id>
			<summary>
				<section label="Choosing an antidepressant" id="88260056">
					<fragment>Tricyclic antidepressants are another reasonable alternative, based upon randomized trials that suggest tricyclics are more efficacious than other antidepressants for severely depressed patients.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0003290" scheme="gov.nih.nlm.semanticType.phsu" label="Tricyclic antidepressants"/>
			<category term="C3653915" scheme="gov.nih.nlm.semanticType.phsu" label="other antidepressants"/>
			<category term="12" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H88260056"/>
			<id>209668</id>
			<summary>
				<section label="Choosing an antidepressant" id="88260056">
					<fragment>Evidence that indicates tricyclics (particularly amitriptyline, clomipramine, and imipramine) are beneficial for severely depressed patients includes the following studies: A meta-analysis of 104 randomized trials compared amitriptyline with other antidepressants (including other tricyclics) in 7422 depressed patients.</fragment>
				</section>
			</summary>
			<category term="C0002600" scheme="gov.nih.nlm.semanticType.phsu" label="amitriptyline"/>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0009010" scheme="gov.nih.nlm.semanticType.phsu" label="clomipramine"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C3653915" scheme="gov.nih.nlm.semanticType.phsu" label="other antidepressants"/>
			<category term="10" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H88260056"/>
			<id>209669</id>
			<summary>
				<section label="Choosing an antidepressant" id="88260056">
					<fragment>In the subgroup of 54 randomized trials that enrolled hospitalized patients (sample size not provided), response was more likely with amitriptyline than other antidepressants (odds ratio 1.22, 95% CI 1.04-1.42) and tolerability was comparable.</fragment>
				</section>
			</summary>
			<category term="C0002600" scheme="gov.nih.nlm.semanticType.phsu" label="amitriptyline"/>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
			<category term="C3653915" scheme="gov.nih.nlm.semanticType.phsu" label="other antidepressants"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H88260056"/>
			<id>209671</id>
			<summary>
				<section label="Choosing an antidepressant" id="88260056">
					<fragment>A meta-analysis of 25 randomized trials compared tricyclics (amitriptyline, clomipramine, desipramine, imipramine, and maprotiline) with SSRIs (citalopram, fluoxetine, fluvoxamine, and paroxetine) for treating depression in 1377 hospitalized patients.</fragment>
				</section>
			</summary>
			<category term="C0002600" scheme="gov.nih.nlm.semanticType.phsu" label="amitriptyline"/>
			<category term="C0008845" scheme="gov.nih.nlm.semanticType.phsu" label="citalopram"/>
			<category term="C0009010" scheme="gov.nih.nlm.semanticType.phsu" label="clomipramine"/>
			<category term="C0011685" scheme="gov.nih.nlm.semanticType.phsu" label="desipramine"/>
			<category term="C0016365" scheme="gov.nih.nlm.semanticType.phsu" label="fluoxetine"/>
			<category term="C0024778" scheme="gov.nih.nlm.semanticType.phsu" label="maprotiline"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C0070122" scheme="gov.nih.nlm.semanticType.phsu" label="paroxetine"/>
			<category term="C0085228" scheme="gov.nih.nlm.semanticType.phsu" label="fluvoxamine"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
			<category term="21" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H88260056"/>
			<id>209672</id>
			<summary>
				<section label="Choosing an antidepressant" id="88260056">
					<fragment>Improvement was greater with tricyclics than SSRIs, but the clinical difference was small and heterogeneity across studies was significant.</fragment>
				</section>
			</summary>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H88260056"/>
			<id>209673</id>
			<summary>
				<section label="Choosing an antidepressant" id="88260056">
					<fragment>In addition, discontinuation of treatment due to adverse effects occurred in more patients treated with tricyclics than SSRIs (14 versus 9 percent).</fragment>
				</section>
			</summary>
			<category term="C0457454" scheme="gov.nih.nlm.semanticType.hlca" label="discontinuation"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H524936"/>
			<id>209675</id>
			<summary>
				<section label="PERSISTENT DEPRESSIVE DISORDER (DYSTHYMIA)" id="524936">
					<fragment>Persistent depressive disorder (dysthymia) is characterized by dysphoria and at least two other depressive symptoms lasting for two or more years.</fragment>
				</section>
			</summary>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H524936"/>
			<id>209679</id>
			<summary>
				<section label="PERSISTENT DEPRESSIVE DISORDER (DYSTHYMIA)" id="524936">
					<fragment>For initial treatment of persistent depressive disorder, we suggest in order of preference pharmacotherapy plus psychotherapy, pharmacotherapy alone, and psychotherapy alone, based upon randomized trials.</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H524936"/>
			<id>209680</id>
			<summary>
				<section label="PERSISTENT DEPRESSIVE DISORDER (DYSTHYMIA)" id="524936">
					<fragment>Evidence for the efficacy of antidepressants plus psychotherapy for persistent depressive disorder includes a meta-analysis of nine trials (1590 patients with chronic major depression or dysthymic disorder) that compared combination treatment with pharmacotherapy alone and psychotherapy alone;</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="5" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H524936"/>
			<id>209682</id>
			<summary>
				<section label="PERSISTENT DEPRESSIVE DISORDER (DYSTHYMIA)" id="524936">
					<fragment>Improvement was superior with combined treatment than psychotherapy alone, and the difference was moderately large such that combination treatment provided one additional positive outcome for every four patients treated with each regimen (number needed to treat of four).</fragment>
				</section>
			</summary>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H524936"/>
			<id>209684</id>
			<summary>
				<section label="PERSISTENT DEPRESSIVE DISORDER (DYSTHYMIA)" id="524936">
					<fragment>Discontinuation of treatment for any reason was comparable for combined treatment, pharmacotherapy alone, and psychotherapy alone.</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="C0457454" scheme="gov.nih.nlm.semanticType.hlca" label="Discontinuation"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H524936"/>
			<id>209685</id>
			<summary>
				<section label="PERSISTENT DEPRESSIVE DISORDER (DYSTHYMIA)" id="524936">
					<fragment>In addition, randomized trials in patients with mild to moderate major depression have demonstrated that combining antidepressants and psychotherapy is superior to either pharmacotherapy alone or psychotherapy alone.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H524936"/>
			<id>209686</id>
			<summary>
				<section label="PERSISTENT DEPRESSIVE DISORDER (DYSTHYMIA)" id="524936">
					<fragment>Although pharmacotherapy alone is not as efficacious as combination therapy, pharmacotherapy alone is superior to placebo in patients with persistent depressive disorder: A meta-analysis of 15 randomized trials (1992 patients with dysthymic disorder) compared antidepressants with placebo and found that response (eg, reduction of baseline symptoms &gt;=50 percent) was more likely with antidepressants (relative risk 1.5, 95% CI 1.4-1.7).</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C0556895" scheme="gov.nih.nlm.semanticType.topp" label="combination therapy"/>
			<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
			<category term="8" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H524936"/>
			<id>209688</id>
			<summary>
				<section label="PERSISTENT DEPRESSIVE DISORDER (DYSTHYMIA)" id="524936">
					<fragment>A meta-analysis of 17 randomized trials (1454 patients with dysthymic disorder treated for an average of 10 weeks) found that response was more probable with antidepressants than placebo (relative risk 1.8, 95% CI 1.5-2.0).</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H524936"/>
			<id>209689</id>
			<summary>
				<section label="PERSISTENT DEPRESSIVE DISORDER (DYSTHYMIA)" id="524936">
					<fragment>A meta-analysis of 20 randomized trials (2918 patients with depression lasting at least two years) found that remission was greater with SSRIs or tricyclics than with placebo, and was comparable for SSRIs and tricyclics.</fragment>
				</section>
			</summary>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H524936"/>
			<id>209690</id>
			<summary>
				<section label="PERSISTENT DEPRESSIVE DISORDER (DYSTHYMIA)" id="524936">
					<fragment>However, discontinuation of treatment as well as adverse effects occurred less often with SSRIs than tricyclics.</fragment>
				</section>
			</summary>
			<category term="C0457454" scheme="gov.nih.nlm.semanticType.hlca" label="discontinuation"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H524936"/>
			<id>209691</id>
			<summary>
				<section label="PERSISTENT DEPRESSIVE DISORDER (DYSTHYMIA)" id="524936">
					<fragment>In addition, pharmacotherapy alone is superior to psychotherapy alone for persistent depressive disorder.</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H524936"/>
			<id>209692</id>
			<summary>
				<section label="PERSISTENT DEPRESSIVE DISORDER (DYSTHYMIA)" id="524936">
					<fragment>As an example, a meta-analysis of 8 randomized trials (1254 patients with chronic major depression or dysthymic disorder) found a significant, but clinically small effect favoring antidepressants over psychotherapy;</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H524936"/>
			<id>209694</id>
			<summary>
				<section label="PERSISTENT DEPRESSIVE DISORDER (DYSTHYMIA)" id="524936">
					<fragment>However, psychotherapy alone is a reasonable choice for patients with persistent depressive disorder who prefer it.</fragment>
				</section>
			</summary>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H524936"/>
			<id>209695</id>
			<summary>
				<section label="PERSISTENT DEPRESSIVE DISORDER (DYSTHYMIA)" id="524936">
					<fragment>A meta-analysis of 6 randomized trials (362 patients with chronic major depression or dysthymic disorder) found a significant, but clinically small effect favoring psychotherapy over control conditions (primarily pill placebo).</fragment>
				</section>
			</summary>
			<category term="C0029151" scheme="gov.nih.nlm.semanticType.topp" label="pill"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H524936"/>
			<id>209696</id>
			<summary>
				<section label="PERSISTENT DEPRESSIVE DISORDER (DYSTHYMIA)" id="524936">
					<fragment>A subsequent trial (n = 30) found that improvement was greater in patients who received body psychotherapy (which includes both talking as well as exercises to increase body awareness) than the waiting list control.</fragment>
				</section>
			</summary>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H524936"/>
			<id>209697</id>
			<summary>
				<section label="PERSISTENT DEPRESSIVE DISORDER (DYSTHYMIA)" id="524936">
					<fragment>Randomized trials that studied interpersonal psychotherapy in patients with persistent depressive disorder (dysthymia) are discussed separately.</fragment>
				</section>
			</summary>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="C0871787" scheme="gov.nih.nlm.semanticType.topp" label="interpersonal psychotherapy"/>
			<category term="5" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H9988692"/>
			<id>209700</id>
			<summary>
				<section label="Mild to moderate major depression" id="9988692">
					<fragment>For the initial treatment of mild to moderate unipolar major depression, we suggest pharmacotherapy plus psychotherapy, rather than pharmacotherapy alone or psychotherapy alone.</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H9988692"/>
			<id>209703</id>
			<summary>
				<section label="Mild to moderate major depression" id="9988692">
					<fragment>For patients with mild to moderate unipolar major depression who are initially treated with antidepressants, we suggest selective serotonin reuptake inhibitors (SSRIs) rather than other antidepressants.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0360105" scheme="gov.nih.nlm.semanticType.phsu" label="selective serotonin reuptake inhibitors"/>
			<category term="C0758711" scheme="gov.nih.nlm.semanticType.orch" label="serotonin"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin reuptake inhibitors"/>
			<category term="C3653915" scheme="gov.nih.nlm.semanticType.phsu" label="other antidepressants"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H9988692"/>
			<id>209706</id>
			<summary>
				<section label="Mild to moderate major depression" id="9988692">
					<fragment>Several psychotherapies are available to treat unipolar major depression.</fragment>
				</section>
			</summary>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapies"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H9988692"/>
			<id>209707</id>
			<summary>
				<section label="Mild to moderate major depression" id="9988692">
					<fragment>For patients with mild to moderate unipolar major depression who are initially treated with psychotherapy, we suggest cognitive-behavioral therapy (CBT) or interpersonal psychotherapy rather than other psychotherapies.</fragment>
				</section>
			</summary>
			<category term="C0004933" scheme="gov.nih.nlm.semanticType.topp" label="behavioral therapy"/>
			<category term="C0009244" scheme="gov.nih.nlm.semanticType.topp" label="cognitive-behavioral therapy"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="C0419168" scheme="gov.nih.nlm.semanticType.topp" label="other psychotherapies"/>
			<category term="C0871787" scheme="gov.nih.nlm.semanticType.topp" label="interpersonal psychotherapy"/>
			<category term="6" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H9988692"/>
			<id>209709</id>
			<summary>
				<section label="Mild to moderate major depression" id="9988692">
					<fragment>There are no biologic or clinical predictors of sufficient utility to help choose between antidepressants alone and psychotherapy alone for the initial treatment of depression, or to make a selection among specific antidepressants or psychotherapies.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H9988692"/>
			<id>209710</id>
			<summary>
				<section label="Mild to moderate major depression" id="9988692">
					<fragment>Antidepressants alone have been studied and used more often than psychotherapy alone.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="Antidepressants"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H9988692"/>
			<id>209714</id>
			<summary>
				<section label="Mild to moderate major depression" id="9988692">
					<fragment>Among patients with mild to moderate unipolar major depression who start antidepressants, improvement is often apparent within two weeks.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H9988685"/>
			<id>209718</id>
			<summary>
				<section label="Severe major depression" id="9988685">
					<fragment>For patients with severe unipolar major depression, we suggest initial treatment with pharmacotherapy plus psychotherapy, rather than other treatment regimens.</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimens"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H9988685"/>
			<id>209721</id>
			<summary>
				<section label="Severe major depression" id="9988685">
					<fragment>For patients with severe unipolar major depression who are treated with antidepressants, we suggest serotonin-norepinephrine reuptake inhibitors or SSRIs, rather than other antidepressants.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0758711" scheme="gov.nih.nlm.semanticType.orch" label="serotonin"/>
			<category term="C1319313" scheme="gov.nih.nlm.semanticType.phsu" label="norepinephrine reuptake inhibitors"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
			<category term="C3537213" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin-norepinephrine reuptake inhibitors"/>
			<category term="C3653915" scheme="gov.nih.nlm.semanticType.phsu" label="other antidepressants"/>
			<category term="11" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H9988744"/>
			<id>209724</id>
			<summary>
				<section label="Persistent Depressive disorder (dysthymia)" id="9988744">
					<fragment>Persistent depressive disorder is characterized by dysphoria and at least two other depressive symptoms lasting for two or more years.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H9988744"/>
			<id>209725</id>
			<summary>
				<section label="Persistent Depressive disorder (dysthymia)" id="9988744">
					<fragment>For patients with persistent depressive disorder, we suggest antidepressants plus psychotherapy rather than antidepressants alone or psychotherapy alone.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H9988744"/>
			<id>209727</id>
			<summary>
				<section label="Persistent Depressive disorder (dysthymia)" id="9988744">
					<fragment>psychotherapy alone is also reasonable for patients who prefer it.</fragment>
				</section>
			</summary>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
	</feed>
	<feed>
		<title>Unipolar major depression in adults: Choosing initial treatment</title>
		<category term="C0031809" scheme="gov.nih.nlm.semanticType.hlca" label="physical examination"/>
		<category term="C0150618" scheme="gov.nih.nlm.semanticType.hlca" label="history, physical"/>
		<category term="C3263684" scheme="gov.nih.nlm.semanticType.topp" label="screened"/>
		<category term="C0619701" scheme="gov.nih.nlm.semanticType.horm" label="II"/>
		<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalization"/>
		<category term="C0013808" scheme="gov.nih.nlm.semanticType.topp" label="Electroconvulsive therapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0035029" scheme="gov.nih.nlm.semanticType.topp" label="Relaxation techniques"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C1259875" scheme="gov.nih.nlm.semanticType.phsu" label="STAR"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="Psychotherapy"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0004933" scheme="gov.nih.nlm.semanticType.topp" label="behavioral therapy"/>
		<category term="C0009244" scheme="gov.nih.nlm.semanticType.topp" label="cognitive therapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0309872" scheme="gov.nih.nlm.semanticType.phsu" label="prevent"/>
		<category term="C0871787" scheme="gov.nih.nlm.semanticType.topp" label="Interpersonal psychotherapy"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="Pharmacotherapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C2003848" scheme="gov.nih.nlm.semanticType.topp" label="drug therapy"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0556895" scheme="gov.nih.nlm.semanticType.topp" label="combination therapy"/>
		<category term="C0556895" scheme="gov.nih.nlm.semanticType.topp" label="combination therapy"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0003290" scheme="gov.nih.nlm.semanticType.phsu" label="tricyclic antidepressants"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0360105" scheme="gov.nih.nlm.semanticType.phsu" label="selective serotonin reuptake inhibitors"/>
		<category term="C0629984" scheme="gov.nih.nlm.semanticType.strd" label="TCAs"/>
		<category term="C0758711" scheme="gov.nih.nlm.semanticType.orch" label="serotonin"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin reuptake inhibitors"/>
		<category term="C3653413" scheme="gov.nih.nlm.semanticType.phsu" label="monoamine oxidase inhibitors"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="Antidepressants"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0016365" scheme="gov.nih.nlm.semanticType.phsu" label="fluoxetine"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0008845" scheme="gov.nih.nlm.semanticType.phsu" label="citalopram"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="Antidepressants"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="Drugs"/>
		<category term="C0391422" scheme="gov.nih.nlm.semanticType.orch" label="impact"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressive"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0074393" scheme="gov.nih.nlm.semanticType.phsu" label="sertraline"/>
		<category term="C1099456" scheme="gov.nih.nlm.semanticType.phsu" label="escitalopram"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0074393" scheme="gov.nih.nlm.semanticType.phsu" label="sertraline"/>
		<category term="C1099456" scheme="gov.nih.nlm.semanticType.phsu" label="escitalopram"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0017313" scheme="gov.nih.nlm.semanticType.hlca" label="care patients"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0162758" scheme="gov.nih.nlm.semanticType.phsu" label="reuptake inhibitors, serotonin"/>
		<category term="C0360105" scheme="gov.nih.nlm.semanticType.phsu" label="selective serotonin reuptake inhibitors"/>
		<category term="C0758711" scheme="gov.nih.nlm.semanticType.orch" label="serotonin"/>
		<category term="C1319313" scheme="gov.nih.nlm.semanticType.phsu" label="norepinephrine reuptake inhibitors"/>
		<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin reuptake inhibitors"/>
		<category term="C3252015" scheme="gov.nih.nlm.semanticType.phsu" label="RR"/>
		<category term="C3537213" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin/norepinephrine reuptake inhibitors"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0003290" scheme="gov.nih.nlm.semanticType.phsu" label="tricyclic antidepressants"/>
		<category term="C3540022" scheme="gov.nih.nlm.semanticType.phsu" label="MAO inhibitors"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0049506" scheme="gov.nih.nlm.semanticType.phsu" label="mirtazapine"/>
		<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
		<category term="C0085208" scheme="gov.nih.nlm.semanticType.phsu" label="bupropion"/>
		<category term="C0245561" scheme="gov.nih.nlm.semanticType.phsu" label="duloxetine"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0049506" scheme="gov.nih.nlm.semanticType.phsu" label="mirtazapine"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRI"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0003290" scheme="gov.nih.nlm.semanticType.phsu" label="tricyclic antidepressants"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0016365" scheme="gov.nih.nlm.semanticType.phsu" label="fluoxetine"/>
		<category term="C0040805" scheme="gov.nih.nlm.semanticType.phsu" label="trazodone"/>
		<category term="C0049506" scheme="gov.nih.nlm.semanticType.phsu" label="mirtazapine"/>
		<category term="C0070122" scheme="gov.nih.nlm.semanticType.phsu" label="paroxetine"/>
		<category term="C0074393" scheme="gov.nih.nlm.semanticType.phsu" label="sertraline"/>
		<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
		<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
		<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
		<category term="C0245561" scheme="gov.nih.nlm.semanticType.phsu" label="duloxetine"/>
		<category term="C1880288" scheme="gov.nih.nlm.semanticType.phsu" label="desvenlafaxine"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
		<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="Venlafaxine"/>
		<category term="C0245561" scheme="gov.nih.nlm.semanticType.phsu" label="Duloxetine"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0039052" scheme="gov.nih.nlm.semanticType.phsu" label="sympathomimetic drug"/>
		<category term="C1875809" scheme="gov.nih.nlm.semanticType.phsu" label="sympathomimetic"/>
		<category term="C0085208" scheme="gov.nih.nlm.semanticType.phsu" label="Bupropion"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
		<category term="C0049506" scheme="gov.nih.nlm.semanticType.phsu" label="Mirtazapine"/>
		<category term="C0758711" scheme="gov.nih.nlm.semanticType.orch" label="serotonin"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
		<category term="C0049506" scheme="gov.nih.nlm.semanticType.phsu" label="Mirtazapine"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
		<category term="C0008845" scheme="gov.nih.nlm.semanticType.phsu" label="citalopram"/>
		<category term="C1259875" scheme="gov.nih.nlm.semanticType.phsu" label="STAR"/>
		<category term="C0008845" scheme="gov.nih.nlm.semanticType.phsu" label="citalopram"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="Drug"/>
		<category term="C3469597" scheme="gov.nih.nlm.semanticType.hlca" label="Drug Administration"/>
		<category term="C3540798" scheme="gov.nih.nlm.semanticType.imft" label="Food"/>
		<category term="C0008845" scheme="gov.nih.nlm.semanticType.phsu" label="citalopram"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
		<category term="C0016365" scheme="gov.nih.nlm.semanticType.phsu" label="fluoxetine"/>
		<category term="C0008845" scheme="gov.nih.nlm.semanticType.phsu" label="citalopram"/>
		<category term="C1259875" scheme="gov.nih.nlm.semanticType.phsu" label="STAR"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
		<category term="C0085208" scheme="gov.nih.nlm.semanticType.phsu" label="bupropion"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="Antidepressant"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C0457454" scheme="gov.nih.nlm.semanticType.hlca" label="discontinuation"/>
		<category term="C0008845" scheme="gov.nih.nlm.semanticType.phsu" label="citalopram"/>
		<category term="C1259875" scheme="gov.nih.nlm.semanticType.phsu" label="STAR"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C2003848" scheme="gov.nih.nlm.semanticType.topp" label="drug therapy"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0332293" scheme="gov.nih.nlm.semanticType.topp" label="treated by"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C1096649" scheme="gov.nih.nlm.semanticType.topp" label="antidepressant therapy"/>
		<category term="C0677908" scheme="gov.nih.nlm.semanticType.topp" label="Maintenance therapy"/>
		<category term="C0677908" scheme="gov.nih.nlm.semanticType.topp" label="maintenance therapy"/>
		<category term="C0332293" scheme="gov.nih.nlm.semanticType.topp" label="treated by"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C0040615" scheme="gov.nih.nlm.semanticType.phsu" label="antipsychotics"/>
		<category term="C0073393" scheme="gov.nih.nlm.semanticType.phsu" label="risperidone"/>
		<category term="C0123091" scheme="gov.nih.nlm.semanticType.phsu" label="quetiapine"/>
		<category term="C0171023" scheme="gov.nih.nlm.semanticType.phsu" label="olanzapine"/>
		<category term="C0299792" scheme="gov.nih.nlm.semanticType.phsu" label="aripiprazole"/>
		<category term="C0006949" scheme="gov.nih.nlm.semanticType.phsu" label="carbamazepine"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0064636" scheme="gov.nih.nlm.semanticType.phsu" label="lamotrigine"/>
		<category term="C0080356" scheme="gov.nih.nlm.semanticType.phsu" label="valproate"/>
		<category term="C0619701" scheme="gov.nih.nlm.semanticType.horm" label="II"/>
		<category term="C0628655" scheme="gov.nih.nlm.semanticType.phsu" label="meet"/>
		<category term="C1276998" scheme="gov.nih.nlm.semanticType.phsu" label="mood stabilizing drug"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C0040616" scheme="gov.nih.nlm.semanticType.phsu" label="Anxiolytics"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0003290" scheme="gov.nih.nlm.semanticType.phsu" label="tricyclic antidepressants"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
		<category term="C0360105" scheme="gov.nih.nlm.semanticType.phsu" label="selective serotonin reuptake inhibitors"/>
		<category term="C0758711" scheme="gov.nih.nlm.semanticType.orch" label="serotonin"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin reuptake inhibitors"/>
		<category term="C0011812" scheme="gov.nih.nlm.semanticType.phsu" label="dextroamphetamine"/>
		<category term="C0025810" scheme="gov.nih.nlm.semanticType.phsu" label="methylphenidate"/>
		<category term="C0030800" scheme="gov.nih.nlm.semanticType.phsu" label="pemoline"/>
		<category term="C0066677" scheme="gov.nih.nlm.semanticType.phsu" label="modafinil"/>
		<category term="C0304403" scheme="gov.nih.nlm.semanticType.phsu" label="Psychostimulants"/>
		<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0066677" scheme="gov.nih.nlm.semanticType.phsu" label="modafinil"/>
		<category term="C0002844" scheme="gov.nih.nlm.semanticType.horm" label="androgen"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0025876" scheme="gov.nih.nlm.semanticType.horm" label="metyrapone"/>
		<category term="C0026088" scheme="gov.nih.nlm.semanticType.phsu" label="mifepristone"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
		<category term="C3252015" scheme="gov.nih.nlm.semanticType.phsu" label="RR"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C0041014" scheme="gov.nih.nlm.semanticType.horm" label="Triiodothyronine"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C1099456" scheme="gov.nih.nlm.semanticType.phsu" label="escitalopram"/>
		<category term="C1572759" scheme="gov.nih.nlm.semanticType.orch" label="monohydrate"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0010132" scheme="gov.nih.nlm.semanticType.horm" label="corticotropin releasing factors"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0050605" scheme="gov.nih.nlm.semanticType.aapp" label="corticotropin"/>
		<category term="C1261322" scheme="gov.nih.nlm.semanticType.hlca" label="investigation"/>
		<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoid"/>
		<category term="C1259875" scheme="gov.nih.nlm.semanticType.phsu" label="STAR"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="Antidepressants"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C2930737" scheme="gov.nih.nlm.semanticType.phsu" label="energy"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="Antidepressants"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C1096649" scheme="gov.nih.nlm.semanticType.topp" label="antidepressant therapy"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
		<category term="C3540763" scheme="gov.nih.nlm.semanticType.phsu" label="various"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0397581" scheme="gov.nih.nlm.semanticType.topp" label="artery"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="Venlafaxine"/>
		<category term="C0085208" scheme="gov.nih.nlm.semanticType.phsu" label="bupropion"/>
		<category term="C0245561" scheme="gov.nih.nlm.semanticType.phsu" label="duloxetine"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0628655" scheme="gov.nih.nlm.semanticType.phsu" label="meet"/>
		<category term="C0001701" scheme="gov.nih.nlm.semanticType.topp" label="aerobic exercise"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C1096649" scheme="gov.nih.nlm.semanticType.topp" label="antidepressant therapy"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0031765" scheme="gov.nih.nlm.semanticType.topp" label="light therapy"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0003290" scheme="gov.nih.nlm.semanticType.phsu" label="tricyclic antidepressants"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0360105" scheme="gov.nih.nlm.semanticType.phsu" label="selective serotonin reuptake inhibitors"/>
		<category term="C0629984" scheme="gov.nih.nlm.semanticType.strd" label="TCAs"/>
		<category term="C0758711" scheme="gov.nih.nlm.semanticType.orch" label="serotonin"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin reuptake inhibitors"/>
		<category term="C3653413" scheme="gov.nih.nlm.semanticType.phsu" label="monoamine oxidase inhibitors"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C0006462" scheme="gov.nih.nlm.semanticType.phsu" label="buspirone"/>
		<category term="C0085208" scheme="gov.nih.nlm.semanticType.phsu" label="bupropion"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C0677908" scheme="gov.nih.nlm.semanticType.topp" label="maintenance therapy"/>
		<category term="C0677908" scheme="gov.nih.nlm.semanticType.topp" label="maintenance therapy"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0963297" scheme="gov.nih.nlm.semanticType.orch" label="benzodiazepine"/>
		<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
		<category term="C2003848" scheme="gov.nih.nlm.semanticType.topp" label="drug therapy"/>
		<category term="C1171947" scheme="gov.nih.nlm.semanticType.phsu" label="commit"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0871787" scheme="gov.nih.nlm.semanticType.topp" label="interpersonal psychotherapy"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C3542961" scheme="gov.nih.nlm.semanticType.phsu" label="nervous system"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0004933" scheme="gov.nih.nlm.semanticType.topp" label="behavioral therapy"/>
		<category term="C0009244" scheme="gov.nih.nlm.semanticType.topp" label="cognitive-behavioral therapy"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0871787" scheme="gov.nih.nlm.semanticType.topp" label="interpersonal psychotherapy"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0556895" scheme="gov.nih.nlm.semanticType.topp" label="combination therapy"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0556895" scheme="gov.nih.nlm.semanticType.topp" label="combination therapy"/>
		<category term="C0556895" scheme="gov.nih.nlm.semanticType.topp" label="combination therapy"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0004933" scheme="gov.nih.nlm.semanticType.topp" label="behavioral therapy"/>
		<category term="C0009244" scheme="gov.nih.nlm.semanticType.topp" label="cognitive-behavioral therapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0033972" scheme="gov.nih.nlm.semanticType.topp" label="combined therapy"/>
		<category term="C0419168" scheme="gov.nih.nlm.semanticType.topp" label="other psychotherapies"/>
		<category term="C0871787" scheme="gov.nih.nlm.semanticType.topp" label="interpersonal psychotherapy"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0242905" scheme="gov.nih.nlm.semanticType.phsu" label="atypical antidepressants"/>
		<category term="C0758711" scheme="gov.nih.nlm.semanticType.orch" label="serotonin"/>
		<category term="C1319313" scheme="gov.nih.nlm.semanticType.phsu" label="norepinephrine reuptake inhibitors"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
		<category term="C3537213" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin-norepinephrine reuptake inhibitors"/>
		<category term="C0074393" scheme="gov.nih.nlm.semanticType.phsu" label="sertraline"/>
		<category term="C1099456" scheme="gov.nih.nlm.semanticType.phsu" label="escitalopram"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0308902" scheme="gov.nih.nlm.semanticType.phsu" label="duration"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
		<category term="C0016365" scheme="gov.nih.nlm.semanticType.phsu" label="fluoxetine"/>
		<category term="C0049506" scheme="gov.nih.nlm.semanticType.phsu" label="mirtazapine"/>
		<category term="C0070122" scheme="gov.nih.nlm.semanticType.phsu" label="paroxetine"/>
		<category term="C0074393" scheme="gov.nih.nlm.semanticType.phsu" label="sertraline"/>
		<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
		<category term="C0085228" scheme="gov.nih.nlm.semanticType.phsu" label="fluvoxamine"/>
		<category term="C0168388" scheme="gov.nih.nlm.semanticType.phsu" label="reboxetine"/>
		<category term="C0245561" scheme="gov.nih.nlm.semanticType.phsu" label="duloxetine"/>
		<category term="C1099456" scheme="gov.nih.nlm.semanticType.phsu" label="escitalopram"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0008845" scheme="gov.nih.nlm.semanticType.phsu" label="citalopram"/>
		<category term="C0074393" scheme="gov.nih.nlm.semanticType.phsu" label="sertraline"/>
		<category term="C0457454" scheme="gov.nih.nlm.semanticType.hlca" label="Discontinuation"/>
		<category term="C1099456" scheme="gov.nih.nlm.semanticType.phsu" label="escitalopram"/>
		<category term="C3653915" scheme="gov.nih.nlm.semanticType.phsu" label="other antidepressants"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0457454" scheme="gov.nih.nlm.semanticType.hlca" label="discontinuation"/>
		<category term="C0008845" scheme="gov.nih.nlm.semanticType.phsu" label="citalopram"/>
		<category term="C1099456" scheme="gov.nih.nlm.semanticType.phsu" label="escitalopram"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0049506" scheme="gov.nih.nlm.semanticType.phsu" label="mirtazapine"/>
		<category term="C3653915" scheme="gov.nih.nlm.semanticType.phsu" label="other antidepressants"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0008845" scheme="gov.nih.nlm.semanticType.phsu" label="citalopram"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0040805" scheme="gov.nih.nlm.semanticType.phsu" label="trazodone"/>
		<category term="C0085208" scheme="gov.nih.nlm.semanticType.phsu" label="bupropion"/>
		<category term="C1099456" scheme="gov.nih.nlm.semanticType.phsu" label="escitalopram"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0008845" scheme="gov.nih.nlm.semanticType.phsu" label="citalopram"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0016365" scheme="gov.nih.nlm.semanticType.phsu" label="fluoxetine"/>
		<category term="C0049506" scheme="gov.nih.nlm.semanticType.phsu" label="mirtazapine"/>
		<category term="C0068485" scheme="gov.nih.nlm.semanticType.phsu" label="nefazodone"/>
		<category term="C0070122" scheme="gov.nih.nlm.semanticType.phsu" label="paroxetine"/>
		<category term="C0074393" scheme="gov.nih.nlm.semanticType.phsu" label="sertraline"/>
		<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
		<category term="C0085208" scheme="gov.nih.nlm.semanticType.phsu" label="bupropion"/>
		<category term="C0085228" scheme="gov.nih.nlm.semanticType.phsu" label="fluvoxamine"/>
		<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
		<category term="C0016365" scheme="gov.nih.nlm.semanticType.phsu" label="fluoxetine"/>
		<category term="C0040805" scheme="gov.nih.nlm.semanticType.phsu" label="trazodone"/>
		<category term="C0049506" scheme="gov.nih.nlm.semanticType.phsu" label="mirtazapine"/>
		<category term="C0070122" scheme="gov.nih.nlm.semanticType.phsu" label="paroxetine"/>
		<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
		<category term="C0085208" scheme="gov.nih.nlm.semanticType.phsu" label="bupropion"/>
		<category term="C0016365" scheme="gov.nih.nlm.semanticType.phsu" label="fluoxetine"/>
		<category term="C0040805" scheme="gov.nih.nlm.semanticType.phsu" label="trazodone"/>
		<category term="C0049506" scheme="gov.nih.nlm.semanticType.phsu" label="mirtazapine"/>
		<category term="C0070122" scheme="gov.nih.nlm.semanticType.phsu" label="paroxetine"/>
		<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
		<category term="C0124598" scheme="gov.nih.nlm.semanticType.phsu" label="kg"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
		<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0758711" scheme="gov.nih.nlm.semanticType.orch" label="serotonin"/>
		<category term="C1319313" scheme="gov.nih.nlm.semanticType.phsu" label="norepinephrine reuptake inhibitors"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
		<category term="C3537213" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin-norepinephrine reuptake inhibitors"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0068485" scheme="gov.nih.nlm.semanticType.phsu" label="nefazodone"/>
		<category term="C0971637" scheme="gov.nih.nlm.semanticType.phsu" label="agomelatine"/>
		<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRI"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0008845" scheme="gov.nih.nlm.semanticType.phsu" label="citalopram"/>
		<category term="C1259875" scheme="gov.nih.nlm.semanticType.phsu" label="STAR"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
		<category term="C1099456" scheme="gov.nih.nlm.semanticType.phsu" label="escitalopram"/>
		<category term="C1099456" scheme="gov.nih.nlm.semanticType.phsu" label="escitalopram"/>
		<category term="C0016365" scheme="gov.nih.nlm.semanticType.phsu" label="fluoxetine"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="Antidepressants"/>
		<category term="C0016365" scheme="gov.nih.nlm.semanticType.phsu" label="fluoxetine"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0002600" scheme="gov.nih.nlm.semanticType.phsu" label="amitriptyline"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="Meta"/>
		<category term="C0070122" scheme="gov.nih.nlm.semanticType.phsu" label="paroxetine"/>
		<category term="C0245561" scheme="gov.nih.nlm.semanticType.phsu" label="duloxetine"/>
		<category term="C0971637" scheme="gov.nih.nlm.semanticType.phsu" label="agomelatine"/>
		<category term="C3653413" scheme="gov.nih.nlm.semanticType.phsu" label="monoamine oxidase inhibitors"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebos"/>
		<category term="C0628655" scheme="gov.nih.nlm.semanticType.phsu" label="meeting"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="Antidepressants"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0004933" scheme="gov.nih.nlm.semanticType.topp" label="behavioral therapy"/>
		<category term="C0009244" scheme="gov.nih.nlm.semanticType.topp" label="Cognitive-behavioral therapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="Psychotherapies"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0871787" scheme="gov.nih.nlm.semanticType.topp" label="interpersonal psychotherapy"/>
		<category term="C0004933" scheme="gov.nih.nlm.semanticType.topp" label="behavioral therapy"/>
		<category term="C0009244" scheme="gov.nih.nlm.semanticType.topp" label="cognitive-behavioral therapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapies"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0344211" scheme="gov.nih.nlm.semanticType.topp" label="supportive therapy"/>
		<category term="C0474215" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapies (behavioral"/>
		<category term="C0599237" scheme="gov.nih.nlm.semanticType.topp" label="psychodynamic therapy"/>
		<category term="C0871787" scheme="gov.nih.nlm.semanticType.topp" label="interpersonal psychotherapy"/>
		<category term="C1303140" scheme="gov.nih.nlm.semanticType.topp" label="problem solving therapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapies"/>
		<category term="C0557035" scheme="gov.nih.nlm.semanticType.hlca" label="help therapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="Psychotherapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0221295" scheme="gov.nih.nlm.semanticType.topp" label="supportive psychotherapy"/>
		<category term="C0419168" scheme="gov.nih.nlm.semanticType.topp" label="other psychotherapies"/>
		<category term="C1261382" scheme="gov.nih.nlm.semanticType.topp" label="psychodynamic psychotherapy"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0871787" scheme="gov.nih.nlm.semanticType.topp" label="interpersonal psychotherapy"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0001758" scheme="gov.nih.nlm.semanticType.hlca" label="after treatment"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="adding"/>
		<category term="C0004361" scheme="gov.nih.nlm.semanticType.topp" label="autogenic training"/>
		<category term="C0035029" scheme="gov.nih.nlm.semanticType.topp" label="relaxation techniques"/>
		<category term="C0150316" scheme="gov.nih.nlm.semanticType.topp" label="progressive muscle relaxation"/>
		<category term="C0150627" scheme="gov.nih.nlm.semanticType.topp" label="imagery"/>
		<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
		<category term="C0004933" scheme="gov.nih.nlm.semanticType.topp" label="behavioral therapy"/>
		<category term="C0009244" scheme="gov.nih.nlm.semanticType.topp" label="cognitive-behavioral therapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="add"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0001701" scheme="gov.nih.nlm.semanticType.topp" label="Aerobic exercise"/>
		<category term="C0624791" scheme="gov.nih.nlm.semanticType.imft" label="running"/>
		<category term="C0872279" scheme="gov.nih.nlm.semanticType.topp" label="resistance training"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C0017313" scheme="gov.nih.nlm.semanticType.hlca" label="care patients"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="Meta"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="Psychotherapy"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0017313" scheme="gov.nih.nlm.semanticType.hlca" label="care patients"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C0040616" scheme="gov.nih.nlm.semanticType.phsu" label="Anxiolytics"/>
		<category term="C1569452" scheme="gov.nih.nlm.semanticType.phsu" label="refusal"/>
		<category term="C3540798" scheme="gov.nih.nlm.semanticType.imft" label="food"/>
		<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalization"/>
		<category term="C0002600" scheme="gov.nih.nlm.semanticType.phsu" label="amitriptyline"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0871787" scheme="gov.nih.nlm.semanticType.topp" label="interpersonal psychotherapy"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0556895" scheme="gov.nih.nlm.semanticType.topp" label="combination therapy"/>
		<category term="C0013806" scheme="gov.nih.nlm.semanticType.topp" label="ECT"/>
		<category term="C0013808" scheme="gov.nih.nlm.semanticType.topp" label="electroconvulsive therapy"/>
		<category term="C0556895" scheme="gov.nih.nlm.semanticType.topp" label="combination therapy"/>
		<category term="C0013806" scheme="gov.nih.nlm.semanticType.topp" label="ECT"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="Meta"/>
		<category term="C0013806" scheme="gov.nih.nlm.semanticType.topp" label="ECT"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0013806" scheme="gov.nih.nlm.semanticType.topp" label="ECT"/>
		<category term="C0556895" scheme="gov.nih.nlm.semanticType.topp" label="combination therapy"/>
		<category term="C0040615" scheme="gov.nih.nlm.semanticType.phsu" label="antipsychotics"/>
		<category term="C0758711" scheme="gov.nih.nlm.semanticType.orch" label="serotonin"/>
		<category term="C1319313" scheme="gov.nih.nlm.semanticType.phsu" label="norepinephrine reuptake inhibitors"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
		<category term="C3537213" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin-norepinephrine reuptake inhibitors"/>
		<category term="C0008845" scheme="gov.nih.nlm.semanticType.phsu" label="citalopram"/>
		<category term="C0016365" scheme="gov.nih.nlm.semanticType.phsu" label="fluoxetine"/>
		<category term="C0070122" scheme="gov.nih.nlm.semanticType.phsu" label="paroxetine"/>
		<category term="C0074393" scheme="gov.nih.nlm.semanticType.phsu" label="sertraline"/>
		<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
		<category term="C0245561" scheme="gov.nih.nlm.semanticType.phsu" label="duloxetine"/>
		<category term="C0758711" scheme="gov.nih.nlm.semanticType.orch" label="serotonin"/>
		<category term="C1099456" scheme="gov.nih.nlm.semanticType.phsu" label="escitalopram"/>
		<category term="C1319313" scheme="gov.nih.nlm.semanticType.phsu" label="norepinephrine reuptake inhibitors"/>
		<category term="C1533126" scheme="gov.nih.nlm.semanticType.phsu" label="milnacipran"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
		<category term="C3537213" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin-norepinephrine reuptake inhibitors"/>
		<category term="C0758711" scheme="gov.nih.nlm.semanticType.orch" label="serotonin"/>
		<category term="C1319313" scheme="gov.nih.nlm.semanticType.phsu" label="norepinephrine reuptake inhibitors"/>
		<category term="C3537213" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin-norepinephrine reuptake inhibitors"/>
		<category term="C0040805" scheme="gov.nih.nlm.semanticType.phsu" label="trazodone"/>
		<category term="C0049506" scheme="gov.nih.nlm.semanticType.phsu" label="mirtazapine"/>
		<category term="C0758711" scheme="gov.nih.nlm.semanticType.orch" label="serotonin"/>
		<category term="C1319313" scheme="gov.nih.nlm.semanticType.phsu" label="norepinephrine reuptake inhibitors"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
		<category term="C3537213" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin-norepinephrine reuptake inhibitors"/>
		<category term="C0040805" scheme="gov.nih.nlm.semanticType.phsu" label="trazodone"/>
		<category term="C0049506" scheme="gov.nih.nlm.semanticType.phsu" label="mirtazapine"/>
		<category term="C0049506" scheme="gov.nih.nlm.semanticType.phsu" label="mirtazapine"/>
		<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
		<category term="C0049506" scheme="gov.nih.nlm.semanticType.phsu" label="mirtazapine"/>
		<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
		<category term="C0457454" scheme="gov.nih.nlm.semanticType.hlca" label="discontinuation"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0003290" scheme="gov.nih.nlm.semanticType.phsu" label="Tricyclic antidepressants"/>
		<category term="C3653915" scheme="gov.nih.nlm.semanticType.phsu" label="other antidepressants"/>
		<category term="C0002600" scheme="gov.nih.nlm.semanticType.phsu" label="amitriptyline"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0009010" scheme="gov.nih.nlm.semanticType.phsu" label="clomipramine"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C3653915" scheme="gov.nih.nlm.semanticType.phsu" label="other antidepressants"/>
		<category term="C0002600" scheme="gov.nih.nlm.semanticType.phsu" label="amitriptyline"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
		<category term="C3653915" scheme="gov.nih.nlm.semanticType.phsu" label="other antidepressants"/>
		<category term="C0002600" scheme="gov.nih.nlm.semanticType.phsu" label="amitriptyline"/>
		<category term="C0008845" scheme="gov.nih.nlm.semanticType.phsu" label="citalopram"/>
		<category term="C0009010" scheme="gov.nih.nlm.semanticType.phsu" label="clomipramine"/>
		<category term="C0011685" scheme="gov.nih.nlm.semanticType.phsu" label="desipramine"/>
		<category term="C0016365" scheme="gov.nih.nlm.semanticType.phsu" label="fluoxetine"/>
		<category term="C0024778" scheme="gov.nih.nlm.semanticType.phsu" label="maprotiline"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0070122" scheme="gov.nih.nlm.semanticType.phsu" label="paroxetine"/>
		<category term="C0085228" scheme="gov.nih.nlm.semanticType.phsu" label="fluvoxamine"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
		<category term="C0457454" scheme="gov.nih.nlm.semanticType.hlca" label="discontinuation"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0457454" scheme="gov.nih.nlm.semanticType.hlca" label="Discontinuation"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0556895" scheme="gov.nih.nlm.semanticType.topp" label="combination therapy"/>
		<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
		<category term="C0457454" scheme="gov.nih.nlm.semanticType.hlca" label="discontinuation"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0029151" scheme="gov.nih.nlm.semanticType.topp" label="pill"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0871787" scheme="gov.nih.nlm.semanticType.topp" label="interpersonal psychotherapy"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0360105" scheme="gov.nih.nlm.semanticType.phsu" label="selective serotonin reuptake inhibitors"/>
		<category term="C0758711" scheme="gov.nih.nlm.semanticType.orch" label="serotonin"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin reuptake inhibitors"/>
		<category term="C3653915" scheme="gov.nih.nlm.semanticType.phsu" label="other antidepressants"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapies"/>
		<category term="C0004933" scheme="gov.nih.nlm.semanticType.topp" label="behavioral therapy"/>
		<category term="C0009244" scheme="gov.nih.nlm.semanticType.topp" label="cognitive-behavioral therapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0419168" scheme="gov.nih.nlm.semanticType.topp" label="other psychotherapies"/>
		<category term="C0871787" scheme="gov.nih.nlm.semanticType.topp" label="interpersonal psychotherapy"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="Antidepressants"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimens"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0758711" scheme="gov.nih.nlm.semanticType.orch" label="serotonin"/>
		<category term="C1319313" scheme="gov.nih.nlm.semanticType.phsu" label="norepinephrine reuptake inhibitors"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
		<category term="C3537213" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin-norepinephrine reuptake inhibitors"/>
		<category term="C3653915" scheme="gov.nih.nlm.semanticType.phsu" label="other antidepressants"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<id>1725</id>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H2"/>
			<id>169590</id>
			<summary>
				<section label="INITIAL EVALUATION" id="2">
					<fragment>Patients who have symptoms of depression should be evaluated with a history, physical examination, and limited laboratory testing (if indicated) to rule out secondary medical causes.</fragment>
				</section>
			</summary>
			<category term="C0031809" scheme="gov.nih.nlm.semanticType.hlca" label="physical examination"/>
			<category term="C0150618" scheme="gov.nih.nlm.semanticType.hlca" label="history, physical"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H3"/>
			<id>169591</id>
			<summary>
				<section label="Distinguishing unipolar and bipolar depression" id="3">
					<fragment>Patients with depressive symptoms should be screened for bipolar disorder.</fragment>
				</section>
			</summary>
			<category term="C3263684" scheme="gov.nih.nlm.semanticType.topp" label="screened"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H3"/>
			<id>169595</id>
			<summary>
				<section label="Distinguishing unipolar and bipolar depression" id="3">
					<fragment>Patients with bipolar disorder are frequently misdiagnosed as having unipolar depression, particularly patients with bipolar II disorder or bipolar disorder NOS who do not exhibit overt symptoms of mania.</fragment>
				</section>
			</summary>
			<category term="C0619701" scheme="gov.nih.nlm.semanticType.horm" label="II"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H4"/>
			<id>169599</id>
			<summary>
				<section label="Suicidal ideation" id="4">
					<fragment>Assessment for the presence of suicidal ideation is of paramount importance in all depressed patients.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H4"/>
			<id>169600</id>
			<summary>
				<section label="Suicidal ideation" id="4">
					<fragment>However, the ability of clinicians to predict suicide attempts and completed suicide is poor.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H4"/>
			<id>169607</id>
			<summary>
				<section label="Suicidal ideation" id="4">
					<fragment>Evaluation in an emergency department and/or hospitalization should be considered for patients at significant risk of suicide.</fragment>
				</section>
			</summary>
			<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalization"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H5"/>
			<id>169608</id>
			<summary>
				<section label="Severe depression" id="5">
					<fragment>Patients who are felt to have severe depression (eg, significant distress or decrease in function), whether or not they are suicidal, should be referred to a psychiatrist for management.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H5"/>
			<id>169613</id>
			<summary>
				<section label="Severe depression" id="5">
					<fragment>Depression, who need treatment for substance abuse.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H5"/>
			<id>169616</id>
			<summary>
				<section label="Severe depression" id="5">
					<fragment>Electroconvulsive therapy should be considered as an initial treatment for life-threatening depression.</fragment>
				</section>
			</summary>
			<category term="C0013808" scheme="gov.nih.nlm.semanticType.topp" label="Electroconvulsive therapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H6"/>
			<id>169617</id>
			<summary>
				<section label="Assessment tool" id="6">
					<fragment>The nine-item Patient Health Questionnaire (PHQ-9) is a self-report, standardized, depression rating scale that can be used to diagnose major depression and measure its severity.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H8"/>
			<id>169623</id>
			<summary>
				<section label="Discussing diagnosis" id="8">
					<fragment>Depression is associated with both emotional symptoms (mood changes) and physical symptoms (ie, fatigue, headache, abdominal pain, muscle tension).</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H8"/>
			<id>169625</id>
			<summary>
				<section label="Discussing diagnosis" id="8">
					<fragment>Depression is a physical illness, associated with biologic changes in neurochemistry in the brain.</fragment>
				</section>
			</summary>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H8"/>
			<id>169626</id>
			<summary>
				<section label="Discussing diagnosis" id="8">
					<fragment>Treatment with medication and/or psychotherapy generally shortens the course of depression and diminishes symptoms.</fragment>
				</section>
			</summary>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H9"/>
			<id>169628</id>
			<summary>
				<section label="Reluctant patients" id="9">
					<fragment>A patient diary that records sleep, mood, appetite, and concentration difficulties during this period may be useful in encouraging patients to accept treatment.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H10"/>
			<id>169630</id>
			<summary>
				<section label="Adherence to medications" id="10">
					<fragment>Patients who will be treated with medication should be told the following, at the initiation of treatment: Do not stop medications without talking with the prescribing clinician.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H11"/>
			<id>169640</id>
			<summary>
				<section label="Lifestyle advice" id="11">
					<fragment>However, exercise alone is not an effective treatment strategy for most patients with major depression.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H11"/>
			<id>169641</id>
			<summary>
				<section label="Lifestyle advice" id="11">
					<fragment>Relaxation techniques may be tried for patients with minimal symptoms.</fragment>
				</section>
			</summary>
			<category term="C0035029" scheme="gov.nih.nlm.semanticType.topp" label="Relaxation techniques"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H11"/>
			<id>169642</id>
			<summary>
				<section label="Lifestyle advice" id="11">
					<fragment>A meta-analysis of 11 trials found that relaxation reduced self-reported symptoms compared to no treatment, but was not as effective as psychological treatment.</fragment>
				</section>
			</summary>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H12"/>
			<id>169644</id>
			<summary>
				<section label="TREATMENT GOALS" id="12">
					<fragment>In the prospective Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study, 3671 outpatients with unipolar major depression who improved following treatment with pharmacotherapy and/or psychotherapy were subsequently followed for up to 12 months.</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="C1259875" scheme="gov.nih.nlm.semanticType.phsu" label="STAR"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H12"/>
			<id>169645</id>
			<summary>
				<section label="TREATMENT GOALS" id="12">
					<fragment>Relapse appeared to occur less frequently in patients who remitted, compared with patients who responded (reduction of baseline symptoms &gt;=50 percent) but did not remit.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H13"/>
			<id>169647</id>
			<summary>
				<section label="PSYCHOTHERAPY" id="13">
					<fragment>Psychotherapy, alone or in combination with antidepressant medication, is an option for patients with mild to moderate major depression.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="Psychotherapy"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H13"/>
			<id>169651</id>
			<summary>
				<section label="PSYCHOTHERAPY" id="13">
					<fragment>Starting antidepressants earlier than twelve weeks may be considered as well, because many patients do not optimally benefit from psychotherapy without a concurrent antidepressant.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H13"/>
			<id>169653</id>
			<summary>
				<section label="PSYCHOTHERAPY" id="13">
					<fragment>A broad range of psychological interventions appear to be effective for the treatment of depression.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H13"/>
			<id>169654</id>
			<summary>
				<section label="PSYCHOTHERAPY" id="13">
					<fragment>The Depression Guideline Panel of the Agency for Health Care Policy and Research (AHCPR) concluded that for patients with major depression, the efficacy of cognitive therapy, behavioral therapy, and interpersonal therapy was 46, 55, and 52 percent, respectively.</fragment>
				</section>
			</summary>
			<category term="C0004933" scheme="gov.nih.nlm.semanticType.topp" label="behavioral therapy"/>
			<category term="C0009244" scheme="gov.nih.nlm.semanticType.topp" label="cognitive therapy"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H13"/>
			<id>169657</id>
			<summary>
				<section label="PSYCHOTHERAPY" id="13">
					<fragment>Interpersonal psychotherapy also appears to prevent recurrence of major depression, but not as effectively as medication.</fragment>
				</section>
			</summary>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="C0309872" scheme="gov.nih.nlm.semanticType.phsu" label="prevent"/>
			<category term="C0871787" scheme="gov.nih.nlm.semanticType.topp" label="Interpersonal psychotherapy"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H13"/>
			<id>169658</id>
			<summary>
				<section label="PSYCHOTHERAPY" id="13">
					<fragment>A 2007 representative survey of the United States general population found that among outpatients treated for unipolar depressive disorders, the proportion using psychotherapy alone was 6 percent, and the proportion using psychotherapy plus pharmacotherapy was 43 percent.</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H13"/>
			<id>169659</id>
			<summary>
				<section label="PSYCHOTHERAPY" id="13">
					<fragment>These percentages are conservative estimates, because they do not include patients treated for an adjustment disorder, many if not most of whom were probably suffering from a depressive syndrome.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H14"/>
			<id>169660</id>
			<summary>
				<section label="PHARMACOTHERAPY VERSUS PSYCHOTHERAPY" id="14">
					<fragment>Pharmacotherapy and manual-based psychotherapy are each efficacious for treating depression.</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="Pharmacotherapy"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H14"/>
			<id>169661</id>
			<summary>
				<section label="PHARMACOTHERAPY VERSUS PSYCHOTHERAPY" id="14">
					<fragment>Multiple randomized trials of patients in the primary care setting have found similar efficacy for each treatment, with no clear predictors of which treatment is best for individual patients.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H14"/>
			<id>169662</id>
			<summary>
				<section label="PHARMACOTHERAPY VERSUS PSYCHOTHERAPY" id="14">
					<fragment>Guidelines from the National Institute for Clinical Excellence (NICE) in the United Kingdom recommend psychotherapy as initial treatment for patients with mild depression, citing that the risk benefit ratio does not warrant pharmacotherapy for mild symptoms.</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H14"/>
			<id>169663</id>
			<summary>
				<section label="PHARMACOTHERAPY VERSUS PSYCHOTHERAPY" id="14">
					<fragment>The AHCPR Guideline Panel recommends drug therapy alone as the initial treatment for severely depressed patients, and either medication or psychotherapy for mild or moderate depression.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="C2003848" scheme="gov.nih.nlm.semanticType.topp" label="drug therapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H14"/>
			<id>169664</id>
			<summary>
				<section label="PHARMACOTHERAPY VERSUS PSYCHOTHERAPY" id="14">
					<fragment>The panel notes the importance of regular follow-up for patients treated with medication to assure compliance, assess response, and develop a supportive relationship with their clinician.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H15"/>
			<id>169665</id>
			<summary>
				<section label="Combined therapy" id="15">
					<fragment>A systematic review of 12 randomized trials comparing antidepressant treatment alone with antidepressant treatment combined with psychotherapy found a higher response rate for patients in the combination group (OR 1.86, 95% CI 1.38-2.52);</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H15"/>
			<id>169668</id>
			<summary>
				<section label="Combined therapy" id="15">
					<fragment>An earlier meta-analysis comparing psychotherapy alone with antidepressant plus psychotherapy found no significant difference in response rates for mild depression, but significantly increased response to combination therapy for more severe and recurrent depression.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C0556895" scheme="gov.nih.nlm.semanticType.topp" label="combination therapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H15"/>
			<id>169669</id>
			<summary>
				<section label="Combined therapy" id="15">
					<fragment>Most data favor combination therapy for patients with severe, chronic (more than two years) or recurrent symptoms.</fragment>
				</section>
			</summary>
			<category term="C0556895" scheme="gov.nih.nlm.semanticType.topp" label="combination therapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H16"/>
			<id>169670</id>
			<summary>
				<section label="ANTIDEPRESSANTS" id="16">
					<fragment>The major classes of drugs used to treat depression are considered "first generation" (monoamine oxidase inhibitors [MAOIs], and tricyclic antidepressants [TCAs]) and "second generation" (selective serotonin reuptake inhibitors [SSRIs], inhibitors of the reuptake of both serotonin and norepinephrine [SNRIs], and a few drugs with unique modes of action).</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0003290" scheme="gov.nih.nlm.semanticType.phsu" label="tricyclic antidepressants"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0360105" scheme="gov.nih.nlm.semanticType.phsu" label="selective serotonin reuptake inhibitors"/>
			<category term="C0629984" scheme="gov.nih.nlm.semanticType.strd" label="TCAs"/>
			<category term="C0758711" scheme="gov.nih.nlm.semanticType.orch" label="serotonin"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin reuptake inhibitors"/>
			<category term="C3653413" scheme="gov.nih.nlm.semanticType.phsu" label="monoamine oxidase inhibitors"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H17"/>
			<id>169671</id>
			<summary>
				<section label="Efficacy" id="17">
					<fragment>Antidepressants are beneficial for patients with unipolar major depression.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="Antidepressants"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H17"/>
			<id>169672</id>
			<summary>
				<section label="Efficacy" id="17">
					<fragment>In a meta-analysis of patient level data from 37 randomized trials (8477 patients with major depression) that compared either fluoxetine (modal dose 20 mg per day) or venlafaxine (modal dose range 75 to 150 mg per day) with placebo for six weeks, the primary findings included the following: Remission occurred in more patients who received active drug than placebo (43 versus 29 percent).</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0016365" scheme="gov.nih.nlm.semanticType.phsu" label="fluoxetine"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H17"/>
			<id>169674</id>
			<summary>
				<section label="Efficacy" id="17">
					<fragment>For patients with acute major depression in the primary care setting, antidepressants are associated with a 50 to 60 percent response rate.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H17"/>
			<id>169675</id>
			<summary>
				<section label="Efficacy" id="17">
					<fragment>In one multicenter "real-world" study (N = 2876 outpatients treated with citalopram), remission occurred in 28 percent, with a mean time to remission of seven weeks.</fragment>
				</section>
			</summary>
			<category term="C0008845" scheme="gov.nih.nlm.semanticType.phsu" label="citalopram"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H13163623"/>
			<id>169680</id>
			<summary>
				<section label="Mild major depression" id="13163623">
					<fragment>Antidepressants appear to be efficacious for unipolar major depression regardless of baseline severity, including patients with mild major depression.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="Antidepressants"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H13163623"/>
			<id>169681</id>
			<summary>
				<section label="Mild major depression" id="13163623">
					<fragment>The belief that pharmacotherapy benefits only severely ill patients stems in part from a meta-analysis of six randomized trials (718 patients, nearly all with major depression) that compared antidepressants with placebo;</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H13163623"/>
			<id>169682</id>
			<summary>
				<section label="Mild major depression" id="13163623">
					<fragment>results suggested a substantial benefit in very severe depression and little or no benefit in mild to moderate depression.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H13163623"/>
			<id>169683</id>
			<summary>
				<section label="Mild major depression" id="13163623">
					<fragment>However, a subsequent, larger meta-analysis of 37 randomized trials (8477 patients with major depression) that compared antidepressants with placebo found that remission at six weeks occurred in more: Mildly ill patients who received active drug than placebo (50 versus 37 percent).</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H13163623"/>
			<id>169684</id>
			<summary>
				<section label="Mild major depression" id="13163623">
					<fragment>Severely ill patients who received active drug than placebo (38 versus 25 percent).</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H13163623"/>
			<id>169686</id>
			<summary>
				<section label="Mild major depression" id="13163623">
					<fragment>Although the larger meta-analysis is more believable than the earlier one and we are confident that antidepressants are efficacious for unipolar major depression of mild severity, nevertheless, there are hundreds of other randomized trials that were not included in the two meta-analyses.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H13163623"/>
			<id>169687</id>
			<summary>
				<section label="Mild major depression" id="13163623">
					<fragment>An analysis that included these other trials would provide a better basis for evaluating the efficacy of pharmacotherapy in mild major depression.</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H18"/>
			<id>169689</id>
			<summary>
				<section label="Choice of antidepressant" id="18">
					<fragment>As an example, a meta-analysis of 93 randomized trials (&gt;20,000 patients with unipolar major depression) found treatment effects among second-generation antidepressants were comparable.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H18"/>
			<id>169695</id>
			<summary>
				<section label="Choice of antidepressant" id="18">
					<fragment>Multiple meta-analyses have evaluated comparisons of antidepressant medications.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H18"/>
			<id>169698</id>
			<summary>
				<section label="Choice of antidepressant" id="18">
					<fragment>Drugs were similar in regard to acute and maintenance phase response rates, impact on quality of life indices, and treatment response for associated symptoms (anxiety, insomnia, pain).</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="Drugs"/>
			<category term="C0391422" scheme="gov.nih.nlm.semanticType.orch" label="impact"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H18"/>
			<id>169705</id>
			<summary>
				<section label="Choice of antidepressant" id="18">
					<fragment>Two meta-analyses evaluated randomized trials of sertraline escitalopram versus other antidepressive agents.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressive"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C0074393" scheme="gov.nih.nlm.semanticType.phsu" label="sertraline"/>
			<category term="C1099456" scheme="gov.nih.nlm.semanticType.phsu" label="escitalopram"/>
			<category term="5" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H18"/>
			<id>169706</id>
			<summary>
				<section label="Choice of antidepressant" id="18">
					<fragment>The studies found both sertraline and escitalopram more effective than the comparator drugs, although it is uncertain if differences were clinically significant.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0074393" scheme="gov.nih.nlm.semanticType.phsu" label="sertraline"/>
			<category term="C1099456" scheme="gov.nih.nlm.semanticType.phsu" label="escitalopram"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H18"/>
			<id>169707</id>
			<summary>
				<section label="Choice of antidepressant" id="18">
					<fragment>In a meta-analysis of 28 randomized, controlled trials involving 5940 primary care patients with major depression, dysthymia, or mixed anxiety depression, newer antidepressants (including selective serotonin reuptake inhibitors, serotonin/norepinephrine reuptake inhibitors, reversible inhibitors of monoamine oxidase, and dopamine antagonists) resulted in higher rates of response than placebo (RR 1.6, 95% CI 1.2-2.1), but rates were similar to those for tricyclic agents.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0017313" scheme="gov.nih.nlm.semanticType.hlca" label="care patients"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C0162758" scheme="gov.nih.nlm.semanticType.phsu" label="reuptake inhibitors, serotonin"/>
			<category term="C0360105" scheme="gov.nih.nlm.semanticType.phsu" label="selective serotonin reuptake inhibitors"/>
			<category term="C0758711" scheme="gov.nih.nlm.semanticType.orch" label="serotonin"/>
			<category term="C1319313" scheme="gov.nih.nlm.semanticType.phsu" label="norepinephrine reuptake inhibitors"/>
			<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin reuptake inhibitors"/>
			<category term="C3252015" scheme="gov.nih.nlm.semanticType.phsu" label="RR"/>
			<category term="C3537213" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin/norepinephrine reuptake inhibitors"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H18"/>
			<id>169708</id>
			<summary>
				<section label="Choice of antidepressant" id="18">
					<fragment>A systematic review of 55 randomized, controlled trials of MAO inhibitors versus tricyclic antidepressants found that MAO inhibitors were less effective for severe depressive disorders but possibly more effective in atypical depressive disorders.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0003290" scheme="gov.nih.nlm.semanticType.phsu" label="tricyclic antidepressants"/>
			<category term="C3540022" scheme="gov.nih.nlm.semanticType.phsu" label="MAO inhibitors"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H18"/>
			<id>169709</id>
			<summary>
				<section label="Choice of antidepressant" id="18">
					<fragment>A systematic review of 46 randomized controlled trials and 24 observational studies of head-to-head comparisons between second-generation antidepressants (SSRIs, bupropion, duloxetine, mirtazapine, and venlafaxine) concluded that there were no significant differences in efficacy or tolerability among these drugs.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0049506" scheme="gov.nih.nlm.semanticType.phsu" label="mirtazapine"/>
			<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
			<category term="C0085208" scheme="gov.nih.nlm.semanticType.phsu" label="bupropion"/>
			<category term="C0245561" scheme="gov.nih.nlm.semanticType.phsu" label="duloxetine"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H18"/>
			<id>169710</id>
			<summary>
				<section label="Choice of antidepressant" id="18">
					<fragment>By contrast, a meta-analysis of 12 randomized trials (2626 patients with major depression) found that response occurred in significantly more patients who received mirtazapine than an SSRI (OR 1.2).</fragment>
				</section>
			</summary>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C0049506" scheme="gov.nih.nlm.semanticType.phsu" label="mirtazapine"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRI"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H18"/>
			<id>169711</id>
			<summary>
				<section label="Choice of antidepressant" id="18">
					<fragment>There is limited evidence that tricyclics may be preferred for more severely depressed patients.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H18"/>
			<id>169712</id>
			<summary>
				<section label="Choice of antidepressant" id="18">
					<fragment>A meta-analysis of 25 randomized controlled trials for treatment of hospitalized, depressed patients found tricyclics were significantly more efficacious compared to SSRIs, but the clinical difference was small.</fragment>
				</section>
			</summary>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H18"/>
			<id>169713</id>
			<summary>
				<section label="Choice of antidepressant" id="18">
					<fragment>The role of tricyclic antidepressants in treating major depression is discussed separately.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0003290" scheme="gov.nih.nlm.semanticType.phsu" label="tricyclic antidepressants"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H18"/>
			<id>169714</id>
			<summary>
				<section label="Choice of antidepressant" id="18">
					<fragment>Patients who have been successfully treated with a well-tolerated drug in the past should resume that agent if depression recurs.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H19"/>
			<id>169719</id>
			<summary>
				<section label="Side effects" id="19">
					<fragment>Prior to prescribing an antidepressant, potential interactions with a patient's preexisting medication regimen should be checked using the drug interaction database available through UpToDate or in other programs.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H19"/>
			<id>169720</id>
			<summary>
				<section label="Side effects" id="19">
					<fragment>Specific antidepressants may cause more weight gain than others.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H19"/>
			<id>169721</id>
			<summary>
				<section label="Side effects" id="19">
					<fragment>A systematic review of second-generation antidepressants evaluated 203 studies and found that mirtazapine and paroxetine were associated more weight gain than other drugs such as fluoxetine, sertraline, trazodone, and venlafaxine.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0016365" scheme="gov.nih.nlm.semanticType.phsu" label="fluoxetine"/>
			<category term="C0040805" scheme="gov.nih.nlm.semanticType.phsu" label="trazodone"/>
			<category term="C0049506" scheme="gov.nih.nlm.semanticType.phsu" label="mirtazapine"/>
			<category term="C0070122" scheme="gov.nih.nlm.semanticType.phsu" label="paroxetine"/>
			<category term="C0074393" scheme="gov.nih.nlm.semanticType.phsu" label="sertraline"/>
			<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H19"/>
			<id>169722</id>
			<summary>
				<section label="Side effects" id="19">
					<fragment>A related issue is the risk of diabetes.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H19"/>
			<id>169724</id>
			<summary>
				<section label="Side effects" id="19">
					<fragment>A cohort study of 1000 people 65 years and older, followed prospectively for up to ten years, found that depressed individuals were more than twice as likely to develop diabetes compared to those without depression, regardless of antidepressant treatment (hazard ratio 2.3, 95% CI 1.3-4.1).</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H19"/>
			<id>169725</id>
			<summary>
				<section label="Side effects" id="19">
					<fragment>In addition, specific antidepressants or antidepressants as a class of medications may possibly be associated with an increased risk of diabetes.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H19"/>
			<id>169726</id>
			<summary>
				<section label="Side effects" id="19">
					<fragment>A nested case-control study found that among approximately 166,000 patients with depression and no sign of diabetes, long-term use (&gt;24 months) of an antidepressant in moderate to high doses was associated with a significantly increased risk of diabetes (incidence rate ratio 1.8, 95% CI 1.4-2.5).</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
			<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H21"/>
			<id>169734</id>
			<summary>
				<section label="SNRIs" id="21">
					<fragment>SNRIs (venlafaxine, duloxetine, and desvenlafaxine) have many similar side effects to SSRIs because of the serotonergic effect of these medications.</fragment>
				</section>
			</summary>
			<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
			<category term="C0245561" scheme="gov.nih.nlm.semanticType.phsu" label="duloxetine"/>
			<category term="C1880288" scheme="gov.nih.nlm.semanticType.phsu" label="desvenlafaxine"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H21"/>
			<id>169737</id>
			<summary>
				<section label="SNRIs" id="21">
					<fragment>Venlafaxine may cause hypertension at dosages of 300 mg or greater.</fragment>
				</section>
			</summary>
			<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="Venlafaxine"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H21"/>
			<id>169739</id>
			<summary>
				<section label="SNRIs" id="21">
					<fragment>Duloxetine may slightly impair glycemic control in patients with diabetes, and has been associated with fatal liver failure in patients with preexisting liver disease and is contraindicated in this subgroup of patients.</fragment>
				</section>
			</summary>
			<category term="C0245561" scheme="gov.nih.nlm.semanticType.phsu" label="Duloxetine"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H23"/>
			<id>169745</id>
			<summary>
				<section label="MAO inhibitors" id="23">
					<fragment>The hypertensive reaction is dose-dependent and can be exacerbated if the patient is also taking a sympathomimetic drug.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0039052" scheme="gov.nih.nlm.semanticType.phsu" label="sympathomimetic drug"/>
			<category term="C1875809" scheme="gov.nih.nlm.semanticType.phsu" label="sympathomimetic"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H24"/>
			<id>169747</id>
			<summary>
				<section label="Other antidepressants" id="24">
					<fragment>Bupropion has significantly fewer adverse effects related to sexual dysfunction than SSRIs, and may be particularly effective for patients who are lethargic.</fragment>
				</section>
			</summary>
			<category term="C0085208" scheme="gov.nih.nlm.semanticType.phsu" label="Bupropion"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H24"/>
			<id>169749</id>
			<summary>
				<section label="Other antidepressants" id="24">
					<fragment>Mirtazapine, a mixed serotonin-norepinephrine antagonist, is sedating.</fragment>
				</section>
			</summary>
			<category term="C0049506" scheme="gov.nih.nlm.semanticType.phsu" label="Mirtazapine"/>
			<category term="C0758711" scheme="gov.nih.nlm.semanticType.orch" label="serotonin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H24"/>
			<id>169750</id>
			<summary>
				<section label="Other antidepressants" id="24">
					<fragment>It has efficacy equivalent to SSRIs and may have a role in the treatment of patients with insomnia and depression.</fragment>
				</section>
			</summary>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
			<category term="5" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H24"/>
			<id>169751</id>
			<summary>
				<section label="Other antidepressants" id="24">
					<fragment>Mirtazapine causes more weight gain than SSRIs.</fragment>
				</section>
			</summary>
			<category term="C0049506" scheme="gov.nih.nlm.semanticType.phsu" label="Mirtazapine"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H25"/>
			<id>169761</id>
			<summary>
				<section label="Dosage" id="25">
					<fragment>In the Sequential Treatment Alternatives to Relieve Depression trial (STAR*D) involving outpatient treatment for 2876 patients with major depression, 80 percent of whom had chronic depression with recurrent episodes, the average dose of citalopram needed to achieve remission was 42 mg daily.</fragment>
				</section>
			</summary>
			<category term="C0008845" scheme="gov.nih.nlm.semanticType.phsu" label="citalopram"/>
			<category term="C1259875" scheme="gov.nih.nlm.semanticType.phsu" label="STAR"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H25"/>
			<id>169762</id>
			<summary>
				<section label="Dosage" id="25">
					<fragment>However, the United States Food and Drug Administration issued warnings that citalopram causes dose-dependent QT interval prolongation that can lead to arrhythmias, and thus recommends that the maximum dose should not exceed 40 mg per day.</fragment>
				</section>
			</summary>
			<category term="C0008845" scheme="gov.nih.nlm.semanticType.phsu" label="citalopram"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="Drug"/>
			<category term="C3469597" scheme="gov.nih.nlm.semanticType.hlca" label="Drug Administration"/>
			<category term="C3540798" scheme="gov.nih.nlm.semanticType.imft" label="Food"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H25"/>
			<id>169763</id>
			<summary>
				<section label="Dosage" id="25">
					<fragment>Additional information about the citalopram warnings and cardiac effects of SSRIs is discussed separately.</fragment>
				</section>
			</summary>
			<category term="C0008845" scheme="gov.nih.nlm.semanticType.phsu" label="citalopram"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H26"/>
			<id>169772</id>
			<summary>
				<section label="up" id="26">
					<fragment>Treatment time to maximal response may be six weeks or longer: In a study of 182 outpatients with major depression who had a sustained acute response to fluoxetine therapy, the probability of response was 56 percent at two weeks, 81 percent at four weeks, and 90 percent at six weeks.</fragment>
				</section>
			</summary>
			<category term="C0016365" scheme="gov.nih.nlm.semanticType.phsu" label="fluoxetine"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H26"/>
			<id>169774</id>
			<summary>
				<section label="up" id="26">
					<fragment>In the multicenter STAR*D trial, 56 percent of those who responded (more than 50 percent improvement) did so at or after eight weeks of treatment with citalopram.</fragment>
				</section>
			</summary>
			<category term="C0008845" scheme="gov.nih.nlm.semanticType.phsu" label="citalopram"/>
			<category term="C1259875" scheme="gov.nih.nlm.semanticType.phsu" label="STAR"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H26"/>
			<id>169782</id>
			<summary>
				<section label="up" id="26">
					<fragment>After two SSRIs have been ineffective, antidepressants from a different class (such as bupropion or venlafaxine) should be chosen.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
			<category term="C0085208" scheme="gov.nih.nlm.semanticType.phsu" label="bupropion"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H26"/>
			<id>169783</id>
			<summary>
				<section label="up" id="26">
					<fragment>Adherence may be further enhanced by facilitating telephone access to the clinician for patient questions about side effects.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H26"/>
			<id>169784</id>
			<summary>
				<section label="up" id="26">
					<fragment>Outcomes and adherence can also be improved with the use of allied health professionals to proactively check on therapeutic response, side effects, and adherence, and to schedule return visits for patients with persistent symptoms.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H27"/>
			<id>169785</id>
			<summary>
				<section label="Duration of treatment" id="27">
					<fragment>Antidepressant medication generally should be taken for a minimum of six to nine months after a first episode of depression.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="Antidepressant"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H27"/>
			<id>169789</id>
			<summary>
				<section label="Duration of treatment" id="27">
					<fragment>Premature discontinuation of antidepressant medication occurs commonly.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="C0457454" scheme="gov.nih.nlm.semanticType.hlca" label="discontinuation"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H27"/>
			<id>169791</id>
			<summary>
				<section label="Duration of treatment" id="27">
					<fragment>In the STAR*D trial, slightly over one quarter of patients treated with citalopram as initial therapy for nonpsychotic major depression discontinued their medication for non-medical reasons within 14 weeks of initiation.</fragment>
				</section>
			</summary>
			<category term="C0008845" scheme="gov.nih.nlm.semanticType.phsu" label="citalopram"/>
			<category term="C1259875" scheme="gov.nih.nlm.semanticType.phsu" label="STAR"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H27"/>
			<id>169795</id>
			<summary>
				<section label="Duration of treatment" id="27">
					<fragment>Patients who have depression in the setting of known precipitants such as psychosocial stresses, bereavement, or loss should continue drug therapy until a significant change in adaptation to those factors has been accomplished, and for a minimum of six months.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C2003848" scheme="gov.nih.nlm.semanticType.topp" label="drug therapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H27"/>
			<id>169799</id>
			<summary>
				<section label="Duration of treatment" id="27">
					<fragment>One study of 251 patients who were being treated by primary care physicians found that 37 percent reported a relapse within 12 months of stopping drug treatment.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0332293" scheme="gov.nih.nlm.semanticType.topp" label="treated by"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H27"/>
			<id>169802</id>
			<summary>
				<section label="Duration of treatment" id="27">
					<fragment>A second prospective study followed 366 patients with depression (median follow-up 10 years) and found that 64 percent who initially recovered from major depression had a recurrence.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H27"/>
			<id>169804</id>
			<summary>
				<section label="Duration of treatment" id="27">
					<fragment>Maintenance antidepressant therapy can decrease the rate of relapse.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="C1096649" scheme="gov.nih.nlm.semanticType.topp" label="antidepressant therapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H27"/>
			<id>169807</id>
			<summary>
				<section label="Duration of treatment" id="27">
					<fragment>Maintenance therapy also appears to be effective in elderly patients.</fragment>
				</section>
			</summary>
			<category term="C0677908" scheme="gov.nih.nlm.semanticType.topp" label="Maintenance therapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H27"/>
			<id>169808</id>
			<summary>
				<section label="Duration of treatment" id="27">
					<fragment>Based upon similar studies, the AHCPR Guideline Panel recommended maintenance therapy for patients with a history of three or more depressive episodes and for those with two previous episodes plus risk factors that would increase the risk of recurrence.</fragment>
				</section>
			</summary>
			<category term="C0677908" scheme="gov.nih.nlm.semanticType.topp" label="maintenance therapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H27"/>
			<id>169809</id>
			<summary>
				<section label="Duration of treatment" id="27">
					<fragment>Patients with double depression (dysthymia and major depression) should also be considered for maintenance treatment.</fragment>
				</section>
			</summary>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H28"/>
			<id>169810</id>
			<summary>
				<section label="OTHER DRUGS" id="28">
					<fragment>Some of the medications used in augmentation therapy for resistant depression may also be appropriate for consideration earlier in therapy in specific patients.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H28"/>
			<id>169811</id>
			<summary>
				<section label="OTHER DRUGS" id="28">
					<fragment>These patients are most appropriately treated by a psychiatrist who can collaborate with the primary care provider.</fragment>
				</section>
			</summary>
			<category term="C0332293" scheme="gov.nih.nlm.semanticType.topp" label="treated by"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H29"/>
			<id>169812</id>
			<summary>
				<section label="Antipsychotics" id="29">
					<fragment>Adjunctive treatment with the second-generation antipsychotics aripiprazole, olanzapine, quetiapine, or risperidone is efficacious for unipolar, nonpsychotic major depression that has not responded to antidepressant monotherapy.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="C0040615" scheme="gov.nih.nlm.semanticType.phsu" label="antipsychotics"/>
			<category term="C0073393" scheme="gov.nih.nlm.semanticType.phsu" label="risperidone"/>
			<category term="C0123091" scheme="gov.nih.nlm.semanticType.phsu" label="quetiapine"/>
			<category term="C0171023" scheme="gov.nih.nlm.semanticType.phsu" label="olanzapine"/>
			<category term="C0299792" scheme="gov.nih.nlm.semanticType.phsu" label="aripiprazole"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H30"/>
			<id>169814</id>
			<summary>
				<section label="Mood stabilizers" id="30">
					<fragment>Patients with mood swings and a strong family history of bipolar disorder may meet criteria for bipolar II disorder, and should be treated with a mood stabilizing drug such as lithium, carbamazepine, valproate, or lamotrigine.</fragment>
				</section>
			</summary>
			<category term="C0006949" scheme="gov.nih.nlm.semanticType.phsu" label="carbamazepine"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0064636" scheme="gov.nih.nlm.semanticType.phsu" label="lamotrigine"/>
			<category term="C0080356" scheme="gov.nih.nlm.semanticType.phsu" label="valproate"/>
			<category term="C0619701" scheme="gov.nih.nlm.semanticType.horm" label="II"/>
			<category term="C0628655" scheme="gov.nih.nlm.semanticType.phsu" label="meet"/>
			<category term="C1276998" scheme="gov.nih.nlm.semanticType.phsu" label="mood stabilizing drug"/>
			<category term="7" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H30"/>
			<id>169817</id>
			<summary>
				<section label="Mood stabilizers" id="30">
					<fragment>Use of lithium to treat unipolar depression is discussed elsewhere.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H31"/>
			<id>169818</id>
			<summary>
				<section label="Anxiolytics" id="31">
					<fragment>Anxiolytics can be used as adjunctive treatment with an antidepressant, particularly for major depression that includes symptoms of anxiety (eg, ruminative thoughts, worrying, and panic attacks), insomnia, or psychomotor agitation.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="C0040616" scheme="gov.nih.nlm.semanticType.phsu" label="Anxiolytics"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H31"/>
			<id>169820</id>
			<summary>
				<section label="Anxiolytics" id="31">
					<fragment>Treatment for anxiety disorders are discussed separately.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H32"/>
			<id>169824</id>
			<summary>
				<section label="St. John&apos;s wort" id="32">
					<fragment>John's wort suggest that it is more effective than placebo and equivalent to tricyclic antidepressants and SSRIs in the short-term treatment of depression.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0003290" scheme="gov.nih.nlm.semanticType.phsu" label="tricyclic antidepressants"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H32"/>
			<id>169825</id>
			<summary>
				<section label="St. John&apos;s wort" id="32">
					<fragment>However, studies in the US do not support its efficacy in the treatment of severe depression, and further research in mild depression is ongoing.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H32"/>
			<id>169827</id>
			<summary>
				<section label="St. John&apos;s wort" id="32">
					<fragment>Patients with mild acute depression can be offered St.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H32"/>
			<id>169830</id>
			<summary>
				<section label="St. John&apos;s wort" id="32">
					<fragment>John's wort not be used in patients with significant major depression.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H32"/>
			<id>169833</id>
			<summary>
				<section label="St. John&apos;s wort" id="32">
					<fragment>Concomitant use with the selective serotonin reuptake inhibitors (SSRIs) may lead to the "serotonin syndrome," characterized by agitation, hyperthermia, diaphoresis, tachycardia, and neuromuscular disturbances including rigidity.</fragment>
				</section>
			</summary>
			<category term="C0360105" scheme="gov.nih.nlm.semanticType.phsu" label="selective serotonin reuptake inhibitors"/>
			<category term="C0758711" scheme="gov.nih.nlm.semanticType.orch" label="serotonin"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin reuptake inhibitors"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H33"/>
			<id>169836</id>
			<summary>
				<section label="Psychostimulants" id="33">
					<fragment>Psychostimulants (dextroamphetamine, methylphenidate, methylamphetamine, and pemoline) and a novel acting agent, modafinil, have been evaluated for both the initial treatment of depression as well as for use as adjunctive therapy in the treatment of resistant depression.</fragment>
				</section>
			</summary>
			<category term="C0011812" scheme="gov.nih.nlm.semanticType.phsu" label="dextroamphetamine"/>
			<category term="C0025810" scheme="gov.nih.nlm.semanticType.phsu" label="methylphenidate"/>
			<category term="C0030800" scheme="gov.nih.nlm.semanticType.phsu" label="pemoline"/>
			<category term="C0066677" scheme="gov.nih.nlm.semanticType.phsu" label="modafinil"/>
			<category term="C0304403" scheme="gov.nih.nlm.semanticType.phsu" label="Psychostimulants"/>
			<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
			<category term="7" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H33"/>
			<id>169838</id>
			<summary>
				<section label="Psychostimulants" id="33">
					<fragment>One study found no difference in symptoms, comparing with treatment with modafinil or placebo.</fragment>
				</section>
			</summary>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0066677" scheme="gov.nih.nlm.semanticType.phsu" label="modafinil"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H35"/>
			<id>169841</id>
			<summary>
				<section label="DHEA" id="35">
					<fragment>Oral supplementation with the adrenal androgen dehydroepiandrosterone (DHEA) may be of some benefit in patients with depression.</fragment>
				</section>
			</summary>
			<category term="C0002844" scheme="gov.nih.nlm.semanticType.horm" label="androgen"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H35"/>
			<id>169842</id>
			<summary>
				<section label="DHEA" id="35">
					<fragment>In a six week crossover trial in 46 patients with major or minor depression who were not treated with an antidepressant medication, patients had significantly lower depression scores while receiving DHEA (30 mg three times daily for three weeks followed by 150 mg three times daily for three weeks) than at baseline or while receiving placebo.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H35"/>
			<id>169844</id>
			<summary>
				<section label="DHEA" id="35">
					<fragment>There is limited evidence on the safety or long-term effectiveness of DHEA and we do not currently recommend it for the treatment of depression.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H35"/>
			<id>169845</id>
			<summary>
				<section label="DHEA" id="35">
					<fragment>Acne and hirsutism have both been described in women participating in longer-term trials of DHEA.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H36"/>
			<id>169846</id>
			<summary>
				<section label="Other" id="36">
					<fragment>Other antiglucocorticoid treatments have also been evaluated for depression.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H36"/>
			<id>169847</id>
			<summary>
				<section label="Other" id="36">
					<fragment>A meta-analysis of five trials in patients with non-psychotic depression found that treatment with one of several antiglucocorticoids (mifepristone, ketoconazole, metyrapone, or DHEA), was associated with a significantly greater response compared to placebo (RR 0.72, 95% CI 0.56-0.91).</fragment>
				</section>
			</summary>
			<category term="C0025876" scheme="gov.nih.nlm.semanticType.horm" label="metyrapone"/>
			<category term="C0026088" scheme="gov.nih.nlm.semanticType.phsu" label="mifepristone"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
			<category term="C3252015" scheme="gov.nih.nlm.semanticType.phsu" label="RR"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H37"/>
			<id>169849</id>
			<summary>
				<section label="Triiodothyronine" id="37">
					<fragment>Triiodothyronine (T3) has been used as augmentation therapy in patients with major depression who have not responded to initial treatment with antidepressant monotherapy, and has been combined with antidepressants at the onset of treatment to accelerate or enhance response.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="C0041014" scheme="gov.nih.nlm.semanticType.horm" label="Triiodothyronine"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H21630324"/>
			<id>169850</id>
			<summary>
				<section label="Creatine" id="21630324">
					<fragment>Creatine may possibly be useful as short term, adjunctive treatment with antidepressants to treat unipolar major depression.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H21630324"/>
			<id>169851</id>
			<summary>
				<section label="Creatine" id="21630324">
					<fragment>An eight-week randomized trial compared creatine monohydrate (5 g per day) plus escitalopram (10 to 20 mg per day) with placebo plus escitalopram in 52 women with unipolar major depression (mostly first episode).</fragment>
				</section>
			</summary>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C1099456" scheme="gov.nih.nlm.semanticType.phsu" label="escitalopram"/>
			<category term="C1572759" scheme="gov.nih.nlm.semanticType.orch" label="monohydrate"/>
			<category term="6" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H21630324"/>
			<id>169853</id>
			<summary>
				<section label="Creatine" id="21630324">
					<fragment>Remission occurred in more patients who received adjunctive creatine than placebo (52 versus 26 percent).</fragment>
				</section>
			</summary>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H38"/>
			<id>169856</id>
			<summary>
				<section label="Investigational drugs" id="38">
					<fragment>Potential drug interventions for depression under investigation include substance P and antagonists of corticotropin releasing factors and glucocorticoid receptors.</fragment>
				</section>
			</summary>
			<category term="C0010132" scheme="gov.nih.nlm.semanticType.horm" label="corticotropin releasing factors"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0050605" scheme="gov.nih.nlm.semanticType.aapp" label="corticotropin"/>
			<category term="C1261322" scheme="gov.nih.nlm.semanticType.hlca" label="investigation"/>
			<category term="C3540777" scheme="gov.nih.nlm.semanticType.horm" label="glucocorticoid"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H39"/>
			<id>169858</id>
			<summary>
				<section label="PSYCHIATRIC CONSULTATION" id="39">
					<fragment>Data from the STAR*D trial indicate that outcomes for initial therapy of depression are the same when identical care is provided either in primary care or psychiatric specialty settings.</fragment>
				</section>
			</summary>
			<category term="C1259875" scheme="gov.nih.nlm.semanticType.phsu" label="STAR"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H40"/>
			<id>169865</id>
			<summary>
				<section label="Collaborative care" id="40">
					<fragment>Collaborative care programs that involve enhanced patient education, integration of psychiatric visits into primary care treatment, and use of non-physician mental health professionals or depression care managers can significantly enhance depression outcomes compared with usual care.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H524936"/>
			<id>169890</id>
			<summary>
				<section label="DYSTHYMIC DISORDER" id="524936">
					<fragment>however, symptoms are not as numerous as in major depression.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H524936"/>
			<id>169892</id>
			<summary>
				<section label="DYSTHYMIC DISORDER" id="524936">
					<fragment>Antidepressants are effective for dysthymic disorder.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="Antidepressants"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H524936"/>
			<id>169893</id>
			<summary>
				<section label="DYSTHYMIC DISORDER" id="524936">
					<fragment>A meta-analysis of 9 randomized trials (1454 patients with dysthymic disorder) found that response (reduction of baseline depression rating scale score &gt;=50 percent) occurred in significantly more patients who received an antidepressant than placebo (52 versus 30 percent).</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H524936"/>
			<id>169896</id>
			<summary>
				<section label="DYSTHYMIC DISORDER" id="524936">
					<fragment>The trials that have examined the use of interpersonal therapy in dysthymic disorder are discussed separately.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H44"/>
			<id>169897</id>
			<summary>
				<section label="Elderly" id="44">
					<fragment>Treatment of depression in older adults is discussed separately.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H45"/>
			<id>169898</id>
			<summary>
				<section label="Pregnancy" id="45">
					<fragment>Treatment of depression in pregnant women is discussed separately.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H46"/>
			<id>169904</id>
			<summary>
				<section label="Depression in medical illness" id="46">
					<fragment>Depression in patients with other medical illnesses is common and an important cause of morbidity.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H46"/>
			<id>169905</id>
			<summary>
				<section label="Depression in medical illness" id="46">
					<fragment>Depression in patients with chronic medical illness is associated with increased physical symptoms;</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H46"/>
			<id>169912</id>
			<summary>
				<section label="Depression in medical illness" id="46">
					<fragment>symptoms such as a low mood and lack of energy may be due to the physical illness and/or to depression.</fragment>
				</section>
			</summary>
			<category term="C2930737" scheme="gov.nih.nlm.semanticType.phsu" label="energy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H351404"/>
			<id>169914</id>
			<summary>
				<section label="Interventions" id="351404">
					<fragment>Antidepressants appear to be effective and safe in patients with medical illness.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="Antidepressants"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H351404"/>
			<id>169915</id>
			<summary>
				<section label="Interventions" id="351404">
					<fragment>In a meta-analysis of 18 efficacy studies including 838 patients with a variety of physical diseases, antidepressant therapy resulted in greater improvement in depressive symptoms than either placebo or no therapy.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C1096649" scheme="gov.nih.nlm.semanticType.topp" label="antidepressant therapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H351404"/>
			<id>169916</id>
			<summary>
				<section label="Interventions" id="351404">
					<fragment>A subsequent meta-analysis of 25 randomized trials, which included 2338 patients with unipolar major depression and various comorbid general medical illnesses, found that response (50 percent or more reduction in baseline depression symptoms) occurred in more patients who received an antidepressant compared with placebo (risk ratio 1.4, 95% CI 1.3-1.6).</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
			<category term="C3540763" scheme="gov.nih.nlm.semanticType.phsu" label="various"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H351404"/>
			<id>169917</id>
			<summary>
				<section label="Interventions" id="351404">
					<fragment>Large trials have found that antidepressants were effective in patients with diabetes and with coronary artery disease.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0397581" scheme="gov.nih.nlm.semanticType.topp" label="artery"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H351404"/>
			<id>169918</id>
			<summary>
				<section label="Interventions" id="351404">
					<fragment>Venlafaxine, bupropion, and duloxetine have been shown to reduce neuropathic pain in patients without depression, and would be preferred drug choices in depressed patients with chronic pain to both alleviate pain symptoms and treat the underlying depression.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="Venlafaxine"/>
			<category term="C0085208" scheme="gov.nih.nlm.semanticType.phsu" label="bupropion"/>
			<category term="C0245561" scheme="gov.nih.nlm.semanticType.phsu" label="duloxetine"/>
			<category term="6" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H351404"/>
			<id>169919</id>
			<summary>
				<section label="Interventions" id="351404">
					<fragment>In a randomized trial of 250 patients with concurrent depression and musculoskeletal pain, a stepped care approach of initial optimization of antidepressant treatment followed by a supervised pain self-management program over 12 weeks significantly improved severity scores for both depression and pain at 6 and 12 month follow-up, compared to usual care.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H351404"/>
			<id>169921</id>
			<summary>
				<section label="Interventions" id="351404">
					<fragment>While treatment of depression in patients with medical illness is effective in improving depression, it is unclear whether such treatment improves medical outcomes.</fragment>
				</section>
			</summary>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H351404"/>
			<id>169922</id>
			<summary>
				<section label="Interventions" id="351404">
					<fragment>There have been conflicting results from clinical trials of treating depression in diabetes and after stroke, and treating depression after acute coronary syndromes has not been shown to improve mortality.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H351404"/>
			<id>169923</id>
			<summary>
				<section label="Interventions" id="351404">
					<fragment>Improvement in medical outcomes may depend upon the specific intervention that is used.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H351404"/>
			<id>169924</id>
			<summary>
				<section label="Interventions" id="351404">
					<fragment>A single-blind, randomized trial, involving 214 patients with depression and poorly controlled diabetes, coronary heart disease, or both, compared treatment as usual with collaborative care, in which a medically supervised nurse provided guideline-based care for managing depression and the medical illness.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H351404"/>
			<id>169926</id>
			<summary>
				<section label="Interventions" id="351404">
					<fragment>For patients with chronic medical illnesses, exercise can reduce depressive symptoms.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H351404"/>
			<id>169927</id>
			<summary>
				<section label="Interventions" id="351404">
					<fragment>A meta-analysis of 90 randomized trials examined the effects of exercise training on depressive symptoms (which did not meet criteria for a depressive disorder) in 10,534 patients with chronic medical illnesses such as cardiovascular disease, chronic pain and fibromyalgia, cancer, spinal cord injury, multiple sclerosis, and chronic obstructive pulmonary disease.</fragment>
				</section>
			</summary>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C0628655" scheme="gov.nih.nlm.semanticType.phsu" label="meet"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H48"/>
			<id>169930</id>
			<summary>
				<section label="Exercise" id="48">
					<fragment>A number of observational studies with methodologic flaws suggest that aerobic exercise is superior to no treatment for patients with major depression.</fragment>
				</section>
			</summary>
			<category term="C0001701" scheme="gov.nih.nlm.semanticType.topp" label="aerobic exercise"/>
			<category term="7" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H48"/>
			<id>169931</id>
			<summary>
				<section label="Exercise" id="48">
					<fragment>A meta-analysis of 25 randomized trials evaluating exercise, compared to standard treatment or no treatment, in patients with depression found that most trials did not analyze by intention to treat, and used inadequate randomization techniques.</fragment>
				</section>
			</summary>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="5" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H48"/>
			<id>169934</id>
			<summary>
				<section label="Exercise" id="48">
					<fragment>Patients who received antidepressant therapy alone had the fastest initial response, but there was no difference between groups at 16 weeks or 10 months.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="C1096649" scheme="gov.nih.nlm.semanticType.topp" label="antidepressant therapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H49"/>
			<id>169937</id>
			<summary>
				<section label="Light therapy" id="49">
					<fragment>A meta-analysis of randomized trials found that bright light therapy in nonseasonal depression was associated with a significant reduction in depression symptom severity with effect sizes similar to those in pharmacotherapy trials.</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0031765" scheme="gov.nih.nlm.semanticType.topp" label="light therapy"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H51"/>
			<id>169951</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="51">
					<fragment>The goal of treatment for depression should be remission of symptoms;</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H51"/>
			<id>169953</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="51">
					<fragment>There are no clear predictors whether psychotherapy or pharmacotherapy is best for individual patients with mild to moderate major depression.</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H51"/>
			<id>169954</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="51">
					<fragment>We recommend that patients with mild to moderate major depression begin either psychotherapy or pharmacotherapy as initial therapy.</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H51"/>
			<id>169955</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="51">
					<fragment>We recommend pharmacotherapy as initial therapy for patients with more severe depression.</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H51"/>
			<id>169956</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="51">
					<fragment>We recommend a combination of pharmacotherapy and psychotherapy for patients with severe chronic (more than two years) or frequently recurrent depression.</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H51"/>
			<id>169957</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="51">
					<fragment>The major classes of drugs used to treat depression are the selective serotonin reuptake inhibitors (SSRIs), inhibitors of the reuptake of both serotonin and norepinephrine (SNRIs), monoamine oxidase inhibitors (MAOIs), and tricyclic antidepressants (TCAs).</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0003290" scheme="gov.nih.nlm.semanticType.phsu" label="tricyclic antidepressants"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0360105" scheme="gov.nih.nlm.semanticType.phsu" label="selective serotonin reuptake inhibitors"/>
			<category term="C0629984" scheme="gov.nih.nlm.semanticType.strd" label="TCAs"/>
			<category term="C0758711" scheme="gov.nih.nlm.semanticType.orch" label="serotonin"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin reuptake inhibitors"/>
			<category term="C3653413" scheme="gov.nih.nlm.semanticType.phsu" label="monoamine oxidase inhibitors"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H51"/>
			<id>169959</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="51">
					<fragment>Patients who have been successfully treated with a well-tolerated drug in the past should resume that agent if depression recurs.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H51"/>
			<id>169969</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="51">
					<fragment>We suggest that patients who have a partial response to an antidepressant at eight weeks be given options of either augmentation (with bupropion or buspirone) or change to another antidepressant.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="C0006462" scheme="gov.nih.nlm.semanticType.phsu" label="buspirone"/>
			<category term="C0085208" scheme="gov.nih.nlm.semanticType.phsu" label="bupropion"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H51"/>
			<id>169972</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="51">
					<fragment>We recommend that antidepressant medication be taken for at least six to nine months after a first episode of depression.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H51"/>
			<id>169974</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="51">
					<fragment>We suggest that maintenance therapy (more than two years of treatment) be given to patients with a history of three or more depressive episodes, for those with dysthymia and major depression, and for those with two previous episodes plus risk factors that would increase the risk of recurrence.</fragment>
				</section>
			</summary>
			<category term="C0677908" scheme="gov.nih.nlm.semanticType.topp" label="maintenance therapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H51"/>
			<id>169975</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="51">
					<fragment>It may be reasonable to consider maintenance therapy for adults who have even one major recurrence.</fragment>
				</section>
			</summary>
			<category term="C0677908" scheme="gov.nih.nlm.semanticType.topp" label="maintenance therapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H51"/>
			<id>169976</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="51">
					<fragment>Anxious patients and those with difficulty sleeping can be offered a short acting benzodiazepine for no more than two weeks along with psychotherapy and/or antidepressant drug therapy.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="C0963297" scheme="gov.nih.nlm.semanticType.orch" label="benzodiazepine"/>
			<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
			<category term="C2003848" scheme="gov.nih.nlm.semanticType.topp" label="drug therapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H51"/>
			<id>169978</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="51">
					<fragment>John's wort . Patients with mild acute depression who nonetheless choose St.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H433147300"/>
			<id>209389</id>
			<summary>
				<section label="DEFINITION OF UNIPOLAR MAJOR DEPRESSION" id="433147300">
					<fragment>Unipolar major depression (major depressive disorder) is diagnosed in patients who have suffered at least one major depressive episode and have no history of mania or hypomania.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H88258302"/>
			<id>209391</id>
			<summary>
				<section label="MILD TO MODERATE MAJOR DEPRESSION" id="88258302">
					<fragment>Patients with mild to moderate major depression manifest: Either no suicidal or homicidal ideation or behavior, or suicidal or homicidal ideation that does not pose an imminent risk (eg, thoughts that family members would be better off if the patient was dead; or fleeting thoughts of killing oneself, with nonexistent or vague plans to commit suicide and no intent).</fragment>
				</section>
			</summary>
			<category term="C1171947" scheme="gov.nih.nlm.semanticType.phsu" label="commit"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H4906985"/>
			<id>209399</id>
			<summary>
				<section label="Choosing treatment" id="4906985">
					<fragment>In addition, randomized trials that compared pharmacotherapy alone with psychotherapy alone in depressed outpatients found that the benefits of each modality were comparable.</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H4906985"/>
			<id>209402</id>
			<summary>
				<section label="Choosing treatment" id="4906985">
					<fragment>However, one advantage provided by psychotherapy (particularly CBT or interpersonal psychotherapy) is that following an acute course of treatment, the benefits often persist and patients remain well.</fragment>
				</section>
			</summary>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="C0871787" scheme="gov.nih.nlm.semanticType.topp" label="interpersonal psychotherapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H4906985"/>
			<id>209406</id>
			<summary>
				<section label="Choosing treatment" id="4906985">
					<fragment>Although preliminary studies suggest that differences in central nervous system functioning (eg, brain glucose metabolism and biochemical changes) may distinguish depressed patients who respond preferentially to pharmacotherapy or psychotherapy, the use of biomarkers to select initial treatment for depression is not standard practice.</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="C3542961" scheme="gov.nih.nlm.semanticType.phsu" label="nervous system"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H4906985"/>
			<id>209407</id>
			<summary>
				<section label="Choosing treatment" id="4906985">
					<fragment>The use of pharmacotherapy plus psychotherapy, pharmacotherapy alone, or psychotherapy alone for mild to moderate depression is consistent with practice guidelines from the American Psychiatric Association and the United Kingdom National Institute for Clinical Excellence (NICE).</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H4906985"/>
			<id>209408</id>
			<summary>
				<section label="Choosing treatment" id="4906985">
					<fragment>However, the NICE guidelines recommend psychotherapy for the initial treatment of patients with mild depression, based upon their judgement that the risk benefit ratio for pharmacotherapy does not justify its use for mild symptoms.</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H4906985"/>
			<id>209409</id>
			<summary>
				<section label="Choosing treatment" id="4906985">
					<fragment>The efficacy of antidepressants alone for mild depression.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H175262611"/>
			<id>209410</id>
			<summary>
				<section label="Antidepressants plus psychotherapy" id="175262611">
					<fragment>For the initial treatment of mild to moderate unipolar major depression, randomized trials indicate that the combination of pharmacotherapy and psychotherapy (eg, cognitive-behavioral therapy or interpersonal psychotherapy) is more efficacious than either pharmacotherapy alone or psychotherapy alone.</fragment>
				</section>
			</summary>
			<category term="C0004933" scheme="gov.nih.nlm.semanticType.topp" label="behavioral therapy"/>
			<category term="C0009244" scheme="gov.nih.nlm.semanticType.topp" label="cognitive-behavioral therapy"/>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="C0871787" scheme="gov.nih.nlm.semanticType.topp" label="interpersonal psychotherapy"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H175262611"/>
			<id>209414</id>
			<summary>
				<section label="Antidepressants plus psychotherapy" id="175262611">
					<fragment>Evidence supporting the superiority of combination therapy over pharmacotherapy alone for the initial treatment of mild to moderate major depression includes many randomized trials.</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0556895" scheme="gov.nih.nlm.semanticType.topp" label="combination therapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H175262611"/>
			<id>209415</id>
			<summary>
				<section label="Antidepressants plus psychotherapy" id="175262611">
					<fragment>As an example, a meta-analysis of 25 randomized trials compared antidepressants alone with combination therapy in 2036 patients with depressive disorders.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C0556895" scheme="gov.nih.nlm.semanticType.topp" label="combination therapy"/>
			<category term="6" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H175262611"/>
			<id>209416</id>
			<summary>
				<section label="Antidepressants plus psychotherapy" id="175262611">
					<fragment>The analysis found a significant, clinically small to moderate effect favoring combination therapy.</fragment>
				</section>
			</summary>
			<category term="C0556895" scheme="gov.nih.nlm.semanticType.topp" label="combination therapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H175262611"/>
			<id>209418</id>
			<summary>
				<section label="Antidepressants plus psychotherapy" id="175262611">
					<fragment>Separate analyses of the three subgroups that received cognitive-behavioral therapy (7 trials), interpersonal psychotherapy (8 trials), or other psychotherapies (10 trials) found that in each case, combined therapy was superior to antidepressants alone.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0004933" scheme="gov.nih.nlm.semanticType.topp" label="behavioral therapy"/>
			<category term="C0009244" scheme="gov.nih.nlm.semanticType.topp" label="cognitive-behavioral therapy"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="C0033972" scheme="gov.nih.nlm.semanticType.topp" label="combined therapy"/>
			<category term="C0419168" scheme="gov.nih.nlm.semanticType.topp" label="other psychotherapies"/>
			<category term="C0871787" scheme="gov.nih.nlm.semanticType.topp" label="interpersonal psychotherapy"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H175262611"/>
			<id>209419</id>
			<summary>
				<section label="Antidepressants plus psychotherapy" id="175262611">
					<fragment>Evidence supporting the superiority of antidepressants plus psychotherapy over psychotherapy alone for the initial treatment of mild to moderate major depression includes many randomized trials.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H175262611"/>
			<id>209420</id>
			<summary>
				<section label="Antidepressants plus psychotherapy" id="175262611">
					<fragment>As an example, a meta-analysis of 16 randomized trials compared psychotherapy alone with combination treatment in 1727 patients with depressive disorders.</fragment>
				</section>
			</summary>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H13396976"/>
			<id>209429</id>
			<summary>
				<section label="Selecting an antidepressant" id="13396976">
					<fragment>For patients with mild to moderate unipolar major depression whose initial treatment includes antidepressants, we suggest SSRIs based upon their efficacy and tolerability in randomized trials.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H13396976"/>
			<id>209430</id>
			<summary>
				<section label="Selecting an antidepressant" id="13396976">
					<fragment>SSRIs are the most widely prescribed class of antidepressants.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H13396976"/>
			<id>209431</id>
			<summary>
				<section label="Selecting an antidepressant" id="13396976">
					<fragment>Reasonable alternatives to SSRIs for the initial treatment of major depression include other second-generation antidepressants such as serotonin-norepinephrine reuptake inhibitors, atypical antidepressants, and serotonin modulators.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0242905" scheme="gov.nih.nlm.semanticType.phsu" label="atypical antidepressants"/>
			<category term="C0758711" scheme="gov.nih.nlm.semanticType.orch" label="serotonin"/>
			<category term="C1319313" scheme="gov.nih.nlm.semanticType.phsu" label="norepinephrine reuptake inhibitors"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
			<category term="C3537213" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin-norepinephrine reuptake inhibitors"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H13396976"/>
			<id>209434</id>
			<summary>
				<section label="Selecting an antidepressant" id="13396976">
					<fragment>Although sertraline is one of the most widely prescribed SSRIs, and there is evidence that suggests escitalopram and sertraline provide the best combination of efficacy and acceptability, each SSRI is suitable for the initial treatment of depression.</fragment>
				</section>
			</summary>
			<category term="C0074393" scheme="gov.nih.nlm.semanticType.phsu" label="sertraline"/>
			<category term="C1099456" scheme="gov.nih.nlm.semanticType.phsu" label="escitalopram"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H13396976"/>
			<id>209435</id>
			<summary>
				<section label="Selecting an antidepressant" id="13396976">
					<fragment>Studies that suggest antidepressants (including SSRIs) differ in their efficacy include a network meta-analysis of 117 randomized trials (mean duration 8 weeks), which compared 12 second-generation antidepressants in nearly 26,000 patients with unipolar major depression.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C0308902" scheme="gov.nih.nlm.semanticType.phsu" label="duration"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H13396976"/>
			<id>209436</id>
			<summary>
				<section label="Selecting an antidepressant" id="13396976">
					<fragment>The investigators concluded that escitalopram and sertraline showed the best combined profile of efficacy and acceptability, based upon the findings that: Response (reduction of baseline symptoms &gt;=50 percent) was more probable with escitalopram, mirtazapine, sertraline, and venlafaxine, compared with duloxetine, fluoxetine, fluvoxamine, paroxetine, and reboxetine.</fragment>
				</section>
			</summary>
			<category term="C0016365" scheme="gov.nih.nlm.semanticType.phsu" label="fluoxetine"/>
			<category term="C0049506" scheme="gov.nih.nlm.semanticType.phsu" label="mirtazapine"/>
			<category term="C0070122" scheme="gov.nih.nlm.semanticType.phsu" label="paroxetine"/>
			<category term="C0074393" scheme="gov.nih.nlm.semanticType.phsu" label="sertraline"/>
			<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
			<category term="C0085228" scheme="gov.nih.nlm.semanticType.phsu" label="fluvoxamine"/>
			<category term="C0168388" scheme="gov.nih.nlm.semanticType.phsu" label="reboxetine"/>
			<category term="C0245561" scheme="gov.nih.nlm.semanticType.phsu" label="duloxetine"/>
			<category term="C1099456" scheme="gov.nih.nlm.semanticType.phsu" label="escitalopram"/>
			<category term="5" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H13396976"/>
			<id>209437</id>
			<summary>
				<section label="Selecting an antidepressant" id="13396976">
					<fragment>Discontinuation of treatment for any reason was less probable with citalopram, escitalopram, and sertraline, compared with other antidepressants.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0008845" scheme="gov.nih.nlm.semanticType.phsu" label="citalopram"/>
			<category term="C0074393" scheme="gov.nih.nlm.semanticType.phsu" label="sertraline"/>
			<category term="C0457454" scheme="gov.nih.nlm.semanticType.hlca" label="Discontinuation"/>
			<category term="C1099456" scheme="gov.nih.nlm.semanticType.phsu" label="escitalopram"/>
			<category term="C3653915" scheme="gov.nih.nlm.semanticType.phsu" label="other antidepressants"/>
			<category term="8" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H13396976"/>
			<id>209438</id>
			<summary>
				<section label="Selecting an antidepressant" id="13396976">
					<fragment>However, a second network meta-analysis (93 randomized trials, &gt;20,000 patients with unipolar major depression) evaluated 13 second-generation antidepressants and concluded that there were no substantial differences in efficacy and discontinuation rates.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C0457454" scheme="gov.nih.nlm.semanticType.hlca" label="discontinuation"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H13396976"/>
			<id>209442</id>
			<summary>
				<section label="Selecting an antidepressant" id="13396976">
					<fragment>As an example, improvement was greater with escitalopram than citalopram, but the average difference on the Montgomery-Asberg Depression Rating Scale, which ranges in score from 0 to 60 points, was 1.5 points.</fragment>
				</section>
			</summary>
			<category term="C0008845" scheme="gov.nih.nlm.semanticType.phsu" label="citalopram"/>
			<category term="C1099456" scheme="gov.nih.nlm.semanticType.phsu" label="escitalopram"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H13396976"/>
			<id>209444</id>
			<summary>
				<section label="Selecting an antidepressant" id="13396976">
					<fragment>Onset of action may be faster with mirtazapine than other antidepressants.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0049506" scheme="gov.nih.nlm.semanticType.phsu" label="mirtazapine"/>
			<category term="C3653915" scheme="gov.nih.nlm.semanticType.phsu" label="other antidepressants"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H13396976"/>
			<id>209447</id>
			<summary>
				<section label="Selecting an antidepressant" id="13396976">
					<fragment>Most depressed patients who are treated with antidepressants require continuation treatment, and beyond that, maintenance treatment may be indicated as well.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H13396976"/>
			<id>209459</id>
			<summary>
				<section label="Selecting an antidepressant" id="13396976">
					<fragment>As an example, trazodone can be beneficial for patients with insomnia, bupropion for patients who prefer to avoid sexual dysfunction or want treatment for comorbid tobacco dependence, and citalopram and escitalopram do not appear to cause drug-drug interactions.</fragment>
				</section>
			</summary>
			<category term="C0008845" scheme="gov.nih.nlm.semanticType.phsu" label="citalopram"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0040805" scheme="gov.nih.nlm.semanticType.phsu" label="trazodone"/>
			<category term="C0085208" scheme="gov.nih.nlm.semanticType.phsu" label="bupropion"/>
			<category term="C1099456" scheme="gov.nih.nlm.semanticType.phsu" label="escitalopram"/>
			<category term="8" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H658861"/>
			<id>209465</id>
			<summary>
				<section label="Side effects" id="658861">
					<fragment>Although some adverse effects (eg, gastrointestinal toxicity) are common across second-generation antidepressants, the incidence of specific side effects during short-term treatment (eg, 6 to 12 weeks) differs among drugs: Diarrhea occurs more often with sertraline than bupropion, citalopram, fluoxetine, fluvoxamine, mirtazapine, nefazodone, paroxetine, and venlafaxine (16 versus 8 percent of patients).</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0008845" scheme="gov.nih.nlm.semanticType.phsu" label="citalopram"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0016365" scheme="gov.nih.nlm.semanticType.phsu" label="fluoxetine"/>
			<category term="C0049506" scheme="gov.nih.nlm.semanticType.phsu" label="mirtazapine"/>
			<category term="C0068485" scheme="gov.nih.nlm.semanticType.phsu" label="nefazodone"/>
			<category term="C0070122" scheme="gov.nih.nlm.semanticType.phsu" label="paroxetine"/>
			<category term="C0074393" scheme="gov.nih.nlm.semanticType.phsu" label="sertraline"/>
			<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
			<category term="C0085208" scheme="gov.nih.nlm.semanticType.phsu" label="bupropion"/>
			<category term="C0085228" scheme="gov.nih.nlm.semanticType.phsu" label="fluvoxamine"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H658861"/>
			<id>209466</id>
			<summary>
				<section label="Side effects" id="658861">
					<fragment>Nausea and vomiting occurs more often with venlafaxine than SSRIs as a class (33 versus 22 percent).</fragment>
				</section>
			</summary>
			<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H658861"/>
			<id>209468</id>
			<summary>
				<section label="Side effects" id="658861">
					<fragment>Somnolence occurs more often with trazodone than bupropion, fluoxetine, mirtazapine, paroxetine, and venlafaxine (42 versus 25 percent).</fragment>
				</section>
			</summary>
			<category term="C0016365" scheme="gov.nih.nlm.semanticType.phsu" label="fluoxetine"/>
			<category term="C0040805" scheme="gov.nih.nlm.semanticType.phsu" label="trazodone"/>
			<category term="C0049506" scheme="gov.nih.nlm.semanticType.phsu" label="mirtazapine"/>
			<category term="C0070122" scheme="gov.nih.nlm.semanticType.phsu" label="paroxetine"/>
			<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
			<category term="C0085208" scheme="gov.nih.nlm.semanticType.phsu" label="bupropion"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H658861"/>
			<id>209469</id>
			<summary>
				<section label="Side effects" id="658861">
					<fragment>Weight gain is greater with mirtazapine than fluoxetine, paroxetine, trazodone, and venlafaxine (0.8 to 3.0 kg after six to eight weeks of treatment).</fragment>
				</section>
			</summary>
			<category term="C0016365" scheme="gov.nih.nlm.semanticType.phsu" label="fluoxetine"/>
			<category term="C0040805" scheme="gov.nih.nlm.semanticType.phsu" label="trazodone"/>
			<category term="C0049506" scheme="gov.nih.nlm.semanticType.phsu" label="mirtazapine"/>
			<category term="C0070122" scheme="gov.nih.nlm.semanticType.phsu" label="paroxetine"/>
			<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
			<category term="C0124598" scheme="gov.nih.nlm.semanticType.phsu" label="kg"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H658861"/>
			<id>209470</id>
			<summary>
				<section label="Side effects" id="658861">
					<fragment>Although antidepressants may be associated with an increased risk of diabetes, the evidence is not compelling and the possible association should not deter clinicians from using antidepressants when indicated.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H658861"/>
			<id>209471</id>
			<summary>
				<section label="Side effects" id="658861">
					<fragment>A nested case-control study found that in approximately 166,000 patients with depression and no sign of diabetes, long-term (&gt;24 months) use of an antidepressant in moderate to high doses was associated with an increased risk of diabetes (incidence rate ratio 1.8, 95% CI 1.4-2.5).</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
			<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H658861"/>
			<id>209473</id>
			<summary>
				<section label="Side effects" id="658861">
					<fragment>A prospective observational study of 1000 people 65 years and older, followed for up to ten years, found that depressed individuals were more than twice as likely to develop diabetes compared to those without depression, regardless of antidepressant treatment (hazard ratio 2.3, 95% CI 1.3-4.1).</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H658861"/>
			<id>209478</id>
			<summary>
				<section label="Side effects" id="658861">
					<fragment>A review of 158 studies estimated that among patients taking antidepressants, asymptomatic mild elevation of serum aminotransferases occurs in 0.5 to 1 percent of patients taking SSRIs or serotonin-norepinephrine reuptake inhibitors, and up to 3 percent of patients taking MAOIs or tricyclics.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0758711" scheme="gov.nih.nlm.semanticType.orch" label="serotonin"/>
			<category term="C1319313" scheme="gov.nih.nlm.semanticType.phsu" label="norepinephrine reuptake inhibitors"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
			<category term="C3537213" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin-norepinephrine reuptake inhibitors"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H658861"/>
			<id>209481</id>
			<summary>
				<section label="Side effects" id="658861">
					<fragment>Although antidepressant induced liver injury is generally idiosyncratic, unpredictable, and not related to dose, patients who are elderly or taking multiple medications may be at higher risk;</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H658861"/>
			<id>209482</id>
			<summary>
				<section label="Side effects" id="658861">
					<fragment>we thus suggest measuring hepatic enzymes in these patients as well as patients with known underlying liver disease, prior to starting antidepressants.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H658861"/>
			<id>209484</id>
			<summary>
				<section label="Side effects" id="658861">
					<fragment>Additional information about drug induced liver injury, including hepatotoxicity due to agomelatine and nefazodone, are discussed separately.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0068485" scheme="gov.nih.nlm.semanticType.phsu" label="nefazodone"/>
			<category term="C0971637" scheme="gov.nih.nlm.semanticType.phsu" label="agomelatine"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H658867"/>
			<id>209488</id>
			<summary>
				<section label="Dose" id="658867">
					<fragment>However, doses lower than the typical starting doses may further reduce adverse effects, particularly in older patients and those sensitive to side effects.</fragment>
				</section>
			</summary>
			<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H658867"/>
			<id>209489</id>
			<summary>
				<section label="Dose" id="658867">
					<fragment>As an example, depressed patients with comorbid anxiety disorders who are started on SSRIs may better tolerate half of the usual starting dose.</fragment>
				</section>
			</summary>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H658867"/>
			<id>209493</id>
			<summary>
				<section label="Dose" id="658867">
					<fragment>As an example, four randomized trials enrolled patients (total N = 609) with unipolar major depression who were unresponsive to three weeks of treatment with an SSRI, and compared increasing the dose with continuing the initial dose.</fragment>
				</section>
			</summary>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRI"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H658867"/>
			<id>209495</id>
			<summary>
				<section label="Dose" id="658867">
					<fragment>However, three weeks is generally regarded as too short an interval for determining whether an antidepressant regimen is beneficial.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H658867"/>
			<id>209498</id>
			<summary>
				<section label="Dose" id="658867">
					<fragment>One review noted that the prevalence of increased metabolism by duplicated genes of CYP2D6 in black Ethiopians was 29 percent, and among whites varied from 1 to 2 percent in Sweden to 7 to 10 percent in Spain.</fragment>
				</section>
			</summary>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H86799927"/>
			<id>209502</id>
			<summary>
				<section label="Early improvement and response" id="86799927">
					<fragment>Among patients with mild to moderate unipolar major depression who start antidepressants, improvement is often apparent within one to two weeks: A meta-analysis of 28 randomized trials (5872 patients with unipolar major depression) that compared SSRIs with placebo found that superior clinical improvement with SSRIs occurred within one week.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H86799927"/>
			<id>209503</id>
			<summary>
				<section label="Early improvement and response" id="86799927">
					<fragment>A pooled analysis of four randomized trials found that the mean time to improvement (reduction of baseline symptoms &gt;=20 percent) in 2532 patients treated with antidepressants was approximately 13 days.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H86799927"/>
			<id>209505</id>
			<summary>
				<section label="Early improvement and response" id="86799927">
					<fragment>A pooled analysis of 41 randomized trials (6562 patients with unipolar major depression who were generally treated for six weeks) found that early improvement (reduction of baseline symptoms within the first two weeks of treatment &gt;=20 percent) was a sensitive predictor of eventual remission (range 87 to 100 percent, depending upon the specific treatment).</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H86799927"/>
			<id>209508</id>
			<summary>
				<section label="Early improvement and response" id="86799927">
					<fragment>A meta-analysis of 41 randomized trials compared antidepressants with placebo in 7121 patients with unipolar major depression.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H658879"/>
			<id>209513</id>
			<summary>
				<section label="Duration of an adequate trial" id="658879">
					<fragment>In addition, the prospective Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study, which treated a sample that was more generalizable than is typically enrolled in randomized trials, found that among 943 patients who were treated with open label citalopram, nearly 25 percent required 10 or 12 weeks of treatment to achieve remission.</fragment>
				</section>
			</summary>
			<category term="C0008845" scheme="gov.nih.nlm.semanticType.phsu" label="citalopram"/>
			<category term="C1259875" scheme="gov.nih.nlm.semanticType.phsu" label="STAR"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H658879"/>
			<id>209515</id>
			<summary>
				<section label="Duration of an adequate trial" id="658879">
					<fragment>A meta-analysis of 28 randomized trials (5872 patients with unipolar major depression) that compared SSRIs with placebo found that the advantage of SSRIs over placebo continued to increase for at least six weeks of treatment, but at a progressively smaller rate.</fragment>
				</section>
			</summary>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H658879"/>
			<id>209516</id>
			<summary>
				<section label="Duration of an adequate trial" id="658879">
					<fragment>A 16 week study enrolled 566 patients with unipolar major depression who were initially treated with open label escitalopram (10 mg per day) for 4 weeks and showed minimal improvement (&lt;30 percent reduction of baseline symptoms).</fragment>
				</section>
			</summary>
			<category term="C1099456" scheme="gov.nih.nlm.semanticType.phsu" label="escitalopram"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H658879"/>
			<id>209518</id>
			<summary>
				<section label="Duration of an adequate trial" id="658879">
					<fragment>Patients who received escitalopram for 8 weeks were then evaluated for response (reduction of baseline symptoms &gt;=50 percent);</fragment>
				</section>
			</summary>
			<category term="C1099456" scheme="gov.nih.nlm.semanticType.phsu" label="escitalopram"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H658879"/>
			<id>209521</id>
			<summary>
				<section label="Duration of an adequate trial" id="658879">
					<fragment>An eight week, prospective, observational study examined response (reduction of baseline symptoms &gt;=50 percent) to fluoxetine 20 mg per day in 143 patients with unipolar major depression.</fragment>
				</section>
			</summary>
			<category term="C0016365" scheme="gov.nih.nlm.semanticType.phsu" label="fluoxetine"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H658879"/>
			<id>209524</id>
			<summary>
				<section label="Duration of an adequate trial" id="658879">
					<fragment>Next step treatments for patients unresponsive to initial treatment of depression are discussed separately.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H9989182"/>
			<id>209525</id>
			<summary>
				<section label="Efficacy of antidepressants" id="9989182">
					<fragment>Antidepressants are beneficial for patients with unipolar major depression.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="Antidepressants"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H9989182"/>
			<id>209526</id>
			<summary>
				<section label="Efficacy of antidepressants" id="9989182">
					<fragment>A meta-analysis of patient level data from 37 randomized trials (N &gt;8400 patients with major depression) compared either fluoxetine (modal dose 20 mg per day) or venlafaxine (modal dose range 75 to 150 mg per day) with placebo for six weeks;</fragment>
				</section>
			</summary>
			<category term="C0016365" scheme="gov.nih.nlm.semanticType.phsu" label="fluoxetine"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H9989182"/>
			<id>209527</id>
			<summary>
				<section label="Efficacy of antidepressants" id="9989182">
					<fragment>remission occurred in more patients who received active drug than placebo (43 versus 29 percent).</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H9989182"/>
			<id>209528</id>
			<summary>
				<section label="Efficacy of antidepressants" id="9989182">
					<fragment>Meta-analyses of randomized, placebo controlled trials have found that many antidepressant classes and other specific antidepressants are efficacious in unipolar major depression, including agomelatine (not available in the United States), duloxetine, paroxetine, tricyclics (including amitriptyline imipramine, and monoamine oxidase inhibitors. However, meta-analyses based upon published randomized trials may overestimate the effect of antidepressants because of selective publication of trials (publication bias).</fragment>
				</section>
			</summary>
			<category term="C0002600" scheme="gov.nih.nlm.semanticType.phsu" label="amitriptyline"/>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="Meta"/>
			<category term="C0070122" scheme="gov.nih.nlm.semanticType.phsu" label="paroxetine"/>
			<category term="C0245561" scheme="gov.nih.nlm.semanticType.phsu" label="duloxetine"/>
			<category term="C0971637" scheme="gov.nih.nlm.semanticType.phsu" label="agomelatine"/>
			<category term="C3653413" scheme="gov.nih.nlm.semanticType.phsu" label="monoamine oxidase inhibitors"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H9989182"/>
			<id>209532</id>
			<summary>
				<section label="Efficacy of antidepressants" id="9989182">
					<fragment>Among the 51 published trials, the results were presented as positive (ie, improvement was greater with the drug than placebo) in 94 percent (48 trials);</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H9989182"/>
			<id>209537</id>
			<summary>
				<section label="Efficacy of antidepressants" id="9989182">
					<fragment>As an example, a meta-analysis of patient level data (37 randomized trials, 8477 patients with unipolar major depression who were assessed with the Hamilton scale) found that improvement with antidepressants and placebo differed by 3 points.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H9989182"/>
			<id>209539</id>
			<summary>
				<section label="Efficacy of antidepressants" id="9989182">
					<fragment>As an example, a meta-analysis of individual patient data from 37 randomized trials found that among 3391 patients with mild to moderate major depression who were treated with placebo, remission occurred in 29 percent.</fragment>
				</section>
			</summary>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H9989182"/>
			<id>209541</id>
			<summary>
				<section label="Efficacy of antidepressants" id="9989182">
					<fragment>Depressed study patients who are treated with placebos receive nonspecific support by meeting regularly with clinicians and research assistants to discuss symptoms and functioning.</fragment>
				</section>
			</summary>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebos"/>
			<category term="C0628655" scheme="gov.nih.nlm.semanticType.phsu" label="meeting"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H9989319"/>
			<id>209544</id>
			<summary>
				<section label="Mildly ill patients" id="9989319">
					<fragment>Antidepressants appear to be efficacious for unipolar major depression regardless of baseline severity, including mild episodes.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="Antidepressants"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H9989319"/>
			<id>209545</id>
			<summary>
				<section label="Mildly ill patients" id="9989319">
					<fragment>A meta-analysis of 37 randomized trials (8477 patients with major depression) that compared antidepressants with placebo found that the rate of remission in mild episodes (scores on the Hamilton rating Scale for Depression &lt;=19; ) at six weeks was greater with active drug than placebo (50 versus 37 percent of patients).</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H9989319"/>
			<id>209548</id>
			<summary>
				<section label="Mildly ill patients" id="9989319">
					<fragment>results suggested a substantial benefit in severe depression and little or no benefit in mild to moderate depression.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H9989319"/>
			<id>209550</id>
			<summary>
				<section label="Mildly ill patients" id="9989319">
					<fragment>In addition, the earlier study included patients with minor depression (N = 77);</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H9989319"/>
			<id>209551</id>
			<summary>
				<section label="Mildly ill patients" id="9989319">
					<fragment>antidepressants are typically not beneficial for minor depression.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H261064214"/>
			<id>209554</id>
			<summary>
				<section label="Psychotherapy" id="261064214">
					<fragment>Psychotherapies that are available to treat unipolar major depression include: Cognitive-behavioral therapy (CBT).</fragment>
				</section>
			</summary>
			<category term="C0004933" scheme="gov.nih.nlm.semanticType.topp" label="behavioral therapy"/>
			<category term="C0009244" scheme="gov.nih.nlm.semanticType.topp" label="Cognitive-behavioral therapy"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="Psychotherapies"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H249197578"/>
			<id>209562</id>
			<summary>
				<section label="Selecting a psychotherapy" id="249197578">
					<fragment>CBT and interpersonal psychotherapy are frequently selected for the initial treatment of mild to moderate unipolar major depression because they have been more widely studied than other types of psychotherapies.</fragment>
				</section>
			</summary>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="C0871787" scheme="gov.nih.nlm.semanticType.topp" label="interpersonal psychotherapy"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H249197578"/>
			<id>209564</id>
			<summary>
				<section label="Selecting a psychotherapy" id="249197578">
					<fragment>As an example, a network meta-analysis of 198 randomized trials (n &gt;15,000 depressed patients) compared the efficacy of seven psychotherapies (behavioral activation, cognitive-behavioral therapy, interpersonal psychotherapy, problem solving therapy, psychodynamic therapy, social skills training, and supportive therapy).</fragment>
				</section>
			</summary>
			<category term="C0004933" scheme="gov.nih.nlm.semanticType.topp" label="behavioral therapy"/>
			<category term="C0009244" scheme="gov.nih.nlm.semanticType.topp" label="cognitive-behavioral therapy"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapies"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C0344211" scheme="gov.nih.nlm.semanticType.topp" label="supportive therapy"/>
			<category term="C0474215" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapies (behavioral"/>
			<category term="C0599237" scheme="gov.nih.nlm.semanticType.topp" label="psychodynamic therapy"/>
			<category term="C0871787" scheme="gov.nih.nlm.semanticType.topp" label="interpersonal psychotherapy"/>
			<category term="C1303140" scheme="gov.nih.nlm.semanticType.topp" label="problem solving therapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H1604650"/>
			<id>209571</id>
			<summary>
				<section label="Clinician guided self help" id="1604650">
					<fragment>Evidence supporting the use of clinician guided self help includes randomized trials.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H1604650"/>
			<id>209573</id>
			<summary>
				<section label="Clinician guided self help" id="1604650">
					<fragment>In addition, patients with moderate depression at baseline appeared to benefit at least as much as mildly ill patients.</fragment>
				</section>
			</summary>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H336164296"/>
			<id>209575</id>
			<summary>
				<section label="Mildly ill patients" id="336164296">
					<fragment>For patients with mild episodes of unipolar major depression who do not require monitoring (eg, patients with no suicidal ideation or behavior), self-guided self help therapy is a reasonable alternative to conventional psychotherapies as well as clinician guided self help therapy.</fragment>
				</section>
			</summary>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapies"/>
			<category term="C0557035" scheme="gov.nih.nlm.semanticType.hlca" label="help therapy"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H336164296"/>
			<id>209576</id>
			<summary>
				<section label="Mildly ill patients" id="336164296">
					<fragment>Self guided interventions utilize similar materials (eg, structured workbook) that are used in clinician guided self help, but self guided self help is conducted independently and involves no contact with a clinician.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H22836773"/>
			<id>209581</id>
			<summary>
				<section label="Efficacy of psychotherapy" id="22836773">
					<fragment>Psychotherapy is efficacious for the initial treatment of mild to moderate unipolar major depression, based upon randomized trials.</fragment>
				</section>
			</summary>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="Psychotherapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H22836773"/>
			<id>209586</id>
			<summary>
				<section label="Efficacy of psychotherapy" id="22836773">
					<fragment>However, meta-analyses appear to overestimate the clinical effect for nearly all types of psychotherapy in treating depression.</fragment>
				</section>
			</summary>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H22836773"/>
			<id>209587</id>
			<summary>
				<section label="Efficacy of psychotherapy" id="22836773">
					<fragment>These inflated effects seem to be the result of low quality studies as well as publication bias.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H22836773"/>
			<id>209589</id>
			<summary>
				<section label="Efficacy of psychotherapy" id="22836773">
					<fragment>Some psychotherapy trials are rigorous and specify a priori hypotheses and analytic tests, develop manuals for the psychotherapies and measure adherence on the part of therapists, use active psychotherapy comparators that control for the nonspecific aspects of psychotherapy, use standardized diagnostic criteria and outcome measures, stratify patients on predetermined risk variables, and blind outcome ratings.</fragment>
				</section>
			</summary>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H22836773"/>
			<id>209593</id>
			<summary>
				<section label="Efficacy of psychotherapy" id="22836773">
					<fragment>As an example, techniques from supportive psychotherapy have been adopted by other psychotherapies, such as psychodynamic psychotherapy.</fragment>
				</section>
			</summary>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="C0221295" scheme="gov.nih.nlm.semanticType.topp" label="supportive psychotherapy"/>
			<category term="C0419168" scheme="gov.nih.nlm.semanticType.topp" label="other psychotherapies"/>
			<category term="C1261382" scheme="gov.nih.nlm.semanticType.topp" label="psychodynamic psychotherapy"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H22836865"/>
			<id>209595</id>
			<summary>
				<section label="Compared with antidepressants" id="22836865">
					<fragment>For patients with mild to moderate unipolar major depression, the evidence indicates that the efficacy of psychotherapy compared with antidepressants at the end of treatment is generally comparable.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H22836865"/>
			<id>209596</id>
			<summary>
				<section label="Compared with antidepressants" id="22836865">
					<fragment>A meta-analysis of 30 randomized trials compared psychotherapy (primarily CBT or interpersonal psychotherapy) with antidepressants in 3178 patients with depressive disorders and found that improvement was comparable for both groups.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C0871787" scheme="gov.nih.nlm.semanticType.topp" label="interpersonal psychotherapy"/>
			<category term="10" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H22836865"/>
			<id>209598</id>
			<summary>
				<section label="Compared with antidepressants" id="22836865">
					<fragment>As an example, a meta-analysis of 28 randomized trials compared psychotherapy with pharmacotherapy for the acute treatment of 3381 patients with unipolar depressive disorders, and found that improvement was comparable;</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="6" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H22836865"/>
			<id>209600</id>
			<summary>
				<section label="Compared with antidepressants" id="22836865">
					<fragment>In the 11 studies (602 patients) that followed patients after treatment ended and assessed their depressive symptoms (mean length of follow-up 15 months), there was a significant, clinically small to moderate effect favoring psychotherapy over antidepressants.</fragment>
				</section>
			</summary>
			<category term="C0001758" scheme="gov.nih.nlm.semanticType.hlca" label="after treatment"/>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H175267570"/>
			<id>209602</id>
			<summary>
				<section label="Relaxation and positive activities" id="175267570">
					<fragment>For patients with mild to moderate unipolar major depression, we suggest adding relaxation techniques (eg, progressive muscle relaxation, relaxation imagery, and autogenic training) to the primary treatment regimen.</fragment>
				</section>
			</summary>
			<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="adding"/>
			<category term="C0004361" scheme="gov.nih.nlm.semanticType.topp" label="autogenic training"/>
			<category term="C0035029" scheme="gov.nih.nlm.semanticType.topp" label="relaxation techniques"/>
			<category term="C0150316" scheme="gov.nih.nlm.semanticType.topp" label="progressive muscle relaxation"/>
			<category term="C0150627" scheme="gov.nih.nlm.semanticType.topp" label="imagery"/>
			<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H175267570"/>
			<id>209604</id>
			<summary>
				<section label="Relaxation and positive activities" id="175267570">
					<fragment>However, a second analysis of nine trials (286 patients) found that relaxation was less effective than psychotherapy (primarily cognitive-behavioral therapy).</fragment>
				</section>
			</summary>
			<category term="C0004933" scheme="gov.nih.nlm.semanticType.topp" label="behavioral therapy"/>
			<category term="C0009244" scheme="gov.nih.nlm.semanticType.topp" label="cognitive-behavioral therapy"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H261064201"/>
			<id>209608</id>
			<summary>
				<section label="Exercise" id="261064201">
					<fragment>We suggest exercise as adjunctive treatment for patients with mild to moderate major depression, based upon evidence from low quality randomized trials.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H261064201"/>
			<id>209610</id>
			<summary>
				<section label="Exercise" id="261064201">
					<fragment>For patients with mild depression, exercise alone rather than as add-on treatment is a reasonable alternative provided patients are sufficiently monitored (eg, every two to four weeks) for worsening symptoms.</fragment>
				</section>
			</summary>
			<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="add"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H261064201"/>
			<id>209614</id>
			<summary>
				<section label="Exercise" id="261064201">
					<fragment>In a separate meta-analysis of four randomized trials that compared exercise with no treatment or placebo in 271 depressed patients who were recruited from clinical settings, there was no advantage for exercise.</fragment>
				</section>
			</summary>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H261064201"/>
			<id>209618</id>
			<summary>
				<section label="Exercise" id="261064201">
					<fragment>Based upon a review of randomized trials, we suggest that clinicians prescribe exercise for depressed patients in the following manner: Modality - Aerobic exercise (eg, walking, running, or cycling) or resistance training (upper and lower body weight lifting).</fragment>
				</section>
			</summary>
			<category term="C0001701" scheme="gov.nih.nlm.semanticType.topp" label="Aerobic exercise"/>
			<category term="C0624791" scheme="gov.nih.nlm.semanticType.imft" label="running"/>
			<category term="C0872279" scheme="gov.nih.nlm.semanticType.topp" label="resistance training"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H167261023"/>
			<id>209629</id>
			<summary>
				<section label="Primary care patients" id="167261023">
					<fragment>Primary care patients with mild to moderate unipolar major depression can benefit when antidepressant treatment occurs within the context of collaborative care.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="C0017313" scheme="gov.nih.nlm.semanticType.hlca" label="care patients"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H167261023"/>
			<id>209631</id>
			<summary>
				<section label="Primary care patients" id="167261023">
					<fragment>Meta-analyses of randomized trials have shown that depression outcomes are superior with collaborative care, compared with usual care (antidepressants alone).</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="Meta"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H167261023"/>
			<id>209633</id>
			<summary>
				<section label="Primary care patients" id="167261023">
					<fragment>Psychotherapy is also a reasonable alternative to collaborative care for depressed patients who are treated in primary care settings.</fragment>
				</section>
			</summary>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="Psychotherapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H167261023"/>
			<id>209634</id>
			<summary>
				<section label="Primary care patients" id="167261023">
					<fragment>The evidence for the efficacy of collaborative care is discussed separately, as is the efficacy of antidepressants alone and psychotherapy alone for primary care patients.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0017313" scheme="gov.nih.nlm.semanticType.hlca" label="care patients"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H1883132"/>
			<id>209635</id>
			<summary>
				<section label="Anxiety and insomnia" id="1883132">
					<fragment>Anxiolytics can be used to augment an antidepressant for initially treating major depressive episodes that include symptoms of anxiety (eg, ruminative thoughts, worrying, and panic attacks), insomnia, or psychomotor agitation.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="C0040616" scheme="gov.nih.nlm.semanticType.phsu" label="Anxiolytics"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H88258338"/>
			<id>209643</id>
			<summary>
				<section label="SEVERE MAJOR DEPRESSION" id="88258338">
					<fragment>Grossly impaired functioning (eg, food and fluid refusal leading to malnutrition and dehydration).</fragment>
				</section>
			</summary>
			<category term="C1569452" scheme="gov.nih.nlm.semanticType.phsu" label="refusal"/>
			<category term="C3540798" scheme="gov.nih.nlm.semanticType.imft" label="food"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H88258338"/>
			<id>209644</id>
			<summary>
				<section label="SEVERE MAJOR DEPRESSION" id="88258338">
					<fragment>Severely ill patients should be referred to a psychiatrist for management and generally require hospitalization.</fragment>
				</section>
			</summary>
			<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalization"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H4906992"/>
			<id>209645</id>
			<summary>
				<section label="Choosing treatment" id="4906992">
					<fragment>For patients with severe unipolar major depression, we suggest initial treatment with the combination of pharmacotherapy and psychotherapy, based upon randomized trials in patients with mild to moderate depressionsertraline or amitriptyline) with clinical management (psychoeducation and support) plus an antidepressant in 124 patients with major depression who were hospitalized for five weeks.</fragment>
				</section>
			</summary>
			<category term="C0002600" scheme="gov.nih.nlm.semanticType.phsu" label="amitriptyline"/>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H4906992"/>
			<id>209646</id>
			<summary>
				<section label="Choosing treatment" id="4906992">
					<fragment>Response (reduction of baseline symptoms &gt;=50 percent) occurred in more patients treated with adjunctive interpersonal psychotherapy than clinical management (70 versus 51 percent), and improvement of functioning was also superior with interpersonal psychotherapy.</fragment>
				</section>
			</summary>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="C0871787" scheme="gov.nih.nlm.semanticType.topp" label="interpersonal psychotherapy"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H4906992"/>
			<id>209648</id>
			<summary>
				<section label="Choosing treatment" id="4906992">
					<fragment>However, a reasonable alternative to combination therapy for severe major depression is pharmacotherapy alone, based upon randomized trials in patients with severe depression.</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0556895" scheme="gov.nih.nlm.semanticType.topp" label="combination therapy"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H4906992"/>
			<id>209649</id>
			<summary>
				<section label="Choosing treatment" id="4906992">
					<fragment>Another reasonable alternative to combination therapy for the initial treatment of severe major depression is electroconvulsive therapy (ECT), especially for patients who require a fast response (eg, patients with suicidal ideation or behavior that is life-threatening).</fragment>
				</section>
			</summary>
			<category term="C0013806" scheme="gov.nih.nlm.semanticType.topp" label="ECT"/>
			<category term="C0013808" scheme="gov.nih.nlm.semanticType.topp" label="electroconvulsive therapy"/>
			<category term="C0556895" scheme="gov.nih.nlm.semanticType.topp" label="combination therapy"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H4906992"/>
			<id>209650</id>
			<summary>
				<section label="Choosing treatment" id="4906992">
					<fragment>Meta-analyses of randomized trials indicate that ECT is more efficacious than any other treatment for severe major depression.</fragment>
				</section>
			</summary>
			<category term="C0013806" scheme="gov.nih.nlm.semanticType.topp" label="ECT"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="Meta"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H4906992"/>
			<id>209653</id>
			<summary>
				<section label="Choosing treatment" id="4906992">
					<fragment>An overview of ECT is discussed separately, as are indications for and efficacy of ECT in unipolar major depression, medical consultation for ECT, and the technique for performing ECT.</fragment>
				</section>
			</summary>
			<category term="C0013806" scheme="gov.nih.nlm.semanticType.topp" label="ECT"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H4906992"/>
			<id>209654</id>
			<summary>
				<section label="Choosing treatment" id="4906992">
					<fragment>The use of combination therapy, pharmacotherapy alone, or ECT for severe unipolar major depression is consistent with practice guidelines from the American Psychiatric Association and the United Kingdom National Institute for Clinical Excellence (NICE).</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0013806" scheme="gov.nih.nlm.semanticType.topp" label="ECT"/>
			<category term="C0556895" scheme="gov.nih.nlm.semanticType.topp" label="combination therapy"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H88260056"/>
			<id>209657</id>
			<summary>
				<section label="Choosing an antidepressant" id="88260056">
					<fragment>Randomized trials have demonstrated that antipsychotics combined with either serotonin-norepinephrine reuptake inhibitors or SSRIs are efficacious for unipolar major depression with psychotic features.</fragment>
				</section>
			</summary>
			<category term="C0040615" scheme="gov.nih.nlm.semanticType.phsu" label="antipsychotics"/>
			<category term="C0758711" scheme="gov.nih.nlm.semanticType.orch" label="serotonin"/>
			<category term="C1319313" scheme="gov.nih.nlm.semanticType.phsu" label="norepinephrine reuptake inhibitors"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
			<category term="C3537213" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin-norepinephrine reuptake inhibitors"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H88260056"/>
			<id>209659</id>
			<summary>
				<section label="Choosing an antidepressant" id="88260056">
					<fragment>A pooled analysis of 15 randomized trials (1752 patient with unipolar major depression) compared serotonin-norepinephrine reuptake inhibitors (duloxetine, milnacipran, and venlafaxine) with SSRIs (citalopram, escitalopram, fluoxetine, paroxetine, and sertraline. In the subgroup of hospitalized patients (n = 436), remission occurred in more patients who received serotonin-norepinephrine reuptake inhibitors than SSRIs (52 versus 29 percent).</fragment>
				</section>
			</summary>
			<category term="C0008845" scheme="gov.nih.nlm.semanticType.phsu" label="citalopram"/>
			<category term="C0016365" scheme="gov.nih.nlm.semanticType.phsu" label="fluoxetine"/>
			<category term="C0070122" scheme="gov.nih.nlm.semanticType.phsu" label="paroxetine"/>
			<category term="C0074393" scheme="gov.nih.nlm.semanticType.phsu" label="sertraline"/>
			<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
			<category term="C0245561" scheme="gov.nih.nlm.semanticType.phsu" label="duloxetine"/>
			<category term="C0758711" scheme="gov.nih.nlm.semanticType.orch" label="serotonin"/>
			<category term="C1099456" scheme="gov.nih.nlm.semanticType.phsu" label="escitalopram"/>
			<category term="C1319313" scheme="gov.nih.nlm.semanticType.phsu" label="norepinephrine reuptake inhibitors"/>
			<category term="C1533126" scheme="gov.nih.nlm.semanticType.phsu" label="milnacipran"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
			<category term="C3537213" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin-norepinephrine reuptake inhibitors"/>
			<category term="15" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H88260056"/>
			<id>209660</id>
			<summary>
				<section label="Choosing an antidepressant" id="88260056">
					<fragment>This was consistent with the finding that remission was greater in outpatients who received serotonin-norepinephrine reuptake inhibitors.</fragment>
				</section>
			</summary>
			<category term="C0758711" scheme="gov.nih.nlm.semanticType.orch" label="serotonin"/>
			<category term="C1319313" scheme="gov.nih.nlm.semanticType.phsu" label="norepinephrine reuptake inhibitors"/>
			<category term="C3537213" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin-norepinephrine reuptake inhibitors"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H88260056"/>
			<id>209661</id>
			<summary>
				<section label="Choosing an antidepressant" id="88260056">
					<fragment>A reasonable alternative to serotonin-norepinephrine reuptake inhibitors or SSRIs is mirtazapine: A six-week randomized trial compared mirtazapine (24 to 72 mg per day) with trazodone (150 to 450 mg per day) in 200 patients hospitalized for major depression.</fragment>
				</section>
			</summary>
			<category term="C0040805" scheme="gov.nih.nlm.semanticType.phsu" label="trazodone"/>
			<category term="C0049506" scheme="gov.nih.nlm.semanticType.phsu" label="mirtazapine"/>
			<category term="C0758711" scheme="gov.nih.nlm.semanticType.orch" label="serotonin"/>
			<category term="C1319313" scheme="gov.nih.nlm.semanticType.phsu" label="norepinephrine reuptake inhibitors"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
			<category term="C3537213" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin-norepinephrine reuptake inhibitors"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H88260056"/>
			<id>209662</id>
			<summary>
				<section label="Choosing an antidepressant" id="88260056">
					<fragment>Response (reduction of baseline symptoms &gt;=50 percent) occurred in more patients treated with mirtazapine than trazodone (78 versus 61 percent).</fragment>
				</section>
			</summary>
			<category term="C0040805" scheme="gov.nih.nlm.semanticType.phsu" label="trazodone"/>
			<category term="C0049506" scheme="gov.nih.nlm.semanticType.phsu" label="mirtazapine"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H88260056"/>
			<id>209664</id>
			<summary>
				<section label="Choosing an antidepressant" id="88260056">
					<fragment>An eight-week randomized trial compared mirtazapine (mean dose 50 mg per day) with venlafaxine (mean dose 255 mg per day) in 157 inpatients and found that response was comparable (62 and 52 percent).</fragment>
				</section>
			</summary>
			<category term="C0049506" scheme="gov.nih.nlm.semanticType.phsu" label="mirtazapine"/>
			<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H88260056"/>
			<id>209665</id>
			<summary>
				<section label="Choosing an antidepressant" id="88260056">
					<fragment>In addition, discontinuation of treatment due to adverse effects occurred in fewer patients who received mirtazapine than venlafaxine (15 versus 5 percent).</fragment>
				</section>
			</summary>
			<category term="C0049506" scheme="gov.nih.nlm.semanticType.phsu" label="mirtazapine"/>
			<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
			<category term="C0457454" scheme="gov.nih.nlm.semanticType.hlca" label="discontinuation"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H88260056"/>
			<id>209666</id>
			<summary>
				<section label="Choosing an antidepressant" id="88260056">
					<fragment>Tricyclic antidepressants are another reasonable alternative, based upon randomized trials that suggest tricyclics are more efficacious than other antidepressants for severely depressed patients.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0003290" scheme="gov.nih.nlm.semanticType.phsu" label="Tricyclic antidepressants"/>
			<category term="C3653915" scheme="gov.nih.nlm.semanticType.phsu" label="other antidepressants"/>
			<category term="12" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H88260056"/>
			<id>209668</id>
			<summary>
				<section label="Choosing an antidepressant" id="88260056">
					<fragment>Evidence that indicates tricyclics (particularly amitriptyline, clomipramine, and imipramine) are beneficial for severely depressed patients includes the following studies: A meta-analysis of 104 randomized trials compared amitriptyline with other antidepressants (including other tricyclics) in 7422 depressed patients.</fragment>
				</section>
			</summary>
			<category term="C0002600" scheme="gov.nih.nlm.semanticType.phsu" label="amitriptyline"/>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0009010" scheme="gov.nih.nlm.semanticType.phsu" label="clomipramine"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C3653915" scheme="gov.nih.nlm.semanticType.phsu" label="other antidepressants"/>
			<category term="10" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H88260056"/>
			<id>209669</id>
			<summary>
				<section label="Choosing an antidepressant" id="88260056">
					<fragment>In the subgroup of 54 randomized trials that enrolled hospitalized patients (sample size not provided), response was more likely with amitriptyline than other antidepressants (odds ratio 1.22, 95% CI 1.04-1.42) and tolerability was comparable.</fragment>
				</section>
			</summary>
			<category term="C0002600" scheme="gov.nih.nlm.semanticType.phsu" label="amitriptyline"/>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
			<category term="C3653915" scheme="gov.nih.nlm.semanticType.phsu" label="other antidepressants"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H88260056"/>
			<id>209671</id>
			<summary>
				<section label="Choosing an antidepressant" id="88260056">
					<fragment>A meta-analysis of 25 randomized trials compared tricyclics (amitriptyline, clomipramine, desipramine, imipramine, and maprotiline) with SSRIs (citalopram, fluoxetine, fluvoxamine, and paroxetine) for treating depression in 1377 hospitalized patients.</fragment>
				</section>
			</summary>
			<category term="C0002600" scheme="gov.nih.nlm.semanticType.phsu" label="amitriptyline"/>
			<category term="C0008845" scheme="gov.nih.nlm.semanticType.phsu" label="citalopram"/>
			<category term="C0009010" scheme="gov.nih.nlm.semanticType.phsu" label="clomipramine"/>
			<category term="C0011685" scheme="gov.nih.nlm.semanticType.phsu" label="desipramine"/>
			<category term="C0016365" scheme="gov.nih.nlm.semanticType.phsu" label="fluoxetine"/>
			<category term="C0024778" scheme="gov.nih.nlm.semanticType.phsu" label="maprotiline"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C0070122" scheme="gov.nih.nlm.semanticType.phsu" label="paroxetine"/>
			<category term="C0085228" scheme="gov.nih.nlm.semanticType.phsu" label="fluvoxamine"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
			<category term="21" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H88260056"/>
			<id>209672</id>
			<summary>
				<section label="Choosing an antidepressant" id="88260056">
					<fragment>Improvement was greater with tricyclics than SSRIs, but the clinical difference was small and heterogeneity across studies was significant.</fragment>
				</section>
			</summary>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H88260056"/>
			<id>209673</id>
			<summary>
				<section label="Choosing an antidepressant" id="88260056">
					<fragment>In addition, discontinuation of treatment due to adverse effects occurred in more patients treated with tricyclics than SSRIs (14 versus 9 percent).</fragment>
				</section>
			</summary>
			<category term="C0457454" scheme="gov.nih.nlm.semanticType.hlca" label="discontinuation"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H524936"/>
			<id>209675</id>
			<summary>
				<section label="PERSISTENT DEPRESSIVE DISORDER (DYSTHYMIA)" id="524936">
					<fragment>Persistent depressive disorder (dysthymia) is characterized by dysphoria and at least two other depressive symptoms lasting for two or more years.</fragment>
				</section>
			</summary>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H524936"/>
			<id>209679</id>
			<summary>
				<section label="PERSISTENT DEPRESSIVE DISORDER (DYSTHYMIA)" id="524936">
					<fragment>For initial treatment of persistent depressive disorder, we suggest in order of preference pharmacotherapy plus psychotherapy, pharmacotherapy alone, and psychotherapy alone, based upon randomized trials.</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H524936"/>
			<id>209680</id>
			<summary>
				<section label="PERSISTENT DEPRESSIVE DISORDER (DYSTHYMIA)" id="524936">
					<fragment>Evidence for the efficacy of antidepressants plus psychotherapy for persistent depressive disorder includes a meta-analysis of nine trials (1590 patients with chronic major depression or dysthymic disorder) that compared combination treatment with pharmacotherapy alone and psychotherapy alone;</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="5" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H524936"/>
			<id>209682</id>
			<summary>
				<section label="PERSISTENT DEPRESSIVE DISORDER (DYSTHYMIA)" id="524936">
					<fragment>Improvement was superior with combined treatment than psychotherapy alone, and the difference was moderately large such that combination treatment provided one additional positive outcome for every four patients treated with each regimen (number needed to treat of four).</fragment>
				</section>
			</summary>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H524936"/>
			<id>209684</id>
			<summary>
				<section label="PERSISTENT DEPRESSIVE DISORDER (DYSTHYMIA)" id="524936">
					<fragment>Discontinuation of treatment for any reason was comparable for combined treatment, pharmacotherapy alone, and psychotherapy alone.</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="C0457454" scheme="gov.nih.nlm.semanticType.hlca" label="Discontinuation"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H524936"/>
			<id>209685</id>
			<summary>
				<section label="PERSISTENT DEPRESSIVE DISORDER (DYSTHYMIA)" id="524936">
					<fragment>In addition, randomized trials in patients with mild to moderate major depression have demonstrated that combining antidepressants and psychotherapy is superior to either pharmacotherapy alone or psychotherapy alone.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H524936"/>
			<id>209686</id>
			<summary>
				<section label="PERSISTENT DEPRESSIVE DISORDER (DYSTHYMIA)" id="524936">
					<fragment>Although pharmacotherapy alone is not as efficacious as combination therapy, pharmacotherapy alone is superior to placebo in patients with persistent depressive disorder: A meta-analysis of 15 randomized trials (1992 patients with dysthymic disorder) compared antidepressants with placebo and found that response (eg, reduction of baseline symptoms &gt;=50 percent) was more likely with antidepressants (relative risk 1.5, 95% CI 1.4-1.7).</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C0556895" scheme="gov.nih.nlm.semanticType.topp" label="combination therapy"/>
			<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
			<category term="8" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H524936"/>
			<id>209688</id>
			<summary>
				<section label="PERSISTENT DEPRESSIVE DISORDER (DYSTHYMIA)" id="524936">
					<fragment>A meta-analysis of 17 randomized trials (1454 patients with dysthymic disorder treated for an average of 10 weeks) found that response was more probable with antidepressants than placebo (relative risk 1.8, 95% CI 1.5-2.0).</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H524936"/>
			<id>209689</id>
			<summary>
				<section label="PERSISTENT DEPRESSIVE DISORDER (DYSTHYMIA)" id="524936">
					<fragment>A meta-analysis of 20 randomized trials (2918 patients with depression lasting at least two years) found that remission was greater with SSRIs or tricyclics than with placebo, and was comparable for SSRIs and tricyclics.</fragment>
				</section>
			</summary>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H524936"/>
			<id>209690</id>
			<summary>
				<section label="PERSISTENT DEPRESSIVE DISORDER (DYSTHYMIA)" id="524936">
					<fragment>However, discontinuation of treatment as well as adverse effects occurred less often with SSRIs than tricyclics.</fragment>
				</section>
			</summary>
			<category term="C0457454" scheme="gov.nih.nlm.semanticType.hlca" label="discontinuation"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H524936"/>
			<id>209691</id>
			<summary>
				<section label="PERSISTENT DEPRESSIVE DISORDER (DYSTHYMIA)" id="524936">
					<fragment>In addition, pharmacotherapy alone is superior to psychotherapy alone for persistent depressive disorder.</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H524936"/>
			<id>209692</id>
			<summary>
				<section label="PERSISTENT DEPRESSIVE DISORDER (DYSTHYMIA)" id="524936">
					<fragment>As an example, a meta-analysis of 8 randomized trials (1254 patients with chronic major depression or dysthymic disorder) found a significant, but clinically small effect favoring antidepressants over psychotherapy;</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H524936"/>
			<id>209694</id>
			<summary>
				<section label="PERSISTENT DEPRESSIVE DISORDER (DYSTHYMIA)" id="524936">
					<fragment>However, psychotherapy alone is a reasonable choice for patients with persistent depressive disorder who prefer it.</fragment>
				</section>
			</summary>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H524936"/>
			<id>209695</id>
			<summary>
				<section label="PERSISTENT DEPRESSIVE DISORDER (DYSTHYMIA)" id="524936">
					<fragment>A meta-analysis of 6 randomized trials (362 patients with chronic major depression or dysthymic disorder) found a significant, but clinically small effect favoring psychotherapy over control conditions (primarily pill placebo).</fragment>
				</section>
			</summary>
			<category term="C0029151" scheme="gov.nih.nlm.semanticType.topp" label="pill"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H524936"/>
			<id>209696</id>
			<summary>
				<section label="PERSISTENT DEPRESSIVE DISORDER (DYSTHYMIA)" id="524936">
					<fragment>A subsequent trial (n = 30) found that improvement was greater in patients who received body psychotherapy (which includes both talking as well as exercises to increase body awareness) than the waiting list control.</fragment>
				</section>
			</summary>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H524936"/>
			<id>209697</id>
			<summary>
				<section label="PERSISTENT DEPRESSIVE DISORDER (DYSTHYMIA)" id="524936">
					<fragment>Randomized trials that studied interpersonal psychotherapy in patients with persistent depressive disorder (dysthymia) are discussed separately.</fragment>
				</section>
			</summary>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="C0871787" scheme="gov.nih.nlm.semanticType.topp" label="interpersonal psychotherapy"/>
			<category term="5" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H9988692"/>
			<id>209700</id>
			<summary>
				<section label="Mild to moderate major depression" id="9988692">
					<fragment>For the initial treatment of mild to moderate unipolar major depression, we suggest pharmacotherapy plus psychotherapy, rather than pharmacotherapy alone or psychotherapy alone.</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H9988692"/>
			<id>209703</id>
			<summary>
				<section label="Mild to moderate major depression" id="9988692">
					<fragment>For patients with mild to moderate unipolar major depression who are initially treated with antidepressants, we suggest selective serotonin reuptake inhibitors (SSRIs) rather than other antidepressants.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0360105" scheme="gov.nih.nlm.semanticType.phsu" label="selective serotonin reuptake inhibitors"/>
			<category term="C0758711" scheme="gov.nih.nlm.semanticType.orch" label="serotonin"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin reuptake inhibitors"/>
			<category term="C3653915" scheme="gov.nih.nlm.semanticType.phsu" label="other antidepressants"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H9988692"/>
			<id>209706</id>
			<summary>
				<section label="Mild to moderate major depression" id="9988692">
					<fragment>Several psychotherapies are available to treat unipolar major depression.</fragment>
				</section>
			</summary>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapies"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H9988692"/>
			<id>209707</id>
			<summary>
				<section label="Mild to moderate major depression" id="9988692">
					<fragment>For patients with mild to moderate unipolar major depression who are initially treated with psychotherapy, we suggest cognitive-behavioral therapy (CBT) or interpersonal psychotherapy rather than other psychotherapies.</fragment>
				</section>
			</summary>
			<category term="C0004933" scheme="gov.nih.nlm.semanticType.topp" label="behavioral therapy"/>
			<category term="C0009244" scheme="gov.nih.nlm.semanticType.topp" label="cognitive-behavioral therapy"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="C0419168" scheme="gov.nih.nlm.semanticType.topp" label="other psychotherapies"/>
			<category term="C0871787" scheme="gov.nih.nlm.semanticType.topp" label="interpersonal psychotherapy"/>
			<category term="6" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H9988692"/>
			<id>209709</id>
			<summary>
				<section label="Mild to moderate major depression" id="9988692">
					<fragment>There are no biologic or clinical predictors of sufficient utility to help choose between antidepressants alone and psychotherapy alone for the initial treatment of depression, or to make a selection among specific antidepressants or psychotherapies.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H9988692"/>
			<id>209710</id>
			<summary>
				<section label="Mild to moderate major depression" id="9988692">
					<fragment>Antidepressants alone have been studied and used more often than psychotherapy alone.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="Antidepressants"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H9988692"/>
			<id>209714</id>
			<summary>
				<section label="Mild to moderate major depression" id="9988692">
					<fragment>Among patients with mild to moderate unipolar major depression who start antidepressants, improvement is often apparent within two weeks.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H9988685"/>
			<id>209718</id>
			<summary>
				<section label="Severe major depression" id="9988685">
					<fragment>For patients with severe unipolar major depression, we suggest initial treatment with pharmacotherapy plus psychotherapy, rather than other treatment regimens.</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimens"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H9988685"/>
			<id>209721</id>
			<summary>
				<section label="Severe major depression" id="9988685">
					<fragment>For patients with severe unipolar major depression who are treated with antidepressants, we suggest serotonin-norepinephrine reuptake inhibitors or SSRIs, rather than other antidepressants.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0758711" scheme="gov.nih.nlm.semanticType.orch" label="serotonin"/>
			<category term="C1319313" scheme="gov.nih.nlm.semanticType.phsu" label="norepinephrine reuptake inhibitors"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
			<category term="C3537213" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin-norepinephrine reuptake inhibitors"/>
			<category term="C3653915" scheme="gov.nih.nlm.semanticType.phsu" label="other antidepressants"/>
			<category term="11" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H9988744"/>
			<id>209724</id>
			<summary>
				<section label="Persistent Depressive disorder (dysthymia)" id="9988744">
					<fragment>Persistent depressive disorder is characterized by dysphoria and at least two other depressive symptoms lasting for two or more years.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H9988744"/>
			<id>209725</id>
			<summary>
				<section label="Persistent Depressive disorder (dysthymia)" id="9988744">
					<fragment>For patients with persistent depressive disorder, we suggest antidepressants plus psychotherapy rather than antidepressants alone or psychotherapy alone.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1725#H9988744"/>
			<id>209727</id>
			<summary>
				<section label="Persistent Depressive disorder (dysthymia)" id="9988744">
					<fragment>psychotherapy alone is also reasonable for patients who prefer it.</fragment>
				</section>
			</summary>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
	</feed>
	<feed>
		<title>Unipolar depression in adults: Management of highly resistant (refractory) depression</title>
		<category term="C1303151" scheme="gov.nih.nlm.semanticType.topp" label="depression management program"/>
		<category term="C0019982" scheme="gov.nih.nlm.semanticType.hlca" label="referral hospital"/>
		<category term="C0034927" scheme="gov.nih.nlm.semanticType.hlca" label="referral"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0556895" scheme="gov.nih.nlm.semanticType.topp" label="combination therapy"/>
		<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
		<category term="C0004933" scheme="gov.nih.nlm.semanticType.topp" label="behavioral therapy"/>
		<category term="C0009244" scheme="gov.nih.nlm.semanticType.topp" label="cognitive-behavioral therapy"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C0360105" scheme="gov.nih.nlm.semanticType.phsu" label="Selective serotonin reuptake inhibitor"/>
		<category term="C0758711" scheme="gov.nih.nlm.semanticType.orch" label="serotonin"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin reuptake inhibitor"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapies"/>
		<category term="C0033972" scheme="gov.nih.nlm.semanticType.topp" label="multiple psychotherapies"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0871787" scheme="gov.nih.nlm.semanticType.topp" label="interpersonal psychotherapy"/>
		<category term="C0034107" scheme="gov.nih.nlm.semanticType.hlca" label="pulse"/>
		<category term="C0022614" scheme="gov.nih.nlm.semanticType.phsu" label="ketamine"/>
		<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgical"/>
		<category term="C0002932" scheme="gov.nih.nlm.semanticType.phsu" label="anesthetic"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0022614" scheme="gov.nih.nlm.semanticType.phsu" label="Ketamine"/>
		<category term="C0022614" scheme="gov.nih.nlm.semanticType.phsu" label="ketamine"/>
		<category term="C0026056" scheme="gov.nih.nlm.semanticType.phsu" label="midazolam"/>
		<category term="C0124598" scheme="gov.nih.nlm.semanticType.phsu" label="kg"/>
		<category term="C0022614" scheme="gov.nih.nlm.semanticType.phsu" label="ketamine"/>
		<category term="C0026056" scheme="gov.nih.nlm.semanticType.phsu" label="midazolam"/>
		<category term="C0022614" scheme="gov.nih.nlm.semanticType.phsu" label="ketamine"/>
		<category term="C0022614" scheme="gov.nih.nlm.semanticType.phsu" label="ketamine"/>
		<category term="C0022614" scheme="gov.nih.nlm.semanticType.phsu" label="ketamine"/>
		<category term="C0013808" scheme="gov.nih.nlm.semanticType.topp" label="electroconvulsive therapy"/>
		<category term="C0022614" scheme="gov.nih.nlm.semanticType.phsu" label="ketamine"/>
		<category term="C0022614" scheme="gov.nih.nlm.semanticType.phsu" label="ketamine"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0013806" scheme="gov.nih.nlm.semanticType.topp" label="ECT"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0034927" scheme="gov.nih.nlm.semanticType.hlca" label="referral"/>
		<category term="C0278293" scheme="gov.nih.nlm.semanticType.topp" label="procedures"/>
		<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimens"/>
		<category term="C0634038" scheme="gov.nih.nlm.semanticType.phsu" label="TMS"/>
		<category term="C1261322" scheme="gov.nih.nlm.semanticType.hlca" label="investigation"/>
		<category term="C0034107" scheme="gov.nih.nlm.semanticType.hlca" label="pulsed"/>
		<category term="C1292856" scheme="gov.nih.nlm.semanticType.topp" label="stimulation"/>
		<category term="C0394162" scheme="gov.nih.nlm.semanticType.topp" label="deep brain stimulation"/>
		<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgical"/>
		<category term="C0870227" scheme="gov.nih.nlm.semanticType.topp" label="brain stimulation"/>
		<category term="C1292856" scheme="gov.nih.nlm.semanticType.topp" label="stimulation"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C0162758" scheme="gov.nih.nlm.semanticType.phsu" label="reuptake inhibitor, serotonin"/>
		<category term="C0242905" scheme="gov.nih.nlm.semanticType.phsu" label="atypical antidepressant"/>
		<category term="C0360105" scheme="gov.nih.nlm.semanticType.phsu" label="selective serotonin reuptake inhibitor"/>
		<category term="C0758711" scheme="gov.nih.nlm.semanticType.orch" label="serotonin"/>
		<category term="C1319313" scheme="gov.nih.nlm.semanticType.phsu" label="norepinephrine reuptake inhibitor"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin reuptake inhibitor"/>
		<category term="C3537213" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin-norepinephrine reuptake inhibitor"/>
		<category term="C3653413" scheme="gov.nih.nlm.semanticType.phsu" label="monoamine oxidase inhibitor"/>
		<category term="C0002932" scheme="gov.nih.nlm.semanticType.phsu" label="anesthetic"/>
		<category term="C0022614" scheme="gov.nih.nlm.semanticType.phsu" label="ketamine"/>
		<category term="C0034107" scheme="gov.nih.nlm.semanticType.hlca" label="pulsed"/>
		<category term="C1292856" scheme="gov.nih.nlm.semanticType.topp" label="stimulation"/>
		<id>87500</id>
		<entry>
			<link href="http://www.uptodate.com/contents/87500#H87698632"/>
			<id>213827</id>
			<summary>
				<section label="Unipolar major depression" id="87698632">
					<fragment>Unipolar major depression (major depressive disorder) is diagnosed in patients who have suffered at least one major depressive episode and have no history of mania ) or hypomania.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/87500#H807206"/>
			<id>213851</id>
			<summary>
				<section label="General approach" id="807206">
					<fragment>A prospective, 48 week, observational study of a depression management program in 19 patients and their family members suggested that this approach may possibly improve depressive symptoms, psychosocial functioning, and quality of life.</fragment>
				</section>
			</summary>
			<category term="C1303151" scheme="gov.nih.nlm.semanticType.topp" label="depression management program"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/87500#H672133"/>
			<id>213855</id>
			<summary>
				<section label="Setting" id="672133">
					<fragment>In a prospective observational study, 113 patients (approximately 70 percent with unipolar depression) were treated in a national-referral hospital unit dedicated to refractory, complex mood disorders.</fragment>
				</section>
			</summary>
			<category term="C0019982" scheme="gov.nih.nlm.semanticType.hlca" label="referral hospital"/>
			<category term="C0034927" scheme="gov.nih.nlm.semanticType.hlca" label="referral"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/87500#H173033627"/>
			<id>213865</id>
			<summary>
				<section label="Measurement based care" id="173033627">
					<fragment>The nine-item Patient Health Questionnaire (PHQ-9) is a self-report, standardized, rating scale that measures the severity of symptoms in patients with major depression, and is widely used to ascertain response to pharmacotherapy or psychotherapy.</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/87500#H807069"/>
			<id>213868</id>
			<summary>
				<section label="Combination therapy" id="807069">
					<fragment>For patients with treatment refractory depression, we suggest pharmacotherapy combined with psychotherapy, based upon randomized trials: A meta-analysis of 16 trials compared combination treatment with pharmacotherapy alone in 1842 depressed patients (who were not selected for treatment resistant or treatment refractory depression).</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/87500#H807069"/>
			<id>213869</id>
			<summary>
				<section label="Combination therapy" id="807069">
					<fragment>Response occurred in more patients who received combination therapy (odds ratio 1.9, 95% CI 1.4-2.5).</fragment>
				</section>
			</summary>
			<category term="C0556895" scheme="gov.nih.nlm.semanticType.topp" label="combination therapy"/>
			<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/87500#H807069"/>
			<id>213871</id>
			<summary>
				<section label="Combination therapy" id="807069">
					<fragment>A subsequent one year randomized trial compared cognitive-behavioral therapy (CBT; 12 to 18 sessions) plus usual care (eg, pharmacotherapy) with usual care alone in 419 outpatients with treatment resistant depression.</fragment>
				</section>
			</summary>
			<category term="C0004933" scheme="gov.nih.nlm.semanticType.topp" label="behavioral therapy"/>
			<category term="C0009244" scheme="gov.nih.nlm.semanticType.topp" label="cognitive-behavioral therapy"/>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/87500#H807069"/>
			<id>213872</id>
			<summary>
				<section label="Combination therapy" id="807069">
					<fragment>Remission occurred in more patients who received CBT plus usual care than usual care alone (28 versus 15 percent).</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/87500#H6077291"/>
			<id>213873</id>
			<summary>
				<section label="Pharmacotherapy" id="6077291">
					<fragment>Patients with treatment refractory unipolar major depression frequently receive an antidepressant augmented with another drug, based upon the efficacy of augmentation in randomized trials of patients with treatment resistant depression.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/87500#H6077291"/>
			<id>213875</id>
			<summary>
				<section label="Pharmacotherapy" id="6077291">
					<fragment>Many antidepressants and adjunctive drugs are available, and the choice begins with drugs that have not been previously used for the current depressive episode.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/87500#H6077291"/>
			<id>213876</id>
			<summary>
				<section label="Pharmacotherapy" id="6077291">
					<fragment>Our general order of preference in choosing an antidepressant is as follows: Selective serotonin reuptake inhibitor.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="C0360105" scheme="gov.nih.nlm.semanticType.phsu" label="Selective serotonin reuptake inhibitor"/>
			<category term="C0758711" scheme="gov.nih.nlm.semanticType.orch" label="serotonin"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin reuptake inhibitor"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/87500#H96384166"/>
			<id>213889</id>
			<summary>
				<section label="Adjunctive psychotherapy" id="96384166">
					<fragment>There are multiple psychotherapies available for patients with treatment refractory depression, and the choice begins with available therapies that have not yet been administered.</fragment>
				</section>
			</summary>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapies"/>
			<category term="C0033972" scheme="gov.nih.nlm.semanticType.topp" label="multiple psychotherapies"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/87500#H96384166"/>
			<id>213890</id>
			<summary>
				<section label="Adjunctive psychotherapy" id="96384166">
					<fragment>CBT has been studied most often in treatment resistant depression, and interpersonal psychotherapy has been widely studied for the initial treatment of depression.</fragment>
				</section>
			</summary>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="C0871787" scheme="gov.nih.nlm.semanticType.topp" label="interpersonal psychotherapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/87500#H96385255"/>
			<id>213894</id>
			<summary>
				<section label="Other options" id="96385255">
					<fragment>the electrode is connected by a wire to a pulse generator implanted subcutaneously in the chest wall.</fragment>
				</section>
			</summary>
			<category term="C0034107" scheme="gov.nih.nlm.semanticType.hlca" label="pulse"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/87500#H173030464"/>
			<id>213903</id>
			<summary>
				<section label="INVESTIGATIONAL APPROACHES" id="173030464">
					<fragment>Patients with treatment refractory depression may be candidates for ketamine and noninvasive neuromodulation interventions, whereas surgical interventions are reserved for patients with severe, intractable, and incapacitating major depression.</fragment>
				</section>
			</summary>
			<category term="C0022614" scheme="gov.nih.nlm.semanticType.phsu" label="ketamine"/>
			<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgical"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/87500#H173030552"/>
			<id>213906</id>
			<summary>
				<section label="Ketamine" id="173030552">
					<fragment>Ketamine is an NMDA receptor antagonist, and is a standard anesthetic drug that may possibly alleviate treatment refractory unipolar major depression.</fragment>
				</section>
			</summary>
			<category term="C0002932" scheme="gov.nih.nlm.semanticType.phsu" label="anesthetic"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0022614" scheme="gov.nih.nlm.semanticType.phsu" label="Ketamine"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/87500#H173030552"/>
			<id>213907</id>
			<summary>
				<section label="Ketamine" id="173030552">
					<fragment>Evidence for the effectiveness of ketamine (0.5 mg per kg) in depression includes the following studies: A randomized trial compared ketamine with midazolam, each given as a single intravenous infusion, in 73 patients.</fragment>
				</section>
			</summary>
			<category term="C0022614" scheme="gov.nih.nlm.semanticType.phsu" label="ketamine"/>
			<category term="C0026056" scheme="gov.nih.nlm.semanticType.phsu" label="midazolam"/>
			<category term="C0124598" scheme="gov.nih.nlm.semanticType.phsu" label="kg"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/87500#H173030552"/>
			<id>213908</id>
			<summary>
				<section label="Ketamine" id="173030552">
					<fragment>Response (reduction of baseline symptoms &gt;=50 percent) 24 hours after infusion occurred in more patients who received ketamine than midazolam (64 versus 28 percent), and there was a trend for the benefits of ketamine to persist for seven days.</fragment>
				</section>
			</summary>
			<category term="C0022614" scheme="gov.nih.nlm.semanticType.phsu" label="ketamine"/>
			<category term="C0026056" scheme="gov.nih.nlm.semanticType.phsu" label="midazolam"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/87500#H173030552"/>
			<id>213909</id>
			<summary>
				<section label="Ketamine" id="173030552">
					<fragment>Adverse effects of ketamine included blood pressure changes that required termination of the infusion in two patients.</fragment>
				</section>
			</summary>
			<category term="C0022614" scheme="gov.nih.nlm.semanticType.phsu" label="ketamine"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/87500#H173030552"/>
			<id>213911</id>
			<summary>
				<section label="Ketamine" id="173030552">
					<fragment>A crossover trial compared a single intravenous infusion of ketamine with a single infusion of saline, administered one week apart, in 18 patients who were randomly assigned to the order in which they received the two infusions.</fragment>
				</section>
			</summary>
			<category term="C0022614" scheme="gov.nih.nlm.semanticType.phsu" label="ketamine"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/87500#H173030552"/>
			<id>213916</id>
			<summary>
				<section label="Ketamine" id="173030552">
					<fragment>Beginning on the day of infusion and persisting through day three post-infusion, improvement was greater with ketamine.</fragment>
				</section>
			</summary>
			<category term="C0022614" scheme="gov.nih.nlm.semanticType.phsu" label="ketamine"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/87500#H173030552"/>
			<id>213917</id>
			<summary>
				<section label="Ketamine" id="173030552">
					<fragment>In addition, a prospective observational study found that ketamine led to a moderately large reduction of depressive symptoms in patients who had previously not responded to electroconvulsive therapy.</fragment>
				</section>
			</summary>
			<category term="C0013808" scheme="gov.nih.nlm.semanticType.topp" label="electroconvulsive therapy"/>
			<category term="C0022614" scheme="gov.nih.nlm.semanticType.phsu" label="ketamine"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/87500#H173030552"/>
			<id>213921</id>
			<summary>
				<section label="Ketamine" id="173030552">
					<fragment>Treatment of depression with ketamine typically occurs in hospital settings in collaboration with anesthesiologists.</fragment>
				</section>
			</summary>
			<category term="C0022614" scheme="gov.nih.nlm.semanticType.phsu" label="ketamine"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/87500#H6077305"/>
			<id>213924</id>
			<summary>
				<section label="Noninvasive neuromodulation" id="6077305">
					<fragment>For patients with unipolar major depression who are refractory to numerous sequential regimens of standard treatments, including pharmacotherapy, psychotherapy, ECT, and repetitive TMS, several noninvasive neuromodulation procedures are under investigation in research settings at tertiary referral centers;</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0013806" scheme="gov.nih.nlm.semanticType.topp" label="ECT"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="C0034927" scheme="gov.nih.nlm.semanticType.hlca" label="referral"/>
			<category term="C0278293" scheme="gov.nih.nlm.semanticType.topp" label="procedures"/>
			<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimens"/>
			<category term="C0634038" scheme="gov.nih.nlm.semanticType.phsu" label="TMS"/>
			<category term="C1261322" scheme="gov.nih.nlm.semanticType.hlca" label="investigation"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/87500#H6077305"/>
			<id>213925</id>
			<summary>
				<section label="Noninvasive neuromodulation" id="6077305">
					<fragment>these include magnetic seizure therapy, focal electrically administered seizure therapy, transcranial direct current stimulation, transcranial low voltage pulsed electromagnetic fields stimulation.</fragment>
				</section>
			</summary>
			<category term="C0034107" scheme="gov.nih.nlm.semanticType.hlca" label="pulsed"/>
			<category term="C1292856" scheme="gov.nih.nlm.semanticType.topp" label="stimulation"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/87500#H14367098"/>
			<id>213928</id>
			<summary>
				<section label="Invasive/surgical neuromodulation" id="14367098">
					<fragment>The most widely studied surgical intervention is deep brain stimulation, followed by direct cortical stimulation and ablative neurosurgery.</fragment>
				</section>
			</summary>
			<category term="C0394162" scheme="gov.nih.nlm.semanticType.topp" label="deep brain stimulation"/>
			<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgical"/>
			<category term="C0870227" scheme="gov.nih.nlm.semanticType.topp" label="brain stimulation"/>
			<category term="C1292856" scheme="gov.nih.nlm.semanticType.topp" label="stimulation"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/87500#H14367195"/>
			<id>213943</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="14367195">
					<fragment>Unipolar major depression (major depressive disorder) is diagnosed in patients who have suffered at least one major depressive episode ) and have no history of mania ) or hypomania.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/87500#H14367195"/>
			<id>213953</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="14367195">
					<fragment>Patients with treatment refractory depression frequently receive an antidepressant augmented with another drug;</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/87500#H14367195"/>
			<id>213956</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="14367195">
					<fragment>Our general order of preference in choosing an antidepressant is as follows: selective serotonin reuptake inhibitor, serotonin-norepinephrine reuptake inhibitor, atypical antidepressant, serotonin modulator, tricyclic, and monoamine oxidase inhibitor.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="C0162758" scheme="gov.nih.nlm.semanticType.phsu" label="reuptake inhibitor, serotonin"/>
			<category term="C0242905" scheme="gov.nih.nlm.semanticType.phsu" label="atypical antidepressant"/>
			<category term="C0360105" scheme="gov.nih.nlm.semanticType.phsu" label="selective serotonin reuptake inhibitor"/>
			<category term="C0758711" scheme="gov.nih.nlm.semanticType.orch" label="serotonin"/>
			<category term="C1319313" scheme="gov.nih.nlm.semanticType.phsu" label="norepinephrine reuptake inhibitor"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin reuptake inhibitor"/>
			<category term="C3537213" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin-norepinephrine reuptake inhibitor"/>
			<category term="C3653413" scheme="gov.nih.nlm.semanticType.phsu" label="monoamine oxidase inhibitor"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/87500#H14367195"/>
			<id>213962</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="14367195">
					<fragment>Patients with treatment refractory depression may be candidates for clinical trials investigating the anesthetic ketamine, and noninvasive neuromodulation interventions that include magnetic seizure therapy, focal electrically administered seizure therapy, transcranial direct current stimulation, and transcranial low voltage pulsed electromagnetic fields stimulation.</fragment>
				</section>
			</summary>
			<category term="C0002932" scheme="gov.nih.nlm.semanticType.phsu" label="anesthetic"/>
			<category term="C0022614" scheme="gov.nih.nlm.semanticType.phsu" label="ketamine"/>
			<category term="C0034107" scheme="gov.nih.nlm.semanticType.hlca" label="pulsed"/>
			<category term="C1292856" scheme="gov.nih.nlm.semanticType.topp" label="stimulation"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
	</feed>
	<feed>
		<title>Unipolar minor depression in adults: Management and treatment</title>
		<category term="C0034927" scheme="gov.nih.nlm.semanticType.hlca" label="referral"/>
		<category term="C0700325" scheme="gov.nih.nlm.semanticType.hlca" label="watchful waiting"/>
		<category term="C0700325" scheme="gov.nih.nlm.semanticType.hlca" label="watchful waiting"/>
		<category term="C0002600" scheme="gov.nih.nlm.semanticType.phsu" label="amitriptyline"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0016365" scheme="gov.nih.nlm.semanticType.phsu" label="fluoxetine"/>
		<category term="C0022154" scheme="gov.nih.nlm.semanticType.phsu" label="isocarboxazid"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0070122" scheme="gov.nih.nlm.semanticType.phsu" label="paroxetine"/>
		<category term="C0700325" scheme="gov.nih.nlm.semanticType.hlca" label="watchful waiting"/>
		<category term="C0070122" scheme="gov.nih.nlm.semanticType.phsu" label="paroxetine"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0009244" scheme="gov.nih.nlm.semanticType.topp" label="Cognitive therapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0017313" scheme="gov.nih.nlm.semanticType.hlca" label="care patients"/>
		<category term="C1303140" scheme="gov.nih.nlm.semanticType.topp" label="problem solving therapy"/>
		<category term="C0029151" scheme="gov.nih.nlm.semanticType.topp" label="pill"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C1303140" scheme="gov.nih.nlm.semanticType.topp" label="problem solving therapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0309872" scheme="gov.nih.nlm.semanticType.phsu" label="prevent"/>
		<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="add"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C0360105" scheme="gov.nih.nlm.semanticType.phsu" label="selective serotonin reuptake inhibitor"/>
		<category term="C0758711" scheme="gov.nih.nlm.semanticType.orch" label="serotonin"/>
		<category term="C1319313" scheme="gov.nih.nlm.semanticType.phsu" label="norepinephrine reuptake inhibitor"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin reuptake inhibitor"/>
		<category term="C3537213" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin-norepinephrine reuptake inhibitor"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0008845" scheme="gov.nih.nlm.semanticType.phsu" label="citalopram"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C0017313" scheme="gov.nih.nlm.semanticType.hlca" label="care patients"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0070122" scheme="gov.nih.nlm.semanticType.phsu" label="paroxetine"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0002600" scheme="gov.nih.nlm.semanticType.phsu" label="amitriptyline"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0700325" scheme="gov.nih.nlm.semanticType.hlca" label="watchful waiting"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<id>87127</id>
		<entry>
			<link href="http://www.uptodate.com/contents/87127#H222383"/>
			<id>213716</id>
			<summary>
				<section label="GENERAL PRINCIPLES" id="222383">
					<fragment>In addition, referral is often indicated for suicidal patients.</fragment>
				</section>
			</summary>
			<category term="C0034927" scheme="gov.nih.nlm.semanticType.hlca" label="referral"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/87127#H222383"/>
			<id>213719</id>
			<summary>
				<section label="GENERAL PRINCIPLES" id="222383">
					<fragment>In addition, treatments that are effective for unipolar major depression are not necessarily beneficial for minor depression.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/87127#H222383"/>
			<id>213725</id>
			<summary>
				<section label="GENERAL PRINCIPLES" id="222383">
					<fragment>The treatment of unipolar major depression is discussed separately, as is the course of illness in minor depression.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/87127#H222397"/>
			<id>213730</id>
			<summary>
				<section label="MILD ILLNESS" id="222397">
					<fragment>For patients with minor depression who are mildly ill, we suggest watchful waiting, during which the patient is monitored every two to six weeks to ensure that symptoms are not worsening and a major depressive episode has not ensued.</fragment>
				</section>
			</summary>
			<category term="C0700325" scheme="gov.nih.nlm.semanticType.hlca" label="watchful waiting"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/87127#H222397"/>
			<id>213733</id>
			<summary>
				<section label="MILD ILLNESS" id="222397">
					<fragment>In addition, if symptoms worsen during watchful waiting, such that the minor depressive episode becomes moderate to severe, patients should be treated with active interventions, which are discussed elsewhere in this topic.</fragment>
				</section>
			</summary>
			<category term="C0700325" scheme="gov.nih.nlm.semanticType.hlca" label="watchful waiting"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/87127#H222397"/>
			<id>213734</id>
			<summary>
				<section label="MILD ILLNESS" id="222397">
					<fragment>Evidence for the safety of watchful waiting in minor depression (as well as the lack of efficacy of pharmacotherapy) includes the following: A meta-analysis of six randomized trials compared antidepressants (amitriptyline, fluoxetine, isocarboxazid, or paroxetine) with placebo in 468 patients who were treated for 6 to 12 weeks.</fragment>
				</section>
			</summary>
			<category term="C0002600" scheme="gov.nih.nlm.semanticType.phsu" label="amitriptyline"/>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0016365" scheme="gov.nih.nlm.semanticType.phsu" label="fluoxetine"/>
			<category term="C0022154" scheme="gov.nih.nlm.semanticType.phsu" label="isocarboxazid"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C0070122" scheme="gov.nih.nlm.semanticType.phsu" label="paroxetine"/>
			<category term="C0700325" scheme="gov.nih.nlm.semanticType.hlca" label="watchful waiting"/>
			<category term="5" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/87127#H222397"/>
			<id>213737</id>
			<summary>
				<section label="MILD ILLNESS" id="222397">
					<fragment>A 12 week, open label randomized trial compared usual care alone with usual care plus paroxetine (20 to 40 mg per day) in 181 patients with either minor depression or mild episodes of major depression.</fragment>
				</section>
			</summary>
			<category term="C0070122" scheme="gov.nih.nlm.semanticType.phsu" label="paroxetine"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/87127#H222397"/>
			<id>213741</id>
			<summary>
				<section label="MILD ILLNESS" id="222397">
					<fragment>A randomized trial in 226 patients with minor depression included a four week, placebo lead-in phase prior to assigning patients to treatment.</fragment>
				</section>
			</summary>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/87127#H222411"/>
			<id>213749</id>
			<summary>
				<section label="First line" id="222411">
					<fragment>For patients with minor depression who are moderately to severely ill, we suggest psychotherapy as first line treatment, based upon randomized trials.</fragment>
				</section>
			</summary>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/87127#H222411"/>
			<id>213754</id>
			<summary>
				<section label="First line" id="222411">
					<fragment>Cognitive therapy attempts to modify the dysfunctional thoughts, beliefs, and attitudes (eg, "I'm no good," "there's nothing I can do," or "my situation is hopeless") that maintain behaviors associated with depression.</fragment>
				</section>
			</summary>
			<category term="C0009244" scheme="gov.nih.nlm.semanticType.topp" label="Cognitive therapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/87127#H222411"/>
			<id>213763</id>
			<summary>
				<section label="First line" id="222411">
					<fragment>Evidence that psychotherapy, particularly CBT, improves minor depression includes the following studies: A meta-analysis of seven randomized trials (700 patients) compared psychotherapy with treatment as usual or a waiting list.</fragment>
				</section>
			</summary>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/87127#H222411"/>
			<id>213765</id>
			<summary>
				<section label="First line" id="222411">
					<fragment>Improvement at the end of treatment was superior with psychotherapy than the control condition, and the difference was clinically small to moderate;</fragment>
				</section>
			</summary>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/87127#H222411"/>
			<id>213767</id>
			<summary>
				<section label="First line" id="222411">
					<fragment>At the one year follow-up, there was a trend for a greater reduction of symptoms among patients who received psychotherapy.</fragment>
				</section>
			</summary>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/87127#H222411"/>
			<id>213768</id>
			<summary>
				<section label="First line" id="222411">
					<fragment>An eight-week randomized trial compared CBT with usual care (a 40 minute videotape discussing depression) in 49 primary care patients.</fragment>
				</section>
			</summary>
			<category term="C0017313" scheme="gov.nih.nlm.semanticType.hlca" label="care patients"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/87127#H222411"/>
			<id>213769</id>
			<summary>
				<section label="First line" id="222411">
					<fragment>After eight weeks, depressive symptoms decreased more in patients who received CBT, and this advantage persisted at the one year follow-up.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/87127#H222411"/>
			<id>213770</id>
			<summary>
				<section label="First line" id="222411">
					<fragment>A randomized trial compared eight sessions of CBT (administered by telephone) plus usual care (a stress reduction program and treatment from other clinicians if desired) with usual care alone in 118 patients.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/87127#H222411"/>
			<id>213771</id>
			<summary>
				<section label="First line" id="222411">
					<fragment>At the end of treatment (assessment after four months), improvement was greater in patients who received CBT, and the clinical difference between CBT and the control condition was moderate to large.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/87127#H222411"/>
			<id>213773</id>
			<summary>
				<section label="First line" id="222411">
					<fragment>A nine-week randomized trial compared problem solving therapy with usual care in 141 patients, and found that improvement was greater with active treatment.</fragment>
				</section>
			</summary>
			<category term="C1303140" scheme="gov.nih.nlm.semanticType.topp" label="problem solving therapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/87127#H222411"/>
			<id>213774</id>
			<summary>
				<section label="First line" id="222411">
					<fragment>Conversely, an 11-week randomized trial that compared problem solving therapy with pill placebo in 161 patients found that improvement was comparable for the two groups.</fragment>
				</section>
			</summary>
			<category term="C0029151" scheme="gov.nih.nlm.semanticType.topp" label="pill"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C1303140" scheme="gov.nih.nlm.semanticType.topp" label="problem solving therapy"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/87127#H222411"/>
			<id>213775</id>
			<summary>
				<section label="First line" id="222411">
					<fragment>For patients with minor depression, psychotherapy may diminish somatization as part of symptomatic improvement.</fragment>
				</section>
			</summary>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/87127#H222411"/>
			<id>213777</id>
			<summary>
				<section label="First line" id="222411">
					<fragment>Evidence that psychotherapy can ameliorate somatization includes an eight-week randomized trial (n = 49) that compared CBT with usual care alone.</fragment>
				</section>
			</summary>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/87127#H222411"/>
			<id>213778</id>
			<summary>
				<section label="First line" id="222411">
					<fragment>At the end of treatment, somatic symptoms decreased more in patients who received CBT, and this benefit persisted at the one year follow-up.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/87127#H222411"/>
			<id>213780</id>
			<summary>
				<section label="First line" id="222411">
					<fragment>In addition, psychotherapy may possibly prevent minor depression from progressing to major depression: A meta-analysis of four randomized trials (533 patients with minor depression) compared CBT with treatment as usual, and found that at the one year follow-up, there was a trend for a lower incidence of major depression in patients treated with psychotherapy (incident rate ratio 0.70, 95% CI 0.47-1.03).</fragment>
				</section>
			</summary>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C0309872" scheme="gov.nih.nlm.semanticType.phsu" label="prevent"/>
			<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
			<category term="5" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/87127#H222411"/>
			<id>213781</id>
			<summary>
				<section label="First line" id="222411">
					<fragment>A subsequent, six-week randomized trial compared CBT with a control condition (a brochure with information that described depression and local treatment options) in 173 high school students with depressive symptoms.</fragment>
				</section>
			</summary>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/87127#H222411"/>
			<id>213782</id>
			<summary>
				<section label="First line" id="222411">
					<fragment>At the two year follow-up, major depression occurred in fewer adolescents who received CBT than the control condition (14 versus 23 percent).</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/87127#H222411"/>
			<id>213783</id>
			<summary>
				<section label="First line" id="222411">
					<fragment>No head to head trials have compared CBT (or other forms of psychotherapy) with pharmacotherapy for minor depression.</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/87127#H222426"/>
			<id>213787</id>
			<summary>
				<section label="Psychotherapy plus pharmacotherapy" id="222426">
					<fragment>Based upon clinical experience, we generally add an antidepressant such as a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor for these resistant patients.</fragment>
				</section>
			</summary>
			<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="add"/>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="C0360105" scheme="gov.nih.nlm.semanticType.phsu" label="selective serotonin reuptake inhibitor"/>
			<category term="C0758711" scheme="gov.nih.nlm.semanticType.orch" label="serotonin"/>
			<category term="C1319313" scheme="gov.nih.nlm.semanticType.phsu" label="norepinephrine reuptake inhibitor"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin reuptake inhibitor"/>
			<category term="C3537213" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin-norepinephrine reuptake inhibitor"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/87127#H222426"/>
			<id>213789</id>
			<summary>
				<section label="Psychotherapy plus pharmacotherapy" id="222426">
					<fragment>Although no high quality studies have evaluated the combination of psychotherapy and an antidepressant for minor depression, randomized trials indicate that combination treatment is beneficial for major depression.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/87127#H222433"/>
			<id>213792</id>
			<summary>
				<section label="Medication monotherapy" id="222433">
					<fragment>Treatment of minor depression with antidepressant medication monotherapy is generally not beneficial: A meta-analysis of six randomized trials (468 patients) compared antidepressants with placebo and found that response was comparable for the two groups (41 and 38 percent).</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/87127#H222433"/>
			<id>213793</id>
			<summary>
				<section label="Medication monotherapy" id="222433">
					<fragment>In a subsequent 12-week randomized trial that compared citalopram (20 mg/day) with placebo in 47 patients, improvement of symptoms was comparable.</fragment>
				</section>
			</summary>
			<category term="C0008845" scheme="gov.nih.nlm.semanticType.phsu" label="citalopram"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/87127#H222433"/>
			<id>213794</id>
			<summary>
				<section label="Medication monotherapy" id="222433">
					<fragment>However, primary care patients with minor depression who have more severe symptoms and functional impairment may possibly benefit from an antidepressant: An 11-week randomized trial that compared paroxetine (10 to 40 mg/day) with placebo in 138 patients found that improvement was comparable for the two groups.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="C0017313" scheme="gov.nih.nlm.semanticType.hlca" label="care patients"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0070122" scheme="gov.nih.nlm.semanticType.phsu" label="paroxetine"/>
			<category term="6" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/87127#H222433"/>
			<id>213796</id>
			<summary>
				<section label="Medication monotherapy" id="222433">
					<fragment>in the group with the greatest severity, improvement was superior in patients who received the antidepressant rather than placebo.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/87127#H222433"/>
			<id>213797</id>
			<summary>
				<section label="Medication monotherapy" id="222433">
					<fragment>A six-week randomized trial compared amitriptyline (median dose 125 mg/day) with placebo in 141 patients with major or minor depression who completed at least four weeks of treatment, and found that improvement was superior with active drug.</fragment>
				</section>
			</summary>
			<category term="C0002600" scheme="gov.nih.nlm.semanticType.phsu" label="amitriptyline"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/87127#H222433"/>
			<id>213800</id>
			<summary>
				<section label="Medication monotherapy" id="222433">
					<fragment>In addition, antidepressants are often acceptable to patients with minor depression.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/87127#H222440"/>
			<id>213807</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="222440">
					<fragment>In addition, treatments that are effective for unipolar major depression (eg, collaborative care) are not necessarily beneficial for minor depression.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/87127#H222440"/>
			<id>213808</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="222440">
					<fragment>For patients with minor depression who are mildly ill (no suicidality and little to no functional impairment), we suggest watchful waiting rather than pharmacotherapy or psychotherapy.</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="C0700325" scheme="gov.nih.nlm.semanticType.hlca" label="watchful waiting"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/87127#H222440"/>
			<id>213814</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="222440">
					<fragment>For patients with minor depression who are moderately to severely ill, we suggest psychotherapy as a first treatment option rather than pharmacotherapy.</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/87127#H222440"/>
			<id>213819</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="222440">
					<fragment>however, patients with more severe symptoms and functional impairment may possibly benefit from an antidepressant alone.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
	</feed>
	<feed>
		<title>Unipolar depression in adults: Treatment of resistant depression</title>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C3469597" scheme="gov.nih.nlm.semanticType.hlca" label="medication, treatment"/>
		<category term="C0033325" scheme="gov.nih.nlm.semanticType.hlca" label="prognosis"/>
		<category term="C2735310" scheme="gov.nih.nlm.semanticType.hlca" label="care management"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0006462" scheme="gov.nih.nlm.semanticType.phsu" label="buspirone"/>
		<category term="C0008845" scheme="gov.nih.nlm.semanticType.phsu" label="citalopram"/>
		<category term="C0074393" scheme="gov.nih.nlm.semanticType.phsu" label="sertraline"/>
		<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
		<category term="C0085208" scheme="gov.nih.nlm.semanticType.phsu" label="bupropion"/>
		<category term="C1259875" scheme="gov.nih.nlm.semanticType.phsu" label="STAR"/>
		<category term="C0006462" scheme="gov.nih.nlm.semanticType.phsu" label="buspirone"/>
		<category term="C0008845" scheme="gov.nih.nlm.semanticType.phsu" label="citalopram"/>
		<category term="C0074393" scheme="gov.nih.nlm.semanticType.phsu" label="sertraline"/>
		<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
		<category term="C0085208" scheme="gov.nih.nlm.semanticType.phsu" label="bupropion"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0299792" scheme="gov.nih.nlm.semanticType.phsu" label="aripiprazole"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRI"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0003290" scheme="gov.nih.nlm.semanticType.phsu" label="Tricyclic antidepressants"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0031392" scheme="gov.nih.nlm.semanticType.phsu" label="phenelzine"/>
		<category term="C0040778" scheme="gov.nih.nlm.semanticType.phsu" label="tranylcypromine"/>
		<category term="C0049506" scheme="gov.nih.nlm.semanticType.phsu" label="mirtazapine"/>
		<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
		<category term="C0085208" scheme="gov.nih.nlm.semanticType.phsu" label="bupropion"/>
		<category term="C0242905" scheme="gov.nih.nlm.semanticType.phsu" label="Atypical antidepressants"/>
		<category term="C0758711" scheme="gov.nih.nlm.semanticType.orch" label="Serotonin"/>
		<category term="C1319313" scheme="gov.nih.nlm.semanticType.phsu" label="norepinephrine reuptake inhibitors"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRI"/>
		<category term="C3537213" scheme="gov.nih.nlm.semanticType.phsu" label="Serotonin-norepinephrine reuptake inhibitors"/>
		<category term="C3653413" scheme="gov.nih.nlm.semanticType.phsu" label="Monoamine oxidase inhibitors"/>
		<category term="C0049506" scheme="gov.nih.nlm.semanticType.phsu" label="mirtazapine"/>
		<category term="C0085208" scheme="gov.nih.nlm.semanticType.phsu" label="bupropion"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0049506" scheme="gov.nih.nlm.semanticType.phsu" label="mirtazapine"/>
		<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
		<category term="C0085208" scheme="gov.nih.nlm.semanticType.phsu" label="bupropion"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRI"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRI"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRI"/>
		<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
		<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
		<category term="C0758711" scheme="gov.nih.nlm.semanticType.orch" label="serotonin"/>
		<category term="C1319313" scheme="gov.nih.nlm.semanticType.phsu" label="norepinephrine reuptake inhibitors"/>
		<category term="C3537213" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin-norepinephrine reuptake inhibitors"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C0049506" scheme="gov.nih.nlm.semanticType.phsu" label="mirtazapine"/>
		<category term="C0074393" scheme="gov.nih.nlm.semanticType.phsu" label="sertraline"/>
		<category term="C0085208" scheme="gov.nih.nlm.semanticType.phsu" label="bupropion"/>
		<category term="C0242905" scheme="gov.nih.nlm.semanticType.phsu" label="atypical antidepressant"/>
		<category term="C1259875" scheme="gov.nih.nlm.semanticType.phsu" label="STAR"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRI"/>
		<category term="C0049506" scheme="gov.nih.nlm.semanticType.phsu" label="mirtazapine"/>
		<category term="C0070122" scheme="gov.nih.nlm.semanticType.phsu" label="paroxetine"/>
		<category term="C0049506" scheme="gov.nih.nlm.semanticType.phsu" label="mirtazapine"/>
		<category term="C0074393" scheme="gov.nih.nlm.semanticType.phsu" label="sertraline"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0003290" scheme="gov.nih.nlm.semanticType.phsu" label="Tricyclic antidepressants"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0457454" scheme="gov.nih.nlm.semanticType.hlca" label="discontinuation"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C3540798" scheme="gov.nih.nlm.semanticType.imft" label="food"/>
		<category term="C3653413" scheme="gov.nih.nlm.semanticType.phsu" label="Monoamine oxidase inhibitors"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0040778" scheme="gov.nih.nlm.semanticType.phsu" label="tranylcypromine"/>
		<category term="C0049506" scheme="gov.nih.nlm.semanticType.phsu" label="mirtazapine"/>
		<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
		<category term="C1259875" scheme="gov.nih.nlm.semanticType.phsu" label="STAR"/>
		<category term="C0040778" scheme="gov.nih.nlm.semanticType.phsu" label="tranylcypromine"/>
		<category term="C0457454" scheme="gov.nih.nlm.semanticType.hlca" label="discontinuation"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C0004933" scheme="gov.nih.nlm.semanticType.topp" label="behavioral therapy"/>
		<category term="C0008845" scheme="gov.nih.nlm.semanticType.phsu" label="citalopram"/>
		<category term="C0009244" scheme="gov.nih.nlm.semanticType.topp" label="cognitive-behavioral therapy"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0074393" scheme="gov.nih.nlm.semanticType.phsu" label="sertraline"/>
		<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
		<category term="C0085208" scheme="gov.nih.nlm.semanticType.phsu" label="bupropion"/>
		<category term="C0457454" scheme="gov.nih.nlm.semanticType.hlca" label="discontinuation"/>
		<category term="C0068485" scheme="gov.nih.nlm.semanticType.phsu" label="nefazodone"/>
		<category term="C0457454" scheme="gov.nih.nlm.semanticType.hlca" label="discontinuation"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0040615" scheme="gov.nih.nlm.semanticType.phsu" label="antipsychotics"/>
		<category term="C0041014" scheme="gov.nih.nlm.semanticType.horm" label="triiodothyronine"/>
		<category term="C1510606" scheme="gov.nih.nlm.semanticType.topp" label="augmentation, drug"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C0758711" scheme="gov.nih.nlm.semanticType.orch" label="serotonin"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRI"/>
		<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="add"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0019932" scheme="gov.nih.nlm.semanticType.horm" label="hormone"/>
		<category term="C0040135" scheme="gov.nih.nlm.semanticType.horm" label="Thyroid hormone"/>
		<category term="C0040615" scheme="gov.nih.nlm.semanticType.phsu" label="antipsychotics"/>
		<category term="C0041014" scheme="gov.nih.nlm.semanticType.horm" label="triiodothyronine"/>
		<category term="C0073393" scheme="gov.nih.nlm.semanticType.phsu" label="risperidone"/>
		<category term="C0123091" scheme="gov.nih.nlm.semanticType.phsu" label="quetiapine"/>
		<category term="C0171023" scheme="gov.nih.nlm.semanticType.phsu" label="olanzapine"/>
		<category term="C0299792" scheme="gov.nih.nlm.semanticType.phsu" label="aripiprazole"/>
		<category term="C0019932" scheme="gov.nih.nlm.semanticType.horm" label="hormone"/>
		<category term="C0040135" scheme="gov.nih.nlm.semanticType.horm" label="thyroid hormone"/>
		<category term="C0040805" scheme="gov.nih.nlm.semanticType.phsu" label="trazodone"/>
		<category term="C0070122" scheme="gov.nih.nlm.semanticType.phsu" label="paroxetine"/>
		<category term="C0073393" scheme="gov.nih.nlm.semanticType.phsu" label="risperidone"/>
		<category term="C0073393" scheme="gov.nih.nlm.semanticType.phsu" label="risperidone"/>
		<category term="C0123091" scheme="gov.nih.nlm.semanticType.phsu" label="quetiapine"/>
		<category term="C0171023" scheme="gov.nih.nlm.semanticType.phsu" label="olanzapine"/>
		<category term="C0019932" scheme="gov.nih.nlm.semanticType.horm" label="hormone"/>
		<category term="C0040135" scheme="gov.nih.nlm.semanticType.horm" label="thyroid hormone"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0073393" scheme="gov.nih.nlm.semanticType.phsu" label="risperidone"/>
		<category term="C0123091" scheme="gov.nih.nlm.semanticType.phsu" label="quetiapine"/>
		<category term="C0171023" scheme="gov.nih.nlm.semanticType.phsu" label="olanzapine"/>
		<category term="C0299792" scheme="gov.nih.nlm.semanticType.phsu" label="aripiprazole"/>
		<category term="C0360105" scheme="gov.nih.nlm.semanticType.phsu" label="selective serotonin reuptake inhibitor"/>
		<category term="C0758711" scheme="gov.nih.nlm.semanticType.orch" label="serotonin"/>
		<category term="C1319313" scheme="gov.nih.nlm.semanticType.phsu" label="norepinephrine reuptake inhibitor"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin reuptake inhibitor"/>
		<category term="C3537213" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin-norepinephrine reuptake inhibitor"/>
		<category term="C0040615" scheme="gov.nih.nlm.semanticType.phsu" label="antipsychotic"/>
		<category term="C0457454" scheme="gov.nih.nlm.semanticType.hlca" label="discontinuation"/>
		<category term="C0073393" scheme="gov.nih.nlm.semanticType.phsu" label="risperidone"/>
		<category term="C0123091" scheme="gov.nih.nlm.semanticType.phsu" label="quetiapine"/>
		<category term="C0299792" scheme="gov.nih.nlm.semanticType.phsu" label="aripiprazole"/>
		<category term="C0457454" scheme="gov.nih.nlm.semanticType.hlca" label="discontinuation"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0171023" scheme="gov.nih.nlm.semanticType.phsu" label="olanzapine"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0040615" scheme="gov.nih.nlm.semanticType.phsu" label="antipsychotic"/>
		<category term="C0441640" scheme="gov.nih.nlm.semanticType.hlca" label="tapering"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0003290" scheme="gov.nih.nlm.semanticType.phsu" label="tricyclic antidepressants"/>
		<category term="C0019932" scheme="gov.nih.nlm.semanticType.horm" label="hormone"/>
		<category term="C0040135" scheme="gov.nih.nlm.semanticType.horm" label="thyroid hormone"/>
		<category term="C0041014" scheme="gov.nih.nlm.semanticType.horm" label="triiodothyronine"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0041014" scheme="gov.nih.nlm.semanticType.horm" label="triiodothyronine"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0041014" scheme="gov.nih.nlm.semanticType.horm" label="T3"/>
		<category term="C1579362" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants other"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0006462" scheme="gov.nih.nlm.semanticType.phsu" label="buspirone"/>
		<category term="C0008845" scheme="gov.nih.nlm.semanticType.phsu" label="citalopram"/>
		<category term="C0085208" scheme="gov.nih.nlm.semanticType.phsu" label="bupropion"/>
		<category term="C1259875" scheme="gov.nih.nlm.semanticType.phsu" label="STAR"/>
		<category term="C0006462" scheme="gov.nih.nlm.semanticType.phsu" label="buspirone"/>
		<category term="C0008845" scheme="gov.nih.nlm.semanticType.phsu" label="citalopram"/>
		<category term="C0085208" scheme="gov.nih.nlm.semanticType.phsu" label="bupropion"/>
		<category term="C0457454" scheme="gov.nih.nlm.semanticType.hlca" label="discontinuation"/>
		<category term="C0040778" scheme="gov.nih.nlm.semanticType.phsu" label="tranylcypromine"/>
		<category term="C0049506" scheme="gov.nih.nlm.semanticType.phsu" label="mirtazapine"/>
		<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
		<category term="C0758711" scheme="gov.nih.nlm.semanticType.orch" label="serotonin"/>
		<category term="C1319313" scheme="gov.nih.nlm.semanticType.phsu" label="norepinephrine reuptake inhibitor"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRI"/>
		<category term="C3537213" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin-norepinephrine reuptake inhibitor"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0004933" scheme="gov.nih.nlm.semanticType.topp" label="behavioral therapy"/>
		<category term="C0009244" scheme="gov.nih.nlm.semanticType.topp" label="Cognitive-behavioral therapy"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0006462" scheme="gov.nih.nlm.semanticType.phsu" label="buspirone"/>
		<category term="C0008845" scheme="gov.nih.nlm.semanticType.phsu" label="citalopram"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0085208" scheme="gov.nih.nlm.semanticType.phsu" label="bupropion"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0457454" scheme="gov.nih.nlm.semanticType.hlca" label="discontinuation"/>
		<category term="C0068485" scheme="gov.nih.nlm.semanticType.phsu" label="nefazodone"/>
		<category term="C0308902" scheme="gov.nih.nlm.semanticType.phsu" label="duration"/>
		<category term="C0068485" scheme="gov.nih.nlm.semanticType.phsu" label="Nefazodone"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="sham treatment"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="Meta"/>
		<category term="C0073980" scheme="gov.nih.nlm.semanticType.phsu" label="sham"/>
		<category term="C0436548" scheme="gov.nih.nlm.semanticType.topp" label="transcranial magnetic stimulation"/>
		<category term="C1292856" scheme="gov.nih.nlm.semanticType.topp" label="stimulation"/>
		<category term="C0436548" scheme="gov.nih.nlm.semanticType.topp" label="transcranial magnetic stimulation"/>
		<category term="C1292856" scheme="gov.nih.nlm.semanticType.topp" label="stimulation"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0074710" scheme="gov.nih.nlm.semanticType.phsu" label="pramipexole"/>
		<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="add"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0173022" scheme="gov.nih.nlm.semanticType.orch" label="barrier"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRI"/>
		<category term="C0758711" scheme="gov.nih.nlm.semanticType.orch" label="serotonin"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRI"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0457454" scheme="gov.nih.nlm.semanticType.hlca" label="discontinuation"/>
		<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="add"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0074710" scheme="gov.nih.nlm.semanticType.phsu" label="Pramipexole"/>
		<category term="C0758711" scheme="gov.nih.nlm.semanticType.orch" label="serotonin"/>
		<category term="C1319313" scheme="gov.nih.nlm.semanticType.phsu" label="norepinephrine reuptake inhibitor"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRI"/>
		<category term="C3537213" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin-norepinephrine reuptake inhibitor"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0013806" scheme="gov.nih.nlm.semanticType.topp" label="ECT"/>
		<category term="C0013808" scheme="gov.nih.nlm.semanticType.topp" label="Electroconvulsive therapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0436548" scheme="gov.nih.nlm.semanticType.topp" label="transcranial magnetic stimulation"/>
		<category term="C0634038" scheme="gov.nih.nlm.semanticType.phsu" label="TMS"/>
		<category term="C1292856" scheme="gov.nih.nlm.semanticType.topp" label="stimulation"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0013806" scheme="gov.nih.nlm.semanticType.topp" label="ECT"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0013806" scheme="gov.nih.nlm.semanticType.topp" label="ECT"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0013806" scheme="gov.nih.nlm.semanticType.topp" label="ECT"/>
		<category term="C0006462" scheme="gov.nih.nlm.semanticType.phsu" label="Buspirone"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRI"/>
		<category term="C0006462" scheme="gov.nih.nlm.semanticType.phsu" label="buspirone"/>
		<category term="C0085208" scheme="gov.nih.nlm.semanticType.phsu" label="bupropion"/>
		<category term="C1259875" scheme="gov.nih.nlm.semanticType.phsu" label="STAR"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0064636" scheme="gov.nih.nlm.semanticType.phsu" label="Lamotrigine"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0031937" scheme="gov.nih.nlm.semanticType.phsu" label="Pindolol"/>
		<category term="C0025810" scheme="gov.nih.nlm.semanticType.phsu" label="methylphenidate"/>
		<category term="C0066677" scheme="gov.nih.nlm.semanticType.phsu" label="modafinil"/>
		<category term="C0304403" scheme="gov.nih.nlm.semanticType.phsu" label="Psychostimulants"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0066677" scheme="gov.nih.nlm.semanticType.phsu" label="Modafinil"/>
		<category term="C0066677" scheme="gov.nih.nlm.semanticType.phsu" label="modafinil"/>
		<category term="C1569452" scheme="gov.nih.nlm.semanticType.phsu" label="refusal"/>
		<category term="C3540798" scheme="gov.nih.nlm.semanticType.imft" label="food"/>
		<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalization"/>
		<category term="C0013806" scheme="gov.nih.nlm.semanticType.topp" label="ECT"/>
		<category term="C0013808" scheme="gov.nih.nlm.semanticType.topp" label="electroconvulsive therapy"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0013806" scheme="gov.nih.nlm.semanticType.topp" label="ECT"/>
		<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimens"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0013806" scheme="gov.nih.nlm.semanticType.topp" label="ECT"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0013806" scheme="gov.nih.nlm.semanticType.topp" label="ECT"/>
		<category term="C1569452" scheme="gov.nih.nlm.semanticType.phsu" label="refusal"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0360105" scheme="gov.nih.nlm.semanticType.phsu" label="selective serotonin reuptake inhibitors"/>
		<category term="C0758711" scheme="gov.nih.nlm.semanticType.orch" label="serotonin"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin reuptake inhibitors"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
		<category term="C0457454" scheme="gov.nih.nlm.semanticType.hlca" label="discontinuation"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0004933" scheme="gov.nih.nlm.semanticType.topp" label="behavioral therapy"/>
		<category term="C0009244" scheme="gov.nih.nlm.semanticType.topp" label="cognitive-behavioral therapy"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0308902" scheme="gov.nih.nlm.semanticType.phsu" label="duration"/>
		<category term="C0015618" scheme="gov.nih.nlm.semanticType.topp" label="family therapy"/>
		<category term="C0310298" scheme="gov.nih.nlm.semanticType.phsu" label="tasks"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C0003290" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants, tricyclics"/>
		<category term="C0242905" scheme="gov.nih.nlm.semanticType.phsu" label="atypical antidepressants"/>
		<category term="C0360105" scheme="gov.nih.nlm.semanticType.phsu" label="selective serotonin reuptake inhibitor"/>
		<category term="C0758711" scheme="gov.nih.nlm.semanticType.orch" label="serotonin"/>
		<category term="C1319313" scheme="gov.nih.nlm.semanticType.phsu" label="norepinephrine reuptake inhibitors"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin reuptake inhibitor"/>
		<category term="C3537213" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin-norepinephrine reuptake inhibitors"/>
		<category term="C3653413" scheme="gov.nih.nlm.semanticType.phsu" label="monoamine oxidase inhibitors"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0040615" scheme="gov.nih.nlm.semanticType.phsu" label="antipsychotics"/>
		<category term="C0041014" scheme="gov.nih.nlm.semanticType.horm" label="triiodothyronine"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0436548" scheme="gov.nih.nlm.semanticType.topp" label="transcranial magnetic stimulation"/>
		<category term="C1292856" scheme="gov.nih.nlm.semanticType.topp" label="stimulation"/>
		<category term="C0013806" scheme="gov.nih.nlm.semanticType.topp" label="ECT"/>
		<category term="C0013808" scheme="gov.nih.nlm.semanticType.topp" label="electroconvulsive therapy"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0013806" scheme="gov.nih.nlm.semanticType.topp" label="ECT"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<id>14685</id>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H96382263"/>
			<id>208607</id>
			<summary>
				<section label="DEFINITIONS" id="96382263">
					<fragment>Unipolar major depression - Unipolar major depression (major depressive disorder) is diagnosed in patients who have suffered at least one major depressive episode and have no history of mania or hypomania.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H29355597"/>
			<id>208618</id>
			<summary>
				<section label="GENERAL PRINCIPLES" id="29355597">
					<fragment>the probability of remission in primary care and psychiatric settings was comparable (odds ratio 1.0).</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H29355597"/>
			<id>208621</id>
			<summary>
				<section label="GENERAL PRINCIPLES" id="29355597">
					<fragment>For patients with unipolar major depression who do not respond to initial treatment with an antidepressant medication, treatment strategies include: Switching treatment.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="C3469597" scheme="gov.nih.nlm.semanticType.hlca" label="medication, treatment"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H29355597"/>
			<id>208629</id>
			<summary>
				<section label="GENERAL PRINCIPLES" id="29355597">
					<fragment>Patients with treatment resistant depression who are receiving a specific therapy may also benefit from nonspecific care management, in which clinicians: Educate patients and families about: Depression, including signs, symptoms ), and prognosis.</fragment>
				</section>
			</summary>
			<category term="C0033325" scheme="gov.nih.nlm.semanticType.hlca" label="prognosis"/>
			<category term="C2735310" scheme="gov.nih.nlm.semanticType.hlca" label="care management"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H29355597"/>
			<id>208638</id>
			<summary>
				<section label="GENERAL PRINCIPLES" id="29355597">
					<fragment>However, many patients with ongoing symptoms of treatment resistant depression who receive education about their illness nevertheless discontinue pharmacotherapy.</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H29355597"/>
			<id>208640</id>
			<summary>
				<section label="GENERAL PRINCIPLES" id="29355597">
					<fragment>A randomized trial that compared imipramine with placebo in 112 patients with unipolar major depression (not selected for treatment resistance) found that about eight percent of the variability in outcome was due to the treating psychiatrist, separate from the study treatment.</fragment>
				</section>
			</summary>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H8046352"/>
			<id>208653</id>
			<summary>
				<section label="MILD TO MODERATE DEPRESSION" id="8046352">
					<fragment>Mild to moderate depression can generally be treated in an outpatient or partial (day) hospital program setting.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H4456801"/>
			<id>208654</id>
			<summary>
				<section label="line treatment strategies" id="4456801">
					<fragment>For mild to moderate depression that is treatment resistant, first- and second-line treatment strategies depend upon the degree to which patients benefit and tolerate the antidepressant that is prescribed at first presentation: For patients who obtain little symptom relief (eg, reduction of baseline symptoms &lt;=25 to 33 percent), we suggest switching antidepressants (ie, monotherapy with a new antidepressant) as first-line treatment and augmentation as second-line treatment.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H4456801"/>
			<id>208661</id>
			<summary>
				<section label="line treatment strategies" id="4456801">
					<fragment>Conversely, patients who partially benefit from the initial antidepressant and experience few adverse effects prefer adjunctive pharmacotherapy rather than switching.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H4456801"/>
			<id>208666</id>
			<summary>
				<section label="line treatment strategies" id="4456801">
					<fragment>The prospective Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study compared side effects in 269 treatment resistant patients who selected switching (from citalopram to bupropion, sertraline, or venlafaxine) as next step treatment, and 269 patients who selected citalopram augmentation (with bupropion or buspirone);</fragment>
				</section>
			</summary>
			<category term="C0006462" scheme="gov.nih.nlm.semanticType.phsu" label="buspirone"/>
			<category term="C0008845" scheme="gov.nih.nlm.semanticType.phsu" label="citalopram"/>
			<category term="C0074393" scheme="gov.nih.nlm.semanticType.phsu" label="sertraline"/>
			<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
			<category term="C0085208" scheme="gov.nih.nlm.semanticType.phsu" label="bupropion"/>
			<category term="C1259875" scheme="gov.nih.nlm.semanticType.phsu" label="STAR"/>
			<category term="5" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H904025"/>
			<id>208681</id>
			<summary>
				<section label="Efficacy of switching compared with augmentation" id="904025">
					<fragment>A prospective observational study compared outcomes in 269 patients who selected switching (from citalopram to bupropion, sertraline, or venlafaxine) as next step treatment, and 269 patients who selected augmentation of citalopram (with bupropion or buspirone);</fragment>
				</section>
			</summary>
			<category term="C0006462" scheme="gov.nih.nlm.semanticType.phsu" label="buspirone"/>
			<category term="C0008845" scheme="gov.nih.nlm.semanticType.phsu" label="citalopram"/>
			<category term="C0074393" scheme="gov.nih.nlm.semanticType.phsu" label="sertraline"/>
			<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
			<category term="C0085208" scheme="gov.nih.nlm.semanticType.phsu" label="bupropion"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H904025"/>
			<id>208686</id>
			<summary>
				<section label="Efficacy of switching compared with augmentation" id="904025">
					<fragment>Although we generally prefer to switch antidepressants for patients who minimally respond to the antidepressant prescribed at first presentation, one randomized trial found that augmentation with aripiprazole may be effective for patients with little to no response to antidepressant monotherapy.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0299792" scheme="gov.nih.nlm.semanticType.phsu" label="aripiprazole"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H4496258"/>
			<id>208694</id>
			<summary>
				<section label="Choosing a drug" id="4496258">
					<fragment>For patients with major depression who are resistant to treatment with an SSRI at first presentation and are switching antidepressants, many options are available ).</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRI"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H4496258"/>
			<id>208695</id>
			<summary>
				<section label="Choosing a drug" id="4496258">
					<fragment>The most commonly studied antidepressants are as follows, and are presented in our general order of preference based upon the number and quality of randomized trials that studied each option, as well as safety issues, side effect profiles, potential for drug-drug interactions, and ease of use: Serotonin-norepinephrine reuptake inhibitors (eg, venlafaxine. Atypical antidepressants (eg, bupropion or mirtazapine. Tricyclic antidepressants (eg, imipramine or nortriptyline. Monoamine oxidase inhibitors (MAOIs; eg, tranylcypromine or phenelzine. However, it is reasonable to use these drugs in a different sequence, or to switch to a different SSRI at any point in the sequence, because in the few head to head studies that have compared different options for treatment resistant depression, efficacy is often comparable. As an example, an eight-week, randomized trial (N = 105 patients) compared switching to either venlafaxine extended release (225 mg per day) or mirtazapine (45 mg per day), and </fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0003290" scheme="gov.nih.nlm.semanticType.phsu" label="Tricyclic antidepressants"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0031392" scheme="gov.nih.nlm.semanticType.phsu" label="phenelzine"/>
			<category term="C0040778" scheme="gov.nih.nlm.semanticType.phsu" label="tranylcypromine"/>
			<category term="C0049506" scheme="gov.nih.nlm.semanticType.phsu" label="mirtazapine"/>
			<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
			<category term="C0085208" scheme="gov.nih.nlm.semanticType.phsu" label="bupropion"/>
			<category term="C0242905" scheme="gov.nih.nlm.semanticType.phsu" label="Atypical antidepressants"/>
			<category term="C0758711" scheme="gov.nih.nlm.semanticType.orch" label="Serotonin"/>
			<category term="C1319313" scheme="gov.nih.nlm.semanticType.phsu" label="norepinephrine reuptake inhibitors"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRI"/>
			<category term="C3537213" scheme="gov.nih.nlm.semanticType.phsu" label="Serotonin-norepinephrine reuptake inhibitors"/>
			<category term="C3653413" scheme="gov.nih.nlm.semanticType.phsu" label="Monoamine oxidase inhibitors"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H4496258"/>
			<id>208697</id>
			<summary>
				<section label="Choosing a drug" id="4496258">
					<fragment>As an example, patients with seizure disorders should avoid bupropion, obese patients should avoid mirtazapine, and patients with cardiovascular disease should avoid tricyclics and MAOIs.</fragment>
				</section>
			</summary>
			<category term="C0049506" scheme="gov.nih.nlm.semanticType.phsu" label="mirtazapine"/>
			<category term="C0085208" scheme="gov.nih.nlm.semanticType.phsu" label="bupropion"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H4496258"/>
			<id>208699</id>
			<summary>
				<section label="Choosing a drug" id="4496258">
					<fragment>Evidence supporting this approach includes a meta-analysis of four randomized trials involving 1496 patients with unipolar major depression who were resistant to initial treatment with an SSRI, and were switched either to a non-SSRI antidepressant (bupropion, mirtazapine, or venlafaxine) or to a different SSRI.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C0049506" scheme="gov.nih.nlm.semanticType.phsu" label="mirtazapine"/>
			<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
			<category term="C0085208" scheme="gov.nih.nlm.semanticType.phsu" label="bupropion"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRI"/>
			<category term="5" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H707450"/>
			<id>208704</id>
			<summary>
				<section label="Venlafaxine" id="707450">
					<fragment>For patients with mild to moderate unipolar major depression who do not respond to initial treatment with an SSRI and are switching antidepressants, we generally choose venlafaxine extended release, because it has been most widely studied.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRI"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H707450"/>
			<id>208707</id>
			<summary>
				<section label="Venlafaxine" id="707450">
					<fragment>As an example, a meta-analysis of three randomized trials (3375 patients with major depression who did not respond sufficiently to initial treatment with an SSRI) compared switching to venlafaxine to switching to a different SSRI.</fragment>
				</section>
			</summary>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRI"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H707450"/>
			<id>208708</id>
			<summary>
				<section label="Venlafaxine" id="707450">
					<fragment>Remission occurred in more patients who received venlafaxine (54 versus 45 percent).</fragment>
				</section>
			</summary>
			<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H707450"/>
			<id>208710</id>
			<summary>
				<section label="Venlafaxine" id="707450">
					<fragment>The pharmacology, administration, and side effects of venlafaxine and other serotonin-norepinephrine reuptake inhibitors are discussed separately.</fragment>
				</section>
			</summary>
			<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
			<category term="C0758711" scheme="gov.nih.nlm.semanticType.orch" label="serotonin"/>
			<category term="C1319313" scheme="gov.nih.nlm.semanticType.phsu" label="norepinephrine reuptake inhibitors"/>
			<category term="C3537213" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin-norepinephrine reuptake inhibitors"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H707457"/>
			<id>208711</id>
			<summary>
				<section label="Atypical antidepressant" id="707457">
					<fragment>For depressed patients who are resistant to initial treatment with an SSRI, randomized trials indicate that remission is comparable for patients who switch to either an atypical antidepressant (bupropion or mirtazapine) or a different SSRI: The Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study included a 14 week trial that compared bupropion sustained release (mean dose 283 mg per day) with sertraline (mean dose 136 mg per day) in 477 treatment resistant patients;</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="C0049506" scheme="gov.nih.nlm.semanticType.phsu" label="mirtazapine"/>
			<category term="C0074393" scheme="gov.nih.nlm.semanticType.phsu" label="sertraline"/>
			<category term="C0085208" scheme="gov.nih.nlm.semanticType.phsu" label="bupropion"/>
			<category term="C0242905" scheme="gov.nih.nlm.semanticType.phsu" label="atypical antidepressant"/>
			<category term="C1259875" scheme="gov.nih.nlm.semanticType.phsu" label="STAR"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRI"/>
			<category term="6" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H707457"/>
			<id>208714</id>
			<summary>
				<section label="Atypical antidepressant" id="707457">
					<fragment>An eight-week trial compared mirtazapine (45 mg per day) with paroxetine (20 mg per day) in 100 treatment resistant patients and found that remission was comparable (36 and 47 percent), as was tolerability.</fragment>
				</section>
			</summary>
			<category term="C0049506" scheme="gov.nih.nlm.semanticType.phsu" label="mirtazapine"/>
			<category term="C0070122" scheme="gov.nih.nlm.semanticType.phsu" label="paroxetine"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H707457"/>
			<id>208715</id>
			<summary>
				<section label="Atypical antidepressant" id="707457">
					<fragment>An eight week trial compared mirtazapine (mean dose 30 mg per day) with sertraline (mean dose 120 mg per day) in 250 treatment resistant patients;</fragment>
				</section>
			</summary>
			<category term="C0049506" scheme="gov.nih.nlm.semanticType.phsu" label="mirtazapine"/>
			<category term="C0074393" scheme="gov.nih.nlm.semanticType.phsu" label="sertraline"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H707464"/>
			<id>208719</id>
			<summary>
				<section label="Tricyclic antidepressant" id="707464">
					<fragment>Tricyclic antidepressants are fourth- or fifth-line drugs for treatment of depression due to their greater safety hazards (eg, cardiotoxicity and potential lethality with overdose) and less favorable side effect profiles.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0003290" scheme="gov.nih.nlm.semanticType.phsu" label="Tricyclic antidepressants"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H707464"/>
			<id>208723</id>
			<summary>
				<section label="Tricyclic antidepressant" id="707464">
					<fragment>However, discontinuation of treatment due to side effects was greater among patients who switched to imipramine (9 versus 0 percent).</fragment>
				</section>
			</summary>
			<category term="C0457454" scheme="gov.nih.nlm.semanticType.hlca" label="discontinuation"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H707471"/>
			<id>208725</id>
			<summary>
				<section label="Monoamine oxidase inhibitor (MAOI)" id="707471">
					<fragment>Monoamine oxidase inhibitors (MAOIs) are seldom prescribed because of potentially lethal drug-drug and drug-food interactions, the danger that MAOIs pose in overdoses, and adverse effects.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C3540798" scheme="gov.nih.nlm.semanticType.imft" label="food"/>
			<category term="C3653413" scheme="gov.nih.nlm.semanticType.phsu" label="Monoamine oxidase inhibitors"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H707471"/>
			<id>208726</id>
			<summary>
				<section label="Monoamine oxidase inhibitor (MAOI)" id="707471">
					<fragment>Nevertheless, switching to an MAOI may be beneficial for patients with major depression that is resistant to other drug classes.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H707471"/>
			<id>208729</id>
			<summary>
				<section label="Monoamine oxidase inhibitor (MAOI)" id="707471">
					<fragment>An open label randomized trial (STAR*D) compared tranylcypromine (mean dose 37 mg per day) with mirtazapine (mean dose 36 mg per day) plus venlafaxine extended release (mean dose 210 mg per day) in 109 patients who had not responded to three prior prospective courses of treatment.</fragment>
				</section>
			</summary>
			<category term="C0040778" scheme="gov.nih.nlm.semanticType.phsu" label="tranylcypromine"/>
			<category term="C0049506" scheme="gov.nih.nlm.semanticType.phsu" label="mirtazapine"/>
			<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
			<category term="C1259875" scheme="gov.nih.nlm.semanticType.phsu" label="STAR"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H707471"/>
			<id>208732</id>
			<summary>
				<section label="Monoamine oxidase inhibitor (MAOI)" id="707471">
					<fragment>In addition, discontinuation of treatment due to side effects occurred in more patients who received tranylcypromine monotherapy than the combination (41 versus 22 percent).</fragment>
				</section>
			</summary>
			<category term="C0040778" scheme="gov.nih.nlm.semanticType.phsu" label="tranylcypromine"/>
			<category term="C0457454" scheme="gov.nih.nlm.semanticType.hlca" label="discontinuation"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H707471"/>
			<id>208734</id>
			<summary>
				<section label="Monoamine oxidase inhibitor (MAOI)" id="707471">
					<fragment>In addition, major depression with atypical features (hypersomnia, hyperphagia, rejection sensitivity, heavy or leaden feelings in limbs, and/or mood brightens in response to positive events) may respond preferentially to MAOIs.</fragment>
				</section>
			</summary>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H947618"/>
			<id>208736</id>
			<summary>
				<section label="Switching to psychotherapy" id="947618">
					<fragment>Although switching from an antidepressant to psychotherapy may be declined by patients with treatment resistant major depression, psychotherapy is a reasonable option for patients who prefer it: A 12-week trial enrolled 122 patients who did not respond to or tolerate citalopram and randomly assigned them to switch to cognitive-behavioral therapy (CBT) or to a different antidepressant (bupropion, sertraline, or venlafaxine. Remission was comparable for CBT and pharmacotherapy (25 and 28 percent of patients), as was discontinuation of treatment due to side effects (17 and 27 percent).</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="C0004933" scheme="gov.nih.nlm.semanticType.topp" label="behavioral therapy"/>
			<category term="C0008845" scheme="gov.nih.nlm.semanticType.phsu" label="citalopram"/>
			<category term="C0009244" scheme="gov.nih.nlm.semanticType.topp" label="cognitive-behavioral therapy"/>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="C0074393" scheme="gov.nih.nlm.semanticType.phsu" label="sertraline"/>
			<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
			<category term="C0085208" scheme="gov.nih.nlm.semanticType.phsu" label="bupropion"/>
			<category term="C0457454" scheme="gov.nih.nlm.semanticType.hlca" label="discontinuation"/>
			<category term="13" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H947618"/>
			<id>208740</id>
			<summary>
				<section label="Switching to psychotherapy" id="947618">
					<fragment>However, discontinuation of treatment occurred in fewer patients who received CBT than nefazodone (13 versus 28).</fragment>
				</section>
			</summary>
			<category term="C0068485" scheme="gov.nih.nlm.semanticType.phsu" label="nefazodone"/>
			<category term="C0457454" scheme="gov.nih.nlm.semanticType.hlca" label="discontinuation"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H8047902"/>
			<id>208742</id>
			<summary>
				<section label="Augmentation" id="8047902">
					<fragment>For patients with treatment resistant depression who receive augmentation, drug-drug interactions between antidepressants and adjunctive medications (eg, second-generation antipsychotics, lithium, or triiodothyronine) are generally not a problem.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0040615" scheme="gov.nih.nlm.semanticType.phsu" label="antipsychotics"/>
			<category term="C0041014" scheme="gov.nih.nlm.semanticType.horm" label="triiodothyronine"/>
			<category term="C1510606" scheme="gov.nih.nlm.semanticType.topp" label="augmentation, drug"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H8047902"/>
			<id>208743</id>
			<summary>
				<section label="Augmentation" id="8047902">
					<fragment>However, combining an MAOI with another antidepressant (eg, SSRI) can cause the serotonin syndrome or a hypertensive crisis.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="C0758711" scheme="gov.nih.nlm.semanticType.orch" label="serotonin"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRI"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H8047902"/>
			<id>208746</id>
			<summary>
				<section label="Augmentation" id="8047902">
					<fragment>Treatment resistant patients who are treated with an add-on drug and do not respond within 6 to 12 weeks of reaching the target dose, or do not tolerate the combination, should be treated with a second medication combination.</fragment>
				</section>
			</summary>
			<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="add"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H5298564"/>
			<id>208753</id>
			<summary>
				<section label="Choosing a drug" id="5298564">
					<fragment>For patients with mild to moderate depression who are treatment resistant and receiving augmentation, many options are available.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H5298564"/>
			<id>208754</id>
			<summary>
				<section label="Choosing a drug" id="5298564">
					<fragment>The most widely studied drugs are as follows, and are presented in our general order of preference, based primarily upon the evidence (especially the number of patients studied in randomized trials) for each option: Second-generation antipsychotics (aripiprazole, quetiapine, risperidone, or olanzapine. Lithium. Thyroid hormone (typically triiodothyronine).</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0019932" scheme="gov.nih.nlm.semanticType.horm" label="hormone"/>
			<category term="C0040135" scheme="gov.nih.nlm.semanticType.horm" label="Thyroid hormone"/>
			<category term="C0040615" scheme="gov.nih.nlm.semanticType.phsu" label="antipsychotics"/>
			<category term="C0041014" scheme="gov.nih.nlm.semanticType.horm" label="triiodothyronine"/>
			<category term="C0073393" scheme="gov.nih.nlm.semanticType.phsu" label="risperidone"/>
			<category term="C0123091" scheme="gov.nih.nlm.semanticType.phsu" label="quetiapine"/>
			<category term="C0171023" scheme="gov.nih.nlm.semanticType.phsu" label="olanzapine"/>
			<category term="C0299792" scheme="gov.nih.nlm.semanticType.phsu" label="aripiprazole"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H5298564"/>
			<id>208757</id>
			<summary>
				<section label="Choosing a drug" id="5298564">
					<fragment>As an example, an eight-week randomized trial compared paroxetine plus risperidone, paroxetine plus thyroid hormone, or paroxetine plus trazodone in 140 treatment resistant patients, and found that remission was comparable (27, 38, and 43 percent).</fragment>
				</section>
			</summary>
			<category term="C0019932" scheme="gov.nih.nlm.semanticType.horm" label="hormone"/>
			<category term="C0040135" scheme="gov.nih.nlm.semanticType.horm" label="thyroid hormone"/>
			<category term="C0040805" scheme="gov.nih.nlm.semanticType.phsu" label="trazodone"/>
			<category term="C0070122" scheme="gov.nih.nlm.semanticType.phsu" label="paroxetine"/>
			<category term="C0073393" scheme="gov.nih.nlm.semanticType.phsu" label="risperidone"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H5298564"/>
			<id>208760</id>
			<summary>
				<section label="Choosing a drug" id="5298564">
					<fragment>overweight patients should avoid quetiapine, risperidone, and olanzapine;</fragment>
				</section>
			</summary>
			<category term="C0073393" scheme="gov.nih.nlm.semanticType.phsu" label="risperidone"/>
			<category term="C0123091" scheme="gov.nih.nlm.semanticType.phsu" label="quetiapine"/>
			<category term="C0171023" scheme="gov.nih.nlm.semanticType.phsu" label="olanzapine"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H5298564"/>
			<id>208761</id>
			<summary>
				<section label="Choosing a drug" id="5298564">
					<fragment>patients with renal or thyroid disease should avoid lithium;</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H5298564"/>
			<id>208762</id>
			<summary>
				<section label="Choosing a drug" id="5298564">
					<fragment>and patients with compromised cardiovascular function should avoid thyroid hormone.</fragment>
				</section>
			</summary>
			<category term="C0019932" scheme="gov.nih.nlm.semanticType.horm" label="hormone"/>
			<category term="C0040135" scheme="gov.nih.nlm.semanticType.horm" label="thyroid hormone"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H5298780"/>
			<id>208765</id>
			<summary>
				<section label="generation antipsychotic" id="5298780">
					<fragment>A meta-analysis of 16 randomized trials, lasting 4 to 12 weeks, compared adjunctive aripiprazole, olanzapine, quetiapine, or risperidone with placebo in 3480 patients with nonpsychotic, unipolar major depression who failed at least one course of antidepressant monotherapy (usually a selective serotonin reuptake inhibitor or a serotonin-norepinephrine reuptake inhibitor).</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C0073393" scheme="gov.nih.nlm.semanticType.phsu" label="risperidone"/>
			<category term="C0123091" scheme="gov.nih.nlm.semanticType.phsu" label="quetiapine"/>
			<category term="C0171023" scheme="gov.nih.nlm.semanticType.phsu" label="olanzapine"/>
			<category term="C0299792" scheme="gov.nih.nlm.semanticType.phsu" label="aripiprazole"/>
			<category term="C0360105" scheme="gov.nih.nlm.semanticType.phsu" label="selective serotonin reuptake inhibitor"/>
			<category term="C0758711" scheme="gov.nih.nlm.semanticType.orch" label="serotonin"/>
			<category term="C1319313" scheme="gov.nih.nlm.semanticType.phsu" label="norepinephrine reuptake inhibitor"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin reuptake inhibitor"/>
			<category term="C3537213" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin-norepinephrine reuptake inhibitor"/>
			<category term="9" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H5298780"/>
			<id>208767</id>
			<summary>
				<section label="generation antipsychotic" id="5298780">
					<fragment>However, discontinuation because of adverse effects was greater in patients who received an antipsychotic (9 versus 2 percent).</fragment>
				</section>
			</summary>
			<category term="C0040615" scheme="gov.nih.nlm.semanticType.phsu" label="antipsychotic"/>
			<category term="C0457454" scheme="gov.nih.nlm.semanticType.hlca" label="discontinuation"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H5298780"/>
			<id>208769</id>
			<summary>
				<section label="generation antipsychotic" id="5298780">
					<fragment>In addition, the pooled rate of discontinuation of treatment due to adverse events for aripiprazole, quetiapine, and risperidone was 4, 12, and 7 percent, and aripiprazole causes fewer adverse metabolic effects than quetiapine and risperidone.</fragment>
				</section>
			</summary>
			<category term="C0073393" scheme="gov.nih.nlm.semanticType.phsu" label="risperidone"/>
			<category term="C0123091" scheme="gov.nih.nlm.semanticType.phsu" label="quetiapine"/>
			<category term="C0299792" scheme="gov.nih.nlm.semanticType.phsu" label="aripiprazole"/>
			<category term="C0457454" scheme="gov.nih.nlm.semanticType.hlca" label="discontinuation"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H5298780"/>
			<id>208771</id>
			<summary>
				<section label="generation antipsychotic" id="5298780">
					<fragment>Although pooled analyses have found that adjunctive olanzapine is efficacious, we often avoid the drug, especially for long-term treatment (eg, &gt;=12 weeks) because it is associated with the highest risk of weight gain and associated metabolic disturbances such as diabetes.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0171023" scheme="gov.nih.nlm.semanticType.phsu" label="olanzapine"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H5298780"/>
			<id>208772</id>
			<summary>
				<section label="generation antipsychotic" id="5298780">
					<fragment>For patients with treatment resistant depression who do not respond to one second-generation antipsychotic within 6 to 12 weeks of reaching the target dose, or do not tolerate the drug, we suggest tapering and discontinuing the failed medication over one to two weeks at the same time that a different adjunctive drug (either a second-generation antipsychotic or another drug such as lithium) is started and titrated up.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0040615" scheme="gov.nih.nlm.semanticType.phsu" label="antipsychotic"/>
			<category term="C0441640" scheme="gov.nih.nlm.semanticType.hlca" label="tapering"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H708501"/>
			<id>208777</id>
			<summary>
				<section label="Lithium" id="708501">
					<fragment>As an example, a meta-analysis of 10 randomized trials (269 patients) found that response occurred in more patients who received adjunctive lithium than placebo (41 versus 14 percent).</fragment>
				</section>
			</summary>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H708501"/>
			<id>208779</id>
			<summary>
				<section label="Lithium" id="708501">
					<fragment>However, most studies that examined lithium augmentation occurred in patients treated with tricyclic antidepressants, and it is not clear whether lithium augmentation is efficacious with other, more widely used classes of antidepressants.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0003290" scheme="gov.nih.nlm.semanticType.phsu" label="tricyclic antidepressants"/>
			<category term="5" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H708501"/>
			<id>208780</id>
			<summary>
				<section label="Lithium" id="708501">
					<fragment>In addition, other augmentation strategies (eg, thyroid hormone) may be preferred over lithium because lithium can be more difficult to use due to the risk of toxicity, the need to monitor serum concentrations, and adverse effects.</fragment>
				</section>
			</summary>
			<category term="C0019932" scheme="gov.nih.nlm.semanticType.horm" label="hormone"/>
			<category term="C0040135" scheme="gov.nih.nlm.semanticType.horm" label="thyroid hormone"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H708501"/>
			<id>208781</id>
			<summary>
				<section label="Lithium" id="708501">
					<fragment>The efficacy, dose, safety issues, and side effects of lithium in treatment resistant depression are discussed separately (including the efficacy of adjunctive lithium compared with adjunctive triiodothyronine).</fragment>
				</section>
			</summary>
			<category term="C0041014" scheme="gov.nih.nlm.semanticType.horm" label="triiodothyronine"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H708508"/>
			<id>208783</id>
			<summary>
				<section label="Thyroid hormone" id="708508">
					<fragment>As an example, a meta-analysis of four randomized trials (95 depressed patients unresponsive to a tricyclic) compared adjunctive triiodothyronine (T3) to either adjunctive placebo or thyroxine (T4).</fragment>
				</section>
			</summary>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0041014" scheme="gov.nih.nlm.semanticType.horm" label="triiodothyronine"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H708508"/>
			<id>208785</id>
			<summary>
				<section label="Thyroid hormone" id="708508">
					<fragment>In addition, it is not clear whether T3 augmentation is efficacious with antidepressants other than tricyclics.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0041014" scheme="gov.nih.nlm.semanticType.horm" label="T3"/>
			<category term="C1579362" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants other"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H708550"/>
			<id>208790</id>
			<summary>
				<section label="A second antidepressant" id="708550">
					<fragment>A systematic review identified five randomized trials (483 patients with treatment resistant depression) that compared an antidepressant plus a second antidepressant with an antidepressant plus placebo, and found that combination treatment was often not beneficial.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H708550"/>
			<id>208792</id>
			<summary>
				<section label="A second antidepressant" id="708550">
					<fragment>In the largest trial (N = 293), at least one adverse effect occurred in more patients who received the combination than monotherapy (77 versus 51 percent).</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H708550"/>
			<id>208793</id>
			<summary>
				<section label="A second antidepressant" id="708550">
					<fragment>However, two open label, 14 week randomized trials (not included in the systematic review) from the STAR*D study found that combining two antidepressants was useful: One trial compared bupropion sustained release (mean dose 268 mg per day) plus citalopram with buspirone (mean dose 41 mg per day) plus citalopram as next step treatment in 565 patients with major depression who did not respond to citalopram alone.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0006462" scheme="gov.nih.nlm.semanticType.phsu" label="buspirone"/>
			<category term="C0008845" scheme="gov.nih.nlm.semanticType.phsu" label="citalopram"/>
			<category term="C0085208" scheme="gov.nih.nlm.semanticType.phsu" label="bupropion"/>
			<category term="C1259875" scheme="gov.nih.nlm.semanticType.phsu" label="STAR"/>
			<category term="6" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H708550"/>
			<id>208795</id>
			<summary>
				<section label="A second antidepressant" id="708550">
					<fragment>in addition, discontinuation of treatment due to side effects occurred in fewer patients with bupropion plus citalopram than buspirone plus citalopram (13 versus 21 percent).</fragment>
				</section>
			</summary>
			<category term="C0006462" scheme="gov.nih.nlm.semanticType.phsu" label="buspirone"/>
			<category term="C0008845" scheme="gov.nih.nlm.semanticType.phsu" label="citalopram"/>
			<category term="C0085208" scheme="gov.nih.nlm.semanticType.phsu" label="bupropion"/>
			<category term="C0457454" scheme="gov.nih.nlm.semanticType.hlca" label="discontinuation"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H708550"/>
			<id>208796</id>
			<summary>
				<section label="A second antidepressant" id="708550">
					<fragment>Another trial found that symptom reduction was greater with mirtazapine plus venlafaxine extended release, compared with tranylcypromine alone.</fragment>
				</section>
			</summary>
			<category term="C0040778" scheme="gov.nih.nlm.semanticType.phsu" label="tranylcypromine"/>
			<category term="C0049506" scheme="gov.nih.nlm.semanticType.phsu" label="mirtazapine"/>
			<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H708550"/>
			<id>208798</id>
			<summary>
				<section label="A second antidepressant" id="708550">
					<fragment>as an example, an MAOI plus an SSRI, a serotonin-norepinephrine reuptake inhibitor, or a tricyclic can cause the serotonin syndrome or a hypertensive crisis.</fragment>
				</section>
			</summary>
			<category term="C0758711" scheme="gov.nih.nlm.semanticType.orch" label="serotonin"/>
			<category term="C1319313" scheme="gov.nih.nlm.semanticType.phsu" label="norepinephrine reuptake inhibitor"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRI"/>
			<category term="C3537213" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin-norepinephrine reuptake inhibitor"/>
			<category term="6" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H947010"/>
			<id>208801</id>
			<summary>
				<section label="Psychotherapy" id="947010">
					<fragment>For patients with unipolar major depression who are resistant to treatment with an antidepressant, augmentation with psychotherapy is often beneficial.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H947010"/>
			<id>208802</id>
			<summary>
				<section label="Psychotherapy" id="947010">
					<fragment>Cognitive-behavioral therapy (CBT) in particular is supported by multiple randomized trials: A one year randomized trial compared CBT (12 to 18 sessions) plus usual care (pharmacotherapy and other interventions deemed appropriate, including CBT) with usual care alone in 419 outpatients with treatment resistant depression.</fragment>
				</section>
			</summary>
			<category term="C0004933" scheme="gov.nih.nlm.semanticType.topp" label="behavioral therapy"/>
			<category term="C0009244" scheme="gov.nih.nlm.semanticType.topp" label="Cognitive-behavioral therapy"/>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H947010"/>
			<id>208803</id>
			<summary>
				<section label="Psychotherapy" id="947010">
					<fragment>Remission occurred in more patients who received CBT plus usual care than usual care alone (28 versus 15 percent).</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H947010"/>
			<id>208806</id>
			<summary>
				<section label="Psychotherapy" id="947010">
					<fragment>A 12 week randomized trial compared citalopram plus CBT (16 sessions) with citalopram plus adjunctive pharmacotherapy (either bupropion or buspirone) in 182 outpatients who did not respond to citalopram monotherapy.</fragment>
				</section>
			</summary>
			<category term="C0006462" scheme="gov.nih.nlm.semanticType.phsu" label="buspirone"/>
			<category term="C0008845" scheme="gov.nih.nlm.semanticType.phsu" label="citalopram"/>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0085208" scheme="gov.nih.nlm.semanticType.phsu" label="bupropion"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H947010"/>
			<id>208808</id>
			<summary>
				<section label="Psychotherapy" id="947010">
					<fragment>In addition, discontinuation of treatment due to adverse effects occurred in about half as many patients who received adjunctive CBT, compared with adjunctive pharmacotherapy (9 versus 19 percent).</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0457454" scheme="gov.nih.nlm.semanticType.hlca" label="discontinuation"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H947010"/>
			<id>208809</id>
			<summary>
				<section label="Psychotherapy" id="947010">
					<fragment>A 12 week randomized trial compared nefazodone plus CBT (16 to 20 sessions) with nefazodone alone in 446 outpatients with chronic major depression (mean duration 8 years);</fragment>
				</section>
			</summary>
			<category term="C0068485" scheme="gov.nih.nlm.semanticType.phsu" label="nefazodone"/>
			<category term="C0308902" scheme="gov.nih.nlm.semanticType.phsu" label="duration"/>
			<category term="6" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H947010"/>
			<id>208813</id>
			<summary>
				<section label="Psychotherapy" id="947010">
					<fragment>Nefazodone has been withdrawn from many countries because of potential adverse effects on the liver.</fragment>
				</section>
			</summary>
			<category term="C0068485" scheme="gov.nih.nlm.semanticType.phsu" label="Nefazodone"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H8047918"/>
			<id>208816</id>
			<summary>
				<section label="line treatment" id="8047918">
					<fragment>Patients with mild to moderate depression may not respond satisfactorily to several courses of first- and second-line treatments.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H8047918"/>
			<id>208818</id>
			<summary>
				<section label="line treatment" id="8047918">
					<fragment>Meta-analyses of randomized trials have found that for patients who have not responded to at least one antidepressant medication, repetitive transcranial magnetic stimulation is superior to sham treatment.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="sham treatment"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="Meta"/>
			<category term="C0073980" scheme="gov.nih.nlm.semanticType.phsu" label="sham"/>
			<category term="C0436548" scheme="gov.nih.nlm.semanticType.topp" label="transcranial magnetic stimulation"/>
			<category term="C1292856" scheme="gov.nih.nlm.semanticType.topp" label="stimulation"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H8047918"/>
			<id>208821</id>
			<summary>
				<section label="line treatment" id="8047918">
					<fragment>The efficacy, administration, safety, and adverse effects of transcranial magnetic stimulation for unipolar depression are discussed separately.</fragment>
				</section>
			</summary>
			<category term="C0436548" scheme="gov.nih.nlm.semanticType.topp" label="transcranial magnetic stimulation"/>
			<category term="C1292856" scheme="gov.nih.nlm.semanticType.topp" label="stimulation"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H8047926"/>
			<id>208823</id>
			<summary>
				<section label="Other options" id="8047926">
					<fragment>These patients are candidates for augmentation with less established drugs, including omega-3 fatty acids, folate, S-adenosyl methionine, and pramipexole.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0074710" scheme="gov.nih.nlm.semanticType.phsu" label="pramipexole"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H8047926"/>
			<id>208825</id>
			<summary>
				<section label="Other options" id="8047926">
					<fragment>Omega-3 fatty acids - Augmentation with omega-3 fatty acids for treatment resistant depression was effective in three small randomized trials, but the optimal dose has yet to be established.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H8047926"/>
			<id>208826</id>
			<summary>
				<section label="Other options" id="8047926">
					<fragment>In the largest trial, patients who did not respond to an antidepressant were assigned add-on treatment with eicosapentaenoic acid (1 gram per day) or placebo for 12 weeks.</fragment>
				</section>
			</summary>
			<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="add"/>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H8047926"/>
			<id>208828</id>
			<summary>
				<section label="Other options" id="8047926">
					<fragment>Folate - In a 60 day randomized trial that compared L-methylfolate (the biologically active form of folate that crosses the blood brain barrier; 15 mg per day) plus an SSRI with placebo plus an SSRI in 75 patients, response (reduction of baseline symptoms &gt;=50 percent) occurred in more patients who received adjunctive L-methylfolate than placebo (32 versus 15 percent), and tolerability was comparable.</fragment>
				</section>
			</summary>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0173022" scheme="gov.nih.nlm.semanticType.orch" label="barrier"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRI"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H8047926"/>
			<id>208832</id>
			<summary>
				<section label="Other options" id="8047926">
					<fragment>S-adenosyl methionine - S-adenosyl methionine (SAMe) is a metabolite of folate that facilitates the synthesis of neurotransmitters (including dopamine, norepinephrine, and serotonin), and may be effective and well-tolerated for treatment resistant depression.</fragment>
				</section>
			</summary>
			<category term="C0758711" scheme="gov.nih.nlm.semanticType.orch" label="serotonin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H8047926"/>
			<id>208833</id>
			<summary>
				<section label="Other options" id="8047926">
					<fragment>A six-week randomized trial compared adjunctive SAMe (800 mg twice per day) with placebo in 73 patients with unipolar major depression who failed treatment with an SSRI, and found that remission occurred in more patients who received SAMe (36 versus 12 percent).</fragment>
				</section>
			</summary>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRI"/>
			<category term="7" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H8047926"/>
			<id>208834</id>
			<summary>
				<section label="Other options" id="8047926">
					<fragment>In addition, discontinuation of treatment because of adverse effects occurred in fewer patients who received augmentation with SAMe than placebo (5 versus 9 percent).</fragment>
				</section>
			</summary>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0457454" scheme="gov.nih.nlm.semanticType.hlca" label="discontinuation"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H8047926"/>
			<id>208836</id>
			<summary>
				<section label="Other options" id="8047926">
					<fragment>Pramipexole - An eight-week randomized trial compared pramipexole (mean daily dose 1.35 mg) with placebo as add-on treatment in 60 patients who remained depressed despite treatment with an SSRI or serotonin-norepinephrine reuptake inhibitor;</fragment>
				</section>
			</summary>
			<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="add"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0074710" scheme="gov.nih.nlm.semanticType.phsu" label="Pramipexole"/>
			<category term="C0758711" scheme="gov.nih.nlm.semanticType.orch" label="serotonin"/>
			<category term="C1319313" scheme="gov.nih.nlm.semanticType.phsu" label="norepinephrine reuptake inhibitor"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRI"/>
			<category term="C3537213" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin-norepinephrine reuptake inhibitor"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H8047926"/>
			<id>208839</id>
			<summary>
				<section label="Other options" id="8047926">
					<fragment>Lithium monotherapy - Older studies suggest that lithium monotherapy may effectively treat unipolar depression, but lithium is generally used as augmentation for treatment resistant patients.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H8047926"/>
			<id>208840</id>
			<summary>
				<section label="Other options" id="8047926">
					<fragment>There is far less evidence for lithium monotherapy than for antidepressants, and lithium can be difficult to use because of the risk of toxicity and need to monitor serum concentrations.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H8047926"/>
			<id>208845</id>
			<summary>
				<section label="Other options" id="8047926">
					<fragment>Electroconvulsive therapy (ECT) - For patients with moderate depression who do not respond to multiple (eg, four to eight) courses of treatment with pharmacotherapy, as well as treatment with psychotherapy (eg, CBT) and repetitive transcranial magnetic stimulation (TMS), we suggest that clinicians consider electroconvulsive therapy (ECT).</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0013806" scheme="gov.nih.nlm.semanticType.topp" label="ECT"/>
			<category term="C0013808" scheme="gov.nih.nlm.semanticType.topp" label="Electroconvulsive therapy"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="C0436548" scheme="gov.nih.nlm.semanticType.topp" label="transcranial magnetic stimulation"/>
			<category term="C0634038" scheme="gov.nih.nlm.semanticType.phsu" label="TMS"/>
			<category term="C1292856" scheme="gov.nih.nlm.semanticType.topp" label="stimulation"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H8047926"/>
			<id>208846</id>
			<summary>
				<section label="Other options" id="8047926">
					<fragment>Although ECT is usually reserved for severely ill patients, meta-analyses of randomized trials indicate that ECT is superior to pharmacotherapy for unipolar major depression, and ECT is generally regarded as the most efficacious treatment for depression.</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0013806" scheme="gov.nih.nlm.semanticType.topp" label="ECT"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="9" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H8047926"/>
			<id>208847</id>
			<summary>
				<section label="Other options" id="8047926">
					<fragment>Use of ECT for moderately ill patients who have repeatedly not responded to pharmacotherapy and psychotherapy is consistent with recommendations in practice guidelines.</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0013806" scheme="gov.nih.nlm.semanticType.topp" label="ECT"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H8047926"/>
			<id>208850</id>
			<summary>
				<section label="Other options" id="8047926">
					<fragment>An overview of ECT is discussed separately, as are indications for and efficacy of ECT in unipolar major depression, medical consultation for ECT, and the technique for performing ECT.</fragment>
				</section>
			</summary>
			<category term="C0013806" scheme="gov.nih.nlm.semanticType.topp" label="ECT"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H8134572"/>
			<id>208852</id>
			<summary>
				<section label="Drugs with little to no benefit" id="8134572">
					<fragment>Buspirone - Two trials (N = 119 and 102) compared buspirone with placebo as augmentation in patients who did not respond to initial treatment of major depression with an SSRI;</fragment>
				</section>
			</summary>
			<category term="C0006462" scheme="gov.nih.nlm.semanticType.phsu" label="Buspirone"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRI"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H8134572"/>
			<id>208854</id>
			<summary>
				<section label="Drugs with little to no benefit" id="8134572">
					<fragment>In addition, a STAR*D trial found that symptomatic improvement and tolerability were inferior with adjunctive buspirone compared to adjunctive bupropion.</fragment>
				</section>
			</summary>
			<category term="C0006462" scheme="gov.nih.nlm.semanticType.phsu" label="buspirone"/>
			<category term="C0085208" scheme="gov.nih.nlm.semanticType.phsu" label="bupropion"/>
			<category term="C1259875" scheme="gov.nih.nlm.semanticType.phsu" label="STAR"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H8134572"/>
			<id>208855</id>
			<summary>
				<section label="Drugs with little to no benefit" id="8134572">
					<fragment>Lamotrigine - Based upon two randomized, placebo controlled trials (N = 96 and 34), augmentation of antidepressants with lamotrigine for treatment resistant, unipolar major depression is not beneficial.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0064636" scheme="gov.nih.nlm.semanticType.phsu" label="Lamotrigine"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H8134572"/>
			<id>208856</id>
			<summary>
				<section label="Drugs with little to no benefit" id="8134572">
					<fragment>Pindolol - We do not augment antidepressants with pindolol for treatment resistant depression, based upon negative results in multiple randomized trials (N = 80, 38, 16, and 10).</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0031937" scheme="gov.nih.nlm.semanticType.phsu" label="Pindolol"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H8134572"/>
			<id>208857</id>
			<summary>
				<section label="Drugs with little to no benefit" id="8134572">
					<fragment>Psychostimulants - For patients with treatment resistant depression, adjunctive psychostimulants such as methylphenidate and modafinil provide little to no benefit.</fragment>
				</section>
			</summary>
			<category term="C0025810" scheme="gov.nih.nlm.semanticType.phsu" label="methylphenidate"/>
			<category term="C0066677" scheme="gov.nih.nlm.semanticType.phsu" label="modafinil"/>
			<category term="C0304403" scheme="gov.nih.nlm.semanticType.phsu" label="Psychostimulants"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H8134572"/>
			<id>208859</id>
			<summary>
				<section label="Drugs with little to no benefit" id="8134572">
					<fragment>no benefit accrued to patients treated with active drug.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H8134572"/>
			<id>208860</id>
			<summary>
				<section label="Drugs with little to no benefit" id="8134572">
					<fragment>Modafinil - Two randomized trials (N = 308 and 136) compared adjunctive modafinil with placebo in patients with major depression who responded incompletely to an antidepressant.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0066677" scheme="gov.nih.nlm.semanticType.phsu" label="Modafinil"/>
			<category term="6" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H8134572"/>
			<id>208861</id>
			<summary>
				<section label="Drugs with little to no benefit" id="8134572">
					<fragment>Although modafinil improved fatigue, it did not improve other depressive symptoms and most outcomes (eg, remission) were comparable for the two groups.</fragment>
				</section>
			</summary>
			<category term="C0066677" scheme="gov.nih.nlm.semanticType.phsu" label="modafinil"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H8047542"/>
			<id>208866</id>
			<summary>
				<section label="SEVERE DEPRESSION" id="8047542">
					<fragment>Impaired functioning (eg, food and fluid refusal leading to malnutrition and dehydration).</fragment>
				</section>
			</summary>
			<category term="C1569452" scheme="gov.nih.nlm.semanticType.phsu" label="refusal"/>
			<category term="C3540798" scheme="gov.nih.nlm.semanticType.imft" label="food"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H8047542"/>
			<id>208867</id>
			<summary>
				<section label="SEVERE DEPRESSION" id="8047542">
					<fragment>Severely ill patients generally require hospitalization.</fragment>
				</section>
			</summary>
			<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalization"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H31138811"/>
			<id>208868</id>
			<summary>
				<section label="Choosing treatment" id="31138811">
					<fragment>For treatment resistant patients with severe unipolar major depression, electroconvulsive therapy (ECT) is often the treatment of choice.</fragment>
				</section>
			</summary>
			<category term="C0013806" scheme="gov.nih.nlm.semanticType.topp" label="ECT"/>
			<category term="C0013808" scheme="gov.nih.nlm.semanticType.topp" label="electroconvulsive therapy"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H31138811"/>
			<id>208873</id>
			<summary>
				<section label="Choosing treatment" id="31138811">
					<fragment>Prior to using ECT, many patients receive a few (eg, one to four) courses of next step pharmacotherapy using the same regimens that are employed for treatment resistant patients with mild to moderate depression;</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0013806" scheme="gov.nih.nlm.semanticType.topp" label="ECT"/>
			<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimens"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H14367501"/>
			<id>208876</id>
			<summary>
				<section label="Electroconvulsive therapy (ECT)" id="14367501">
					<fragment>ECT is superior to pharmacotherapy for unipolar major depression, based upon meta-analyses of randomized trials.</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0013806" scheme="gov.nih.nlm.semanticType.topp" label="ECT"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H14367501"/>
			<id>208880</id>
			<summary>
				<section label="Electroconvulsive therapy (ECT)" id="14367501">
					<fragment>However, ECT is associated with safety risks, adverse effects, logistical constraints, and patient refusal, and relapse rates following remission are high, especially in patients with treatment resistant depression.</fragment>
				</section>
			</summary>
			<category term="C0013806" scheme="gov.nih.nlm.semanticType.topp" label="ECT"/>
			<category term="C1569452" scheme="gov.nih.nlm.semanticType.phsu" label="refusal"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H14367778"/>
			<id>208884</id>
			<summary>
				<section label="Pharmacotherapy" id="14367778">
					<fragment>A meta-analysis of 25 randomized trials compared tricyclics with selective serotonin reuptake inhibitors (SSRIs) in 1377 hospitalized patients who were not selected for treatment resistance.</fragment>
				</section>
			</summary>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C0360105" scheme="gov.nih.nlm.semanticType.phsu" label="selective serotonin reuptake inhibitors"/>
			<category term="C0758711" scheme="gov.nih.nlm.semanticType.orch" label="serotonin"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin reuptake inhibitors"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H14367778"/>
			<id>208885</id>
			<summary>
				<section label="Pharmacotherapy" id="14367778">
					<fragment>Although tricyclics were more efficacious than SSRIs, the difference was small, and heterogeneity across studies was significant.</fragment>
				</section>
			</summary>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H14367778"/>
			<id>208886</id>
			<summary>
				<section label="Pharmacotherapy" id="14367778">
					<fragment>In addition, discontinuation of treatment was greater with tricyclics than SSRIs (14 versus 9 percent).</fragment>
				</section>
			</summary>
			<category term="C0457454" scheme="gov.nih.nlm.semanticType.hlca" label="discontinuation"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="SSRIs"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H14367778"/>
			<id>208888</id>
			<summary>
				<section label="Pharmacotherapy" id="14367778">
					<fragment>Augmentation of the antidepressant with a second drug is often indicated for severe, treatment resistant major depression.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H14367778"/>
			<id>208892</id>
			<summary>
				<section label="Pharmacotherapy" id="14367778">
					<fragment>Other severely ill, treatment resistant patients may benefit from adjunctive medications, based upon randomized trials in mild to moderately ill patients.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H14367839"/>
			<id>208893</id>
			<summary>
				<section label="Adjunctive psychotherapy" id="14367839">
					<fragment>We typically include adjunctive psychotherapy for severe episodes of major depression that are treatment resistant, based upon indirect evidence from randomized trials in patients with mild to moderate major depression.</fragment>
				</section>
			</summary>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H14367839"/>
			<id>208894</id>
			<summary>
				<section label="Adjunctive psychotherapy" id="14367839">
					<fragment>A 12 week randomized trial compared cognitive-behavioral therapy (CBT) plus pharmacotherapy with pharmacotherapy alone in 20 patients hospitalized for chronic (duration &gt;=2 years) depression;</fragment>
				</section>
			</summary>
			<category term="C0004933" scheme="gov.nih.nlm.semanticType.topp" label="behavioral therapy"/>
			<category term="C0009244" scheme="gov.nih.nlm.semanticType.topp" label="cognitive-behavioral therapy"/>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0308902" scheme="gov.nih.nlm.semanticType.phsu" label="duration"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H14367839"/>
			<id>208897</id>
			<summary>
				<section label="Adjunctive psychotherapy" id="14367839">
					<fragment>Functioning was impaired to the point that many patients had difficulty with basic self care tasks, and most patients also received family therapy.</fragment>
				</section>
			</summary>
			<category term="C0015618" scheme="gov.nih.nlm.semanticType.topp" label="family therapy"/>
			<category term="C0310298" scheme="gov.nih.nlm.semanticType.phsu" label="tasks"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H29355745"/>
			<id>208911</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="29355745">
					<fragment>Unipolar major depression (major depressive disorder) is diagnosed in patients who have suffered at least one major depressive episode ) and have no history of mania or hypomania.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H14367762"/>
			<id>208916</id>
			<summary>
				<section label="Mild to moderate depression" id="14367762">
					<fragment>For patients with mild to moderate major depression who obtain little symptom relief from an antidepressant, we suggest switching antidepressants as first-line treatment, rather than augmenting the initial antidepressant with a second drug and/or psychotherapy, or switching from pharmacotherapy to psychotherapy.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H14367762"/>
			<id>208917</id>
			<summary>
				<section label="Mild to moderate depression" id="14367762">
					<fragment>However, reasonable alternatives include augmentation with a second drug and/or psychotherapy, as well as switching from pharmacotherapy to psychotherapy.</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H14367762"/>
			<id>208920</id>
			<summary>
				<section label="Mild to moderate depression" id="14367762">
					<fragment>In choosing a new antidepressant for patients who fail a selective serotonin reuptake inhibitor, our general order of preference is serotonin-norepinephrine reuptake inhibitors, atypical antidepressants, tricyclics, and monoamine oxidase inhibitors.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="C0003290" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants, tricyclics"/>
			<category term="C0242905" scheme="gov.nih.nlm.semanticType.phsu" label="atypical antidepressants"/>
			<category term="C0360105" scheme="gov.nih.nlm.semanticType.phsu" label="selective serotonin reuptake inhibitor"/>
			<category term="C0758711" scheme="gov.nih.nlm.semanticType.orch" label="serotonin"/>
			<category term="C1319313" scheme="gov.nih.nlm.semanticType.phsu" label="norepinephrine reuptake inhibitors"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin reuptake inhibitor"/>
			<category term="C3537213" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin-norepinephrine reuptake inhibitors"/>
			<category term="C3653413" scheme="gov.nih.nlm.semanticType.phsu" label="monoamine oxidase inhibitors"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H14367762"/>
			<id>208922</id>
			<summary>
				<section label="Mild to moderate depression" id="14367762">
					<fragment>For patients with mild to moderate major depression who obtain little symptom relief despite repeated (eg, one to three) antidepressant switches, we suggest augmentation with a second medication and/or psychotherapy as second-line treatment, rather than additional trials of antidepressant monotherapy.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H14367762"/>
			<id>208923</id>
			<summary>
				<section label="Mild to moderate depression" id="14367762">
					<fragment>For patients with mild to moderate major depression who obtain definite symptom relief that is not satisfactory and can tolerate the antidepressant, we suggest augmentation with a second medication and/or psychotherapy as first-line treatment, rather than continuing the initial antidepressant alone.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H14367762"/>
			<id>208925</id>
			<summary>
				<section label="Mild to moderate depression" id="14367762">
					<fragment>In choosing an adjunctive drug, our general order of preference is second-generation antipsychotics, lithium, triiodothyronine, and a second antidepressant from a different class.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0040615" scheme="gov.nih.nlm.semanticType.phsu" label="antipsychotics"/>
			<category term="C0041014" scheme="gov.nih.nlm.semanticType.horm" label="triiodothyronine"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H14367762"/>
			<id>208928</id>
			<summary>
				<section label="Mild to moderate depression" id="14367762">
					<fragment>Patients with mild to moderate major depression who obtain definite symptom relief that is not satisfactory despite augmentation with different drugs (eg, two to four) should switch antidepressants as second-line treatment.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H14367762"/>
			<id>208929</id>
			<summary>
				<section label="Mild to moderate depression" id="14367762">
					<fragment>Patients who do not respond satisfactorily to several (eg, three to nine) courses of first- and second-line treatments should receive repetitive transcranial magnetic stimulation as third-line treatment.</fragment>
				</section>
			</summary>
			<category term="C0436548" scheme="gov.nih.nlm.semanticType.topp" label="transcranial magnetic stimulation"/>
			<category term="C1292856" scheme="gov.nih.nlm.semanticType.topp" label="stimulation"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H14367762"/>
			<id>208931</id>
			<summary>
				<section label="Mild to moderate depression" id="14367762">
					<fragment>Although electroconvulsive therapy (ECT) is usually reserved for severely depressed patients, it is a reasonable option for patients with moderate depression who are resistant to first-, second-, and third-line treatments.</fragment>
				</section>
			</summary>
			<category term="C0013806" scheme="gov.nih.nlm.semanticType.topp" label="ECT"/>
			<category term="C0013808" scheme="gov.nih.nlm.semanticType.topp" label="electroconvulsive therapy"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14685#H14367770"/>
			<id>208935</id>
			<summary>
				<section label="Severe depression" id="14367770">
					<fragment>Treatment for severely depressed patients who do not respond to or accept ECT consists of pharmacotherapy, as well as adjunctive psychotherapy if it is feasible.</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0013806" scheme="gov.nih.nlm.semanticType.topp" label="ECT"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
	</feed>
	<feed>
		<title>Unipolar depression in adults: Continuation and maintenance treatment</title>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C1720205" scheme="gov.nih.nlm.semanticType.hlca" label="then discontinue"/>
		<category term="C0004933" scheme="gov.nih.nlm.semanticType.topp" label="behavioral therapy"/>
		<category term="C0009244" scheme="gov.nih.nlm.semanticType.topp" label="cognitive-behavioral therapy"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0004933" scheme="gov.nih.nlm.semanticType.topp" label="behavioral therapy"/>
		<category term="C0009244" scheme="gov.nih.nlm.semanticType.topp" label="cognitive-behavioral therapy"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0040805" scheme="gov.nih.nlm.semanticType.phsu" label="trazodone"/>
		<category term="C0049506" scheme="gov.nih.nlm.semanticType.phsu" label="mirtazapine"/>
		<category term="C0085208" scheme="gov.nih.nlm.semanticType.phsu" label="bupropion"/>
		<category term="C0242905" scheme="gov.nih.nlm.semanticType.phsu" label="atypical antidepressants"/>
		<category term="C0360105" scheme="gov.nih.nlm.semanticType.phsu" label="selective serotonin reuptake inhibitors"/>
		<category term="C0758711" scheme="gov.nih.nlm.semanticType.orch" label="serotonin"/>
		<category term="C1319313" scheme="gov.nih.nlm.semanticType.phsu" label="norepinephrine reuptake inhibitors"/>
		<category term="C1530072" scheme="gov.nih.nlm.semanticType.phsu" label="vilazodone"/>
		<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin reuptake inhibitors"/>
		<category term="C3537213" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin-norepinephrine reuptake inhibitors"/>
		<category term="C3653413" scheme="gov.nih.nlm.semanticType.phsu" label="monoamine oxidase inhibitors"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0040615" scheme="gov.nih.nlm.semanticType.phsu" label="antipsychotics"/>
		<category term="C0041014" scheme="gov.nih.nlm.semanticType.horm" label="triiodothyronine"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0871787" scheme="gov.nih.nlm.semanticType.topp" label="interpersonal psychotherapy"/>
		<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="add"/>
		<category term="C0009244" scheme="gov.nih.nlm.semanticType.topp" label="cognitive therapy"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0009244" scheme="gov.nih.nlm.semanticType.topp" label="cognitive therapy"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
		<category term="C3252015" scheme="gov.nih.nlm.semanticType.phsu" label="RR"/>
		<category term="C0009244" scheme="gov.nih.nlm.semanticType.topp" label="cognitive therapy"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0009244" scheme="gov.nih.nlm.semanticType.topp" label="cognitive therapy"/>
		<category term="C0016365" scheme="gov.nih.nlm.semanticType.phsu" label="fluoxetine"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0016365" scheme="gov.nih.nlm.semanticType.phsu" label="fluoxetine"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0309872" scheme="gov.nih.nlm.semanticType.phsu" label="Prevent"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0008952" scheme="gov.nih.nlm.semanticType.hlca" label="clinic visits"/>
		<category term="C0029151" scheme="gov.nih.nlm.semanticType.topp" label="pill"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0871787" scheme="gov.nih.nlm.semanticType.topp" label="interpersonal psychotherapy"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0008952" scheme="gov.nih.nlm.semanticType.hlca" label="clinic visits"/>
		<category term="C0029151" scheme="gov.nih.nlm.semanticType.topp" label="pill"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0871787" scheme="gov.nih.nlm.semanticType.topp" label="interpersonal psychotherapy"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0441640" scheme="gov.nih.nlm.semanticType.hlca" label="tapering"/>
		<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="adding"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
		<category term="C0441640" scheme="gov.nih.nlm.semanticType.hlca" label="tapering"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0030695" scheme="gov.nih.nlm.semanticType.hlca" label="monitor patients"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0457454" scheme="gov.nih.nlm.semanticType.hlca" label="discontinuation"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0871787" scheme="gov.nih.nlm.semanticType.topp" label="interpersonal psychotherapy"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0663764" scheme="gov.nih.nlm.semanticType.orch" label="ng"/>
		<category term="C0871787" scheme="gov.nih.nlm.semanticType.topp" label="interpersonal psychotherapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0871787" scheme="gov.nih.nlm.semanticType.topp" label="interpersonal psychotherapy"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C0309872" scheme="gov.nih.nlm.semanticType.phsu" label="prevent"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0457454" scheme="gov.nih.nlm.semanticType.hlca" label="Discontinuation"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
		<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0009244" scheme="gov.nih.nlm.semanticType.topp" label="cognitive therapy"/>
		<category term="C0009244" scheme="gov.nih.nlm.semanticType.topp" label="cognitive therapy"/>
		<category term="C0016365" scheme="gov.nih.nlm.semanticType.phsu" label="fluoxetine"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0029151" scheme="gov.nih.nlm.semanticType.topp" label="pill"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0070122" scheme="gov.nih.nlm.semanticType.phsu" label="paroxetine"/>
		<category term="C0871787" scheme="gov.nih.nlm.semanticType.topp" label="interpersonal psychotherapy"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0871787" scheme="gov.nih.nlm.semanticType.topp" label="interpersonal psychotherapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0871787" scheme="gov.nih.nlm.semanticType.topp" label="interpersonal psychotherapy"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0663764" scheme="gov.nih.nlm.semanticType.orch" label="ng"/>
		<category term="C0871787" scheme="gov.nih.nlm.semanticType.topp" label="interpersonal psychotherapy"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0309872" scheme="gov.nih.nlm.semanticType.phsu" label="prevent"/>
		<category term="C0004933" scheme="gov.nih.nlm.semanticType.topp" label="behavior therapy"/>
		<category term="C0009244" scheme="gov.nih.nlm.semanticType.topp" label="cognitive therapy"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0009244" scheme="gov.nih.nlm.semanticType.topp" label="cognitive therapy"/>
		<category term="C0029151" scheme="gov.nih.nlm.semanticType.topp" label="pill"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0009244" scheme="gov.nih.nlm.semanticType.topp" label="cognitive therapy"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0013806" scheme="gov.nih.nlm.semanticType.topp" label="ECT"/>
		<category term="C0013808" scheme="gov.nih.nlm.semanticType.topp" label="electroconvulsive therapy"/>
		<category term="C0033971" scheme="gov.nih.nlm.semanticType.topp" label="group therapy"/>
		<category term="C0441640" scheme="gov.nih.nlm.semanticType.hlca" label="tapered"/>
		<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="add"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0013806" scheme="gov.nih.nlm.semanticType.topp" label="ECT"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0871787" scheme="gov.nih.nlm.semanticType.topp" label="interpersonal psychotherapy"/>
		<category term="C0009244" scheme="gov.nih.nlm.semanticType.topp" label="cognitive therapy"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0309872" scheme="gov.nih.nlm.semanticType.phsu" label="prevent"/>
		<category term="C0409102" scheme="gov.nih.nlm.semanticType.topp" label="application"/>
		<category term="C0009244" scheme="gov.nih.nlm.semanticType.topp" label="cognitive therapy"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0040615" scheme="gov.nih.nlm.semanticType.phsu" label="antipsychotic"/>
		<category term="C0123091" scheme="gov.nih.nlm.semanticType.phsu" label="Quetiapine"/>
		<category term="C0309872" scheme="gov.nih.nlm.semanticType.phsu" label="prevent"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0123091" scheme="gov.nih.nlm.semanticType.phsu" label="quetiapine"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0123091" scheme="gov.nih.nlm.semanticType.phsu" label="quetiapine"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0013806" scheme="gov.nih.nlm.semanticType.topp" label="ECT"/>
		<category term="C0013808" scheme="gov.nih.nlm.semanticType.topp" label="Electroconvulsive therapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0013806" scheme="gov.nih.nlm.semanticType.topp" label="ECT"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0013806" scheme="gov.nih.nlm.semanticType.topp" label="ECT"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0436548" scheme="gov.nih.nlm.semanticType.topp" label="transcranial magnetic stimulation"/>
		<category term="C0634038" scheme="gov.nih.nlm.semanticType.phsu" label="TMS"/>
		<category term="C1292856" scheme="gov.nih.nlm.semanticType.topp" label="stimulation"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0309872" scheme="gov.nih.nlm.semanticType.phsu" label="prevent"/>
		<category term="C1720205" scheme="gov.nih.nlm.semanticType.hlca" label="then discontinue"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0871787" scheme="gov.nih.nlm.semanticType.topp" label="interpersonal psychotherapy"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="Pharmacotherapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0871787" scheme="gov.nih.nlm.semanticType.topp" label="interpersonal psychotherapy"/>
		<category term="C0677908" scheme="gov.nih.nlm.semanticType.topp" label="maintenance therapy"/>
		<category term="C0677908" scheme="gov.nih.nlm.semanticType.topp" label="maintenance therapy"/>
		<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
		<category term="C0004933" scheme="gov.nih.nlm.semanticType.topp" label="behavioral therapy"/>
		<category term="C0009244" scheme="gov.nih.nlm.semanticType.topp" label="cognitive-behavioral therapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="add"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
		<category term="C0013808" scheme="gov.nih.nlm.semanticType.topp" label="electroconvulsive therapy"/>
		<category term="C0123091" scheme="gov.nih.nlm.semanticType.phsu" label="quetiapine"/>
		<category term="C0436548" scheme="gov.nih.nlm.semanticType.topp" label="transcranial magnetic stimulation"/>
		<category term="C1292856" scheme="gov.nih.nlm.semanticType.topp" label="stimulation"/>
		<id>14674</id>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H2080222"/>
			<id>208343</id>
			<summary>
				<section label="Unipolar major depression" id="2080222">
					<fragment>Unipolar major depression (major depressive disorder) is diagnosed in patients who have suffered at least one major depressive episode and have no history of mania or hypomania.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H7164739"/>
			<id>208358</id>
			<summary>
				<section label="RELAPSE/RECURRENCE IN THE ABSENCE OF TREATMENT" id="7164739">
					<fragment>Relapse and recurrence are common in patients with unipolar major depression, including acutely ill patients who remit/recover with treatment and then discontinue it: In a meta-analysis of 11 randomized trials that included 1019 patients who were successfully treated with acute pharmacotherapy and then assigned to placebo, relapse/recurrence occurred within one year in 51 percent and within two years in 62 percent.</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C1720205" scheme="gov.nih.nlm.semanticType.hlca" label="then discontinue"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H7164739"/>
			<id>208359</id>
			<summary>
				<section label="RELAPSE/RECURRENCE IN THE ABSENCE OF TREATMENT" id="7164739">
					<fragment>In a meta-analysis of 13 randomized and observational studies that included 364 patients with major depression who were successfully treated with acute cognitive-behavioral therapy (CBT) and received no subsequent treatment, relapse and recurrence during follow-up (mean 74 weeks) occurred in 39 percent.</fragment>
				</section>
			</summary>
			<category term="C0004933" scheme="gov.nih.nlm.semanticType.topp" label="behavioral therapy"/>
			<category term="C0009244" scheme="gov.nih.nlm.semanticType.topp" label="cognitive-behavioral therapy"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H7164739"/>
			<id>208361</id>
			<summary>
				<section label="RELAPSE/RECURRENCE IN THE ABSENCE OF TREATMENT" id="7164739">
					<fragment>Patients acutely ill with unipolar major depression who improve with pharmacotherapy and subsequently discontinue it appear to be at greater risk for relapse/recurrence than patients who improve with and discontinue CBT: A meta-analysis of eight randomized trials (393 patients followed for up to one year) found that the probability of remaining well was greater in patients treated acutely with CBT than pharmacotherapy (odds ratio 2.6, 95% CI 1.6-4.3).</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H7164739"/>
			<id>208362</id>
			<summary>
				<section label="RELAPSE/RECURRENCE IN THE ABSENCE OF TREATMENT" id="7164739">
					<fragment>In a meta-analysis of seven randomized and observational studies (335 patients with major depression) with a mean follow-up of 68 weeks, relapse/recurrence occurred in more patients who received acute pharmacotherapy than acute CBT (61 versus 39 percent).</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H14391901"/>
			<id>208375</id>
			<summary>
				<section label="INDICATIONS" id="14391901">
					<fragment>For patients with unipolar major depression who respond to acute therapy, continuation/maintenance treatment is consistent with practice guidelines from the American Psychiatric Association, United Kingdom National Institute of Health and Clinical Excellence, Canadian Network for Mood and Anxiety Treatments, British Association for Psychopharmacology, and World Federation of Societies of Biological Psychiatry.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H14391901"/>
			<id>208376</id>
			<summary>
				<section label="INDICATIONS" id="14391901">
					<fragment>However, patients with unipolar major depression who respond to acute treatment with cognitive-behavioral therapy (CBT) and are not at increased risk of relapse/recurrence may reasonably decline continuation treatment, provided the presenting episode was neither chronic nor severe.</fragment>
				</section>
			</summary>
			<category term="C0004933" scheme="gov.nih.nlm.semanticType.topp" label="behavioral therapy"/>
			<category term="C0009244" scheme="gov.nih.nlm.semanticType.topp" label="cognitive-behavioral therapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H14391901"/>
			<id>208379</id>
			<summary>
				<section label="INDICATIONS" id="14391901">
					<fragment>Patients with unipolar major depression who respond to acute treatment with behavioral activation and are not at increased risk of relapse/recurrence may also reasonably decline continuation treatment, provided the presenting episode was neither chronic nor severe.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H86758411"/>
			<id>208385</id>
			<summary>
				<section label="TREATMENT SELECTION" id="86758411">
					<fragment>For patients with unipolar major depression who respond to acute phase therapy, standard continuation and maintenance treatments include pharmacotherapy, psychotherapy, or pharmacotherapy plus psychotherapy.</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H86758411"/>
			<id>208391</id>
			<summary>
				<section label="TREATMENT SELECTION" id="86758411">
					<fragment>Although selective serotonin reuptake inhibitors (SSRIs) and tricyclics have been most widely studied, other reasonable options include serotonin-norepinephrine reuptake inhibitors (SNRIs), serotonin modulators (eg, trazodone and vilazodone), atypical antidepressants (eg, bupropion and mirtazapine), and monoamine oxidase inhibitors (MAOIs).</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0040805" scheme="gov.nih.nlm.semanticType.phsu" label="trazodone"/>
			<category term="C0049506" scheme="gov.nih.nlm.semanticType.phsu" label="mirtazapine"/>
			<category term="C0085208" scheme="gov.nih.nlm.semanticType.phsu" label="bupropion"/>
			<category term="C0242905" scheme="gov.nih.nlm.semanticType.phsu" label="atypical antidepressants"/>
			<category term="C0360105" scheme="gov.nih.nlm.semanticType.phsu" label="selective serotonin reuptake inhibitors"/>
			<category term="C0758711" scheme="gov.nih.nlm.semanticType.orch" label="serotonin"/>
			<category term="C1319313" scheme="gov.nih.nlm.semanticType.phsu" label="norepinephrine reuptake inhibitors"/>
			<category term="C1530072" scheme="gov.nih.nlm.semanticType.phsu" label="vilazodone"/>
			<category term="C2911696" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin reuptake inhibitors"/>
			<category term="C3537213" scheme="gov.nih.nlm.semanticType.phsu" label="serotonin-norepinephrine reuptake inhibitors"/>
			<category term="C3653413" scheme="gov.nih.nlm.semanticType.phsu" label="monoamine oxidase inhibitors"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H86758411"/>
			<id>208396</id>
			<summary>
				<section label="TREATMENT SELECTION" id="86758411">
					<fragment>During acute treatment of unipolar major depression, antidepressants may be augmented with other medications such as second-generation antipsychotics, lithium, triiodothyronine, or a second antidepressant.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0040615" scheme="gov.nih.nlm.semanticType.phsu" label="antipsychotics"/>
			<category term="C0041014" scheme="gov.nih.nlm.semanticType.horm" label="triiodothyronine"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H86758411"/>
			<id>208400</id>
			<summary>
				<section label="TREATMENT SELECTION" id="86758411">
					<fragment>The most widely studied psychotherapy for continuation and maintenance treatment of unipolar major depression is CBT.</fragment>
				</section>
			</summary>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H86758411"/>
			<id>208404</id>
			<summary>
				<section label="TREATMENT SELECTION" id="86758411">
					<fragment>Randomized trials indicate that continuation and maintenance treatment with pharmacotherapy plus interpersonal psychotherapy is superior to either pharmacotherapy alone or psychotherapy alone.</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="C0871787" scheme="gov.nih.nlm.semanticType.topp" label="interpersonal psychotherapy"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H86758477"/>
			<id>208405</id>
			<summary>
				<section label="Sequential treatment" id="86758477">
					<fragment>Patients with unipolar major depression who successfully complete acute phase pharmacotherapy may switch to or add psychotherapy (eg, CBT or mindfulness-based cognitive therapy) for continuation/maintenance treatment;</fragment>
				</section>
			</summary>
			<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="add"/>
			<category term="C0009244" scheme="gov.nih.nlm.semanticType.topp" label="cognitive therapy"/>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H86758477"/>
			<id>208411</id>
			<summary>
				<section label="Sequential treatment" id="86758477">
					<fragment>Improve interpersonal or occupational functioning.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H86758477"/>
			<id>208413</id>
			<summary>
				<section label="Sequential treatment" id="86758477">
					<fragment>A meta-analysis of eight randomized trials compared sequential treatment (using CBT or mindfulness-based cognitive therapy) with a control treatment in 875 patients with major depression who responded to acute phase pharmacotherapy;</fragment>
				</section>
			</summary>
			<category term="C0009244" scheme="gov.nih.nlm.semanticType.topp" label="cognitive therapy"/>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="6" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H86758477"/>
			<id>208414</id>
			<summary>
				<section label="Sequential treatment" id="86758477">
					<fragment>relapse/recurrence was reduced in patients who received sequential treatment (RR 0.80, 95% CI 0.66-0.96).</fragment>
				</section>
			</summary>
			<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
			<category term="C3252015" scheme="gov.nih.nlm.semanticType.phsu" label="RR"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H86758477"/>
			<id>208415</id>
			<summary>
				<section label="Sequential treatment" id="86758477">
					<fragment>Conversely, for patients with major depression who respond to acute phase cognitive therapy but remain at high risk for relapse, it is reasonable to stop cognitive therapy and initiate pharmacotherapy for continuation/maintenance treatment.</fragment>
				</section>
			</summary>
			<category term="C0009244" scheme="gov.nih.nlm.semanticType.topp" label="cognitive therapy"/>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H86758477"/>
			<id>208416</id>
			<summary>
				<section label="Sequential treatment" id="86758477">
					<fragment>As an example, a randomized trial compared fluoxetine (modal dose 40 mg per day) with placebo as continuation treatment for eight months in 155 patients who initially responded to acute phase cognitive therapy, but remained at higher risk for relapse due to partial or unstable remission during acute phase therapy.</fragment>
				</section>
			</summary>
			<category term="C0009244" scheme="gov.nih.nlm.semanticType.topp" label="cognitive therapy"/>
			<category term="C0016365" scheme="gov.nih.nlm.semanticType.phsu" label="fluoxetine"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H86758477"/>
			<id>208417</id>
			<summary>
				<section label="Sequential treatment" id="86758477">
					<fragment>Relapse occurred in fewer patients who received fluoxetine than placebo (18 versus 33 percent).</fragment>
				</section>
			</summary>
			<category term="C0016365" scheme="gov.nih.nlm.semanticType.phsu" label="fluoxetine"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H86757420"/>
			<id>208418</id>
			<summary>
				<section label="Continuation treatment" id="86757420">
					<fragment>For patients with unipolar major depression who respond to acute therapy, multiple reviews and treatment guidelines recommend that clinicians administer continuation treatment for four to nine months to: Prevent relapse.</fragment>
				</section>
			</summary>
			<category term="C0309872" scheme="gov.nih.nlm.semanticType.phsu" label="Prevent"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H86757420"/>
			<id>208421</id>
			<summary>
				<section label="Continuation treatment" id="86757420">
					<fragment>Evidence for the efficacy of continuation treatment includes a meta-analysis of five trials that compared antidepressants with placebo in 2000 patients who were treated with antidepressants for four to six months prior to random assignment.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H86757420"/>
			<id>208422</id>
			<summary>
				<section label="Continuation treatment" id="86757420">
					<fragment>Relapse occurred in fewer patients who received antidepressants than placebo (18 versus 35 percent).</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H86757427"/>
			<id>208428</id>
			<summary>
				<section label="Maintenance treatment" id="86757427">
					<fragment>In addition, randomized trials lasting up to three years have found that maintenance treatment is efficacious: A meta-analysis of 10 randomized maintenance trials lasting 18 to 36 months (703 recovered patients) found that recurrence occurred in fewer patients who received antidepressants than placebo (24 versus 63 percent).</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H86757427"/>
			<id>208429</id>
			<summary>
				<section label="Maintenance treatment" id="86757427">
					<fragment>A three-year randomized trial assigned 50 recovered patients to either monthly maintenance sessions of interpersonal psychotherapy plus pill placebo or to monthly medication clinic visits with placebo.</fragment>
				</section>
			</summary>
			<category term="C0008952" scheme="gov.nih.nlm.semanticType.hlca" label="clinic visits"/>
			<category term="C0029151" scheme="gov.nih.nlm.semanticType.topp" label="pill"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="C0871787" scheme="gov.nih.nlm.semanticType.topp" label="interpersonal psychotherapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H86757427"/>
			<id>208430</id>
			<summary>
				<section label="Maintenance treatment" id="86757427">
					<fragment>Recurrence occurred in fewer patients who received psychotherapy plus placebo than placebo alone (64 versus 90 percent).</fragment>
				</section>
			</summary>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H86757427"/>
			<id>208431</id>
			<summary>
				<section label="Maintenance treatment" id="86757427">
					<fragment>A three-year randomized trial assigned 49 recovered patients to either monthly maintenance sessions of interpersonal psychotherapy plus pill placebo or to monthly medication clinic visits with placebo.</fragment>
				</section>
			</summary>
			<category term="C0008952" scheme="gov.nih.nlm.semanticType.hlca" label="clinic visits"/>
			<category term="C0029151" scheme="gov.nih.nlm.semanticType.topp" label="pill"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="C0871787" scheme="gov.nih.nlm.semanticType.topp" label="interpersonal psychotherapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H86757427"/>
			<id>208432</id>
			<summary>
				<section label="Maintenance treatment" id="86757427">
					<fragment>The median time to recurrence was longer in patients who received psychotherapy plus placebo than placebo alone (61 versus 21 weeks).</fragment>
				</section>
			</summary>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H86757434"/>
			<id>208437</id>
			<summary>
				<section label="MONITORING PATIENTS" id="86757434">
					<fragment>Patients receiving continuation and maintenance treatment for unipolar major depression should be regularly monitored for reemerging symptoms, with particular emphasis upon suicidal ideation.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H86757434"/>
			<id>208438</id>
			<summary>
				<section label="MONITORING PATIENTS" id="86757434">
					<fragment>Patients treated with pharmacotherapy are also evaluated for adverse side effects.</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H86757434"/>
			<id>208441</id>
			<summary>
				<section label="MONITORING PATIENTS" id="86757434">
					<fragment>Continuously stable patients receiving pharmacotherapy can eventually be seen every three to six months.</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H86757434"/>
			<id>208442</id>
			<summary>
				<section label="MONITORING PATIENTS" id="86757434">
					<fragment>Stable patients receiving psychotherapy are typically seen once per month, following careful tapering from weekly to twice a month visits.</fragment>
				</section>
			</summary>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="C0441640" scheme="gov.nih.nlm.semanticType.hlca" label="tapering"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H86757434"/>
			<id>208443</id>
			<summary>
				<section label="MONITORING PATIENTS" id="86757434">
					<fragment>More frequent visits should be scheduled for patients who develop symptoms or side effects;</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H86757434"/>
			<id>208444</id>
			<summary>
				<section label="MONITORING PATIENTS" id="86757434">
					<fragment>monitoring acutely ill patients is discussed separately.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H86757434"/>
			<id>208445</id>
			<summary>
				<section label="MONITORING PATIENTS" id="86757434">
					<fragment>For patients with unipolar depression who receive maintenance treatment, we suggest measurement based care using a self-report instrument.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H8286945"/>
			<id>208447</id>
			<summary>
				<section label="ADHERENCE" id="8286945">
					<fragment>Many patients have difficulty adhering to (complying with) continuation and maintenance treatment.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H173034179"/>
			<id>208450</id>
			<summary>
				<section label="REEMERGING SYMPTOMS DURING TREATMENT" id="173034179">
					<fragment>If this does not control symptoms within four to eight weeks, or doses are already at the maximum of the therapeutic range, we suggest adding a depression specific psychotherapy (ie, a psychotherapy shown to reduce depressive symptoms);</fragment>
				</section>
			</summary>
			<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="adding"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H87348931"/>
			<id>208455</id>
			<summary>
				<section label="DISCONTINUATION" id="87348931">
					<fragment>These discussions often include family members and generate contingency plans for seeking treatment should the need arise.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H87348931"/>
			<id>208462</id>
			<summary>
				<section label="DISCONTINUATION" id="87348931">
					<fragment>In addition, tapering allows clinicians to detect recrudescent symptoms of major depression and reinstitute the full dose used initially to achieve remission.</fragment>
				</section>
			</summary>
			<category term="C0441640" scheme="gov.nih.nlm.semanticType.hlca" label="tapering"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H87348931"/>
			<id>208464</id>
			<summary>
				<section label="DISCONTINUATION" id="87348931">
					<fragment>Following discontinuation of continuation/maintenance pharmacotherapy or psychotherapy for unipolar major depression, it is prudent to monitor patients for several (eg, three to eight) months, because the risk of relapse or recurrence is greatest in the first several months after stopping treatment.</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0030695" scheme="gov.nih.nlm.semanticType.hlca" label="monitor patients"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="C0457454" scheme="gov.nih.nlm.semanticType.hlca" label="discontinuation"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H8038589"/>
			<id>208466</id>
			<summary>
				<section label="Compared with antidepressants alone" id="8038589">
					<fragment>For patients with acute unipolar major depression who respond to the combination of pharmacotherapy and interpersonal psychotherapy, randomized trials indicate that continuation and maintenance treatment with combination treatment is superior to pharmacotherapy alone.</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="C0871787" scheme="gov.nih.nlm.semanticType.topp" label="interpersonal psychotherapy"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H8038589"/>
			<id>208467</id>
			<summary>
				<section label="Compared with antidepressants alone" id="8038589">
					<fragment>A meta-analysis of four randomized trials (282 patients who remitted from an episode of unipolar major depression with combination treatment) found that relapse/recurrence was more likely in patients who received pharmacotherapy alone than combination treatment.</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H8038596"/>
			<id>208469</id>
			<summary>
				<section label="Compared with psychotherapy alone" id="8038596">
					<fragment>Based upon randomized maintenance trials in patients with unipolar major depression, pharmacotherapy plus interpersonal psychotherapy is superior to psychotherapy alone: A three-year randomized trial compared nortriptyline (target serum concentration 80 to 100 ng per mL) plus interpersonal psychotherapy (one session per month) with placebo plus interpersonal psychotherapy in 50 patients who initially recovered with combination treatment;</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="C0663764" scheme="gov.nih.nlm.semanticType.orch" label="ng"/>
			<category term="C0871787" scheme="gov.nih.nlm.semanticType.topp" label="interpersonal psychotherapy"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H8038596"/>
			<id>208470</id>
			<summary>
				<section label="Compared with psychotherapy alone" id="8038596">
					<fragment>there were fewer recurrences in patients who received combination treatment than in patients who received psychotherapy alone (20 versus 64 percent).</fragment>
				</section>
			</summary>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H8038596"/>
			<id>208471</id>
			<summary>
				<section label="Compared with psychotherapy alone" id="8038596">
					<fragment>In a three-year randomized trial that compared imipramine (mean dose 208 mg per day) plus monthly interpersonal psychotherapy with placebo plus interpersonal psychotherapy in 51 patients who initially recovered with combination treatment, the mean time to recurrence of depression was nearly twice as long for combination treatment compared with interpersonal psychotherapy alone (131 versus 74 weeks).</fragment>
				</section>
			</summary>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="C0871787" scheme="gov.nih.nlm.semanticType.topp" label="interpersonal psychotherapy"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H8038603"/>
			<id>208472</id>
			<summary>
				<section label="Antidepressant medications" id="8038603">
					<fragment>For patients with unipolar major depression who respond to antidepressant medications, continuation and maintenance treatment can delay or prevent reemerging episodes.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="C0309872" scheme="gov.nih.nlm.semanticType.phsu" label="prevent"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H8038646"/>
			<id>208482</id>
			<summary>
				<section label="Compared with placebo" id="8038646">
					<fragment>As an example, a meta-analysis of 31 randomized trials compared antidepressants with placebo in 4410 depressed patients who initially responded to acute treatment with antidepressants;</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H8038646"/>
			<id>208484</id>
			<summary>
				<section label="Compared with placebo" id="8038646">
					<fragment>The primary findings were as follows: Relapse and recurrence occurred in fewer patients who received antidepressants than placebo (18 versus 41 percent).</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H8038646"/>
			<id>208486</id>
			<summary>
				<section label="Compared with placebo" id="8038646">
					<fragment>Discontinuation of treatment for any reason (eg, adverse effects or lack of efficacy) occurred in more patients who received antidepressants than placebo (18 versus 15 percent).</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0457454" scheme="gov.nih.nlm.semanticType.hlca" label="Discontinuation"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H8038646"/>
			<id>208487</id>
			<summary>
				<section label="Compared with placebo" id="8038646">
					<fragment>A subsequent two year, randomized maintenance trial compared venlafaxine extended release (mean dose 214 mg per day) with placebo in 258 patients with recurrent unipolar major depression who were successfully treated for an acute episode and remained well through 6 months of continuation treatment.</fragment>
				</section>
			</summary>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H8038646"/>
			<id>208488</id>
			<summary>
				<section label="Compared with placebo" id="8038646">
					<fragment>The estimated rate of recurrence was lower in patients treated with venlafaxine than placebo (29 versus 47 percent).</fragment>
				</section>
			</summary>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H8038646"/>
			<id>208489</id>
			<summary>
				<section label="Compared with placebo" id="8038646">
					<fragment>Adverse effects in venlafaxine patients included weight gain, headache, and upper respiratory infection.</fragment>
				</section>
			</summary>
			<category term="C0078569" scheme="gov.nih.nlm.semanticType.phsu" label="venlafaxine"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H8038646"/>
			<id>208490</id>
			<summary>
				<section label="Compared with placebo" id="8038646">
					<fragment>Continuation/maintenance antidepressants may provide greater benefits in patients with one lifetime major depressive episode than patients with multiple lifetime episodes.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H191813182"/>
			<id>208493</id>
			<summary>
				<section label="Compared with psychotherapy" id="191813182">
					<fragment>Two randomized trials that compared antidepressants with cognitive therapy as continuation/maintenance treatment for patients with unipolar major depression have found that relapse/recurrence was comparable.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="C0009244" scheme="gov.nih.nlm.semanticType.topp" label="cognitive therapy"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H191813328"/>
			<id>208495</id>
			<summary>
				<section label="Cognitive therapy" id="191813328">
					<fragment>A randomized trial compared eight months of continuation phase fluoxetine (10 to 40 mg per day) with cognitive therapy (10 sessions, each lasting 60 minutes) in 172 patients who initially responded to acute phase cognitive therapy.</fragment>
				</section>
			</summary>
			<category term="C0009244" scheme="gov.nih.nlm.semanticType.topp" label="cognitive therapy"/>
			<category term="C0016365" scheme="gov.nih.nlm.semanticType.phsu" label="fluoxetine"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H8038653"/>
			<id>208500</id>
			<summary>
				<section label="Interpersonal psychotherapy" id="8038653">
					<fragment>Based upon small randomized trials that compared pharmacotherapy with interpersonal psychotherapy for maintenance treatment of major depression, the efficacy of pharmacotherapy may be superior: A two-year randomized continuation/maintenance trial compared pharmacotherapy (paroxetine monotherapy or paroxetine plus a second antidepressant) with monthly interpersonal psychotherapy plus pill placebo in 70 patients who recovered or partially recovered from an episode of major depression;</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0029151" scheme="gov.nih.nlm.semanticType.topp" label="pill"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="C0070122" scheme="gov.nih.nlm.semanticType.phsu" label="paroxetine"/>
			<category term="C0871787" scheme="gov.nih.nlm.semanticType.topp" label="interpersonal psychotherapy"/>
			<category term="5" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H8038653"/>
			<id>208501</id>
			<summary>
				<section label="Interpersonal psychotherapy" id="8038653">
					<fragment>relapse/recurrence occurred in fewer patients who received pharmacotherapy than interpersonal psychotherapy (37 versus 68 percent).</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="C0871787" scheme="gov.nih.nlm.semanticType.topp" label="interpersonal psychotherapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H8038653"/>
			<id>208502</id>
			<summary>
				<section label="Interpersonal psychotherapy" id="8038653">
					<fragment>A three-year trial (N = 54 patients) found that the mean time to recurrence for patients who received imipramine (mean dose 208 mg per day) and patients who received interpersonal psychotherapy (one session per month) was 124 and 82 weeks.</fragment>
				</section>
			</summary>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="C0871787" scheme="gov.nih.nlm.semanticType.topp" label="interpersonal psychotherapy"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H8038653"/>
			<id>208504</id>
			<summary>
				<section label="Interpersonal psychotherapy" id="8038653">
					<fragment>In a three-year trial that compared nortriptyline (target serum concentration 80 to 100 ng per mL, N = 28) with monthly interpersonal psychotherapy (N = 25), recurrent episodes occurred in 12 (43 percent) patients treated with nortriptyline and 16 (64 percent) patients who received interpersonal psychotherapy plus placebo.</fragment>
				</section>
			</summary>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="C0663764" scheme="gov.nih.nlm.semanticType.orch" label="ng"/>
			<category term="C0871787" scheme="gov.nih.nlm.semanticType.topp" label="interpersonal psychotherapy"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H8038660"/>
			<id>208506</id>
			<summary>
				<section label="Dose" id="8038660">
					<fragment>The same antidepressant dose that is used to acutely treat unipolar major depression is typically used for continuation/maintenance treatment.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressant"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H8038682"/>
			<id>208511</id>
			<summary>
				<section label="Psychotherapy" id="8038682">
					<fragment>For patients with unipolar major depression who respond to depression specific psychotherapy, continuation and maintenance psychotherapy can delay or prevent reemerging episodes and may be especially beneficial for patients with a lifetime history of multiple unipolar major depressive episodes.</fragment>
				</section>
			</summary>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="C0309872" scheme="gov.nih.nlm.semanticType.phsu" label="prevent"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H8038740"/>
			<id>208512</id>
			<summary>
				<section label="behavioral therapy" id="8038740">
					<fragment>CBT is a time-limited, structured therapy that combines cognitive therapy and behavior therapy to help depressed patients change dysfunctional cognitions (distorted thoughts and beliefs about oneself, the world, and future) and problematic behaviors (eg, inactivity).</fragment>
				</section>
			</summary>
			<category term="C0004933" scheme="gov.nih.nlm.semanticType.topp" label="behavior therapy"/>
			<category term="C0009244" scheme="gov.nih.nlm.semanticType.topp" label="cognitive therapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H8038740"/>
			<id>208514</id>
			<summary>
				<section label="behavioral therapy" id="8038740">
					<fragment>Continuation CBT reduces relapse of unipolar major depression: A meta-analysis of four randomized trials compared continuation CBT with no continuation treatment in 234 patients who initially remitted with acute CBT;</fragment>
				</section>
			</summary>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H8038740"/>
			<id>208515</id>
			<summary>
				<section label="behavioral therapy" id="8038740">
					<fragment>over a mean follow-up of 41 weeks, relapse occurred in fewer patients who received CBT (12 versus 38 percent).</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H8038740"/>
			<id>208516</id>
			<summary>
				<section label="behavioral therapy" id="8038740">
					<fragment>A subsequent randomized trial compared eight months of continuation phase cognitive therapy (10 sessions) with pill placebo in 155 patients who initially responded to acute phase cognitive therapy, but remained at higher risk for relapse due to partial or unstable remission during acute phase therapy.</fragment>
				</section>
			</summary>
			<category term="C0009244" scheme="gov.nih.nlm.semanticType.topp" label="cognitive therapy"/>
			<category term="C0029151" scheme="gov.nih.nlm.semanticType.topp" label="pill"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H8038740"/>
			<id>208517</id>
			<summary>
				<section label="behavioral therapy" id="8038740">
					<fragment>Relapse occurred in fewer patients who received cognitive therapy than placebo (18 versus 33 percent).</fragment>
				</section>
			</summary>
			<category term="C0009244" scheme="gov.nih.nlm.semanticType.topp" label="cognitive therapy"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H8038740"/>
			<id>208518</id>
			<summary>
				<section label="behavioral therapy" id="8038740">
					<fragment>In another trial, 60 patients who responded (baseline symptoms decreased by at least 50 percent) to an acute course of electroconvulsive therapy (ECT) were randomly assigned to six months of continuation treatment with CBT (15 sessions of weekly group therapy) plus pharmacotherapy, continuation ECT (11 treatments; frequency was tapered from weekly to biweekly to monthly) plus pharmacotherapy, or pharmacotherapy alone.</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0013806" scheme="gov.nih.nlm.semanticType.topp" label="ECT"/>
			<category term="C0013808" scheme="gov.nih.nlm.semanticType.topp" label="electroconvulsive therapy"/>
			<category term="C0033971" scheme="gov.nih.nlm.semanticType.topp" label="group therapy"/>
			<category term="C0441640" scheme="gov.nih.nlm.semanticType.hlca" label="tapered"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H8038740"/>
			<id>208520</id>
			<summary>
				<section label="behavioral therapy" id="8038740">
					<fragment>Sustained response was greater in patients who received add-on CBT than add-on ECT or pharmacotherapy alone (77 versus 40 and 44 percent).</fragment>
				</section>
			</summary>
			<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="add"/>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0013806" scheme="gov.nih.nlm.semanticType.topp" label="ECT"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H8038740"/>
			<id>208523</id>
			<summary>
				<section label="behavioral therapy" id="8038740">
					<fragment>In a randomized trial, depressed patients were treated with pharmacotherapy or CBT;</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H8038740"/>
			<id>208526</id>
			<summary>
				<section label="behavioral therapy" id="8038740">
					<fragment>In addition, relapse occurred in fewer patients who received prior CBT compared with patients who received continuation pharmacotherapy (31 and 47 percent);</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H8038762"/>
			<id>208533</id>
			<summary>
				<section label="Interpersonal psychotherapy" id="8038762">
					<fragment>Evidence for the efficacy of maintenance interpersonal psychotherapy for unipolar major depression includes randomized trials showing recurrence is decreased in patients who receive interpersonal psychotherapy plus placebo compared with patients who receive placebo alone.</fragment>
				</section>
			</summary>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="C0871787" scheme="gov.nih.nlm.semanticType.topp" label="interpersonal psychotherapy"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H8038769"/>
			<id>208535</id>
			<summary>
				<section label="based cognitive therapy" id="8038769">
					<fragment>Mindfulness-based cognitive therapy is a skills-training group program that combines the clinical application of mindfulness meditation with elements of CBT to delay or prevent recurrence in patients with unipolar major depression who have responded to acute phase treatment (typically with pharmacotherapy) and have a history of at least three lifetime episodes.</fragment>
				</section>
			</summary>
			<category term="C0009244" scheme="gov.nih.nlm.semanticType.topp" label="cognitive therapy"/>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0309872" scheme="gov.nih.nlm.semanticType.phsu" label="prevent"/>
			<category term="C0409102" scheme="gov.nih.nlm.semanticType.topp" label="application"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H8038769"/>
			<id>208536</id>
			<summary>
				<section label="based cognitive therapy" id="8038769">
					<fragment>Mindfulness is purposeful, nonjudgmental attention to the present moment, which is developed through meditation and other practices.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H8038769"/>
			<id>208539</id>
			<summary>
				<section label="based cognitive therapy" id="8038769">
					<fragment>Evidence for the efficacy of mindfulness-based cognitive therapy in patients with unipolar major depression includes randomized trials that compared continuation/maintenance mindfulness-based cognitive therapy with continuation/maintenance pharmacotherapy and found that relapse/recurrence may possibly occur less often with psychotherapy.</fragment>
				</section>
			</summary>
			<category term="C0009244" scheme="gov.nih.nlm.semanticType.topp" label="cognitive therapy"/>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H8038776"/>
			<id>208541</id>
			<summary>
				<section label="Other approaches" id="8038776">
					<fragment>Patients with unipolar major depression may benefit from maintenance treatment with: Quetiapine - Monotherapy with the second generation antipsychotic quetiapine may prevent relapse of major depression.</fragment>
				</section>
			</summary>
			<category term="C0040615" scheme="gov.nih.nlm.semanticType.phsu" label="antipsychotic"/>
			<category term="C0123091" scheme="gov.nih.nlm.semanticType.phsu" label="Quetiapine"/>
			<category term="C0309872" scheme="gov.nih.nlm.semanticType.phsu" label="prevent"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H8038776"/>
			<id>208542</id>
			<summary>
				<section label="Other approaches" id="8038776">
					<fragment>A one-year randomized trial compared quetiapine extended release (mean dose 177 mg per day) with placebo in 776 patients with unipolar major depression who were stabilized for at least 12 weeks with open label quetiapine.</fragment>
				</section>
			</summary>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0123091" scheme="gov.nih.nlm.semanticType.phsu" label="quetiapine"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H8038776"/>
			<id>208543</id>
			<summary>
				<section label="Other approaches" id="8038776">
					<fragment>Relapse occurred in fewer patients treated with quetiapine than placebo (14 versus 34 percent).</fragment>
				</section>
			</summary>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0123091" scheme="gov.nih.nlm.semanticType.phsu" label="quetiapine"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H8038776"/>
			<id>208545</id>
			<summary>
				<section label="Other approaches" id="8038776">
					<fragment>Electroconvulsive therapy - For patients with unipolar major depression who respond with electroconvulsive therapy (ECT), continuation/maintenance treatment generally consists of pharmacotherapy plus psychotherapy or pharmacotherapy alone.</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0013806" scheme="gov.nih.nlm.semanticType.topp" label="ECT"/>
			<category term="C0013808" scheme="gov.nih.nlm.semanticType.topp" label="Electroconvulsive therapy"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H8038776"/>
			<id>208546</id>
			<summary>
				<section label="Other approaches" id="8038776">
					<fragment>However, continuation/maintenance ECT should be considered for patients who repeatedly (eg, two to three times) respond to acute ECT and then fail standard maintenance treatment.</fragment>
				</section>
			</summary>
			<category term="C0013806" scheme="gov.nih.nlm.semanticType.topp" label="ECT"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H8038776"/>
			<id>208547</id>
			<summary>
				<section label="Other approaches" id="8038776">
					<fragment>The evidence for pharmacotherapy plus psychotherapy as continuation/maintenance following acute ECT is discussed separately, as is the evidence for continuation/maintenance ECT.</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0013806" scheme="gov.nih.nlm.semanticType.topp" label="ECT"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H8038776"/>
			<id>208548</id>
			<summary>
				<section label="Other approaches" id="8038776">
					<fragment>Repetitive transcranial magnetic stimulation - For patients with unipolar major depression who respond to repetitive transcranial magnetic stimulation (TMS), continuation/maintenance treatment generally consists of pharmacotherapy or pharmacotherapy plus psychotherapy.</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="C0436548" scheme="gov.nih.nlm.semanticType.topp" label="transcranial magnetic stimulation"/>
			<category term="C0634038" scheme="gov.nih.nlm.semanticType.phsu" label="TMS"/>
			<category term="C1292856" scheme="gov.nih.nlm.semanticType.topp" label="stimulation"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H8038776"/>
			<id>208551</id>
			<summary>
				<section label="Other approaches" id="8038776">
					<fragment>In a prospective observational study, 172 patients with unipolar major depression received pharmacotherapy, psychotherapy, or no treatment;</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H8038776"/>
			<id>208553</id>
			<summary>
				<section label="Other approaches" id="8038776">
					<fragment>Fewer depressive symptoms were found in patients who exercised (moderate to vigorous intensity) for three hours per week compared with patients who did not exercise.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H6998467"/>
			<id>208554</id>
			<summary>
				<section label="PREVENTING SUICIDE" id="6998467">
					<fragment>Patients with unipolar major depression are at increased risk of suicide, and continuation and maintenance treatment with lithium can prevent suicide.</fragment>
				</section>
			</summary>
			<category term="C0309872" scheme="gov.nih.nlm.semanticType.phsu" label="prevent"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H7164921"/>
			<id>208555</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="7164921">
					<fragment>Unipolar major depression is diagnosed in patients who have suffered at least one major depressive episode and have no history of mania, mixed mania, or hypomania.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H7164921"/>
			<id>208562</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="7164921">
					<fragment>Relapse and recurrence are common in patients with unipolar major depression who improve with treatment and then discontinue it.</fragment>
				</section>
			</summary>
			<category term="C1720205" scheme="gov.nih.nlm.semanticType.hlca" label="then discontinue"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H7164921"/>
			<id>208563</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="7164921">
					<fragment>Continuation treatment is generally indicated for patients with unipolar major depression who respond to acute treatment;</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H7164921"/>
			<id>208574</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="7164921">
					<fragment>Randomized trials indicate that pharmacotherapy plus interpersonal psychotherapy is more efficacious than pharmacotherapy alone or psychotherapy alone.</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="C0871787" scheme="gov.nih.nlm.semanticType.topp" label="interpersonal psychotherapy"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H7164921"/>
			<id>208575</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="7164921">
					<fragment>The efficacy of monotherapy with either pharmacotherapy or psychotherapy is superior to no treatment.</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="8" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H7164921"/>
			<id>208576</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="7164921">
					<fragment>Pharmacotherapy alone may possibly be more effective than interpersonal psychotherapy alone.</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="Pharmacotherapy"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="C0871787" scheme="gov.nih.nlm.semanticType.topp" label="interpersonal psychotherapy"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H7164921"/>
			<id>208577</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="7164921">
					<fragment>For most patients with unipolar major depression who respond to acute therapy, we recommend continuation treatment rather than no treatment.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H7164921"/>
			<id>208579</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="7164921">
					<fragment>For patients with unipolar major depression who respond to acute phase and continuation phase therapy and are at risk of recurrence, we recommend maintenance therapy rather than discontinuing treatment.</fragment>
				</section>
			</summary>
			<category term="C0677908" scheme="gov.nih.nlm.semanticType.topp" label="maintenance therapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H7164921"/>
			<id>208581</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="7164921">
					<fragment>For patients with unipolar major depression who respond to acute phase and continuation phase therapy and are at low risk of recurrence, we suggest discontinuing treatment rather than administering maintenance therapy.</fragment>
				</section>
			</summary>
			<category term="C0677908" scheme="gov.nih.nlm.semanticType.topp" label="maintenance therapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H7164921"/>
			<id>208584</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="7164921">
					<fragment>For patients treated with continuation/maintenance antidepressants, we suggest maintaining the same dose that achieved remission rather than decreasing the dose.</fragment>
				</section>
			</summary>
			<category term="C0003289" scheme="gov.nih.nlm.semanticType.phsu" label="antidepressants"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H7164921"/>
			<id>208588</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="7164921">
					<fragment>The most widely studied psychotherapy for continuation/maintenance treatment of unipolar major depression is cognitive-behavioral therapy (CBT);</fragment>
				</section>
			</summary>
			<category term="C0004933" scheme="gov.nih.nlm.semanticType.topp" label="behavioral therapy"/>
			<category term="C0009244" scheme="gov.nih.nlm.semanticType.topp" label="cognitive-behavioral therapy"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H7164921"/>
			<id>208591</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="7164921">
					<fragment>Patients with unipolar major depression who successfully complete acute pharmacotherapy may switch to or add on psychotherapy for continuation/maintenance treatment (called sequential treatment).</fragment>
				</section>
			</summary>
			<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="add"/>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="psychotherapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/14674#H7164921"/>
			<id>208597</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="7164921">
					<fragment>Other options for continuation/maintenance treatment of patients with unipolar major depression include quetiapine, exercise, electroconvulsive therapy, and repetitive transcranial magnetic stimulation.</fragment>
				</section>
			</summary>
			<category term="C0013808" scheme="gov.nih.nlm.semanticType.topp" label="electroconvulsive therapy"/>
			<category term="C0123091" scheme="gov.nih.nlm.semanticType.phsu" label="quetiapine"/>
			<category term="C0436548" scheme="gov.nih.nlm.semanticType.topp" label="transcranial magnetic stimulation"/>
			<category term="C1292856" scheme="gov.nih.nlm.semanticType.topp" label="stimulation"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
	</feed>
</aggregateKnowledgeResponse>
